
<html lang="en"     class="pb-page"  data-request-id="540b0d25-b1be-48ec-a2ea-9d4afd900f8a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-7;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b02004;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors" /></meta><meta name="dc.Creator" content="Simona  Di Martino" /></meta><meta name="dc.Creator" content="Piero  Tardia" /></meta><meta name="dc.Creator" content="Vincenzo  Cilibrasi" /></meta><meta name="dc.Creator" content="Samantha  Caputo" /></meta><meta name="dc.Creator" content="Marco  Mazzonna" /></meta><meta name="dc.Creator" content="Debora  Russo" /></meta><meta name="dc.Creator" content="Ilaria  Penna" /></meta><meta name="dc.Creator" content="Natalia  Realini" /></meta><meta name="dc.Creator" content="Natasha  Margaroli" /></meta><meta name="dc.Creator" content="Marco  Migliore" /></meta><meta name="dc.Creator" content="Daniela  Pizzirani" /></meta><meta name="dc.Creator" content="Giuliana  Ottonello" /></meta><meta name="dc.Creator" content="Sine Mandrup  Bertozzi" /></meta><meta name="dc.Creator" content="Andrea  Armirotti" /></meta><meta name="dc.Creator" content="Duc  Nguyen" /></meta><meta name="dc.Creator" content="Ying  Sun" /></meta><meta name="dc.Creator" content="Ernesto R.  Bongarzone" /></meta><meta name="dc.Creator" content="Peter  Lansbury" /></meta><meta name="dc.Creator" content="Min  Liu" /></meta><meta name="dc.Creator" content="Renato  Skerlj" /></meta><meta name="dc.Creator" content="Rita  Scarpelli" /></meta><meta name="dc.Description" content="Sphingolipids (SphLs) are a diverse class of molecules that are regulated by a complex network of enzymatic pathways. A disturbance in these pathways leads to lipid accumulation and initiation of s..." /></meta><meta name="Description" content="Sphingolipids (SphLs) are a diverse class of molecules that are regulated by a complex network of enzymatic pathways. A disturbance in these pathways leads to lipid accumulation and initiation of s..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 16, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02004" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02004" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02004" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02004" /></link>
        
    
    

<title>Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02004" /></meta><meta property="og:title" content="Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0001.jpeg" /></meta><meta property="og:description" content="Sphingolipids (SphLs) are a diverse class of molecules that are regulated by a complex network of enzymatic pathways. A disturbance in these pathways leads to lipid accumulation and initiation of several SphL-related disorders. Acid ceramidase is one of the key enzymes that regulate the metabolism of ceramides and glycosphingolipids, which are important members of the SphL family. Herein, we describe the lead optimization studies of benzoxazolone carboxamides resulting in piperidine 22m, where we demonstrated target engagement in two animal models of neuropathic lysosomal storage diseases (LSDs), Gaucher’s and Krabbe’s diseases. After daily intraperitoneal administration at 90 mg kg–1, 22m significantly reduced the brain levels of the toxic lipids glucosylsphingosine (GluSph) in 4L;C* mice and galactosylsphingosine (GalSph) in Twitcher mice. We believe that 22m is a lead molecule that can be further developed for the correction of severe neurological LSDs where GluSph or GalSph play a significant role in disease pathogenesis." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02004"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02004">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02004&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02004&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02004&amp;href=/doi/10.1021/acs.jmedchem.9b02004" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3634-3664</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02080" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b02163" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Simona Di Martino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simona Di Martino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simona++Di+Martino">Simona Di Martino</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5817-751X" title="Orcid link">http://orcid.org/0000-0001-5817-751X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Piero Tardia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Piero Tardia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Piero++Tardia">Piero Tardia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vincenzo Cilibrasi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vincenzo Cilibrasi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vincenzo++Cilibrasi">Vincenzo Cilibrasi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samantha Caputo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samantha Caputo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samantha++Caputo">Samantha Caputo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marco Mazzonna</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marco Mazzonna</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marco++Mazzonna">Marco Mazzonna</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Debora Russo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Debora Russo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D3-Pharma Chemistry, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Debora++Russo">Debora Russo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ilaria Penna</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ilaria Penna</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D3-Pharma Chemistry, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ilaria++Penna">Ilaria Penna</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Natalia Realini</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Natalia Realini</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Natalia++Realini">Natalia Realini</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Natasha Margaroli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Natasha Margaroli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Natasha++Margaroli">Natasha Margaroli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marco Migliore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marco Migliore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marco++Migliore">Marco Migliore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniela Pizzirani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniela Pizzirani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniela++Pizzirani">Daniela Pizzirani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Giuliana Ottonello</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Giuliana Ottonello</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Analytical Chemistry Lab, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Giuliana++Ottonello">Giuliana Ottonello</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sine Mandrup Bertozzi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sine Mandrup Bertozzi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Analytical Chemistry Lab, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sine+Mandrup++Bertozzi">Sine Mandrup Bertozzi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrea Armirotti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea Armirotti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Analytical Chemistry Lab, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Armirotti">Andrea Armirotti</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3766-8755" title="Orcid link">http://orcid.org/0000-0002-3766-8755</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Duc Nguyen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Duc Nguyen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Myelin Regeneration Group at the Dept. Anatomy & Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Duc++Nguyen">Duc Nguyen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ying Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ying Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229-3039, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ying++Sun">Ying Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ernesto R. Bongarzone</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ernesto R. Bongarzone</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Myelin Regeneration Group at the Dept. Anatomy & Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ernesto+R.++Bongarzone">Ernesto R. Bongarzone</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Lansbury</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Lansbury</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lysosomal Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Lansbury">Peter Lansbury</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Min Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Min Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lysosomal Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Min++Liu">Min Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Renato Skerlj</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Renato Skerlj</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lysosomal Therapeutics Inc., 19 Blackstone Street, Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#bdcfd8d3dcc9d293ced6d8cfd1d7fdc589cdd5dccfd0dc93ded2d0"><span class="__cf_email__" data-cfemail="2351464d42574c0d504846514f49635b17534b42514e420d404c4e">[email protected]</span></a>. Phone: +1 617 610 8624.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Renato++Skerlj">Renato Skerlj</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Rita Scarpelli</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rita Scarpelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development (D3)-Validation, Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#4b39223f2a6538282a393b2e2727220b22223f65223f"><span class="__cf_email__" data-cfemail="592b302d38772a3a382b293c3535301930302d77302d">[email protected]</span></a>. Phone: +39 010 2896233.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rita++Scarpelli">Rita Scarpelli</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2623-306X" title="Orcid link">http://orcid.org/0000-0002-2623-306X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02004&amp;href=/doi/10.1021%2Facs.jmedchem.9b02004" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3634–3664</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 16, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 December 2019</li><li><span class="item_label"><b>Published</b> online</span>16 March 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 April 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02004" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02004</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="https://acsopenscience.org/open-access/licensing-options/"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by"><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_cc-1612971093887.svg" alt="CC: Creative Commons" /></img><span><strong>CC: </strong>Creative Commons</span></a><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_by-1612971093257.svg" alt="BY: Credit must be given to the creator" /></img><span><strong>BY: </strong>Credit must be given to the creator</span></a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02004"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1723</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02004" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Simona&quot;,&quot;last_name&quot;:&quot;Di Martino&quot;},{&quot;first_name&quot;:&quot;Piero&quot;,&quot;last_name&quot;:&quot;Tardia&quot;},{&quot;first_name&quot;:&quot;Vincenzo&quot;,&quot;last_name&quot;:&quot;Cilibrasi&quot;},{&quot;first_name&quot;:&quot;Samantha&quot;,&quot;last_name&quot;:&quot;Caputo&quot;},{&quot;first_name&quot;:&quot;Marco&quot;,&quot;last_name&quot;:&quot;Mazzonna&quot;},{&quot;first_name&quot;:&quot;Debora&quot;,&quot;last_name&quot;:&quot;Russo&quot;},{&quot;first_name&quot;:&quot;Ilaria&quot;,&quot;last_name&quot;:&quot;Penna&quot;},{&quot;first_name&quot;:&quot;Natalia&quot;,&quot;last_name&quot;:&quot;Realini&quot;},{&quot;first_name&quot;:&quot;Natasha&quot;,&quot;last_name&quot;:&quot;Margaroli&quot;},{&quot;first_name&quot;:&quot;Marco&quot;,&quot;last_name&quot;:&quot;Migliore&quot;},{&quot;first_name&quot;:&quot;Daniela&quot;,&quot;last_name&quot;:&quot;Pizzirani&quot;},{&quot;first_name&quot;:&quot;Giuliana&quot;,&quot;last_name&quot;:&quot;Ottonello&quot;},{&quot;first_name&quot;:&quot;Sine&quot;,&quot;last_name&quot;:&quot;Mandrup Bertozzi&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Armirotti&quot;},{&quot;first_name&quot;:&quot;Duc&quot;,&quot;last_name&quot;:&quot;Nguyen&quot;},{&quot;first_name&quot;:&quot;Ying&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Ernesto&quot;,&quot;last_name&quot;:&quot;R. Bongarzone&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Lansbury&quot;},{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Renato&quot;,&quot;last_name&quot;:&quot;Skerlj&quot;},{&quot;first_name&quot;:&quot;Rita&quot;,&quot;last_name&quot;:&quot;Scarpelli&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;3634-3664&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02004&quot;},&quot;abstract&quot;:&quot;Sphingolipids (SphLs) are a diverse class of molecules that are regulated by a complex network of enzymatic pathways. A disturbance in these pathways leads to lipid accumulation and initiation of several SphL-related disorders. Acid ceramidase is one of the key enzymes that regulate the metabolism of ceramides and glycosphingolipids, which are important members of the SphL family. Herein, we describe the lead optimization studies of benzoxazolone carboxamides resulting in piperidine 22m, where we demonstrated target engagement in two animal models of neuropathic lysosomal storage diseases (LSDs), Gaucher’s and Krabbe’s diseases. After daily intraperitoneal administration at 90 mg kg–1, 22m significantly reduced the brain levels of the toxic lipids glucosylsphingosine (GluSph) in 4L;C* mice and galactosylsphingosine (GalSph) in Twitcher mice. We believe that 22m is a lead molecule that can be further developed for the correction of severe neurological LSDs where GluSph or GalSph play a significant role in dise&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02004&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02004" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02004&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02004" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02004&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02004" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02004&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02004&amp;href=/doi/10.1021/acs.jmedchem.9b02004" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02004" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02004" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02004%26sid%3Dliteratum%253Aachs%26pmid%3D32176488%26genre%3Darticle%26aulast%3DDi%2BMartino%26date%3D2020%26atitle%3DLead%2BOptimization%2Bof%2BBenzoxazolone%2BCarboxamides%2Bas%2BOrally%2BBioavailable%2Band%2BCNS%2BPenetrant%2BAcid%2BCeramidase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D7%26spage%3D3634%26epage%3D3664%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=291870" title="Piperidines">Piperidines</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/jmcmar.2020.63.issue-7/20200409/jmcmar.2020.63.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Sphingolipids (SphLs) are a diverse class of molecules that are regulated by a complex network of enzymatic pathways. A disturbance in these pathways leads to lipid accumulation and initiation of several SphL-related disorders. Acid ceramidase is one of the key enzymes that regulate the metabolism of ceramides and glycosphingolipids, which are important members of the SphL family. Herein, we describe the lead optimization studies of benzoxazolone carboxamides resulting in piperidine <b>22m</b>, where we demonstrated target engagement in two animal models of neuropathic lysosomal storage diseases (LSDs), Gaucher’s and Krabbe’s diseases. After daily intraperitoneal administration at 90 mg kg<sup>–1</sup>, <b>22m</b> significantly reduced the brain levels of the toxic lipids glucosylsphingosine (GluSph) in 4L;C* mice and galactosylsphingosine (GalSph) in Twitcher mice. We believe that <b>22m</b> is a lead molecule that can be further developed for the correction of severe neurological LSDs where GluSph or GalSph play a significant role in disease pathogenesis.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Sphingolipids (SphLs) are a large class of diverse amphipathic molecules found in abundance in plasma membranes.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Besides being important as structural cellular components, SphLs play a central role in different biological processes, which are essential to maintain the homeostasis and the development of eukaryotic cells. These processes include signaling, angiogenesis, cell growth, proliferation, and death, senescence, inflammation, immune responses, metabolism, autophagy, and brain development and functions.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Aided by recent technological advances, much has been accomplished in terms of the identification of the basic biological components of the complex network in dynamic and interconnected enzymatic pathways that regulate the biosynthesis of SphLs and the formation of a variety of bioactive metabolites in distinct cellular compartments.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">In recent years, both academia and industry have shown growing interest in advancing our understanding of the multifaceted roles of SphL species under physiological and pathological conditions.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Collected evidence suggests that a disturbance between the synthesis and catabolism of SphLs leads to their accumulation in specific cellular compartments, such as the lysosomes, and the initiation of several SphL-related disorders. Lysosomes are critical organelles responsible for cellular homeostasis.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> They contain different degradative enzymes that can hydrolyze proteins, DNA, RNA, polysaccharides, and lipids.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Acid ceramidase (AC, also known as <i>N</i>-acylsphingosine amidohydrolase-1, ASAH-1) is a lysosomal cysteine amidase that catalyzes the hydrolysis of ceramides (Cer) into fatty acids and sphingosine, which is then converted into sphingosine 1-phosphate (Sph1P) by sphingosine kinase.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> Cer and Sph1P are important members of the SphL class and have opposing actions in the control of the cellular fate;<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> while Cer mediates cellular senescence<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and apoptosis,<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Sph1P promotes cell survival and proliferation.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17">(14−17)</a> Recent studies have shown that AC is abnormally expressed in various types of human cancer (for example, prostate, head and neck, colon, and glioblastoma), and serum AC levels are elevated in patients with melanoma relative to control subjects.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Therefore, inhibition of AC has been envisaged as a potential cancer drug target (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Aberrant AC activity has also been described in several other common diseases, including inflammation, pain, and various pulmonary disorders.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0028.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Some potential applications of AC inhibition therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Over the recent years, the multifaceted catabolic role of AC has attracted much attention for its potential therapeutic applications in many other altered conditions. Important genetic studies have identified specific mutations in several genes that encode defective expressions of some lysosomal enzymes as the causes of the onset and progression of severe pathological conditions, called lysosomal storage diseases (LSDs).<a onclick="showRef(event, 'ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24">(21−24)</a> For example, Gaucher’s disease (GD) is caused by a defective function of acid β-glucocerebrosidase (GCase), a lysosomal membrane-associated protein responsible for the hydrolysis of glucosylceramide (GluCer) to glucose and ceramides.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> Krabbe’s disease (KD) is associated with defective β-galactosyl-ceramidase (GALC) activity, a lysosomal enzyme responsible for the hydrolysis of galactosylceramide (GalCer).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">As a result of either enzyme absences or deficiencies, these metabolic lysosomal disorders are characterized by an abnormal storage of substrates or metabolites to concentration levels that are toxic or otherwise detrimental to the cells in various compartments, including the skeleton, skin, liver, spleen, lung, heart, and central nervous system (CNS). The substrate or metabolite accumulations are believed to be responsible for the disease progression.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> In GD patients, for example, the accumulation of GluCer (3-fold) and/or glucosylsphingosine (GluSph) (200-fold) has been related to the brain pathogenesis of neuronopathic GD patients due to neuronal death, which is propagated by the toxic effects of GluCer and/or GluSph.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Recent evidence demonstrates an active role of AC in an alternative catabolic pathway, which causes GluSph accumulation through the deacylation of the lysosomal GluCer.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> In KD patients, deficiency of GALC activity leads to accumulation of neurotoxic galactosylsphingosine (GalSph or psychosine) in tissues, especially in the brain. It is possible that accumulation of GalSph mediates pathology of KD. A very recent report suggests that genetic ablation of AC or pharmacological inhibition of AC could eliminate psychosine accumulation and prolong the life span of Twitcher mice, a model of KD.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> No approved therapeutic approaches are available to treat neuropathic GD and KD; inhibiting AC may provide an efficacious strategy for treating these two devastating diseases.</div><div class="NLM_p">Efforts over the last decade to develop potent AC inhibitors have resulted in limited success. The first structural analysis of mammalian AC has recently been solved by Gebai and co-workers,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> which may aid future medicinal chemistry programs. In 2013, Realini et al. reported the discovery of carmofur <b>1</b> and some close uracil analogs as the first class of single-digit nanomolar inhibitors of intracellular AC activity and studied their potential use as chemosensitizing agents (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Despite being potent AC inhibitors, the uracil derivatives suffered from low chemical and metabolic stability. Subsequently, Diamanti et al. selected compound <b>1</b> as a ligand template for a computational-assisted virtual screening approach, leading to the identification of a new class of potent AC inhibitors, the pyrazole carboxamides.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> However, although very potent against AC activity, as exemplified by pyrazole <b>3</b>, this class of molecules suffered from low metabolic stability, limiting their therapeutic potential (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0027.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of representative known AC inhibitors (<b>1</b>–<b>4</b>) (top) and general structure of the benzoxazolone carboxamide series <b>5</b> explored in this study (bottom).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An alternative approach, consisting of a screening campaign of a small compound library, led to the identification of a novel and very promising class of covalent AC inhibitors, the benzoxazolone carboxamides, exemplified by the hit <b>2a</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Preliminary chemical exploration of this series led to the identification of <b>2b</b><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and <b>2c</b><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> as more advanced and systematically active analogs. More recently, Ortega et al. reported a systematic computational investigation of the general pharmacophore model for AC inhibition, comprising a 6 + 5 fused ring heterocycle linked to an aliphatic substituent via a urea moiety. These studies resulted in the identification of the novel class of benzimidazole derivatives <b>4a</b>–<b>d</b> with promising activity in different melanoma cell lines (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p last">Although some of the molecules discussed above exhibited potent inhibitory effects toward AC, they generally suffer from low aqueous solubility and moderate chemical or metabolic stability, which hamper their further development. As part of our continued efforts to optimize the class of benzoxazolone carboxamides, we further extended the preliminary studies around <b>2b</b><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (and <b>2c</b>)<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and performed a focused structure–activity relationship (SAR) study around this scaffold (compound <b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), with the aim of identifying an optimal compound with improved physicochemical and pharmacokinetic profiles favoring oral administration. The subject of this manuscript describes the lead optimization and medicinal chemistry strategies that led to the discovery of <b>22m</b> as a lead candidate with improved oral bioavailability and excellent distribution to the CNS.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54118" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54118" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All target compounds were prepared by synthetic routes outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<named-content content-type="anchor" rid="sch2" type="simple"></named-content><named-content content-type="anchor" rid="sch3" type="simple"></named-content><named-content content-type="anchor" rid="sch4" type="simple"></named-content><named-content content-type="anchor" rid="sch5" type="simple"></named-content><named-content content-type="anchor" rid="sch6" type="simple"></named-content><named-content content-type="anchor" rid="sch7" type="simple"></named-content><named-content content-type="anchor" rid="sch8" type="simple"></named-content><named-content content-type="anchor" rid="sch9" type="simple"></named-content><named-content content-type="anchor" rid="sch10" type="simple"></named-content><a class="ref internalNav" href="#sch11" aria-label="11">11</a>. Compounds <b>8a</b>–<b>d</b> were synthesized under standard conditions by reacting <b>7a–d</b> with 4-phenylbutyl isocyanate (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The novel core scaffold of <b>12a</b> was prepared in three steps from the α-bromo ketone <b>9</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>A). Reaction with TZD gave compound <b>10</b>, which was then converted in moderate yield to the fused bicyclic derivative <b>11</b> via an intramolecular cyclization under basic conditions in anhydrous THF. Subsequent coupling of <b>11</b> to 4-phenylbutyl isocyanate gave <b>12a</b>, which upon removal of the <i>N</i>-Boc protecting group gave the key intermediate <b>12b</b>, which was subsequently transformed to <b>12c</b>–<b>e</b> via standard reductive amination and acetylation reactions. Alternatively, the isomeric key intermediate <b>17b</b> was prepared in four steps from the commercially available epoxide <b>13</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>B). Ring opening<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and subsequent oxidation of the corresponding alcohol <b>14a</b> followed by intramolecular cyclization of <b>15</b> afforded compound <b>16</b>. Finally, as discussed for the synthesis of <b>12b</b>, standard reactions transformed <b>16</b> to <b>17b</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0020.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>8a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CDI, MeCN, rt, 2 h; (b) 4-phenylbutyl isocyanate, DMAP, toluene/DMF, rt, 2 h (20–60% over two steps for <b>8a</b> and <b>8b</b>); 4-phenylbutyl isocyanate, Et<sub>3</sub>N, MeCN, rt, 2 h (20–26% for <b>8c</b> and <b>8d</b>).</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0019.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of fused bicyclic piperidine-oxazolone derivatives <b>12a</b>–<b>e</b>, <b>17a</b>, and <b>17b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: for the synthesis of <b>12a</b>–<b>e</b>: (a) TZD, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 2 h (85%); (b) <i>t</i>BuOK, THF, rt, 30 min (60%); (c) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 16 h (68%); (d) 4 M HCl, dioxane, rt, 1 h (60%); (e) HCHO (for <b>12c</b>) or PhCHO (for <b>12d</b>), NaBH(OAc)<sub>3</sub>, AcOH, MeCN, rt, 3 h (56–90%); (f) AcCl, Et<sub>3</sub>N, DCM, rt, 3 h (62%). For the synthesis of <b>17a</b> and <b>17b</b>: (a) TZD, Mg(ClO<sub>4</sub>)<sub>2</sub>, DMF, 115 °C, 5 h (50%); (b) Dess–Martin reagent, DCM, 0 °C to rt, 12 h (70%); (c) <i>t</i>BuOK, THF, rt, 30 min; (d) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 30 min (25% over two steps); (e) 4 M HCl, dioxane, rt, 1 h (60%).</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0018.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of C(6)-substituted benzoxazolone carboxamides <b>22a</b>–<b>d</b> and <b>22i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-bromo-2-nitrophenol (for <b>19a</b>–<b>c</b>), 5-bromo-4-fluoro-2-nitrophenol (for <b>19d</b>), Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, dioxane, reflux, 18 h (56–90%); (b) H-Cube, Pd/C, EtOAc, rt, 1–2 h; (c) CDI, MeCN, 60 °C, 2 h (60–84% over two steps); (d) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 16 h (50–98%); (e) 4 M HCl, dioxane, rt, 3 h (86%); (f) AcCl, Et<sub>3</sub>N, THF, rt, 4 h (90%).</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0017.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of C(6)-substituted benzoxazolone carboxamides <b>22e</b>–<b>h</b> and <b>22j</b>–<b>p</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4 M HCl, dioxane, rt, 3 h; (b) RCHO, AcOH, NaBH(OAc)<sub>3</sub>, DCE, THF or MeCN, rt, 1–3 h (40% over two steps for <b>21i</b>, quant. For <b>21h</b>); (c) RNCO, DMAP, MeCN, rt, 2–16 h (50–73% for <b>22e</b>–<b>h</b>, <b>22k</b>, and <b>22p</b>); or RNH<sub>2</sub>, triphosgene, Et<sub>3</sub>N, DCM, 0 °C to rt, 2 h (45% for <b>22m</b>), or RNH<sub>2</sub>, Boc<sub>2</sub>O, DMAP, MeCN, rt, 1 h (24–40% for <b>22j</b>, <b>22l</b>, <b>22n</b>, and <b>22o</b>).</p></p></figure><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0016.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>22q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>,<i>N</i>-bis(trifluoromethanesulfonyl)aniline, Et<sub>3</sub>N, THF, 0 °C, 16 h (74%); (b) Pd(dppf)Cl<sub>2</sub>, [B<sub>2</sub>(pin)<sub>2</sub>], KOAc, dioxane, 70 °C, 3 h; (c) 2-(benzyloxy)-4-bromo-1-nitrobenzene, Na<sub>2</sub>CO<sub>3</sub> 2 M, 70 °C, 1 h (93% over two steps) (d) NaH, MeI, THF, 0 °C, 20 h (45%); (e) H<sub>2</sub>, 10% Pd/C, EtOH, rt, 1 h; (f) CDI, MeCN, rt, 1 h (70% over two steps); (g) 4-phenylbutyl isocyanate, DMAP, pyridine, rt, 16 h (90%).</p></p></figure><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>24c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-bromo-2-nitrophenol, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, dioxane, reflux, 2 h (95%); (b) 10% Pd/C, cyclohexene, MeOH, reflux, 4 h; (c) CDI, MeCN, rt, 3 h (60% over two steps); (d) isobutylamine, triphosgene, Et<sub>3</sub>N, DCM (70%); (e) 4 M HCl, dioxane (95%); (f) HCHO, NaBH(OAc)<sub>3</sub>, AcOH, MeCN, rt, 2 h (83%).</p></p></figure><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0014.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-benzyloxy-4-bromo-1-nitrobenzene, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane, reflux, 16 h (40%); (b) cyclohexene, Pd/C, MeOH, 70 °C, 2 h; (c) CDI, MeCN, rt, 16 h; (d) HCHO, NaBH(OAc)<sub>3</sub>, AcOH, MeCN, rt, 2 h (43% over three steps); (e) isobutylamine, triphosgene, Et<sub>3</sub>N, DCM, rt, 4 h (30%).</p></p></figure><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0013.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-bromo-2-nitrophenol, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane, reflux, 2 h (53%); (b) 10% Pd/C, cyclohexene, EtOH, 65 °C, 4 h; (c) CDI, MeCN, rt, 1 h (90% over two steps) (d) 4 M HCl, dioxane, rt, 30 min; (e) HCHO, NaBH(OAc)<sub>3</sub>, AcOH, MeCN, rt, 30 min (70% over two steps); (f) isobutylamine, triphosgene, Et<sub>3</sub>N, DCM, rt, 3 h (70%).</p></p></figure><figure id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0012.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of <b>22r</b> and <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: for the synthesis of <b>22r</b>: (a) 6-bromo-3<i>H</i>-1,3-benzoxazol-2-one, MeMgBr, <i>n</i>-BuLi, THF, −78 °C, 2 h (30%); (b) <i>p</i>-TsOH, toluene, reflux, 1 h (quant.); (c) H<sub>2</sub>, 10% Pd/C, MeOH, 60 °C, 2 h; (d) 4-phenylbutyl isocyanate, DMAP, pyridine (73% over two steps). For the synthesis of <b>25</b>: (a) 7-bromo-3<i>H</i>-1,3-benzoxazol-2-one, MeMgBr, <i>n</i>-BuLi, THF, −78 °C 1.5 h (44%); (b) <i>p</i>-TsOH, toluene, 90 °C, 3 h (quant.); (c) HCHO, NaBH(OAc)<sub>3</sub>, MeCN, rt, 16 h; (d) H<sub>2</sub>, Pd/C, MeOH, 40 °C, 2 h; (e) isobutylamine, triphosgene, Et<sub>3</sub>N, DCM (30% over three steps).</p></p></figure><figure id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0011.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of C(6)-substituted benzoxazolone carboxamides <b>23a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-fluoro-2-nitrophenol, DIPEA, MeCN, 60–80 °C, 15 h (40% for <b>49c</b>); (b) 10% Pd/C, cyclohexene, MeOH, reflux, 2–16 h; (c) CDI, MeCN, rt (or 50 °C for <b>49g</b>), 2 h (75–80% over three steps for <b>50a</b> and <b>50d</b>; 45–60% over two steps for <b>50b</b> and <b>50c</b>); (d) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 16 h (20–85%); (e) 4 M HCl, dioxane, rt, 3 h (quant.); (f) RCHO, AcOH, NaBH(OAc)<sub>3</sub>, DCE, THF or MeCN, rt, 2 h (60–90%); (g) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 16 h (30–75%).</p></p></figure><figure id="sch11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0010.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of <b>23j</b> and <b>23</b>k<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1-methylpiperazin-2-one (for <b>52a</b>), Et<sub>3</sub>N, MeCN, 80 °C, 16 h (60%); 4-methylpiperazin-2-one (for <b>52b</b>), CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i>,<i>N</i>-dimethyl-1,2-ethanediamine, dioxane, reflux, 24 h (50%); (b) 10% Pd/C, cyclohexene, EtOH, 65 °C, 16 h; (c) CDI, MeCN, rt, 1 h (70–80% over two steps); (d) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 16 h (10–20%).</p></p></figure><div class="NLM_p">We introduced cyclic and heterocyclic groups at C(5)-, C(6)-, and C(7)-positions of the benzoxazolone cores by exploring different synthetic pathways (<a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a>–<a class="ref internalNav" href="#sch11" aria-label="11">11</a>). The exploration at the C(4)-position of the benzoxazolone scaffold was abandoned because, in accordance with previously reported results on the 4-Me and 4-Ph derivatives of <b>2a</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> we experienced a pronounced chemical instability of our targeted C(4)-derivatives.</div><div class="NLM_p">The C(6)-substituted benzoxazolones <b>21a</b>–<b>d</b> were prepared in three steps starting from boronic esters <b>18a</b>–<b>c</b>, using Pd-catalyzed cross coupling reactions with the corresponding bromo-nitrophenols followed by hydrogenation and intramolecular cyclization in the presence of CDI (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). An additional step consisting of the in situ formation of boronic ester <b>29b</b>, from ketone <b>28</b> via enol triflate <b>29a</b>, was necessary for the preparation of the benzoxazolone <b>21l</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). A Pd-catalyzed cross coupling procedure was also used for the synthesis of the C(5)-substituted benzoxazolone <b>33</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>) and other C(6)-substituted benzoxazolones, such as <b>37a</b> and <b>41a</b> (<a class="ref internalNav" href="#sch7" aria-label="Schemes 7">Schemes 7</a> and <a class="ref internalNav" href="#sch8" aria-label="8">8</a>). In contrast, to overcome some synthetic problems in the Pd-catalyzed cross coupling reaction, we performed an alternative synthetic approach for the preparation of the benzoxazolone <b>21m</b> (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>A). Lithium-halogen exchange of 6-bromo-3<i>H-</i>1,3-benzoxazol-2-one<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> followed by the addition of the ketone <b>42a</b> afforded the alcohol <b>43</b>, which upon dehydration and hydrogenation led to the key intermediate <b>21m</b>. A similar synthetic procedure was applied to insert the functionalization at the C(7)-position of the benzoxazolone, as in <b>47</b> (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>B).</div><div class="NLM_p">Other C(6)-substituted benzoxazolones, for example, <b>23a</b>–<b>d</b> and <b>50j</b> (<a class="ref internalNav" href="#sch10" aria-label="Schemes 10">Schemes 10</a> and <a class="ref internalNav" href="#sch11" aria-label="11">11</a>), were prepared in three steps and in satisfactory yields using a nucleophilic aromatic substitution (SNAr)<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> reaction of activated fluoro-phenyls with a set of heterocyclic amines followed by hydrogenation and intramolecular cyclization reaction with CDI. An alternative approach was used for the synthesis of <b>50k</b> (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>). In this case, a Cu-catalyzed cross coupling <i>N</i>-arylation of <i>O</i>-Bn-protected bromo-nitrophenol <b>51b</b> with 4-methylpiperazin-2-one afforded <b>52b</b> in acceptable yield,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> which upon standard reactions led to the benzoxazolone <b>50k</b>.</div><div class="NLM_p last">Finally, the carboxamide functionalities were introduced under standard conditions, which involved the reaction of the benzoxazolone intermediates with the corresponding commercially available isocyanates, as in the preparation of <b>22a</b>–<b>c</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) and <b>23a</b>–<b>d</b> (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>). Alternatively, the isocyanates were prepared in situ, upon activation of the corresponding amines by reaction with Boc<sub>2</sub>O in the presence of DMAP in MeCN,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> as in the synthesis of <b>22j</b>, <b>22l</b>, <b>22n</b>, and <b>22o</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), or by reaction with triphosgene in the presence of Et<sub>3</sub>N in DCM,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> as in the synthesis of <b>22m</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44384" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44384" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The four most potent classes of AC inhibitors described to date are illustrated in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. Each class is defined by the presence of a common chemical warhead—the urea-like functionality—that can covalently react with the catalytic cysteine (Cys-143) of AC to form a thioester bond.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> It has been reported that carboxamides <b>2a</b><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and <b>4a</b>–<b>b</b><a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> form, upon incubation experiments with the protein, the corresponding cysteine adducts. This has recently been confirmed by Dementiev and co-workers, who described the crystal structural analysis of the uracil <b>1</b> covalently bound to Cys-143 at 2.7 Å resolution.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><div class="NLM_p">While potent and, in some cases, systemically active,<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> these molecules share two features that limit their use as oral drugs. First, the presence of a reactive warhead on the molecular scaffolds described to date contributes to their chemical and metabolic instability (e.g., uracil <b>1</b>),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and second, the hydrophobic linear side chain that ensures target recognition and some degree of specificity negatively affects their drug-likeness (e.g., benzoxazolone <b>2a</b>).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Thus, the need for optimized AC inhibitors remains an important issue to be addressed.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">As previously reported, preliminary structural modifications of <b>2a</b> by variation of the lateral side chain of the urea functionality (<i>Region A</i>) and substitution of the benzoxazolone moiety (<i>Region B</i>) led to the identification of <b>2b</b><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and <b>2c</b><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Despite good potency and enhanced drug-likeness compared to the previous uracil<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> series, compounds <b>2b</b> and <b>2c</b> suffer from low solubility in aqueous media and moderate chemical and metabolic stability that limit their utility as oral drugs.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> To address these issues, our lead optimization strategy focused on designing additional structural modifications on <i>Regions A</i> and <i>B</i> (compound <b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) with the aim of improving the physicochemical and metabolic properties while maintaining inhibitory potency.</div><figure id="fig3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0026.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibitory potencies (IC<sub>50</sub> in μM) of compounds <b>2d</b>–<b>g</b>, <b>8a</b>–<b>d</b>, <b>12b</b>–<b>e</b>, and <b>17b</b> on the activity of <i>h</i>AC expressed in HEK-293 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We initially investigated modifications of the lateral side chain (<i>Region A</i>) of <b>2c</b> confirming that, as previously reported with <b>2a</b> analogs,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> this region is involved in lipophilic interactions important for target recognition (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). In fact, different attempts to improve solubility and metabolic stability by reducing lipophilicity of the side chain were detrimental regarding potency (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Although the removal of the phenyl ring was tolerated, as for the <i>n</i>-pentyl analog <b>2e</b> (<i>h</i>AC IC<sub>50</sub> = 60 nM), no enhancement of solubility was observed (<1 μM, PBS, pH 7.4). Replacement of one methylene unit with an oxygen (e.g., ethers <b>2d</b>, <b>2f</b>, and <b>2g</b>) to increase the hydrophilicity significantly reduced the inhibitory potency to the μM range. A similar trend was observed for the corresponding analogs in the <b>2b</b> series (data not shown), indicating that the lipophilic side chain of the urea was very likely occupying a hydrophobic pocket.</div><div class="NLM_p">We then shifted our attention to the left-hand side (<i>Region B</i>) of the scaffold by evaluating the replacement of the benzoxazolone moiety with some bioisosteric 6 + 5 fused ring heterocyclic systems (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), alternative to those already reported by Ortega et al.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p">However, both the isatin analog <b>8c</b> and the oxindole analog <b>8d</b> were inactive at concentrations up to 10 μM. We then investigated the bioisosteric insertion of an aza-group in the phenyl ring of the benzoxazolone moiety, and this change resulted in very potent compounds. For example, compounds <b>8a</b> and <b>8b</b> gave <i>h</i>AC IC<sub>50</sub>’s of 6 and 3 nM, respectively, compared to the earlier compound <b>2a</b>,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> which has an <i>h</i>AC IC<sub>50</sub> of 64 nM. We envisaged that the insertion of a polar group on the left-hand side of the scaffold (<i>Region B</i>) could have an impact on the solubility of this series in aqueous buffer (PBS, pH 7.4), but, unfortunately, both <b>8a</b> and <b>8b</b> had very poor chemical stability in these conditions (<i>t</i><sub>1/2</sub> < 15 min).</div><div class="NLM_p">These findings prompted us to evaluate the inhibitory potency of the fused bicyclic derivatives <b>12b</b> and <b>17b</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). We speculated that changing the left-hand-side leaving group at the urea functionality could have an effect on the chemical stability of the scaffold. Although we generally observed a loss in potency to the sub-μM range, regardless of the substituent (<b>12b</b>–<b>e</b>) or the position of the nitrogen atom (<b>17b</b>), we were pleased to notice that, as for <b>12b</b> and <b>17b</b>, this novel class of <i>h</i>AC inhibitors showed improved chemical stability in PBS at pH 7.4 (<i>t</i><sub>1/2</sub> > 8 h) and improved aqueous solubility (82 and 230 μM, respectively). Despite the novel chemotype of these AC inhibitors with promising physicochemical properties, our attempts to improve the potency of this series were unsuccessful (data not shown). In addition, although these compounds exhibited high mouse plasma stability (e.g., <i>t</i><sub>1/2</sub> > 2 h, for <b>12b</b> and <b>17b</b>), this class of molecules also suffered from poor mouse liver microsomal stability (<i>t</i><sub>1/2</sub> < 15 min).</div><div class="NLM_p">Overall, these results confirmed the benzoxazolone moiety as a “privileged scaffold”, thus focusing our SAR strategy on <i>Region B</i> with the intention of reducing the lipophilicity by replacing the phenyl ring of <b>2c</b> at the C(6)-position with aliphatic heterocyclic rings (<b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). We envisaged that the reduction of the number of sp<sup>2</sup>-hybridized carbon atoms and the insertion of heteroatoms in this region could improve the overall physicochemical and metabolic stability of this class of inhibitors.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a></div><div class="NLM_p">We were pleased to observe that both the cyclohexyl analog <b>22a</b> and the tetrahydropyrane analog <b>22b</b> resulted in equipotent inhibition (<i>h</i>AC IC<sub>50</sub> = 0.089 and 0.068 μM, respectively) compared to the corresponding phenyl derivative <b>2c</b><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). With these results in hand, we were then interested in evaluating the effect of increasing the hydrophilicity by the addition of a polar basic amine, as in the piperidine analogs <b>22d</b> and <b>22e</b>. With this modification, we observed that both compounds showed only a slight loss of potency compared to the aliphatic analog <b>22a</b> (<i>h</i>AC IC<sub>50</sub> = 0.134 and 0.129 μM, respectively). Encouraged by these results, we explored the effect of other <i>N</i>-containing heterocyclic systems, such as the piperidine <b>23a</b>, the morpholine <b>23b</b>, the 1,1-dioxothiomorpholine <b>23c</b>, and the piperazines <b>23e</b> and <b>23f</b>. Overall, this set of compounds showed similar potency to the initial cyclohexyl analog <b>22a</b>. Notably, the piperidine <b>23a</b> and the piperazine <b>23f</b> were the most potent compounds, showing IC<sub>50</sub> values of 0.080 and 0.116 μM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Based on these promising results, we selected the piperidine and piperazine series, exemplified by <b>22d</b> and <b>23e</b>, respectively, as novel scaffolds for further studies, exploiting the presence of a distal nitrogen atom as an anchor point for additional structural modifications (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). First, we evaluated the SAR exploration around the piperidine series by introducing both linear and branched alkyl chains on the nitrogen atom, such as the ethyl <b>22f</b>, isopropyl <b>22g</b>, and isobutyl <b>22h</b> analogs (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In general, no significant differences were observed on the inhibitory potency of these derivatives, with <b>22f</b>–<b>h</b> almost being equipotent to the unsubstituted <b>22d</b>. Moreover, the removal of the basic center by the introduction of either an exocyclic (<b>22i</b>) or endocyclic <i>N</i>-acyl group (<b>22q</b>) was tolerated, showing IC<sub>50</sub> values of 0.064 and 0.105 μM, respectively. These results further confirmed that different polar groups were tolerated in this region of the scaffold.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Potencies of Compounds <b>22a</b>, <b>22b</b>, <b>22d</b>, <b>22e</b>, <b>23a</b>–<b>c</b>, <b>23e</b>, and <b>23f</b> on the Activity of <i>h</i>AC</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0009.gif" alt="" id="gr20" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0008.gif" alt="" id="gr21" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are the mean of at least three independent experiments, performed in three technical replicates.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibitory Potencies of Piperidines <b>22f</b>–<b>i</b> and <b>22q</b> and Piperazines <b>23g</b>–<b>k</b> on the Activity of <i>h</i>AC</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0007.gif" alt="" id="gr22" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0006.gif" alt="" id="gr23" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are the mean of at least three independent experiments performed in three technical replicates.</p></div></div><div></div></div><div class="NLM_p">The same strategy was applied to the piperazine series (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Specifically, both the <i>N</i>-alkyl derivatives <b>23g</b>–<b>i</b> and the piperazinones <b>23j</b> and <b>23k</b> resulted in more potent AC inhibition than the parent <b>23e</b>. For example, the <i>N</i>-ethyl piperazine <b>23g</b> and the piperazinone <b>23k</b> were almost 7-fold more potent than <b>23e</b> (<i>h</i>AC IC<sub>50</sub> = 0.363 μM), showing IC<sub>50</sub> values of 0.056 and 0.052 μM, respectively.</div><div class="NLM_p">However, a comparison of the piperazine and piperidine series in terms of aqueous kinetic solubility (PBS, pH 7.4) in vitro metabolism highlighted some significant differences (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Interestingly, the piperidine analogs, bearing small linear alkyl groups (<b>22d</b>–<b>f</b>), were highly soluble (kinetic solubility >100 μM) and, in some cases (<b>22d</b>), had acceptable stability profiles both in mouse plasma and in liver microsomes. On the other hand, the piperidine derivatives, bearing more sterically hindered lipophilic alkyl groups, such as the isopropyl <b>22g</b> and isobutyl <b>22h</b>, or the acyls <b>22i</b> and <b>22q</b> suffered from low solubility and, with the exception of <b>22h</b>, poor stability in mouse plasma (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Conversely, all the piperazine derivatives generally suffered from poor aqueous solubility and poor microsomal and plasma stability (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). As illustrative examples, the piperazines <b>23f</b> and <b>23g</b> showed poor solubility in water (<1 μM), rapid metabolism in liver microsomes, and poor plasma stability (<i>m</i>-plasma and <i>m</i>-liver microsomes, <i>t</i><sub>1/2</sub> < 5 min). Some improvement in microsomal stability was observed with the <i>des</i>-methylated <b>23e</b> and with <b>23k</b>, which bears a heterocyclic ring at a higher oxidative state compared to <b>23f</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Aqueous Kinetic Solubility and In Vitro Metabolism of Some Selected Compounds in the Piperidines <b>22d</b>–<b>i</b>, <b>22q</b> and Piperazines <b>23e</b>–<b>g</b>, <b>23j</b>, and <b>23k</b> Series</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">solubility (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (PBS, pH 7.4)</th><th class="colsep0 rowsep0" align="center" char="."><i>m-</i>plasma<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a><i>t</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center"><i>m-</i>LM<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a> <i>t</i><sub>1/2</sub> (min)[% at 60 min]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">piperidine series</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22d</b></td><td class="colsep0 rowsep0" align="char" char=".">150</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="left">>60 [70%]</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22e</b></td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="left">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22f</b></td><td class="colsep0 rowsep0" align="char" char=".">198</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="left">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22g</b></td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="left">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22h</b></td><td class="colsep0 rowsep0" align="char" char="."><1</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="left">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22i</b></td><td class="colsep0 rowsep0" align="char" char="."><1</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="left">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22q</b></td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="left">35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">piperazine series</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23e</b></td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="left">45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23f</b></td><td class="colsep0 rowsep0" align="char" char="."><1</td><td class="colsep0 rowsep0" align="char" char="."><5</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23g</b></td><td class="colsep0 rowsep0" align="char" char="."><1</td><td class="colsep0 rowsep0" align="char" char="."><5</td><td class="colsep0 rowsep0" align="left"><5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23j</b></td><td class="colsep0 rowsep0" align="char" char="."><1</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23k</b></td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="left"><5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Aqueous kinetic solubility in phosphate-buffered saline. Values are the mean of at least two independent experiments performed in two technical replicates.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Mouse plasma. Values are the mean of at least two independent experiments performed in two technical replicates.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Mouse liver microsomes. Values are the mean of at least two independent experiments performed in two technical replicates.</p></div></div></div><div class="NLM_p">With these results in hand, we focused our efforts on exploring <i>Regions A</i> and <i>B</i> of the <i>N</i>-methyl piperidine <b>22e</b>, as reported in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. In order to reduce the lipophilicity and improve metabolic stability of this scaffold, we followed different strategies: (a) insertion of a heteroatom, removal of the phenyl ring, and reduction of the side chain length (<i>Region A</i>); and (b) removal of potential metabolic soft spots (<i>Regions A</i> and <i>B</i>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Inhibitory Potencies of Piperidines <b>22j</b>–<b>p</b> and <b>22r</b> on the Activity of <i>h</i>AC and Aqueous Kinetic Solubility and In Vitro Metabolism of Some Selected Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0005.gif" alt="" id="gr24" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0004.gif" alt="" id="gr25" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are the mean of at least three independent experiments performed in three technical replicates.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Aqueous kinetic solubility in phosphate-buffered saline. Values are the mean of at least two independent experiments performed in two technical replicates.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Mouse plasma. Values are the mean of at least two independent experiments performed in two technical replicates.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Mouse liver microsomes. Values are the mean of at least two independent experiments performed in two technical replicates.</p></div></div><div></div></div><div class="NLM_p">An immediate loss in potency was observed with the removal of the lipophilic phenyl ring (<b>22 k</b>) or the insertion of an oxygen on the lateral chain (<b>22j</b> and <b>22l</b>), while the bioisosteric replacement of a fluorine on the distal phenyl ring resulted in <b>22o</b>, being almost equipotent to <b>22e</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Nonetheless, exploration of <i>Region A</i> continued with the insertion of branched alkyl groups. We were pleased that the isobutyl analog <b>22m</b> (<i>h</i>AC IC<sub>50</sub> = 0.166 μM) was equipotent to the corresponding butyl phenyl <b>22e</b>, demonstrating that it was possible to remove the phenyl group and reduce the overall lipophilicity without compromising potency. On the other hand, a methyl group adjacent to the urea functionality, such as the <i>sec</i>-butyl analog <b>22n</b>, was detrimental for potency, with an IC<sub>50</sub> of 2.1 μM. Moving the SAR exploration back to <i>Region B</i>, insertion of a fluorine on the benzoxazolone ring <b>22p</b> boosted the inhibitory potency (IC<sub>50</sub> = 0.024 μM), while the difluoroethyl analog <b>22r</b> showed similar potency (IC<sub>50</sub> = 0.095 μM) to <b>22e</b>. The kinetic aqueous solubility and in vitro metabolic stability of a selection of compounds in the piperidine series are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. Notably, while the insertion of an oxygen did not affect either the solubility or metabolic stability in microsomes of <b>22j</b> compared to <b>22e</b>, reducing lipophilicity with small aliphatic groups (<b>22k</b> and <b>22m</b>) was particularly beneficial. For example, <b>22k</b> and <b>22m</b> showed high aqueous solubility (240 μM) and improved plasma and liver microsomal stabilities (<i>t</i><sub>1/2</sub> > 60 min). On the other hand, attempts to improve the liver microsomal stability of <b>22e</b> by inserting a fluorine atom at different potential metabolic soft spots of both <i>Regions A</i> and <i>B</i> (compounds <b>22o</b>, <b>22p</b>, and <b>22r</b>) were not successful. Not surprisingly, these bioisosteric replacements negatively affected the aqueous solubilities of <b>22o</b>, <b>22p</b>, and <b>22r</b>, without a substantial improvement of the metabolic stability in microsomes.</div><div class="NLM_p">With these results in hand, SAR studies continued on the scaffold of compound <b>22m</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Specifically, we evaluated the effect of the location of both the <i>N-methyl piperidine ring</i>, at C(5)- and C(7)-positions of the benzoxazolone moiety (compounds <b>24c</b> and <b>25</b>), and the <i>N-methylated nitrogen atom</i>, within the piperidine nucleus (compounds <b>26</b> and <b>27</b>). Overall, we generally observed a loss in the inhibitory potency of these targeted analogs compared to <b>22m</b>, which was even more pronounced with compounds <b>26</b> and <b>27</b>, showing IC<sub>50</sub> values in the μM range. Finally, the evaluation of the kinetic aqueous solubility and in vitro metabolism of <b>22m</b> and close analogs was completed (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In general, all the targeted compounds showed high solubility values in aqueous media, except for <b>24c</b>, which bears the piperidine ring at the C(5)-position of the benzoxazolone system. On the other hand, major differences were observed comparing their metabolic stability properties. In particular, we observed that substitution at the C(6)-position was critical to maintaining acceptable mouse plasma and liver microsomal stabilities (compound <b>22m</b>, <i>m</i>-plasma <i>t</i><sub>1/2</sub> = 80 min and <i>m</i>-liver microsomes <i>t</i><sub>1/2</sub> > 60 min (76% remaining at 1 h)). On the other hand, both derivatives with the piperidine ring at the C(5)- and C(7)-positions, <b>24c</b> and <b>25</b> showed reduced mouse plasma and liver microsomal stability. A similar trend was observed by moving the nitrogen atom to a different position on the piperidine ring, except for <b>27</b>, which showed a similar liver microsomal stability to <b>22m</b>. Due to its inhibitory potency and improved overall drug-likeness profile, the piperidine <b>22m</b> was selected for further biological and pharmacological investigations.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Inhibitory Potencies of Compounds <b>24c</b> and <b>25</b>–<b>27</b> on <i>h</i>AC and Aqueous Kinetic Solubility and In Vitro Metabolism</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0003.gif" alt="" id="gr26" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0002.gif" alt="" id="gr27" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are the mean of at least three independent experiments performed in three technical replicates.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Aqueous kinetic solubility in phosphate-buffered saline. Values are the mean of at least two independent experiments performed in two technical replicates.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Mouse plasma. Values are the mean of at least two independent experiments performed in two technical replicates.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Mouse liver microsomes. Values are the mean of at least two independent experiments performed in two technical replicates.</p></div></div><div></div></div><div class="NLM_p">We first envisaged that the inhibition of <b>22m</b>, belonging to the same class of the benzoxazolone carboxamide <b>2c</b>,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> should occur through the same covalent AC modification. According to our hypothesis, the corresponding benzoxazolone <b>21g</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), tested at 1 and 10 μM, was not able to inhibit <i>h</i>AC due to the lack of the reactive urea-like functionality. Moreover, kinetic studies on <i>h</i>AC-enriched lysates showed that <b>22m</b> causes a concentration-dependent reduction in the maximal catalytic velocity of AC (<i>V</i><sub>max</sub>) without influencing the Michaelis–Menten constant (<i>K</i><sub>M</sub>) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B and <a href="/doi/suppl/10.1021/acs.jmedchem.9b02004/suppl_file/jm9b02004_si_001.pdf" class="ext-link">Table S1</a>) and time-dependent inhibition at different <b>22m</b> concentrations with <i>k</i><sub>i</sub>/<i>K</i><sub>I</sub> = 0.02 μM<sup>–1</sup> min<sup>–1</sup> and <i>k</i><sub>i</sub> = 0.15 min<sup>–1</sup> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C,D), suggesting a very fast covalent bond formation to the enzyme.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a></div><figure id="fig4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0025.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Concentration–response curve for inhibition of <i>h</i>AC activity by <b>22m</b>; (B) Michaelis–Menten analysis of the reaction of <i>h</i>AC in the presence of vehicle (DMSO 1%, ●) or <b>22m</b> (100 nM, ▲; 400 nM, ■). Rbm 14–12: fluorogenic substrate of <i>h</i>AC; (C) time-dependent inhibition of <i>h</i>AC by <b>22m</b> (two independent experiments, each performed in two technical replicates); (D) determination of kinetic parameter <i>k</i><sub>i</sub>/<i>K</i><sub>I</sub> of <b>22m</b> (two independent experiments, each performed in two technical replicates).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The selectivity of <b>22m</b> was evaluated against a set of related lysosomal enzymes. The compound showed only a weak inhibitory effect (IC<sub>50</sub> = 8.0 μM) on human <i>N</i>-acylethanolamine acid amidase (<i>h</i>NAAA), a lysosomal cysteine amidase that shares 33–34% sequence identity and a very similar reactive site to AC.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a><b>22m</b> had no effect at the concentrations tested (1 and 10 μM) on the activity of either acid sphingomyelinase (ASM) and GCase. We next assessed the selectivity of <b>22m</b> against two of the most representative members of serine hydrolases, human fatty acid amide hydrolyase (FAAH)<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and monoacylglycerol lipase (MAGL):<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a><b>22m</b> showed inhibitory activity on FAAH with an IC<sub>50</sub> of 0.070 μM and no effect on monoacylglycerol lipase (MAGL) at the concentrations tested (1 and 10 μM). Although off-target activity of <b>22m</b> against FAAH is observed, to our knowledge, no evidence for biological cross-talk between the sphingolipid-signaling pathways<sup>2</sup> and the FAAH-signaling pathway<a onclick="showRef(event, 'ref55 ref57'); return false;" href="javascript:void(0);" class="ref ref55 ref57">(55,57)</a> has been reported that could preclude further development of <b>22m</b>.</div><div class="NLM_p">The favorable overall profile of <b>22m</b> prompted us to test its ability to inhibit AC in intact cells. Human neuroblastoma SH-SY5Y cells were incubated in the presence of <b>22m</b> at different doses (1, 2.5, 5, and 10 μM). AC activity was measured with a liquid chromatography/mass spectrometry (LC/MS)-based activity assay after different incubation times (30 min, 1 h, 3 h, and 6 h), and SphL levels were identified and quantified by LC/MS, showing that <b>22m</b> effectively engages AC in these cells leading to the expected variations in the SphL levels, as reported in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>. Treatment of cultures of human neuroblastoma SH-SY5Y cells with <b>22m</b> caused a concentration- (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A) and time-dependent reduction of AC activity (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). After 3 h of incubation, this effect resulted in an intracellular accumulation of various ceramide species, including Cer (d18:0/16:0) and Cer (d18:1/16:0) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B,C) and a corresponding decrease in the levels of sphingosine (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D) in a concentration-dependent manner. The effect of <b>22m</b> (10 μM) on AC activity inhibition and SphL persisted for up to 6 h under our experimental conditions (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B–D). The results indicated that <b>22m</b> inhibits AC in the complex cellular environment leading to an increased Cer (d18:0/16:0) and Cer (d18:1/16:0) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B,C) and decreased sphingosine levels with a partial recovery of sphingosine levels after 3–6 h (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D). Conversely, as expected, no major variations were observed in the levels of sphingomyelin (SM) (d18:1/16:0) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>E) and hexosylceramide (HexCer) (d18:1/16:0) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>F and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>F).</div><figure id="fig5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0024.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of <b>22m</b> in SH-SY5Y cells after a 3 h of incubation. Concentration dependence of the effects on AC activity (A) and sphingolipid levels (B–F). GraphPad Prism software (GraphPad Software, Inc., USA) was used for statistical analysis. Data were analyzed using the Student <i>t</i> test or one-way ANOVA followed by the Bonferroni post hoc test for multiple comparisons. Differences between groups were considered statistically significant at values of <i>p</i> < 0.05. Values are expressed as means ± S.E.M of at least six determinations. Experiments were repeated twice with similar results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0023.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Time course of the effects of <b>22m</b> (10 μM) in SH-SY5Y cells on AC activity (A) and sphingolipid levels (B–F). GraphPad Prism software (GraphPad Software, Inc., USA) was used for statistical analysis. Data were analyzed using the Student <i>t</i> test or one-way ANOVA followed by the Bonferroni post hoc test for multiple comparisons. Differences between groups were considered statistically significant at values of <i>p</i> < 0.05. Values are expressed as means ± S.E.M of at least six determinations. Experiments were repeated twice with similar results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pharmacokinetic studies of <b>22m</b> were determined in CD1 mice, and relevant pharmacokinetic parameters are reported in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Values of plasma clearance (Cl<sub>p</sub>), volume of distribution (Vd<sub>ss</sub>), and plasma half-life (<i>t</i><sub>1/2</sub>) were calculated after intravenous administration of <b>22m</b> at 3 mg kg<sup>–1</sup>. Clearance was moderately high (14.1 L h<sup>–1</sup> kg<sup>–1</sup>), with a relatively short plasma half-life (1 h) and high Vd<sub>ss</sub> (12.5 L kg<sup>–1</sup>) indicating that <b>22m</b> well distributed out of the circulating plasma compartment. Good oral bioavailability was observed dosing <b>22m</b> at 10 mg kg<sup>–1</sup> (<i>F</i> = 58%), with significant exposures in plasma, brain, and cerebrospinal fluid (CSF) (AUC values = 412, 14648, and 119 (h × ng mL<sup>–1</sup>), respectively). A maximum tolerated dose (MTD) study in mice was also conducted in the same background as the pharmacodynamic model using C57BL/6 mice at intraperitoneal dose escalation of 20, 40, 80, and 120 mg kg<sup>–1</sup> in the time range of 4 days, and no clinical abnormalities were observed in any animals within the doses and time range used.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Properties of <b>22m</b> after Intravenous (A, 3 mg kg<sup>–1</sup>, <i>N</i> = 18) and Oral Administration (B, 10 mg kg<sup>–1</sup>, <i>N</i> = 18) in Male CD1 Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" char="." /></col><col align="center" char="." /></col><col align="center" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center">A</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter (3mpk, i.v.)</th><th class="colsep0 rowsep0" align="center" char=".">plasma</th><th class="colsep0 rowsep0" align="center" char=".">brain</th><th class="colsep0 rowsep0" align="center" char=".">CSF</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="center" char=".">-</td><td class="colsep0 rowsep0" align="center" char=".">0.250</td><td class="colsep0 rowsep0" align="center" char=".">0.250</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng mL<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="center" char=".">-</td><td class="colsep0 rowsep0" align="center" char=".">6443</td><td class="colsep0 rowsep0" align="center" char=".">71.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center" char=".">1.26</td><td class="colsep0 rowsep0" align="center" char=".">1.01</td><td class="colsep0 rowsep0" align="center" char=".">0.661</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (L h<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="center" char=".">14.1</td><td class="colsep0 rowsep0" align="center" char=".">-</td><td class="colsep0 rowsep0" align="center" char=".">-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vd<sub>ss</sub> (L kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="center" char=".">12.5</td><td class="colsep0 rowsep0" align="center" char=".">-</td><td class="colsep0 rowsep0" align="center" char=".">-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (h × ng mL<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="center" char=".">212</td><td class="colsep0 rowsep0" align="center" char=".">10128</td><td class="colsep0 rowsep0" align="center" char=".">77.8</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="center" char="." /></col><col align="center" char="." /></col><col align="center" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center">B</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter (10mpk, p.o.)</th><th class="colsep0 rowsep0" align="center" char=".">plasma</th><th class="colsep0 rowsep0" align="center" char=".">brain</th><th class="colsep0 rowsep0" align="center" char=".">CSF</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="center" char=".">0.5</td><td class="colsep0 rowsep0" align="center" char=".">1.00</td><td class="colsep0 rowsep0" align="center" char=".">1.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng mL<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="center" char=".">216</td><td class="colsep0 rowsep0" align="center" char=".">6900</td><td class="colsep0 rowsep0" align="center" char=".">52.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center" char=".">1.03</td><td class="colsep0 rowsep0" align="center" char=".">1.18</td><td class="colsep0 rowsep0" align="center" char=".">1.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (h × ng mL<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="center" char=".">412</td><td class="colsep0 rowsep0" align="center" char=".">14648</td><td class="colsep0 rowsep0" align="center" char=".">119</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="center" char=".">58.3</td><td class="colsep0 rowsep0" align="center" char=".">-</td><td class="colsep0 rowsep0" align="center" char=".">-</td></tr></tbody></table></div></div><div class="NLM_p">Based on these results, we decided to study the effect of dosing <b>22m</b> in 4L;C* mice, a validated genetic mutated animal model for neuropathic GD.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> 4L;C* mice have a marked increase (20- to 30-fold) of GluSph and moderate elevation (1.5- to 3-fold) of GluCer in the brain; therefore, they are a unique model suitable for testing GluSph reduction therapy. <b>22m</b> was administered at selected doses of 30 and 90 mg kg<sup>–1</sup> by intraperitoneal injection (i.p.) once a day for 14 days starting at postnatal day 5. Preliminary results showed that compound <b>22m</b> significantly reduces GluSph (d18:1) in the brain of 4L;C* mice in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Target engagement was demonstrated at a high dose of 90 mg kg<sup>–1</sup> with 54% reduction of the GluSph levels relative to control.</div><figure id="fig7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0022.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose response reduction of brain levels of GluSph (d18:1) after intraperitoneal injection of <b>22m</b> at 30 and 90 mg kg<sup>–1</sup> in 4L;C* mice (<i>N</i> = 4–8 with mixed males and females for each group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we evaluated <b>22m</b> in the Twitcher mouse, an animal model of Krabbe’s disease. The Twitcher mice naturally carry a GALC mutation that contains a premature stop codon in GALC and leads to a complete loss of GALC activity. As a result, a dramatic increase of the extremely toxic lipid GalSph is observed in Twitcher mouse brains. After i.p. administration at 30 and 90 mg kg<sup>–1</sup> once daily for a treatment period of 20 days starting at postnatal day 10, <b>22m</b> showed dose-dependent reduction of the toxic lipid GalSph (d18:1) levels in the brains of Twitcher mice by 72 and 41% at high and low doses, respectively (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0021.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dose response reduction of brain levels of GalSph (d18:1) after intraperitoneal injection of <b>22m</b> at 30 and 90 mg kg<sup>–1</sup> in Twitcher (Twi) mice (<i>N</i> = 3 males + <i>N</i> = 3 females for each group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the group of 4L;C* mice at 90 mg kg<sup>–1</sup> doses, the unbound drug level in the brain 1 h post last dose (day 14) is 2.6 μM (6.4-fold higher than the EC<sub>50</sub> value) (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), while at a lower dose of 30 mg kg<sup>–1</sup>, the unbound drug level is 0.77 μM (1.9-fold higher than the EC<sub>50</sub> value). In the group of Twitcher mice at 90 mg kg<sup>–1</sup> doses, the unbound drug level in the brain 1 h post last dose (day 20) is 2.15 μM (5.2-fold higher than the EC<sub>50</sub> value), while at a lower dose of 30 mg kg<sup>–1</sup>, the unbound drug level is 0.80 μM (2.0-fold higher than the EC<sub>50</sub> value). Overall, these data support the observed dose responses in the two animal models.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Plasma and Brain Concentrations of <b>22m</b> in 4L;C* and Twitcher Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Fp, u (%)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Fb, u (%)<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">mouse model</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">Cp (μM)<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">Cp,u (μM)<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">Cb (μM)<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">Cb, u (μM)<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">0.410 ± 0.100</td><td class="colsep0 rowsep0" rowspan="4" align="left">13.8</td><td class="colsep0 rowsep0" rowspan="4" align="left">0.70</td><td class="colsep0 rowsep0" rowspan="2" align="left">4L;C*<a class="ref internalNav" href="#t7fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">16.81</td><td class="colsep0 rowsep0" align="char" char=".">2.32</td><td class="colsep0 rowsep0" align="char" char=".">373.34</td><td class="colsep0 rowsep0" align="char" char=".">2.61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">3.08</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">110.12</td><td class="colsep0 rowsep0" align="char" char=".">0.77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">Twitcher<a class="ref internalNav" href="#t7fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">3.85</td><td class="colsep0 rowsep0" align="char" char=".">0.52</td><td class="colsep0 rowsep0" align="char" char=".">307.92</td><td class="colsep0 rowsep0" align="char" char=".">2.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">0.85</td><td class="colsep0 rowsep0" align="char" char=".">0.11</td><td class="colsep0 rowsep0" align="char" char=".">114.50</td><td class="colsep0 rowsep0" align="char" char=".">0.80</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">EC<sub>50</sub> value as a mean of two independent experiments, each performed in two technical replicates. Primary fibroblast cells from Krabbe’s disease patients were incubated with <b>22m</b> for 2 h at different concentrations.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Fp, u: plasma fraction unbounded. Values are the mean of two technical replicates.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Fb, u: brain fraction unbounded. Values are the mean of two technical replicates.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">Cp: plasma concentration.</p></div><div class="footnote" id="t7fn5"><sup><sup>e</sup></sup><p class="last">Cp, u: plasma unbounded concentration.</p></div><div class="footnote" id="t7fn6"><sup><sup>f</sup></sup><p class="last">Cb: brain concentration.</p></div><div class="footnote" id="t7fn7"><sup><sup>g</sup></sup><p class="last">Cb, u: brain unbounded concentration.</p></div><div class="footnote" id="t7fn8"><sup><sup>h</sup></sup><p class="last">4L;C* mice were sacrificed 1 h after the last doses (day 14), and the compound <b>22m</b> levels were measured in plasma and brain (<i>N</i> = 4–8 with mixed males and females).</p></div><div class="footnote" id="t7fn9"><sup><sup>i</sup></sup><p class="last">Twitcher mice were sacrificed 1 h after the last doses (day 20), and the compound <b>22m</b> levels were measured in plasma and brain (<i>N</i> = 3 males + <i>N</i> = 3 females for each group).</p></div></div></div><div class="NLM_p">To our knowledge, this is the first report showing the efficacy of inhibiting AC on reducing the neurotoxic lipids GluSph in the brains of 4L;C* mice. Our result that inhibiting AC reduces neurotoxic lipid GalSph levels in the brains of Twitcher mice is consistent with the recent report.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p last">Further pharmacological studies of <b>22m</b> will be reported in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00332" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00332" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The present work outlines the lead optimization studies of a class of benzoxazolone carboxamides as AC inhibitors. We further extended the preliminary studies around <b>2b</b> (and <b>2c</b>)<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> and performed a focused structure–activity relationship (SAR) study on <i>Regions A</i> and <i>B</i> of this scaffold with the aim of improving the physicochemical and metabolic properties of the series while maintaining the inhibitory potency. Introduction of different heterocyclic groups on the benzoxazolone moiety was tolerated regarding inhibitory potency, as for the tetrahydropyrane <b>22b</b>, the piperidines <b>22d</b> and <b>23a</b>, and the piperazines <b>23e</b> and <b>23f</b>. A more focused exploration around <b>22d</b> and <b>23e</b> by changing the nature of substitution on the distal nitrogen atom led to the identification of novel potent analogs with improved solubility, for example, the piperidines <b>22e</b> and <b>22f</b>. Targeted modifications on different positions of <i>Regions A</i> and <i>B</i> of the <i>N</i>-methylated piperidine series led to compound <b>22m</b> as a potent and oral bioavailable AC inhibitor with excellent brain penetration in mice. Preliminary results demonstrated target engagement of <b>22m</b> both in the 4L;C* and Twitcher mouse models where dose-dependent reductions in GluSph and GalSph were observed, supporting that further optimized AC inhibitors may be used in the correction of severe pathological neurological states of LSD where these toxic lipids may play a significant role in the pathology, such as GD and KD.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23265" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23265" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Chemicals, Materials, and Methods</h3><div class="NLM_p last">Solvents and reagents were obtained from commercial suppliers and were used without further purification. Automated column chromatography purifications were done using a Teledyne ISCO apparatus (CombiFlash Rf) with prepacked SiO<sub>2</sub> columns of different sizes (from 4 to 40 g). Mixtures of increasing polarity of Cy and EtOAc or DCM and MeOH were used as eluents. TLC analyses were performed using a Supelco on TLC Al foils 0.2 mm with a fluorescence indicator at 254 nm. Purifications of basic compounds were done using an IST ISOLUTE SCX packed into SPE cartridges (SCX). Hydrogenation reactions were performed using H-Cube continuous hydrogenation equipment (SS-reaction line version), employing disposable catalyst cartridges (CatCart) preloaded with the required heterogeneous catalyst. Microwave heating was performed using an Explorer-48 positions instrument (CEM). NMR experiments of all the intermediates and final compounds were run on a Bruker Avance III 400 system (400.13 MHz for <sup>1</sup>H and 100.62 MHz for <sup>13</sup>C) equipped with a BBI probe and Z-gradients. Spectra were acquired at 300 K using deuterated dimethylsulfoxide (DMSO-<i>d</i><sub>6</sub>) or deuterated chloroform (CDCl<sub>3</sub>) as solvent. Chemical shifts for <sup>1</sup>H and <sup>13</sup>C spectra were recorded in parts per million using the residual non-deuterated solvent as the internal standard (for DMSO-<i>d</i><sub>6</sub>: 2.50 ppm, <sup>1</sup>H; 39.52 ppm, <sup>13</sup>C; for CDCl<sub>3</sub>: 7.26 ppm, <sup>1</sup>H and 77.16 ppm, <sup>13</sup>C). Data are reported as follows: chemical shift (ppm), multiplicity (indicated as bs, broad singlet; s, singlet; d, doublet; t, triplet; q, quartet; p, quintet, sx, sextet; m, multiplet, and combinations thereof), coupling constants (<i>J</i>) in hertz (Hz), and integrated intensity. Quantitative <sup>1</sup>H-NMR analyses of the freshly prepared 10 mM DMSO-<i>d</i><sub>6</sub> stock solutions (used for biological screenings) of the final compounds were performed using the PULCON method (PUlse Length based CONcentration determination, Bruker software, topspin 3.0. References: (a) Wider G., Reires L. <i>J. Am. Chem. Soc</i>. <b>2006</b>, <i>128</i> (8), 2571–2576; (b) Burton I. W., Quilliam M. A., Valter J. A., <i>Anal. Chem</i>. <b>2005</b>, <i>77</i>, 3123–3131). UPLC/MS analyses of all the intermediates and final compounds were performed on a Waters ACQUITY UPLC/MS system consisting of a Single Quadrupole Detector (SQD) Mass Spectrometer (MS) equipped with an Electrospray Ionization (ESI) interface and a Photodiode Array Detector (PDA). The PDA range was 210–400 nm. Analyses were performed on an ACQUITY UPLC BEH C18 column (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C18 precolumn (5 × 2.1 mm ID, particle size 1.7 μm). The mobile phase was 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O at pH 5 adjusted with AcOH (A) and 10 mM NH<sub>4</sub>OAc in MeCN/H<sub>2</sub>O (95:5) at pH 5 (B). ESI in both positive and negative modes was used in the mass scan range of 100–650 Da. Analyses were performed with <i>method A</i>, <i>B</i>, <i>C</i>, or <i>D</i>. <i>Method A</i>: gradient 5 to 95% B over 2.5 min. Flow rate 0.5 mL min<sup>–1</sup>. Temperature 40 °C. <i>Method B</i>: gradient 50 to 100% B over 2.5 min. Flow rate 0.5 mL min<sup>–1</sup>. Temperature 40 °C. <i>Method C</i>: gradient 0 to 100% B over 2.5 min. Flow rate 0.5 mL min<sup>–1</sup>. Temperature 40 °C. <i>Method D</i>: isocratic 55% B over 5 min. Flow rate 0.5 mL min<sup>–1</sup>. Temperature 40 °C. UPLC/MS analyses of the final compounds were performed with <i>method E</i> or <i>F</i> using freshly prepared 10 mM DMSO-<i>d</i><sub>6</sub> stock solutions (used for biological screenings), diluted 20-fold or 100 fold in MeCN/H<sub>2</sub>O (1:1), and directly analyzed. An ACQUITY UPLC BEH C18 (100 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C18 precolumn (5 × 2.1 mm ID, particle size 1.7 μm) was used. The mobile phase was 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O at pH 5 adjusted with AcOH (A) and 10 mM NH<sub>4</sub>OAc in MeCN/H<sub>2</sub>O (95:5) at pH 5 (B). ESI in both positive and negative modes was used in the mass scan range of 100–650 Da. <i>Method E</i>: gradient: 10 to 90% B over 6 min. Flow rate 0.5 mL min<sup>–1</sup>. Temperature 40 °C. <i>Method F</i>: gradient: 50 to 100% B over 6 min. Flow rate 0.5 mL min<sup>–1</sup>. Temperature 40 °C. The detection wavelength (λ) was set at 215 nm for relative purity determination. <i>R<sub>t</sub></i> of the final compounds are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.9b02004/suppl_file/jm9b02004_si_001.pdf" class="ext-link">Table S2</a>. Accurate mass measurements were performed on a Synapt G2 Quadrupole-ToF Instrument (Waters, USA) equipped with an ESI ion source; compounds were diluted to 50 μM in H<sub>2</sub>O/MeCN and analyzed. Leucine enkephalin (2 ng mL<sup>–1</sup>) was used as a lock mass reference compound for spectral recalibration. All final compounds displayed ≥95% purity as determined by NMR and UPLC/MS analysis.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure for Palladium-Catalyzed Cross Coupling Reaction (Procedure A)</h3><div class="NLM_p last">To a solution of the appropriate phenyl bromide (1.0 equiv.) in dry 1,4-dioxane (0.5 M, previously degassed under a nitrogen atmosphere) was added the appropriate boronic acid or its corresponding boronic ester (1.1 equiv.) followed by the addition of Pd(PPh<sub>3</sub>)<sub>4</sub> or Pd(dppf)Cl<sub>2</sub> (0.05–0.2 equiv.) and 2 M Na<sub>2</sub>CO<sub>3</sub> (2.5 equiv.). The dark reaction mixture was stirred at reflux for 15 h, then diluted with EtOAc, and filtered through a pad of Celite. The filtrate was concentrated under reduced pressure, and the crude was purified by column chromatography, eluting with Cy/EtOAc as indicated in each case.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure for Catalytic Hydrogenation Reaction (Procedure B)</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Method A</h4><div class="NLM_p last">To a suspension of the appropriate 2-nitrophenol (1.0 equiv.) in MeOH, EtOH, or EtOAc (0.4 M) were added 10% Pd/C (0.25 equiv.) and cyclohexene (30 equiv.), and the reaction mixture was stirred at reflux until the disappearance of the starting material, as indicated by UPLC/MS analysis. The suspension was filtered through a pad of Celite, and the filtrate was quickly evaporated under reduced pressure. The crude was used in the next step without further purification.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Method B</h4><div class="NLM_p last">A suspension of the appropriate 2-nitrophenol (1.0 equiv.) in MeOH (0.4 M) was hydrogenated with the H-Cube apparatus using 10% Pd/C at 60 °C and full H<sub>2</sub> mode. After complete conversion (UPLC/MS analysis monitoring), the solvent was evaporated under reduced pressure. The crude was used in the next step without further purification.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedure for Intramolecular Cyclization Using CDI (Procedure C)</h3><div class="NLM_p last">To a solution of the appropriate 2-aminophenol (1.0 equiv.) in MeCN (0.1 M) was added CDI (1.0–1.5 equiv.). The reaction mixture was stirred at rt for 2 h. Then the solvent was evaporated under reduced pressure, and the crude was redissolved in EtOAc, washed with H<sub>2</sub>O and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by column chromatography, eluting with Cy/EtOAc or DCM/MeOH, or used in the next step without further purification, as indicated in each case.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure for Carboxamide Synthesis (Procedure D)</h3><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Method A</h4><div class="NLM_p last">To a stirred solution of the appropriate oxazolone (1.0 equiv.) and DMAP (1.1 equiv.) in dry MeCN was added the appropriate isocyanate (1.1–3.0 equiv.). The reaction mixture was stirred at rt for 30 min under a nitrogen atmosphere. After evaporation of the solvent, the crude was purified by column chromatography, eluting with Cy/EtOAc or DCM/MeOH as indicated in each case.</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Method B</h4><div class="NLM_p last">To a stirred solution of triphosgene (0.33 equiv.) in dry DCM (0.2 M) were added the appropriate amine (1.5–3.0 equiv.) and dry Et<sub>3</sub>N (3.0 equiv.) at −15 °C. The resulting mixture was stirred at rt for 30 min under a nitrogen atmosphere and then added to a solution of the appropriate oxazolone (1.0 equiv.) and Et<sub>3</sub>N (1.0 equiv.) in dry DCM. The reaction mixture was stirred at rt for 30 min under nitrogen and then diluted with DCM. The organic phase was washed with saturated aqueous NH<sub>4</sub>Cl solution and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by column chromatography, eluting with Cy/EtOAc or DCM/MeOH, as indicated in each case.</div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Method C</h4><div class="NLM_p last">To a stirred solution of Boc<sub>2</sub>O (2.0 equiv.) in MeCN (0.4 M) were added DMAP (2.0 equiv.) and the appropriate amine (2.0 equiv.). The resulting solution was stirred at rt for 10 min, then the appropriate oxazolone derivative (1.0 equiv.) was added, and the mixture was stirred at rt for 1 h. After evaporation of the solvent, the crude was purified by flash column chromatography, eluting with Cy/EtOAc or DCM/MeOH, as indicated in each case.</div></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> General Procedure for N-Boc Removal (Procedure E)</h3><div class="NLM_p last">To a suspension of the appropriate N-Boc-protected derivative (1.0 equiv.) in 1,4-dioxane or DCM (0.1 M) was added HCl (30 equiv., 4 M in 1,4-dioxane), and the reaction mixture was stirred at rt for 2 h. After evaporation of the solvent, the crude was triturated with Et<sub>2</sub>O or used in the next step without further purification, as indicated in each case.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> General Procedure for Reductive Amination Reaction (Procedure F)</h3><div class="NLM_p last">To a solution of the appropriate secondary amine (1.0 equiv.) in MeCN or THF (0.1 M) were added the appropriate aldehyde or ketone (1.6–5.0 equiv.), AcOH (1.6–5.0 equiv.), and NaBH(OAc)<sub>3</sub> (1.6–3.0 equiv.). The mixture was stirred at rt for 2–16 h under a nitrogen atmosphere. Then the reaction mixture was poured into saturated aqueous NaHCO<sub>3</sub> solution and extracted with EtOAc. The organic phase was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by SCX.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> General Procedure for Nucleophilic Aromatic Substitution Reaction (SNAr) (Procedure G)</h3><div class="NLM_p last">To a solution of the appropriate 4-fluoronitrobenzene (1.0 equiv.) in MeCN were added the appropriate amine (2.0 equiv.) and DIPEA (2.0 equiv.). The reaction mixture was refluxed (or stirred under MW irradiation, 90 °C, power 200 W) until the disappearance of the starting material, as indicated by UPLC/MS analysis. After evaporation of the solvent, the crude was purified by flash column chromatography, eluting with Cy/EtOAc or DCM/MeOH, as indicated in each case.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> General Procedure for Intramolecular Cyclization under Basic Conditions (Procedure H)</h3><div class="NLM_p last">To a solution of the appropriate thiazolidinedione derivative (1.0 equiv.) in dry THF (0.1 M) was added <i>t</i>BuOK (2.0–4.0 equiv.) at rt under a nitrogen atmosphere. After 30 min, the reaction mixture was diluted with EtOAc, washed with saturated aqueous NH<sub>4</sub>Cl solution and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was used in the next step without further purification.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> General Procedure for Lithium/Halogen Exchange - Addition Reaction (Procedure I)</h3><div class="NLM_p last">To a solution of the appropriate bromobenzoxazolone (1.0 equiv.) in dry THF (0.1 M) was added MeMgBr (1.5 equiv., 3.0 M in Et<sub>2</sub>O) at −78 °C under a nitrogen atmosphere for 30 min followed by the addition of <i>n</i>-BuLi (1.2 equiv., 2.5 M in hexanes). After 30 min, a solution of the appropriate piperidone (1.7 equiv.) in dry THF (0.7 M) was added dropwise at −78 °C under a nitrogen atmosphere, and then the reaction mixture was allowed to warm to rt. After 30 min, the reaction was quenched by addition of saturated aqueous NH<sub>4</sub>Cl solution, diluted with EtOAc, washed with brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by column chromatography, eluting with Cy/EtOAc or DCM/MeOH, as indicated in each case.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> General Procedure for Dehydration Reaction of Tertiary Alcohols (Procedure L)</h3><div class="NLM_p">To a suspension of the appropriate tertiary alcohol (1.0 equiv.) in dry toluene (0.1 M) was added <i>p</i>-TsOH (3.0 equiv.), and the reaction mixture was stirred at reflux for 2 h. After evaporation of the solvent, the crude was purified by SCX or used in the next step without further purification, as indicated in each case.</div><div id="sec5_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Synthesis of <i>N</i>-(2-Benzyloxyethyl)-6-(4-fluorophenyl)-2-oxo-1,3-benzoxazole-3-carboxamide (<b>2d</b>)</h4><div class="NLM_p last">Compound <b>2d</b> was prepared according to general procedure D (method B) using 6-(4-fluorophenyl)-3<i>H</i>-1,3-benzoxazol-2-one<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (0.060 g, 0.26 mmol), 2-(benzyloxy)-1-ethanamine hydrochloride (0.073 g, 0.39 mmol), and Et<sub>3</sub>N (0.11 mL, 0.079 g, 0.78 mmol) in dry DCM (3 mL). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>2d</b> as a white solid (0.06 g, 57%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.35 (bs, 1H), 8.08 (d, <i>J</i> = 8.3 Hz, 1H), 7.52 (dd, <i>J</i> = 8.8, 5.2 Hz, 2H), 7.43 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 7.40 (d, <i>J</i> = 1.7 Hz, 2H), 7.39–7.33 (m, 4H), 7.28 (tt, <i>J</i> = 7.0, 1.6 Hz, 1H), 7.14 (t, <i>J</i> = 8.6 Hz, 2H), 4.59 (s, 2H), 3.74–3.65 (m, 4H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 162.82 (d, <i>J</i><sub>C–F</sub> = 247.5 Hz), 153.12, 149.94, 142.43, 137.91, 137.51, 136.18, 136.16, 128.86 (d, <i>J</i><sub>C–F</sub> = 8.2 Hz), 128.62, 127.96, 127.95, 127.28, 123.87, 116.03 (d, <i>J</i><sub>C–F</sub> = 21.4 Hz), 115.78, 108.57, 73.40, 68.26, 40.37. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.78 min. MS (ES) C<sub>23</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>4</sub> requires 406, found 407 [M + H]<sup>+</sup>. HRMS C<sub>23</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>: calculated 407.1407, measured: 407.1424, Δppm 4.2.</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Synthesis of 6-(4-Fluorophenyl)-2-oxo-<i>N</i>-pentyl-1,3-benzoxazole-3-carboxamide (<b>2e</b>)</h4><div class="NLM_p last">Compound <b>2e</b> was prepared according to general procedure D (method A) using 6-(4-fluorophenyl)-3<i>H</i>-1,3-benzoxazol-2-one (0.080 g, 0.35 mmol) and 1-pentyl isocyanate (0.05 mL, 0.040 g, 0.39 mmol) in dry MeCN (3 mL). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>2e</b> as a white solid (0.100 g, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ. 8.10 (d, <i>J</i> = 8.3 Hz, 1H), 8.04 (bs, 1H), 7.52 (dd, <i>J</i> = 8.6, 5.3 Hz, 2H), 7.47–7.42 (m, 1H), 7.41–7.38 (m, 1H), 7.14 (t, <i>J</i> = 8.6 Hz, 2H), 3.44 (q, <i>J</i> = 6.9 Hz, 2H), 1.66 (p, <i>J</i> = 7.2 Hz, 2H), 1.45–1.32 (m, 4H), 0.93 (t, <i>J</i> = 6.9 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.70 (d, <i>J</i><sub>C–F</sub> = 247.6 Hz), 153.23, 149.71, 142.28, 137.38, 136.06, 128.73 (d, <i>J</i><sub>C–F</sub> = 8.8 Hz), 123.78, 116.00 (d, <i>J</i><sub>C–F</sub> = 25.3 Hz), 115.75, 108.42, 99.96, 40.34, 29.12, 28.96, 22.30, 13.94. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.43 min. MS (ES) C<sub>19</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>3</sub> requires 342, found 343 [M + H]<sup>+</sup>. HRMS C<sub>19</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 343.1458, measured: 343.1449, Δppm −2.6.</div></div><div id="sec5_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Synthesis of <i>N</i>-(2-Ethoxyethyl)-6-(4-fluorophenyl)-2-oxo-1,3-benzoxazole-3-carboxamide (<b>2f</b>)</h4><div class="NLM_p last">Compound <b>2f</b> was prepared according to general procedure D (method B) using 6-(4-fluorophenyl)-3<i>H</i>-1,3-benzoxazol-2-one (0.130 g, 0.57 mmol), 2-ethoxyethylamine (0.09 mL, 0.080 g, 0.85 mmol), and Et<sub>3</sub>N (0.20 mL, 0.140 g, 1.42 mmol) in dry DCM (15 mL). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>2f</b> as a white solid (0.03 g, 13%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.32 (bs, 1H), 8.10 (d, <i>J</i> = 8.3 Hz, 1H), 7.57–7.49 (m, 2H), 7.46–7.38 (m, 2H), 7.18–7.10 (m, 2H), 3.68–3.61 (m, 4H), 3.56 (q, <i>J</i> = 7.0 Hz, 2H), 1.24 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.69 (d, <i>J</i><sub>C–F</sub> = 247.7 Hz), 153.16, 149.98, 142.47, 137.54, 136.20, 128.88 (d, <i>J</i><sub>C–F</sub> = 8.2 Hz), 127.34, 123.89, 116.04 (d, <i>J</i><sub>C–F</sub> = 21.7 Hz), 115.81, 108.60, 68.63, 66.81, 40.43, 15.25. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.56 min. MS (ES) C<sub>18</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>4</sub> requires 344, found 345 [M + H]<sup>+</sup>. HRMS C<sub>18</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>: calculated 345.1251, measured: 345.1258, Δppm 2.</div></div><div id="sec5_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Synthesis of 6-(4-Fluorophenyl)-<i>N</i>-(3-methoxypropyl)-2-oxo-1,3-benzoxazole-3-carboxamide (<b>2g</b>)</h4><div class="NLM_p last">Compound <b>2g</b> was prepared according to general procedure D (method B) using 6-(4-fluorophenyl)-3<i>H</i>-1,3-benzoxazol-2-one (0.08 g, 0.35 mmol), 3-methoxypropylamine (0.06 mL, 0.050 g, 0.52 mmol), and Et<sub>3</sub>N (0.12 mL, 0.09 g, 0.88 mmol) in dry DCM (15 mL). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>2g</b> as a white solid (0.020 g, 18%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.35 (bs, 1H), 8.10 (d, <i>J</i> = 8.3 Hz, 1H), 7.52 (dd, <i>J</i> = 8.6, 5.3 Hz, 2H), 7.43 (dd, <i>J</i> = 8.4, 1.4 Hz, 1H), 7.41–7.39 (m, 1H), 7.14 (t, <i>J</i> = 8.6 Hz, 2H), 3.55 (dt, <i>J</i> = 16.4, 6.0 Hz, 4H), 3.39 (s, 3H), 1.92 (p, <i>J</i> = 6.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.67 (d, <i>J</i><sub>C–F</sub> = 247.4 Hz), 153.16, 142.84, 142.43, 137.44, 136.23, 128.70 (d, <i>J</i><sub>C–F</sub> = 8.1 Hz, 2C), 127.40, 123.84, 116.12, 115.88 (d, <i>J</i><sub>C–F</sub> = 11.3 Hz, 2C), 108.53, 70.95, 58.95, 38.60, 29.28. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.49 min. MS (ES) C<sub>18</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>4</sub> requires 344, found 345 [M + H]<sup>+</sup>. HRMS C<sub>18</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>: calculated 345.1251, measured: 345.1258, Δppm 2.</div></div><div id="sec5_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Synthesis of 3<i>H</i>-Oxazolo[4,5-<i>c</i>]pyridin-2-one (<b>7a</b>)</h4><div class="NLM_p last">Compound <b>7a</b> was prepared according to general procedure C using <b>6a</b> (0.10 g, 0.91 mmol) and CDI (0.290 g, 1.82 mmol, 2.0 equiv.) in a mixture of MeCN/DMF (9 mL, 2:1). The crude was triturated with DCM to afford <b>7a</b> as a whitish solid (0.100 g, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (s, 1H), 8.32 (d, <i>J</i> = 5.3 Hz, 1H), 7.38 (d, <i>J</i> = 5.3 Hz, 1H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.61 min. MS (ES) C<sub>6</sub>H<sub>4</sub>N<sub>2</sub>O<sub>2</sub> requires 136, found 137 [M + H]<sup>+</sup>, 135 [M–H]<sup>−</sup>.</div></div><div id="sec5_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Synthesis of 1<i>H</i>-Oxazolo[5,4-<i>c</i>]pyridin-2-one (<b>7b</b>)</h4><div class="NLM_p last">Compound <b>7b</b> was prepared according to general procedure C using <b>6b</b> (0.100 g, 0.91 mmol) and CDI (0.441 g, 2.72 mmol) in a mixture of MeCN/DMF (9 mL, 1:4). The crude was triturated with Et<sub>2</sub>O to afford <b>7b</b> as a brown solid (0.123 g, quant.). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.51 (bs, 1H), 8.38 (s, 1H), 8.23 (d, <i>J</i> = 5.5 Hz, 1H), 7.16 (d, <i>J</i> = 5.5 Hz, 1H). UPLC/MS (<i>method C</i>): <i>R<sub>t</sub></i> 1.06 min. MS (ES) C<sub>6</sub>H<sub>4</sub>N<sub>2</sub>O<sub>2</sub> requires 136, found 137 [M + H]<sup>+</sup>, 135 [M–H]<sup>−</sup>.</div></div><div id="sec5_11_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)oxazolo[4,5-<i>c</i>]pyridine-3-carboxamide (<b>8a</b>)</h4><div class="NLM_p last">Compound <b>8a</b> was prepared according to general procedure D (method A) using <b>7a</b> (0.03 g, 0.22 mmol) and 4-phenylbutyl isocyanate (0.045 mL, 0.046 g, 0.26 mmol) in a mixture of DMF/toluene (3 mL, 2:1). The crude was purified by column chromatography (Cy/EtOAc, from 95:5 to 70:30) to afford <b>8a</b> as a white solid (0.015 g, 41%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.28 (s, 1H), 8.55 (d, <i>J</i> = 5.1 Hz, 1H), 7.85 (bs, 1H), 7.31–7.21 (m, overlapped with CDCl<sub>3</sub> signal, 3H), 7.21–7.13 (m, 3H), 3.47 (q, <i>J</i> = 6.5 Hz, 2H), 2.68 (t, <i>J</i> = 7.1 Hz, 2H), 1.79–1.64 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 151.67, 148.95, 148.06, 146.45, 141.91, 136.75, 136.72, 128.53 (4C), 126.06, 105.75, 40.48, 35.54, 29.11, 28.63. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.23 min. MS (ES) C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub> requires 311, found 312 [M + H]<sup>+</sup>. HRMS C<sub>17</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 312.1348, measured: 312.134, Δppm −2.6.</div></div><div id="sec5_11_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)oxazolo[5,4-<i>c</i>]pyridine-1-carboxamide (<b>8b</b>)</h4><div class="NLM_p last">Compound <b>8b</b> was prepared according to general procedure D (method A) using <b>7b</b> (0.08 g, 0.59 mmol) and 4-phenylbutyl isocyanate (0.11 mL, 0.113 g, 0.65 mmol) in a mixture of DMF/MeCN (12 mL, 4:1). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>8b</b> as a white solid (0.107 g, 59%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.58 (s, 1H), 8.54 (d, <i>J</i> = 5.3 Hz, 1H), 8.04 (d, <i>J</i> = 5.3 Hz, 1H), 7.91 (bs, 1H), 7.33–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.23–7.13 (m, 3H), 3.46 (q, <i>J</i> = 6.4 Hz, 2H), 2.68 (t, <i>J</i> = 7.1 Hz, 2H), 1.80–1.61 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 151.99, 148.79, 146.15, 141.86, 139.86, 130.48, 128.55 (4C), 128.53, 126.10, 110.80, 40.52, 35.54, 29.04, 28.62. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.26 min. MS (ES) C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub> requires 311, found 312 [M + H]+. HRMS C<sub>17</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 312.1348, measured: 312.1341, Δppm −2.2.</div></div><div id="sec5_11_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Synthesis of 2,3-Dioxo-<i>N</i>-(4-phenylbutyl)indoline-1-carboxamide (<b>8c</b>)</h4><div class="NLM_p last">Compound <b>8c</b> was prepared according to general procedure D (method A) using <b>7c</b> (0.074 g, 0.50 mmol) and 4-phenylbutyl isocyanate (0.097 mL, 0.100 g, 0.55 mmol). The crude was purified by column chromatography (Cy/EtOAc, 85:15) to afford <b>8c</b> as a yellow solid (0.029 g, 21%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (t, <i>J</i> = 5.7 Hz, 1H), 8.16 (d, <i>J</i> = 8.2 Hz, 1H), 7.75–7.64 (m, 2H), 7.31–7.23 (m, 3H), 7.23–7.13 (m, 3H), 3.39–3.24 (m, overlapped with H<sub>2</sub>O signal, 2H), 2.62 (t, <i>J</i> = 7.3 Hz, 2H), 1.68–1.51 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 180.90, 159.48, 151.08, 148.69, 142.51, 138.04, 128.70 (4C), 126.14, 125.16, 124.81, 119.47, 116.97, 39.70, 35.23, 29.14, 28.66. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.41 min. MS (ES) C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub> requires 322, found 323 [M + H]<sup>+</sup>. HRMS C<sub>19</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 323.1396, measured: 323.1391, Δppm −1.5.</div></div><div id="sec5_11_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)indoline-1-carboxamide (<b>8d</b>)</h4><div class="NLM_p last">Compound <b>8d</b> was prepared according to general procedure D (method A) using <b>7d</b> (0.066 g, 0.50 mmol) and 4-phenylbutyl isocyanate (0.094 mL, 0.096 g, 0.55 mmol). The crude was purified by column chromatography (Cy/EtOAc, 90:10) to afford <b>8d</b> as a white solid (0.04 g, 26%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.60 (bs, 1H), 8.25 (d, <i>J</i> = 8.2 Hz, 1H), 7.35–7.22 (m, overlapped with CDCl<sub>3</sub> signal, 4H), 7.21–7.11 (m, 4H), 3.71 (s, 2H), 3.42 (q, <i>J</i> = 6.7 Hz, 2H), 2.67 (t, <i>J</i> = 7.3 Hz, 2H), 1.79–1.62 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 177.17, 152.03, 141.89, 141.69, 128.22, 128.15, 128.11, 125.62, 124.11, 123.61, 122.71, 116.28, 39.52, 36.80, 35.32, 28.96, 28.50. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.61 min. MS (ES) C<sub>19</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> requires 308, found 309 [M + H]<sup>+</sup>. HRMS C<sub>19</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>: calculated 309.1603, measured 309.1598, Δppm −1.6.</div></div><div id="sec5_11_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Synthesis of <i>tert</i>-Butyl 3-(2,4-dioxothiazolidin-3-yl)-4-oxo-piperidine-1-carboxylate (<b>10</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (0.782 g, 1.00 mmol, 1.0 equiv.) in dry DMF (5 mL) were added TZD (0.141 g, 1.20 mmol, 1.2 equiv.) and K<sub>2</sub>CO<sub>3</sub> (0.207 g, 1.50 mmol, 1.5 eq.). The reaction was stirred at rt for 2 h and then diluted with EtOAc. The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to afford <b>10</b> as an orange oil (0.247 g, 79%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.80–4.67 (m, 1H), 4.57–4.19 (m, 2H), 4.02 (s, 2H), 3.79–3.58 (m, 1H), 3.30–3.10 (m, 1H), 2.68–2.47 (m, 2H), 1.49 (s, 9H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.88 min. MS (ES) C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O<sub>5</sub>S requires 314, found 313[M–H]<sup>−</sup>.</div></div><div id="sec5_11_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Synthesis of <i>tert</i>-Butyl 2-oxo-3,4,6,7-tetrahydrooxazolo[4,5-<i>c</i>]pyridine-5-carboxylate (<b>11</b>)</h4><div class="NLM_p last">Compound <b>11</b> was prepared according to general procedure H using <b>10</b> (0.247 g, 0.79 mmol, 1.0 equiv.) and <i>t</i>BuOK (0.176 g, 1.57 mmol, 2.0 equiv.) in dry THF (8 mL). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>11</b> as yellow oil (0.055 g, 29%). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.64 min. MS (ES) C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> requires 240, found 241 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Synthesis of <i>tert</i>-Butyl 2-oxo-3-(4-phenylbutylcarbamoyl)-6,7-dihydro-4<i>H</i>-oxazolo[4,5-<i>c</i>]pyridine-5-carboxylate (<b>12a</b>)</h4><div class="NLM_p last">Compound <b>12a</b> was prepared according to general procedure D (method A) using <b>11</b> (0.055 g, 0.23 mmol) and 4-phenylbutyl isocyanate (0.079 mL, 0.081 g, 0.46 mmol, 2.0 equiv.) in dry MeCN (1 mL). The crude was purified by column chromatography (Cy/EtOAc, 90:10) to afford <b>12a</b> as an off-white solid (0.070 g, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (bs, 1H), 7.31–7.23 (m, overlapped signals with CDCl<sub>3</sub>, 2H), 7.21–7.11 (m, 3H), 4.64–4.58 (m, 2H), 3.74–3.66 (m, 2H), 3.35 (q, <i>J</i> = 6.7 Hz, 2H), 2.64 (q, <i>J</i> = 7.6 Hz, 2H), 2.56–2.46 (m, 2H), 1.78–1.58 (m, overlapped with H<sub>2</sub>O signal, 4H), 1.48 (s, 9H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.81 min. MS (ES) C<sub>22</sub>H<sub>29</sub>N<sub>3</sub>O<sub>5</sub> requires 415, found 416 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-4,5,6,7-tetrahydrooxazolo[4,5-<i>c</i>]pyridine-3-carboxamide Hydrochloride (<b>12b</b>)</h4><div class="NLM_p last">Compound <b>12b</b> was prepared according to general procedure E using compound <b>12a</b> (0.065 g, 0.16 mmol). The crude was triturated with Et<sub>2</sub>O to afford <b>12b</b> as a yellow solid (0.030 g, 60%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.33 (bs, 2H), 7.82 (t, <i>J</i> = 5.6 Hz, 1H), 7.31–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.21–7.13 (m, 3H), 4.58–4.38 (m, 2H), 3.63–3.45 (m, 2H), 3.33 (q, <i>J</i> = 6.5 Hz, 2H), 2.99–2.87 (m, 2H), 2.65 (t, <i>J</i> = 7.3 Hz, 2H), 1.74–1.53 (m, 4H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 152.81, 149.01, 141.92, 133.04, 128.54 (4C), 126.04, 114.29, 40.31, 35.53, 29.06, 28.63, 19.24. MS UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.83 min. MS (ES) C<sub>17</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub> requires 315, found 316 [M + H]<sup>+</sup>. HRMS C<sub>17</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 316.1661, measured: 316.1661, Δppm 0.0.</div></div><div id="sec5_11_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Synthesis of 5-Methyl-2-oxo-<i>N</i>-(4-phenylbutyl)-6,7-dihydro-4<i>H</i>-oxazolo[4,5-<i>c</i>]pyridine-3-carboxamide Hydrochloride (<b>12c</b>)</h4><div class="NLM_p last">Compound <b>12c</b> was prepared according to general procedure F using compound <b>12b</b> (0.030 g, 0.09 mmol), 37% aqueous solution of formaldehyde (0.005 mL, 0.18 mmol), NaBH(OAc)<sub>3</sub> (0.381 g, 1.80 mmol), and AcOH (0.008 mL, 0.008 g, 0.14 mmol) in dry MeCN (1.0 mL). The crude was dissolved in DCM (1 mL) followed by the addition of HCl (0.68 mL, 2.70 mmol, 4 M in 1,4-dioxane). After evaporation of the solvent, the residue was triturated with Et<sub>2</sub>O to afford <b>12c</b> as a white solid (0.026 g, 90%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 13.62 (bs, 1H), 7.80 (t, <i>J</i> = 5.5 Hz, 1H), 7.31–7.25 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.21–7.14 (m, 3H), 4.71 (d, <i>J</i> = 16.0 Hz, 1H), 4.14–4.01 (m, 1H), 3.75–3.60 (m, 1H), 3.54–3.39 (m, 1H), 3.34 (p, <i>J</i> = 6.3 Hz, 2H), 3.28–3.14 (m, 1H), 2.96 (s, 3H), 2.64 (t, <i>J</i> = 7.3 Hz, 2H), 1.74–1.51 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 152.71, 149.00, 141.89, 132.64, 128.52 (4C), 126.04, 113.48, 50.56 (2C), 49.25 (2C), 43.26, 40.32, 35.52, 29.03 (2C), 28.60 (2C), 19.49. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.13 min. MS (ES) C<sub>18</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub> requires 329, found 330[M + H]<sup>+</sup>. HRMS C<sub>18</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 330.1818, measured: 330.182, Δppm 0.6.</div></div><div id="sec5_11_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Synthesis of 5-Benzyl-2-oxo-<i>N</i>-(4-phenylbutyl)-6,7-dihydro-4<i>H</i>-oxazolo[4,5-<i>c</i>]pyridine-3-carboxamide (<b>12d</b>)</h4><div class="NLM_p last">Compound <b>12d</b> was prepared according to general procedure F using compound <b>12b</b> (0.050 g, 0.16 mmol), benzaldehyde (0.033 mL, 0.32 mmol), NaBH(OAc)<sub>3</sub> (0.054 g, 0.26 mmol), and AcOH (0.015 mL, 0.015 g, 0.26 mmol) in dry MeCN (2 mL). The crude was purified by column chromatography (Cy/EtOAc, 85:15) to afford <b>12d</b> as a white solid (0.043 g, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01 (bs, 1H), 7.41–7.23 (overlapped with CDCl<sub>3</sub> signal, m, 7H), 7.21–7.13 (m, 3H), 3.85–3.64 (m, 4H), 3.32 (q, <i>J</i> = 6.8 Hz, 2H), 2.89–2.76 (m, 2H), 2.64 (t, <i>J</i> = 7.4 Hz, 2H), 2.58–2.43 (m, 2H), 1.82–1.52 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 149.72, 142.06, 128.68 (2C), 128.53 (3C), 128.49 (4C), 125.99, 61.29, 48.43 (2C), 40.07, 35.58, 29.18, 28.67, 21.84. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.98 min. MS (ES) C<sub>24</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub> requires 405, found 406 [M + H]<sup>+</sup>. HRMS C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 406.2131, measured: 406.2126, Δppm −1.2.</div></div><div id="sec5_11_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Synthesis of 5-Acetyl-2-oxo-<i>N</i>-(4-phenylbutyl)-6,7-dihydro-4<i>H</i>-oxazolo[4,5-<i>c</i>]pyridine-3-carboxamide (<b>12e</b>)</h4><div class="NLM_p last">To a solution of <b>12b</b> (0.030 g, 0.09 mmol) in dry DCM (0.9 mL) were added Et<sub>3</sub>N (0.025 mL, 0.018 g, 0.18 mmol, 2.0 equiv.) and acetyl chloride (0.008 g, 0.10 mmol, 1.1 equiv.) at 0 °C. The reaction mixture was stirred at rt for 3 h and then was diluted with EtOAc, washed with saturated aqueous NH<sub>4</sub>Cl solution and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was triturated with Et<sub>2</sub>O to afford <b>12e</b> as a white solid (0.018 g, 56%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.07–7.85 (m, 1H), 7.31–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.21–7.13 (m, 3H), 4.87–4.58 (m, 2H), 3.96–3.64 (m, 2H), 3.36 (q, <i>J</i> = 6.6 Hz, 2H), 2.65 (t, <i>J</i> = 7.2 Hz, 2H), 2.61–2.49 (m, 2H), 2.17 (s, 3H), 1.76–1.58 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 128.52 (4C), 126.04, 43.33, 40.19, 38.26, 35.56, 29.16, 28.64, 22.23, 21.66. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.12 min. MS (ES) C<sub>19</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub> requires 357, found 358 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Synthesis of <i>tert</i>-Butyl 4-(2,4-Dioxothiazolidin-3-yl)-3-hydroxy-piperidine-1-carboxylate (<b>14a</b>)</h4><div class="NLM_p last">To a solution of <b>13</b> (0.220 g, 1.10 mmol, 1.2 equiv.) in dry DMF (2 mL) were added TZD (0.100 g, 0.89 mmol, 1 equiv.) and magnesium perchlorate (0.040 g, 0.18 mmol, 0.2 equiv.). The reaction mixture was stirred at rt for 20 min and then gradually heated to 115 °C over 2 h. After 3 h, the reaction was cooled, diluted with EtOAc, washed with H<sub>2</sub>O, brine, and 15% LiCl in H<sub>2</sub>O, and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by column chromatography (Cy/EtOAc, 60:40) to afford <b>14a</b> as a white solid (0.139 g, 50%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.37 (d, <i>J</i> = 3.3 Hz, 1H), 4.13 (d, <i>J</i> = 4.7 Hz, 2H), 4.11–3.86 (m, 4H), 2.88–2.61 (m, 1H), 2.06 (qd, <i>J</i> = 12.7, 4.7 Hz, 1H), 1.65–1.53 (m, 1H), 1.40 (s, 9H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.77 min, MS (ES) C<sub>13</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub>S requires 316, found 315 [M–H]<sup>−</sup>.</div></div><div id="sec5_11_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Synthesis of 3-(1-Methyl-3-oxo-4-piperidyl)thiazolidine-2,4-dione (<b>15</b>)</h4><div class="NLM_p last">To a solution of <b>14a</b> (0.100 g, 0.32 mmol) in dry DCM (3 mL) was added portionwise Dess–Martin periodinane (0.300 g, 0.70 mmol, 2.2 equiv.) under an argon atmosphere. The reaction was stirred at rt for 16 h, and then saturated aqueous NaHCO<sub>3</sub> solution was added followed by the addition of 10% Na<sub>2</sub>SO<sub>3</sub> in H<sub>2</sub>O. The mixture was stirred at rt for 30 min, and then the organic phase was separated, and the aqueous layer was extracted with DCM (3 times). The collected organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure. The crude was purified by column chromatography (Cy/EtOAc, 75:15) to afford <b>15</b> as a white solid (0.070 g, 70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.80 (dd, <i>J</i> = 12.3, 6.6 Hz, 1H), 4.40 (d, <i>J</i> = 18.5 Hz, 1H), 4.24–3.91 (m, 3H), 3.29–3.49 (m, 1H), 2.63 (qd, <i>J</i> = 12.4, 5.1 Hz, 1H), 2.16–2.04 (m, 1H), 1.51–1.49 (m, 1H), 1.48 (s, 9H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.83 min, MS (ES) C<sub>13</sub>H<sub>18</sub>N<sub>2</sub>O<sub>5</sub>S requires 314, found 315 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Synthesis of <i>tert</i>-Butyl 2-Oxo-1,4,6,7-tetrahydrooxazolo[5,4-<i>c</i>]pyridine-5-carboxylate (<b>16</b>)</h4><div class="NLM_p last">Compound <b>16</b> was prepared according to general procedure H using <b>15</b> (0.070 g, 0.22 mmol) and <i>t</i>BuOK (0.190 g, 0.89 mmol, 4.0 equiv.) in dry THF (2 mL). The crude was used in the next step without further purification. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.64 min. MS (ES) C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> requires 240, found 239 [M–H]<sup>−</sup>.</div></div><div id="sec5_11_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Synthesis of <i>tert</i>-Butyl 2-Oxo-1-(4-phenylbutylcarbamoyl)-6,7-dihydro-4<i>H</i>-oxazolo[5,4-<i>c</i>]pyridine-5-carboxylate (<b>17a</b>)</h4><div class="NLM_p last">Compound <b>17a</b> was prepared according to general procedure D (method A) using <b>16</b> (0.052 g, 0.22 mmol) and 4-phenylbutyl isocyanate (0.039 mL, 0.040 g, 0.22 mmol, 1.0 equiv.) in dry MeCN (2 mL). The crude was purified by column chromatography (Cy/EtOAc, 90:10) to afford <b>17a</b> as a white solid (0.023 g, 25% over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01 (bs, 1H), 7.31–7.24 (m, overlapped  with CDCl<sub>3</sub> signal, 2H), 7.22–7.14 (m, 3H), 4.32–4.19 (m, 2H), 3.72–3.59 (m, 2H), 3.34 (q, <i>J</i> = 6.7 Hz, 2H), 2.99–2.86 (m, 2H), 2.64 (t, <i>J</i> = 7.3 Hz, 2H), 1.75–1.59 (m, 4H), 1.48 (s, 9H). UPLC/MS (<i>method B</i>): <i>R<sub>t</sub></i> 1.91 min. MS (ES) C<sub>22</sub>H<sub>29</sub>N<sub>3</sub>O<sub>5</sub> requires 415, found 416 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-4,5,6,7-tetrahydrooxazolo[5,4-<i>c</i>]pyridine-1-carboxamide Hydrochloride (<b>17b</b>)</h4><div class="NLM_p last">Compound <b>17b</b> was prepared according to general procedure E using <b>17a</b> (0.023 g, 0.055 mmol). After evaporation of the solvent, the crude was triturated with Et<sub>2</sub>O to obtain <b>17b</b> as a white solid (0.012 g, 60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.96 (bs, 2H), 8.05 (bs, 1H), 7.31–7.23 (m, 2H), 7.22–7.12 (m, 3H), 4.08–3.99 (m, 2H), 4.04 (s, 2H), 3.26 (q, <i>J</i> = 6.4 Hz, 2H), 3.01–2.93 (m, 2H), 2.59 (t, <i>J</i> = 6.9 Hz, 2H), 1.66–1.44 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.08, 149.11, 141.97, 128.54 (2C), 126.02, 40.28 (2C), 38.16, 36.03, 35.56, 29.09, 28.66. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.88 min. MS (ES) C<sub>17</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub> requires 315, found 316 [M + H]<sup>+</sup>. HRMS C<sub>17</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 316.1661, measured: 316.1669, Δppm 2.5.</div></div><div id="sec5_11_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Synthesis of 5-(Cyclohexen-1-yl)-2-nitrophenol (<b>19a</b>)</h4><div class="NLM_p last">Compound <b>19a</b> was prepared according to general procedure A using 5-bromo-2-nitrophenol (0.218 g, 1.0 mmol), <b>18a</b> (0.229 g, 1.10 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.058 g, 0.05 mmol), and 2 M Na<sub>2</sub>CO<sub>3</sub> (1.30 mL, 2.50 mmol) in degassed 1,4-dioxane (20 mL). The crude was purified by column chromatography (Cy) to afford <b>19a</b> as colorless oil (0.200 g, 90%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.66 (s, 1H), 8.01 (d, <i>J</i> = 9.0 Hz, 1H), 7.09 (d, <i>J</i> = 1.9 Hz, 1H), 7.03 (dd, <i>J</i> = 9.0, 2.0 Hz, 1H), 6.39 (tt, <i>J</i> = 4.0, 1.6 Hz, 1H), 2.43–2.34 (m, 2H), 2.31–2.22 (m, 2H), 1.85–1.74 (m, 2H), 1.73–1.62 (m, 2H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.35 min. MS (ES) C<sub>12</sub>H<sub>13</sub>NO<sub>3</sub> requires 219, found 220 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Synthesis of 5-(3,6-Dihydro-2<i>H</i>-pyran-4-yl)-2-nitrophenol (<b>19b</b>)</h4><div class="NLM_p last">Compound <b>19b</b> was prepared according to general procedure A using 5-bromo-2-nitrophenol (0.218 g, 1.00 mmol), <b>18b</b> (0.231 g, 1.10 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.058 g, 0.05 mmol), and 2 M Na<sub>2</sub>CO<sub>3</sub> (1.30 mL, 2.50 mmol) in degassed 1,4-dioxane (20 mL). The crude was purified by column chromatography (Cy/EtOAc, 85:15) to afford <b>19b</b> as a white powder (0.123 g, 56%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.89 (s, 1H), 7.95–7.85 (m, 1H), 7.15–7.10 (m, 2H), 6.50–6.45 (m, 1H), 4.30–4.20 (m, 2H), 3.82 (t, <i>J</i> = 5.4 Hz, 2H), 2.44–2.35 (m, 2H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.51 min. MS (ES) C<sub>11</sub>H<sub>11</sub>NO<sub>4</sub> requires 221, found 220 [M–H]<sup>−</sup>.</div></div><div id="sec5_11_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Synthesis of <i>tert</i>-Butyl 4-(3-Hydroxy-4-nitrophenyl)-3,6-dihydro-2<i>H</i>-pyridine-1-carboxylate (<b>19c</b>)</h4><div class="NLM_p last">Compound <b>19c</b> was prepared according to general procedure A using 5-bromo-2-nitrophenol (1.60 g, 7.35 mmol), <b>18c</b> (2.50 g, 8.09 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.424 g, 0.36 mmol), and 2 M Na<sub>2</sub>CO<sub>3</sub> (9.2 mL, 18.38 mmol) in degassed 1,4-dioxane (15 mL). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>19c</b> as a white powder (1.88 g, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.89 (s, 1H), 7.91 (d, <i>J</i> = 8.7 Hz, 1H), 7.19–7.02 (m, 2H), 6.44–6.27 (m, 1H), 4.09–3.97 (m, 2H), 3.54 (t, <i>J</i> = 5.7 Hz, 2H), 2.48–2.41 (m, 2H), 1.43 (s, 9H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.54 min. MS (ES) C<sub>16</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub> requires 320, found 319 [M–H]<sup>−</sup>.</div></div><div id="sec5_11_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Synthesis of <i>tert</i>-Butyl 4-(2-Fluoro-5-hydroxy-4-nitrophenyl)-3,6-dihydro-2<i>H</i>-pyridine-1-carboxylate (<b>19d</b>)</h4><div class="NLM_p last">Compound <b>19d</b> was prepared according to general procedure A using 5-bromo-4-fluoro-2-nitrophenol (0.280 g, 1.18 mmol), <b>18c</b> (0.402 g, 1.3 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.07 g, 0.06 mmol), and 2 M Na<sub>2</sub>CO<sub>3</sub> (1.48 mL, 2.95 mmol) in degassed 1,4-dioxane (12 mL). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>19d</b> as a yellow solid (0.267 g, 67%). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.45 min. MS (ES) C<sub>16</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>5</sub> requires 338, found 339 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Synthesis of 2-Amino-5-cyclohexylphenol (<b>20a</b>)</h4><div class="NLM_p last">Compound <b>20a</b> was prepared according to general procedure B (method B) using <b>19a</b> (0.200 g, 0.91 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.74–6.68 (m, 1H), 6.67–6.60 (m, 2H), 2.43–2.30 (m, 1H), 1.93–1.76 (m, 4H), 1.76–1.67 (m, 1H), 1.43–1.29 (m, 4H), 1.29–1.15 (m, 1H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.98 min. MS (ES) C<sub>12</sub>H<sub>17</sub>NO requires 191, found 192 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Synthesis of 2-Amino-5-tetrahydropyran-4-ylphenol (<b>20b</b>)</h4><div class="NLM_p last">Compound <b>20b</b> was prepared according to general procedure B (method B) using <b>19b</b> (0.123 g, 0.56 mmol). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.60 min. MS (ES) C<sub>11</sub>H<sub>15</sub>NO<sub>2</sub> requires 193, found 194 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Synthesis of <i>tert</i>-Butyl 4-(4-Amino-3-hydroxyphenyl)piperidine-1-carboxylate (<b>20c</b>)</h4><div class="NLM_p last">Compound <b>20c</b> was prepared according to general procedure B (method B) using <b>19c</b> (0.239 g, 0.75 mmol). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.98 min. MS (ES) C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub> requires 292, found 293 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Synthesis of <i>tert</i>-Butyl 4-(4-Amino-2-fluoro-5-hydroxyphenyl)piperidine-1-carboxylate (<b>20d</b>)</h4><div class="NLM_p last">Compound <b>20d</b> was prepared according to general procedure B (method B) using <b>19d</b> (0.265 g, 0.78 mmol). UPLC/MS (<i>method D</i>): <i>R<sub>t</sub></i> 1.51 min. MS (ES) C<sub>16</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>3</sub> requires 310, found 311 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Synthesis of 6-Cyclohexyl-3<i>H</i>-1,3-benzoxazol-2-one (<b>21a</b>)</h4><div class="NLM_p last">Compound <b>21a</b> was prepared according to general procedure C using <b>20a</b> (0.174 g, 0.91 mmol) and CDI (0.295 g, 1.82 mmol) in dry MeCN (9 mL). The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.07 (bs, 1H), 7.09–7.06 (m, 1H), 7.04–6.89 (m, 2H), 2.61–2.44 (m, 1H), 1.96–1.80 (m, 4H), 1.81–1.62 (m, 1H), 1.47–1.31 (m, 4H), 1.31–1.16 (m, 1H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.38 min. MS (ES) C<sub>13</sub>H<sub>15</sub>NO<sub>2</sub> requires 217, found 218 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Synthesis of 6-Tetrahydropyran-4-yl-3<i>H</i>-1,3-benzoxazol-2-one (<b>21b</b>)</h4><div class="NLM_p last">Compound <b>21b</b> was prepared according to general procedure C using <b>20b</b> (0.108 g, 0.56 mmol) and CDI (0.136 g, 0.84 mmol) in dry MeCN (6 mL). The crude was purified by column chromatography (Cy/EtOAc, 70:30) to afford <b>21b</b> as a white powder (0.089 g, 72% over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.48 (s, 1H), 7.23–7.18 (m, 1H), 7.05–6.95 (m, 2H), 4.00–3.85 (m, 2H), 3.45–3.35 (m, 2H), 2.80–2.70 (m, 1H), 1.70–1.60 (m, 4H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.59 min. MS (ES) C<sub>12</sub>H<sub>13</sub>NO<sub>3</sub> requires 219, found 220 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Synthesis of <i>tert</i>-Butyl 4-(2-Oxo-3<i>H</i>-1,3-benzoxazol-6-yl)piperidine-1-carboxylate (<b>21c</b>)</h4><div class="NLM_p last">Compound <b>21c</b> was prepared according to general procedure D using <b>20c</b> (0.219 g, 0.75 mmol) and CDI (0.183 g, 1.13 mmol) in dry MeCN (8 mL). The crude was purified by column chromatography (Cy/EtOAc, 45:55) to afford <b>21c</b> as a white powder (0.195 g, 82% over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.49 (bs, 1H), 7.24–7.16 (m, 1H), 7.06–6.96 (m, 2H), 4.18–3.94 (m, 2H), 2.94–2.73 (m, 2H), 2.68 (tt, <i>J</i> = 11.9, 3.4 Hz, 1H), 1.78–1.70 (m, 2H), 1.55–1.43 (m, 2H), 1.42 (s, 9H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.16 min. MS (ES) C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> requires 318, found 317 [M–H]<sup>−</sup>.</div></div><div id="sec5_11_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Synthesis of <i>tert</i>-Butyl 4-(5-Fluoro-2-oxo-3<i>H</i>-1,3-benzoxazol-6-yl)piperidine-1-carboxylate (<b>21d</b>)</h4><div class="NLM_p last">Compound <b>21d</b> was prepared according to general procedure C using <b>20d</b> (0.242 g, 0.78 mmol) and CDI (0.19 g, 1.17 mmol) in dry MeCN (8 mL). The crude was purified by column chromatography (Cy/EtOAc, 70:30) to afford <b>21d</b> as a white solid (0.157 g, 60% over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.68 (bs, 1H), 7.29 (d, <i>J</i> = 6.0 Hz, 1H), 6.95 (d, <i>J</i> = 9.7 Hz, 1H), 4.18–3.97 (m, 2H), 2.95 (ddd, <i>J</i> = 12.0, 8.7, 3.4 Hz, 1H), 2.90–2.67 (m, 2H), 1.74–1.63 (m, 2H), 1.54 (qd, <i>J</i> = 12.5, 4.1 Hz, 2H), 1.41 (s, 9H). UPLC/MS (<i>method D</i>): <i>R<sub>t</sub></i> 2.21 min. MS (ES) C<sub>17</sub>H<sub>21</sub>FN<sub>2</sub>O<sub>4</sub> requires 336, found 337 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Synthesis of 6-(4-Piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one; Hydrochloric Salt (<b>21e</b>)</h4><div class="NLM_p last">Compound <b>21e</b> was prepared according to general procedure E using <b>21c</b> (0.193 g, 0.61 mmol). The crude was used in the next step without further purification. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.91 min. MS (ES) C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> requires 218, found 219 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Synthesis of 5-Fluoro-6-(4-piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one; Hydrochloric Salt (<b>21f</b>)</h4><div class="NLM_p last">Compound <b>21f</b> was prepared according to general procedure E using <b>21d</b> (0.157 g, 0.47 mmol). The crude used in the next step without further purification. UPLC/MS (<i>method D</i>): <i>R<sub>t</sub></i> 0.37 min. MS (ES) C<sub>12</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>2</sub> requires 236, found 237 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Synthesis of 6-(1-Methyl-4-piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>21g</b>)</h4><div class="NLM_p last">Compound <b>21g</b> was prepared according to general procedure F using <b>21e</b> (0.155 g, 0.61 mmol), 37% aqueous solution of formaldehyde (0.03 mL, 1.22 mmol), NaBH(OAc)<sub>3</sub> (0.386 g, 1.83 mmol), and AcOH (0.07 mL, 0.073 g, 1.22 mmol) in dry MeCN (6 mL). The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.19–7.15 (m, 1H), 7.03–6.96 (m, 2H), 2.90–2.80 (m, 2H), 2.53–2.40 (m, overlapped with DMSO signal, 1H), 2.18 (s, 3H), 1.95 (td, <i>J</i> = 11.5, 2.7 Hz, 2H), 1.76–1.57 (m, 4H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.91 min. MS (ES) C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> requires 232, found 233 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Synthesis of 6-(1-Ethyl-4-piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>21h</b>)</h4><div class="NLM_p last">Compound <b>21h</b> was prepared according to general procedure F using <b>21e</b> (0.254 g, 1.00 mmol), acetaldehyde (0.21 mL, 1.05 mmol, 5 M in THF), NaBH(OAc)<sub>3</sub> (0.318 g, 1.6 mmol), and AcOH (0.150 g, 2.5 mmol) in dry THF (10 mL). The crude was purified by SCX to afford <b>21h</b> as a yellow powder (0.245 g, quant.). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.82 (s, 1H), 6.80 (d, <i>J</i> = 6.0 Hz, 1H), 6.59 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 3.04–2.97 (m, 4H), 2.52–2.43 (m, overlapped with DMSO signal, 5H), 2.35 (q, <i>J</i> = 7.2 Hz, 2H), 1.02 (t, <i>J</i> = 7.2 Hz, 3H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.98 min. MS (ES) C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> requires 246, found 247[M + H]<sup>+</sup>.</div></div><div id="sec5_11_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Synthesis of 6-(1-Isopropyl-4-piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>21i</b>)</h4><div class="NLM_p last">Compound <b>21i</b> was prepared according to general procedure F using <b>21e</b> (0.254 g, 1.00 mmol), NaBH(OAc)<sub>3</sub> (0.318 g, 1.6 mmol), and AcOH (0.29 mL, 0.30 g, 5.0 mmol) in acetone (10 mL). The residue was purified by column chromatography (DCM/MeOH, 80:20) to afford <b>21i</b> as a pink powder (0.104 g, 40%). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.99 min. MS (ES) C<sub>15</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> requires 261, found 262 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Synthesis of 6-(1-Isobutyl-4-piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>21j</b>)</h4><div class="NLM_p last">Compound <b>21j</b> was prepared according to general procedure F using <b>21e</b> (0.254 g, 1.00 mmol), NaBH(OAc)<sub>3</sub> (0.318 g, 1.5 mmol), AcOH (0.29 mL, 0.30 g, 5.0 mmol), and isobutyraldehyde (0.36 g, 5.0 mmol) in dry MeCN (10 mL). The crude was purified by SCX to afford <b>21j</b> as a white solid (0.236 g, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.16–7.13 (m, 1H), 7.02–6.93 (m, 2H), 2.95–2.85 (m, 2H), 2.53–2.43 (m, overlapped with DMSO signal, 1H), 2.05 (d, <i>J</i> = 7.4 Hz, 2H), 1.93 (td, <i>J</i> = 11.6, 2.5 Hz, 2H), 1.84–1.69 (m, 3H), 1.69–1.56 (m, 2H), 0.86 (d, <i>J</i> = 6.5 Hz, 6H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.23 min. MS (ES) C<sub>16</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub> requires 274, found 275 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Synthesis of 5-Fluoro-6-(1-methyl-4-piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>21k</b>)</h4><div class="NLM_p last">Compound <b>21k</b> was prepared according to general procedure F using <b>21f</b> (0.123 g, 0.47 mmol) 37% aqueous solution of formaldehyde (0.03 mL, 0.94 mmol), NaBH(OAc)<sub>3</sub> (0.386 g, 1.83 mmol), and AcOH (0.054 mL, 0.056 g, 0.94 mmol) in dry MeCN (5 mL). The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.24 (d, <i>J</i> = 6.03 Hz, 1H), 6.94 (d, <i>J</i> = 9.7 Hz, 1H), 2.93–2.84 (m, 2H), 2.73 (ddd, <i>J</i> = 15.5, 10.1, 4.4 Hz, 1H), 2.22 (s, 3H), 2.02 (td, <i>J</i> = 11.3, 3.1 Hz, 2H), 1.79–1.60 (m, 4H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.99 min. MS (ES) C<sub>13</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>2</sub> requires 250, found 251 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Synthesis of 6-Cyclohexyl-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>22a</b>)</h4><div class="NLM_p last">Compound <b>22a</b> was prepared following general procedure D (method A) using <b>21a</b> (0.169 g, 0.78 mmol) and 4-phenylbutyl isocyanate (0.15 mL, 0.86 mmol) in dry pyridine (8 mL). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>22a</b> as a white solid (0.300 g, 98%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04 (t, <i>J</i> = 5.4 Hz, 1H), 7.93 (d, <i>J</i> = 8.2 Hz, 1H), 7.32–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.14 (m, 3H), 7.13–7.06 (m, 2H), 3.44 (q, <i>J</i> = 6.8 Hz, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 2.61–2.48 (m, 1H), 1.93–1.80 (m, 4H), 1.80–1.59 (m, 5H), 1.41 (q, <i>J</i> = 10.9, 9.8 Hz, 4H), 1.32–1.19 (m, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.60, 150.06, 145.57, 142.06, 128.56, 128.52, 126.01, 125.90, 123.62, 115.31, 108.28, 44.64, 40.21, 35.60, 34.78, 29.22, 28.71, 26.91, 26.16. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.45 min. MS (ES) C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub> requires 392, found 393 [M + H]<sup>+</sup>. HRMS C<sub>24</sub>H<sub>29</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 393.2178, measured: 393.218, Δppm 0.5.</div></div><div id="sec5_11_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-6-tetrahydropyran-4-yl-1,3-benzoxazole-3-carboxamide (<b>22b</b>)</h4><div class="NLM_p last">Compound <b>22b</b> was prepared according to general procedure D (method A) using <b>21b</b> (0.080 g, 0.37 mmol) and 4-phenylbutyl isocyanate (0.07 mL, 0.072 g, 0.41 mmol) in dry MeCN (2 mL). The crude was purified by column chromatography (Cy/EtOAc, 90:10) to afford <b>22b</b> as a white solid (0.075 g, 51%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (t, <i>J</i> = 5.4 Hz, 1H), 7.97 (d, <i>J</i> = 8.2 Hz, 1H), 7.35–7.25 (m, overlapped with H<sub>2</sub>O signal, 2H), 7.25–7.17 (m, 3H), 7.17–7.10 (m, 2H), 4.20–4.05 (m, 2H), 3.61–3.51 (m, 2H), 3.44 (q, <i>J</i> = 6.7 Hz, 2H), 2.88–2.76 (m, 1H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 1.88–1.68 (m, 8H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.45, 149.96, 143.24, 142.14, 142.03, 128.53, 128.50, 126.01, 123.52, 115.56, 108.24, 68.33, 41.61, 40.23, 35.58, 34.20, 29.19, 28.68. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.83 min. MS (ES) C<sub>23</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub> requires 394, found 218 [M-H-CONH(CH<sub>2</sub>)<sub>4</sub>Ph]<sup>−</sup>. HRMS C<sub>23</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>: calculated 395.1955, measured: 395.1971, Δppm −4.0.</div></div><div id="sec5_11_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Synthesis of <i>tert</i>-Butyl 4-[2-Oxo-3-(4-phenylbutylcarbamoyl)-1,3-benzoxazol-6-yl]piperidine-1-carboxylate (<b>22c</b>)</h4><div class="NLM_p last">Compound <b>22c</b> was prepared according to general procedure D (method A) using <b>21c</b> (0.087 g, 0.27 mmol), DMAP (0.037 g, 0.30 mmol), and 4-phenylbutyl isocyanate (0.05 mL, 0.053, 0.30 mmol) in dry MeCN (3 mL). The crude was purified by column chromatography (DCM/MeOH, 90:10) to afford <b>22c</b> as a white solid (0.112 g, 84%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (t, <i>J</i> = 5.6 Hz, 1H), 7.96 (d, <i>J</i> = 8.2 Hz, 1H), 7.31–7.24 (m, overlapped signals with CDCl<sub>3</sub>, 2H), 7.24–7.14 (m, 3H), 7.14–7.05 (m, 2H), 4.39–4.17 (m, 2H), 3.44 (q, <i>J</i> = 6.7 Hz, 2H), 2.80 (t, <i>J</i> = 12.3 Hz, 2H), 2.74–2.62 (m, 3H), 1.89–1.78 (m, 2H), 1.78–1.54 (m, overlapped with H<sub>2</sub>O signal, 6H), 1.48 (s, 9H). UPLC/MS (<i>method B</i>): <i>R<sub>t</sub></i> 2.42 min. MS (ES) C<sub>28</sub>H<sub>35</sub>N<sub>3</sub>O<sub>5</sub> requires 493, found 494 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-6-(4-piperidyl)-1,3-benzoxazole-3-carboxamide Hydrochloride (<b>22d</b>)</h4><div class="NLM_p last">Compound <b>22d</b> was prepared according to general procedure E using <b>22c</b> (0.112 g, 0.23 mmol). The crude was triturated with Et<sub>2</sub>O to afford <b>22d</b> as a white solid (0.085 g, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.00 (bs, 2H), 8.11 (t, <i>J</i> = 5.8 Hz, 1H), 7.83 (d, <i>J</i> = 8.3 Hz, 1H), 7.32–7.23 (m, 3H), 7.23–7.08 (m, 4H), 3.40–3.28 (m, overlapped with H<sub>2</sub>O signal, 3H), 3.05–2.82 (m, 3H), 2.61 (t, <i>J</i> = 7.2 Hz, 2H), 2.02–1.77 (m, 4H), 1.68–1.49 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 152.25, 149.26, 142.00, 141.70, 141.21, 128.27, 128.21, 126.64, 125.65, 122.52, 114.48, 108.08, 43.36, 38.67, 34.73, 29.38, 28.59, 28.12. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.40 min. MS (ES) C<sub>23</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub> requires 393, found 394 [M + H]<sup>+</sup>. HRMS C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 394.213, measured: 394.2131, Δppm −0.3.</div></div><div id="sec5_11_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Synthesis of 6-(1-Methyl-4-piperidyl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>22e</b>)</h4><div class="NLM_p last">Compound <b>22e</b> was prepared according to general procedure D using <b>21g</b> (0.142 g, 0.61 mmol) and 4-phenylbutyl isocyanate (0.11 mL, 0.118 g, 0.67 mmol) in dry MeCN (3 mL). The crude was purified by column chromatography (DCM/MeOH, 70:30) to afford <b>22e</b> as a white solid (0.181 g, 73% over three steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.10 (t, <i>J</i> = 5.8 Hz, 1H), 7.78 (d, <i>J</i> = 8.2 Hz, 1H), 7.32 (d, <i>J</i> = 1.5 Hz, 1H), 7.30–7.24 (m, 2H), 7.23–7.13 (m, 4H), 3.38–3.25 (m, overlapped with H<sub>2</sub>O signal, 2H), 2.85 (d, <i>J</i> = 11.4 Hz, 2H), 2.61 (t, <i>J</i> = 7.3 Hz, 2H), 2.54–2.46 (m, overlapped with DMSO signal, 1H), 2.19 (s, 3H), 1.95 (dd, <i>J</i> = 11.4 , 2.8 Hz, 2H), 1.77–1.49 (m, 8H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 154.40, 149.98, 143.59, 142.05, 140.24, 128.55, 128.51, 126.30, 126.01, 123.69, 115.50, 108.32, 56.28, 46.43, 42.04, 40.23, 35.60, 33.65, 29.21, 28.69. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.21 min. MS (ES) C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O<sub>3</sub> requires 407, found 408 [M + H]<sup>+</sup>. HRMS C<sub>24</sub>H<sub>30</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 408.2287, measured: 408.2291, Δppm 1.0.</div></div><div id="sec5_11_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Synthesis of 6-(1-Ethyl-4-piperidyl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>22f</b>)</h4><div class="NLM_p last">Compound <b>22f</b> was prepared according to general procedure D (method A) using <b>21h</b> (0.100 g, 0.41 mmol) and 4-phenylbutyl isocyanate (0.08 mL, 0.079 g, 0.45 mmol). The crude was purified by column chromatography (DCM/MeOH, 70:30) to afford <b>22f</b> as a yellow solid (0.105 g, 61%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (t, <i>J</i> = 5.7 Hz, 1H), 7.95 (d, <i>J</i> = 8.9 Hz, 1H), 7.32–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.21–7.15 (m, 3H), 7.15–7.10 (m, 2H), 3.44 (q, <i>J</i> = 6.6 Hz, 2H), 3.09 (d, <i>J</i> = 12.0 Hz, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 2.61–2.51 (m, 1H), 2.47 (q, <i>J</i> = 7.2 Hz, 2H), 2.04 (td, <i>J</i> = 11.7, 2.9 Hz, 2H), 1.92–1.76 (m, 4H), 1.76–1.60 (m, 4H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.49, 149.97, 143.81, 142.09, 142.04, 128.54 (2C), 128.50, 126.00, 123.69, 115.44, 108.30, 53.89, 52.74, 42.81, 40.21, 35.59, 33.73, 29.20, 28.69, 12.25. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.22 min, MS (ES) C<sub>25</sub>H<sub>31</sub>N<sub>3</sub>O<sub>3</sub> requires 421, found 422 [M + H]+, 245 [M–CONH(CH<sub>2</sub>)<sub>4</sub>Ph)]<sup>−</sup>. HRMS C<sub>25</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 422.2444, measured 422.2449, Δppm 1.2.</div></div><div id="sec5_11_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Synthesis of 6-(1-Isopropyl-4-piperidyl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>22g</b>)</h4><div class="NLM_p last">Compound <b>22g</b> was prepared according to general procedure D (method A) using <b>21i</b> (0.100 g, 0.38 mmol) and 4-phenylbutyl isocyanate (0.074 g, 0.42 mmol) in dry MeCN (2 mL). The crude was purified by column chromatography (DCM/MeOH, 70:30) to afford <b>22g</b> as a white solid (0.113 g, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (t, <i>J</i> = 5.7 Hz, 1H), 7.94 (d, <i>J</i> = 8.84 Hz, 1H), 7.31–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.21–7.15 (m, 3H), 7.15–7.10 (m, 2H), 3.44 (q, <i>J</i> = 6.59 Hz, 2H), 3.09–2.96 (m, 2H), 2.85–2.72 (m, 1H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 2.53 (tt, <i>J</i> = 12.1, 4.0 Hz, 1H), 2.32–2.20 (m, 2H), 1.92–1.61 (m, 8H), 1.09 (d, <i>J</i> = 6.5 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.50, 149.98, 144.01, 142.08, 128.53 (2C), 128.50, 126.15, 126.00, 123.70, 115.40, 108.32, 54.85, 49.44, 43.11, 40.21, 35.59, 34.12, 29.20, 28.69, 18.55. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.25 min, MS (ES) C<sub>26</sub>H<sub>33</sub>N<sub>3</sub>O<sub>3</sub> requires 435, found 436 [M + H]<sup>+</sup>. HRMS C<sub>26</sub>H<sub>34</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 436.2603, measured 436.26, Δppm 0.6.</div></div><div id="sec5_11_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> Synthesis of 6-(1-Isobutyl-4-piperidyl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>22h</b>)</h4><div class="NLM_p last">Compound <b>22h</b> was prepared according to general procedure D (method A) using <b>21j</b> (0.10 g, 0.36 mmol) and 4-phenylbutyl isocyanate (0.07 mL, 0.07 g, 0.4 mmol). The residue was purified by column chromatography (Cy/EtOAc, 75:25) to afford <b>22h</b> as a white powder (0.115 g, 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04 (t, <i>J</i> = 5.7 Hz, 1H), 7.94 (d, <i>J</i> = 8.86 Hz, 1H), 7.32–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.15 (m, 3H), 7.15–7.07 (m, 2H), 3.44 (q, <i>J</i> = 6.5 Hz, 2H), 3.08–2.92 (m, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 2.60–2.46 (m, 1H), 2.19–2.07 (m, 2H), 2.07–1.93 (m, 2H), 1.90–1.50 (m, 9H), 0.92 (d, <i>J</i> = 6.5 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.54, 150.01, 142.66, 142.09, 128.55 (2C), 128.52, 126.01, 123.70, 115.40, 108.35, 67.38, 54.75, 42.87, 40.23, 35.60, 33.83, 29.22, 28.71, 25.79, 21.21 (2C). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.43 min, MS (ES) C<sub>27</sub>H<sub>35</sub>N<sub>3</sub>O<sub>3</sub> requires 449, found 450 [M + H]<sup>+</sup>. HRMS C<sub>27</sub>H<sub>36</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 450.2756, measured 450.2757, Δppm −0.2.</div></div><div id="sec5_11_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Synthesis of 6-(1-Acetyl-4-piperidyl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>22i</b>)</h4><div class="NLM_p last">To a solution of <b>22d</b> (0.184 g, 0.47 mmol, 1.0 equiv.) in dry THF (5 mL) was added Et<sub>3</sub>N (0.10 g, 0.98 mmol, 2.0 equiv.) dropwise at 0 °C followed by the addition of AcCl (0.039 g, 0.49 mmol, 1.05 equiv.). The reaction mixture was stirred at rt for 4 h, then diluted with EtOAc, washed with saturated aqueous NH<sub>4</sub>Cl solution and brine, and dried over NaSO<sub>4</sub>. After evaporation of the solvent, the crude was purified by column chromatography (DCM/MeOH, 90:10) to afford <b>22i</b> as a white powder (0.181 g, 89%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (t, <i>J</i> = 5.6 Hz, 1H), 7.97 (d, <i>J</i> = 8.2 Hz, 1H), 7.31–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.21–7.14 (m, 3H), 7.12–7.05 (m, 2H), 4.90–4.70 (m, 1H), 4.05–3.84 (m, 1H), 3.43 (q, <i>J</i> = 6.6 Hz, 2H), 3.28–3.07 (m, 1H), 2.79 (tt, <i>J</i> = 12.1, 3.6 Hz, 1H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 2.65–2.55 (m,1H), 2.13 (s, 3H), 1.99–1.83 (m, 2H), 1.80–1.49 (m, overlapped with H<sub>2</sub>O signal, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.02, 149.90, 144.12, 142.54, 142.02, 128.53 (2C), 128.45, 126.56, 126.02, 123.53, 115.66, 108.24, 47.01, 42.78, 42.17, 40.24, 35.58, 29.19, 28.69, 21.64. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.48 min, MS (ES) C<sub>25</sub>H<sub>29</sub>N<sub>3</sub>O<sub>4</sub> requires 435, found 436 [M + H]<sup>+</sup>. HRMS C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: calculated 436.2244, measured 436.2236, Δppm 1.8.</div></div><div id="sec5_11_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Synthesis of <i>N</i>-(2-Benzyloxyethyl)-6-(1-methyl-4-piperidyl)-2-oxo-1,3-benzoxazole-3-carboxamide (<b>22j</b>)</h4><div class="NLM_p last">Compound <b>22j</b> was prepared according to general procedure D (method C) using <b>21g</b> (0.080 g, 0.34 mmol) and 2-(benzyloxy)-1-ethanamine (0.056 g, 0.37 mmol) in dry MeCN (3 mL). The crude was purified by column chromatography (DCM/MeOH, 94:6) to afford <b>22j</b> as a white solid (0.033 g, 24%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.32 (bs, 1H), 7.93 (d, <i>J</i> = 8.8 Hz, 1H), 7.40–7.30 (m, 4H), 7.29–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 1H), 7.16–7.08 (m, 2H), 4.57 (s, 2H), 3.71–3.60 (m, 4H), 3.06–2.94 (m, 2H), 2.59–2.48 (m, 1H), 2.35 (s, 3H), 2.09 (td, <i>J</i> = 11.4, 3.5 Hz, 2H), 1.92–1.74 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.27, 150.07, 143.59, 128.61 (2C), 127.93 (2C), 127.90, 126.26, 123.63, 115.42, 108.33, 73.39, 68.32, 56.29 46.46, 42.05, 40.32, 33.68. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.92 min, MS (ES) C<sub>23</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub> requires 409, found 410 [M + H]<sup>+</sup>. HRMS C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: calculated 410.208, measured 410.2087, Δppm 1.7.</div></div><div id="sec5_11_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> Synthesis of 6-(1-Methyl-4-piperidyl)-2-oxo-<i>N</i>-pentyl-1,3-benzoxazole-3-carboxamide (<b>22k</b>)</h4><div class="NLM_p last">Compound <b>22k</b> was prepared according to general procedure D (method A) using <b>21g</b> (0.050 g, 0.22 mmol) and pentyl isocyanate (0.031 mL, 0.027 g, 0.24 mmol) in dry MeCN (1 mL). The crude was purified by column chromatography (DCM/MeOH, 95:5) to afford <b>22k</b> as a white solid (0.039 g, 51%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (t, <i>J</i> = 5.8 Hz, 1H), 7.95 (d, <i>J</i> = 8.2 Hz, 1H), 7.16–7.07 (m, 2H), 3.41 (q, <i>J</i> = 7.0 Hz, 2H), 3.08–2.92 (m, 2H), 2.62–2.45 (m, 1H), 2.35 (s, 3H), 2.09 (td, <i>J</i> = 11.3, 3.8 Hz, 2H), 1.91–1.74 (m, 4H), 1.69–1.57 (m, 2H), 1.44–1.29 (m, 4H), 0.98–0.85 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.50, 149.96, 143.55, 126.32, 123.68, 115.50, 108.30, 56.28, 46.44, 42.03, 40.40, 33.66, 29.27, 29.11, 22.45, 14.09. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.00 min, MS (ES) C<sub>19</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub> requires 345, found 346 [M + H]<sup>+</sup>. HRMS C<sub>19</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 346.2131, measured 346.2116, Δppm −4.3.</div></div><div id="sec5_11_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> Synthesis of <i>N</i>-(2-Ethoxyethyl)-6-(1-methyl-4-piperidyl)-2-oxo-1,3-benzoxazole-3-carboxamide (<b>22l</b>)</h4><div class="NLM_p last">Compound <b>22l</b> was prepared according to general procedure D (method C) using <b>21g</b> (0.050 g, 0.22 mmol) and 2-ethoxyethylamine (0.021 g, 0.24 mmol) in dry MeCN (2 mL). The crude was purified by column chromatography (DCM/MeOH, 92:8) to afford <b>22l</b> as a white solid (0.030 g, 39%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.29 (bs, 1H), 7.94 (d, <i>J</i> = 9.0 Hz, 1H), 7.14–7.08 (m, 2H), 3.63–3.59 (m, 4H), 3.54 (q, <i>J</i> = 7.0 Hz, 2H), 3.04–2.94 (m, 2H), 2.59–2.47 (m, 1H), 2.33 (s, 3H), 2.07 (td, <i>J</i> = 11.5, 3.3 Hz, 2H), 1.90–1.72 (m, 4H), 1.23 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 153.26, 150.06, 143.10, 142.13, 126.36, 123.63, 115.46, 108.35, 68.64, 66.77, 56.11, 46.13, 41.78, 40.33, 33.24, 15.23. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.57 min, MS (ES) C<sub>18</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub> requires 347, found 348 [M + H]<sup>+</sup>. HRMS C<sub>18</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: calculated 348.1923, measured 348.1921, Δppm 0.6.</div></div><div id="sec5_11_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Synthesis of <i>N</i>-Isobutyl-6-(1-methyl-4-piperidyl)-2-oxo-1,3-benzoxazole-3-carboxamide (<b>22m</b>)</h4><div class="NLM_p last">Compound <b>22m</b> was prepared according to general procedure D (method B) using <b>21g</b> (0.404 g, 1.74 mmol) and isobutylamine (0.382 g, 5.22 mmol) in dry DCM (20 mL). The crude was purified by column chromatography (DCM/MeOH, 92:8) to afford <b>22m</b> as a white solid (0.259 g, 45%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.08 (t, <i>J</i> = 5.9 Hz, 1H), 7.94 (d, <i>J</i> = 8.9 Hz, 1H), 7.16–7.05 (m, 2H), 3.24 (t, <i>J</i> = 6.4 Hz, 2H), 3.05–2.93 (m, 2H), 2.59–2.45 (m, 1H), 2.33 (s, 3H), 2.07 (td, <i>J</i> = 11.4, 3.4 Hz, 2H), 1.97–1.86 (m, 1H), 1.86–1.72 (m, 4H), 0.96 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.51, 150.06, 143.58, 142.08, 126.29, 123.65, 115.47, 108.27, 56.27, 47.66, 46.45, 42.03, 33.68, 28.58, 20.14. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.82 min, MS (ES) C<sub>18</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> requires 331, found 332 [M + H]<sup>+</sup>. HRMS C<sub>18</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 332.1974, measured 332.1969, Δppm −1.5.</div></div><div id="sec5_11_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> Synthesis of 6-(1-Methyl-4-piperidyl)-2-oxo-<i>N</i>-<i>sec</i>-butyl-1,3-benzoxazole-3-carboxamide (<b>22n</b>)</h4><div class="NLM_p last">Compound <b>22n</b> was prepared according to general procedure D (method C) using <b>21g</b> (0.08 g, 0.34 mmol) and <i>sec</i>-butylamine (0.027 g, 0.37 mmol) in dry MeCN (1 mL). The crude was purified by column chromatography (DCM/MeOH, 95:5) to afford <b>22n</b> as a white solid (0.029 g, 26%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.95 (d, <i>J</i> = 8.0 Hz, 1H), 7.87 (d, <i>J</i> = 7.8 Hz, 1H), 7.14–7.08 (m, 2H), 4.07–3.83 (m, 1H), 3.07–2.94 (m, 2H), 2.60–2.46 (m, 1H), 2.35 (s, 3H), 2.09 (td, <i>J</i> = 11.4, 3.3 Hz, 2H), 1.89–1.75 (m, 4H), 1.61 (p, <i>J</i> = 7.3, 6.9 Hz, 2H), 1.26 (d, <i>J</i> = 6.6 Hz, 3H), 0.97 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.92, 154.18, 149.39, 143.50, 126.36, 123.65, 115.51, 108.27, 56.28, 48.18, 46.45, 42.02, 33.67, 29.63, 20.49, 10.41. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.83 min. MS (ES) C<sub>18</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> requires 331, found 332 [M + H]<sup>+</sup>. HRMS C<sub>18</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 332.1974, measured: 332.1967, Δppm −2.1.</div></div><div id="sec5_11_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> Synthesis of <i>N</i>-[4-(4-Fluorophenyl)butyl]-6-(1-methyl-4-piperidyl)-2-oxo-1,3-benzoxazole-3-carboxamide (<b>22o</b>)</h4><div class="NLM_p last">Compound <b>22o</b> was prepared according to general procedure D (method C) using <b>21g</b> (0.085 g, 0.51 mmol) and 4-fluorobenzenebutanamine (0.085 g, 0.51 mmol) in dry MeCN (2 mL). The crude was purified by column chromatography (DCM/MeOH, 87:13) to afford <b>22o</b> as a white solid (0.042 g, 29%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.03 (t, <i>J</i> = 5.5 Hz, 1H), 7.94 (d, <i>J</i> = 8.2 Hz, 1H), 7.19–7.06 (m, 4H), 7.01–6.89 (m, 2H), 3.43 (q, <i>J</i> = 6.5 Hz, 2H), 3.06–2.95 (m, 2H), 2.63 (t, <i>J</i> = 7.0 Hz, 2H), 2.59–2.47 (m, 1H), 2.34 (s, 3H), 2.08 (td, <i>J</i> = 11.4, 3.2 Hz, 2H), 1.90–1.76 (m, 4H), 1.74–1.56 (m, 4H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 161.41 (d, <i>J</i><sub>C–F</sub> = 243.5 Hz), 153.45, 149.96, 143.29, 142.08, 137.61 (d, <i>J</i><sub>C–F</sub> = 3.2 Hz), 129.82 (d, <i>J</i><sub>C–F</sub> = 7.7 Hz), 126.30, 123.70, 115.48, 115.22 (d, <i>J</i><sub>C–F</sub> = 21.0 Hz), 108.33, 56.14, 46.21, 41.84, 40.14, 34.75, 33.36, 29.10, 28.81. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.20 min. MS (ES) C<sub>24</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>3</sub> requires 425, found 426 [M + H]<sup>+</sup>. HRMS C<sub>24</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 426.2193, measured: 426.2188, Δppm −1.2.</div></div><div id="sec5_11_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Synthesis of 5-Fluoro-6-(1-methyl-4-piperidyl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>22p</b>)</h4><div class="NLM_p last">Compound <b>22p</b> was prepared according to general procedure D (method A) using <b>21k</b> (0.117 g, 0.47 mmol) and 4-phenylbutyl isocyanate (0.088 mL, 0.091 g, 0.52 mmol) in dry MeCN (5 mL). The crude was purified by column chromatography (DCM/MeOH, 92:8) to afford <b>22p</b> as a white solid (0.099 g, 50% over three steps). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.98 (t, <i>J</i> = 5.3 Hz, 1H), 7.77 (d, <i>J</i> = 9.9 Hz, 1H), 7.31–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.14 (m, 3H), 7.11 (d, <i>J</i> = 5.8 Hz, 1H), 3.43 (q, <i>J</i> = 6.6 Hz, 2H), 3.05–2.97 (m, 2H), 2.95–2.84 (m, 1H), 2.66 (t, <i>J</i> = 7.4 Hz, 2H), 2.35 (s, 3H), 2.17 (td, <i>J</i> = 11.5, 2.9 Hz, 2H), 1.89–1.78 (m, 4H), 1.75–1.58 (m, overlapped with H<sub>2</sub>O signal, 4H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 157.38 (d, <i>J</i><sub>C–F</sub> = 241.2 Hz), 153.43, 149.58, 141.98, 138.08 (d, <i>J</i><sub>C–F</sub> = 2.2 Hz), 129.37 (d, <i>J</i> = 17.7 Hz), 128.53, 128.51, 126.42 (d, <i>J</i> = 14.5 Hz), 126.02, 108.44 (d, <i>J</i><sub>C–F</sub> = 5.6 Hz), 103.97 (d, <i>J</i><sub>C–F</sub> = 33.4 Hz), 56.08, 46.27, 40.26, 35.56, 34.29, 32.05, 29.13, 28.66. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.20 min. MS (ES) C<sub>24</sub>H<sub>28</sub>FN<sub>3</sub>O<sub>3</sub> requires 425, found 426 [M + H]<sup>+</sup>. HRMS C<sub>24</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 426.2193, measured: 426.2191, Δppm −0.5.</div></div><div id="sec5_11_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Synthesis of (6-Oxo-2,3-dihydro-1<i>H</i>-pyridin-4-yl) trifluoromethanesulfonate (<b>29a</b>)</h4><div class="NLM_p last">To a solution of <b>28</b> (0.400 g, 3.54 mmol, 1.0 equiv.) in dry THF (30 mL) were added at 0 °C under stirring Et<sub>3</sub>N (0.716 g, 7.08 mmol, 2.0 equiv.) and <i>N</i>,<i>N</i>-bis(trifluoromethylsulfonyl)aniline (1.388 g, 4.24 mmol, 1.2 equiv.) dissolved in dry THF (6 mL). The reaction mixture was slowly warmed to rt and stirred for 16 h. The mixture was diluted with EtOAc, washed with a saturated aqueous NH<sub>4</sub>Cl solution, and dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent, the crude was purified by column chromatography (DCM/MeOH, 94:6) to afford <b>29a</b> as a white solid (0.640 g, 74%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.79 (s, 1H), 5.95–5.93 (m, 1H), 3.37 (td, <i>J</i> = 7.1, 2.7 Hz, 2H), 2.72 (td, <i>J</i> = 7.2, 1.4 Hz, 2H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.47 min, MS (ES) C<sub>6</sub>H<sub>6</sub>F<sub>3</sub>NO<sub>4</sub>S requires 245, found 246 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> Synthesis of 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1<i>H</i>-pyridin-6-one (<b>29b</b>)</h4><div class="NLM_p last">To a stirred solution of compound <b>29a</b> (0.100 g, 0.41 mmol, 1.0 equiv.) in degassed dioxane (4 mL) were added ([B<sub>2</sub>(pin)<sub>2</sub>]) (0.124 g, 0.49 mmol, 1.2 equiv.), Pd(dppf)Cl<sub>2</sub> (0.058 g, 0.08 mmol, 0.2 equiv.), and KOAc (0.080 g, 0.82 mmol, 2.0 equiv.). The reaction mixture was stirred at 70 °C for 90 min, then cooled to rt, and used directly in the next step. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.44 min, MS (ES) C<sub>11</sub>H<sub>18</sub>BNO<sub>3</sub> requires 223, found 141 [M–(CH<sub>3</sub>)<sub>2</sub>CC(CH<sub>3</sub>)<sub>2</sub>]<sup>+</sup>.</div></div><div id="sec5_11_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> Synthesis of 4-(3-Benzyloxy-4-nitrophenyl)-2,5-dihydro-1<i>H</i>-pyridin-6-ne (<b>30a</b>)</h4><div class="NLM_p last">Compound <b>30a</b> was prepared according to general procedure A using <b>29b</b> (0.091 g, 0.41 mmol), 2-benzyloxy-4-bromo-1-nitrobenzene (0.138 g, 0.45 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.023 g, 0.02 mmol), and 2 M Na<sub>2</sub>CO<sub>3</sub> (0.51 mL, 1.025 mmol) in degassed 1,4-dioxane (10 mL). The crude was purified by column chromatography (DCM/MeOH, 90:10) to afford <b>30a</b> as a brown powder (0.124 g, 93% over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.93 (d, <i>J</i> = 8.5 Hz, 1H), 7.61 (d, <i>J</i> = 1.7 Hz, 1H), 7.60 (bs, 1H), 7.50–7.47 (m, 2H), 7.46–7.40 (m, 2H), 7.39–7.33 (m, 2H), 6.34 (q, <i>J</i> = 1.5 Hz, 1H), 5.42 (s, 2H), 3.39 (td, <i>J</i> = 7.0, 2.6 Hz, 2H), 2.74 (td, <i>J</i> = 7.0, 1.5 Hz, 2H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.80 min, MS (ES) C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> requires 324, found 325 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Synthesis of 4-(3-Benzyloxy-4-nitrophenyl)-1-methyl-2,3-dihydropyridin-6-one (<b>30b</b>)</h4><div class="NLM_p last">To a stirred solution of <b>30a</b> (0.124 g, 0.38 mmol, 1.0 equiv.) in dry THF (4 mL) was added NaH (0.018 g, 60% in mineral oil, 0.46 mmol, 1.2 equiv.) at 0 °C under stirring. After 30 min, CH<sub>3</sub>I (0.047 mL, 0.76 mmol, 2.0 equiv.) was added, and the mixture was slowly warmed to rt. After 5 h, saturated aqueous NH<sub>4</sub>Cl solution was added, and the mixture extracted with EtOAc. The combined organic phases were washed with brine, dried over MgSO<sub>4</sub>, and concentrated. The crude was purified by column chromatography (DCM/EtOAc, 70:30) to afford <b>30b</b> as a brown solid (0.058 g, 45%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.94 (d, <i>J</i> = 8.5 Hz, 1H), 7.63 (d, <i>J</i> = 1.8 Hz, 1H), 7.51–7.46 (m, 2H), 7.46–7.39 (m, 2H), 7.40–7.32 (m, 2H), 6.41 (t, <i>J</i> = 1.4 Hz, 1H), 5.42 (s, 2H), 3.53 (t, <i>J</i> = 7.1 Hz, 2H), 2.92 (s, 3H), 2.83 (td, <i>J</i> = 7.2, 1.4 Hz, 2H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.89 min, MS (ES) C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub> requires 338, found 339 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Synthesis of 4-(4-Amino-3-hydroxyphenyl)-1-methyl-piperidin-2-one (<b>31</b>)</h4><div class="NLM_p last">Compound <b>31</b> was prepared according to general procedure B (method B) using <b>30b</b> (0.056 g, 0.16 mmol). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.05 min, MS (ES) C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> requires 220, found 221 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Synthesis of 6-(1-Methyl-2-oxo-4-piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>21l</b>)</h4><div class="NLM_p last">Compound <b>21l</b> was prepared according to general procedure C using <b>31</b> (0.035 g, 0.16 mmol) and CDI (0.039 g, 0.24 mmol) in dry MeCN (2 mL). The crude was purified by column chromatography (DCM/MeOH, 95:5) to afford <b>21l</b> as a white powder (0.028 g, 70% over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.26–7.23 (m, 1H), 7.08–6.96 (m, 2H), 3.45–3.23 (m, 2H), 3.14–3.03 (m, 1H), 2.85 (s, 3H), 2.49–2.28 (m, 2H), 2.06–1.76 (m, 2H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.17 min, MS (ES) C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub> requires 246, found 247 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> Synthesis of 6-(1-Methyl-2-oxo-4-piperidyl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>22q</b>)</h4><div class="NLM_p last">Compound <b>22q</b> was prepared according to general procedure D (method A) using <b>21l</b> (0.025 g, 0.10 mmol) and 4-phenylbutyl isocyanate (0.019 mL, 0.019 g, 0.11 mmol) in dry MeCN (1 mL). The crude was purified by column chromatography (DCM/EtOAc, 70:30) to afford <b>22q</b> as a white solid (0.038 g, 90%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.07–7.95 (m, 2H), 7.33–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.13 (m, 3H), 7.13–7.05 (m, 2H), 3.51–3.38 (m, 3H), 3.38–3.28 (m, 1H), 3.21–3.08 (m, 1H), 2.99 (s, 3H), 2.79–2.68 (m, 1H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 2.46 (dd, <i>J</i> = 17.3, 11.1 Hz, 1H), 2.19–2.08 (m, 1H), 2.07–1.91 (m, 1H), 1.80–1.67 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.96, 149.85, 142.26, 142.01, 140.73, 128.53 (2C), 126.87, 126.02, 123.31, 115.86, 108.10, 100.13, 49.07, 40.27, 39.61, 38.89, 35.59, 34.65, 30.45, 29.19, 28.68. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.09 min, MS (ES) C<sub>24</sub>H<sub>27</sub>N<sub>3</sub>O<sub>4</sub> requires 421, found 422 [M + H]<sup>+</sup>. HRMS C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: calculated 422.208, measured 422.2074, Δppm −1.4.</div></div><div id="sec5_11_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> Synthesis of 6-[1-(2,2-Difluoroethyl)-4-hydroxy-4-piperidyl]-3<i>H</i>-1,3-benzoxazol-2-one (<b>43</b>)</h4><div class="NLM_p last">Compound <b>43</b> was prepared according to general procedure I using 6-bromo-3<i>H</i>-1,3-benzoxazol-2-one (0.150 g, 0.7 mmol), <b>42a</b> (0.171 g, 1.05 mmol), MeMgBr (0.35 mL, 0.125 g, 1.05 mmol, 3 M in Et<sub>2</sub>O), and <i>n-</i>BuLi (0.336 mL, 0.84 mmol, 2.5 M in hexanes) in dry THF (7 mL). The crude was purified by column chromatography (DCM/MeOH, 98:4) to afford <b>43</b> as a white solid (0.063 g, 30%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.37 (d, <i>J</i> = 1.4 Hz, 1H), 7.26 (dd, <i>J</i> = 8.2, 1.7 Hz, 1H), 7.01 (d, <i>J</i> = 8.1 Hz, 1H), 6.14 (tt, <i>J</i> = 55.9, 4.3 Hz, 1H), 4.88 (bs, 1H), 2.82–2.68 (m, 4H), 2.63 (td, <i>J</i> = 11.6, 2.4 Hz, 2H), 1.93 (td, <i>J</i> = 12.8, 4.7 Hz, 2H), 1.57 (dd, <i>J</i> = 13.8, 2.5 Hz, 2H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.11 min, MS (ES) C<sub>14</sub>H<sub>16</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub> requires 298, found 299 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> Synthesis of 6-[1-(2,2-Difluoroethyl)-3,6-dihydro-2<i>H</i>-pyridin-4-yl]-3<i>H</i>-1,3-benzoxazol-2-one (<b>44</b>)</h4><div class="NLM_p last">Compound <b>44</b> was prepared according to general procedure L using <b>43</b> (0.033 g, 0.11 mmol). The crude was purified by SCX to afford <b>44</b> as a pale brown solid (0.031 g, quant.). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.57 (bs, 1H), 7.38 (d, <i>J</i> = 1.6 Hz, 1H), 7.22 (dd, <i>J</i> = 8.2, 1.7 Hz, 1H), 7.03 (d, <i>J</i> = 8.1 Hz, 1H), 6.18 (tt, <i>J</i> = 55.8, 4.3 Hz, 1H), 6.10 (td, <i>J</i> = 3.5, 1.7 Hz, 1H), 3.27–3.19 (m, 2H), 2.92–2.74 (m, 4H), 2.49–2.41 (m, 2H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.56 min, MS (ES) C<sub>14</sub>H<sub>14</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> requires 280, found 281 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> Synthesis of 6-[1-(2,2-Difluoroethyl)-4-piperidyl]-3<i>H</i>-1,3-benzoxazol-2-one (<b>21m</b>)</h4><div class="NLM_p last">Compound <b>21m</b> was prepared according to general procedure B (method B) using <b>44</b> (0.028 g, 0.1 mmol). The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.46 (bs, 1H), 7.20 (d, <i>J</i> = 1.4 Hz, 1H), 7.08–6.95 (m, 2H), 6.14 (tt, <i>J</i> = 55.8, 4.4 Hz, 1H), 3.04–2.95 (m, 2H), 2.75 (td, <i>J</i> = 15.7, 4.4 Hz, 2H), 2.26 (td, <i>J</i> = 11.6, 2.8 Hz, 2H), 1.80–1.56 (m, 4H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.50 min, MS (ES) C<sub>14</sub>H<sub>16</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> requires 282, found 283 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> Synthesis of 6-[1-(2,2-Difluoroethyl)-4-piperidyl]-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>22r</b>)</h4><div class="NLM_p last">Compound <b>22r</b> was prepared according to general procedure D (method A) using <b>21m</b> (0.028 g, 0.1 mmol) and 4-phenylbutyl isocyanate (0.019 mL, 0.019 g, 0.11 mmol) in dry MeCN (2.0 mL). The crude was purified by column chromatography (DCM/EtOAc, 90:10) to afford <b>22r</b> as a white solid (0.033 g, 73% over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (t, <i>J</i> = 5.7 Hz, 1H), 7.95 (d, <i>J</i> = 8.3 Hz, 1H), 7.32–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.15 (m, 3H), 7.15–7.08 (m, 2H), 5.92 (tt, <i>J</i> = 56.0, 4.3 Hz, 1H), 3.44 (q, <i>J</i> = 6.6 Hz, 2H), 3.07 (d, <i>J</i> = 11.6 Hz, 2H), 2.79 (td, <i>J</i> = 15.0, 4.3 Hz, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 2.61–2.49 (m, 1H), 2.34 (td, <i>J</i> = 11.3, 3.5 Hz, 2H), 1.91–1.78 (m, 4H), 1.78–1.66 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.47, 150.61, 149.97, 143.39, 142.04, 128.54 (2C), 128.49, 126.02, 123.62, 115.52 (2C), 108.28, 60.57 (t, <i>J</i><sub>C–F</sub> = 24.9 Hz), 55.07, 42.14, 40.24, 35.59, 33.63, 29.20, 28.69. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.82 min, MS (ES) C<sub>25</sub>H<sub>29</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub> requires 457, found 458 [M + H]<sup>+</sup>. HRMS C<sub>25</sub>H<sub>30</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 458.2255, measured 458.2258, Δppm 0.7.</div></div><div id="sec5_11_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> Synthesis of 2-Nitro-5-(1-piperidyl)phenol (<b>49a</b>)</h4><div class="NLM_p last">Compound <b>49a</b> was prepared according to general procedure G using 5-fluoro-2-nitrophenol (0.150 g, 0.95 mmol), <b>48a</b> (0.265 g, 1.43 mmol), and DIPEA (0.33 mL, 0.25 g, 1.90 mmol) in dry MeCN (8 mL) under MW irradiation. Saturated aqueous NH<sub>4</sub>Cl solution was added, and the aqueous phase was extracted with DCM. The organic layers were collected, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.31 (s, 1H), 7.93 (d, <i>J</i> = 9.7 Hz, 1H), 6.45 (dd, <i>J</i> = 9.7, 2.7 Hz, 1H), 6.31 (d, <i>J</i> = 2.7 Hz, 1H), 3.47 (d, <i>J</i> = 5.8 Hz, 4H), 1.70 (s, 6H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.45 min. MS (ES) C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub> requires 222, found 223 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> Synthesis of 5-(1,1-Dioxo-1,4-thiazinan-4-yl)-2-nitrophenol (<b>49c</b>)</h4><div class="NLM_p last">Compound <b>49c</b> was prepared according to general procedure G using 5-fluoro-2-nitrophenol (0.470 g, 3.00 mmol), <b>48c</b> (0.811 g, 6.00 mmol), and DIPEA (1.05 mL, 0.775 g, 6.00 mmol) in MeCN (15 mL), heating at reflux for 16 h. The crude was purified by column chromatography (EtOAc) to afford <b>49c</b> as a yellow powder (0.33 g, 40%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.85 (bs, 1H), 7.91 (d, <i>J</i> = 9.6 Hz, 1H), 6.73 (dd, <i>J</i> = 9.6, 2.8 Hz, 1H), 6.59 (d, <i>J</i> = 2.8 Hz, 1H), 4.02–3.94 (m, 4H), 3.20–3.14 (m, 4H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.49 min. MS (ES) C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>O<sub>5</sub>S requires 272, found 273 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Synthesis of <i>tert-</i>Butyl 4-(3-Hydroxy-4-nitrophenyl)piperazine-1-carboxylate (<b>49d</b>)</h4><div class="NLM_p last">Compound <b>49d</b> was prepared according to general procedure G using 5-fluoro-2-nitrophenol (2.00 g, 12.73 mmol), <b>48d</b> (3.56 g, 19.09 mmol), and DIPEA (2.47 g, 19.1 mmol) in MeCN (25 mL), heating at reflux for 16 h. The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.94 (bs, 1H), 7.88 (d, <i>J</i> = 9.7 Hz, 1H), 6.64 (dd, <i>J</i> = 9.7, 2.7 Hz, 1H), 6.42 (d, J = 2.7 Hz, 1H), 3.56–3.40 (m, 8H), 1.42 (s, 9H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.36 min, MS (ES) C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub> requires 323, found 324 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Synthesis of 2-Amino-5-(1-piperidyl)phenol (<b>49e</b>)</h4><div class="NLM_p last">Compound <b>49e</b> was prepared according to general procedure B (method A) using <b>49a</b> (0.130 g, 0.59 mmol). After evaporation of the solvent, the crude was used in the next step without purification. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.94 min. MS (ES) C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O requires 192, found 193 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> Synthesis of 2-Amino-5-morpholinophenol (<b>49f</b>)</h4><div class="NLM_p last">Compound <b>49f</b> was prepared according to general procedure B (method A) using the commercially available <b>49b</b> (0.224 g, 1.0 mmol). After evaporation of the solvent, the crude was used in the next step without purification. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.18 min. MS (ES) C<sub>10</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> requires 194, found 195 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> Synthesis of 2-Amino-5-(1,1-dioxo-1,4-thiazinan-4-yl)phenol (<b>49g</b>)</h4><div class="NLM_p last">Compound <b>49g</b> was prepared according to general procedure B (method A) using <b>49c</b> (0.272 g, 1.00 mmol). After evaporation of the solvent, the crude was used in the next step without purification. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.52 min. MS (ES) C<sub>10</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>S requires 242, found 243 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> Synthesis of <i>tert</i>-Butyl 4-(4-Amino-3-hydroxyphenyl)piperazine-1-carboxylate (<b>49h</b>)</h4><div class="NLM_p last">Compound <b>49h</b> was prepared according to general procedure B (method B) using <b>49d</b> (4.11 g, 12.73 mmol). After evaporation of the solvent, the crude was used in the next step without purification. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.77 min. MS (ES) C<sub>15</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub> requires 293, found 294 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> Synthesis of 6-(1-Piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>50a</b>)</h4><div class="NLM_p last">Compound <b>50a</b> was prepared according to general procedure C using <b>49e</b> (0.110 g, 0.58 mmol) and CDI (0.141 g, 0.87 mmol) in dry MeCN (6 mL). The pink solid was triturated with Et<sub>2</sub>O to afford <b>50a</b> as a pinkish solid (0.165 g, 80% over three steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.26 (bs, 1H), 6.93 (d, <i>J</i> = 2.2 Hz, 1H), 6.90 (d, <i>J</i> = 8.5 Hz, 1H), 6.70 (dd, <i>J</i> = 2.3, 8.5 Hz, 1H), 3.08–2.93 (m, 4H), 1.61 (p, <i>J</i> = 5.7 Hz, 4H), 1.50 (p, <i>J</i> = 5.7 Hz, 2H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.38 min. MS (ES) C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> requires 218, found 219 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> Synthesis of 6-Morpholino-3<i>H</i>-1,3-benzoxazol-2-one (<b>50b</b>)</h4><div class="NLM_p last">Compound <b>50b</b> was prepared according to general procedure C using <b>49f</b> (0.194 g, 1.00 mmol) and CDI (0.243 g, 1.50 mmol) in dry MeCN (10 mL). The crude was purified by column chromatography (Cy/EtOAc, 70:30) to afford <b>50b</b> as a pink powder (0.132 g, 60%, over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.31 (bs, 1H), 6.98 (d, <i>J</i> = 2.3 Hz, 1H), 6.94 (d, <i>J</i> = 8.5 Hz, 1H), 6.72 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 3.81–3.65 (m, 4H), 3.10–2.93 (m, 4H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.32 min. MS (ES) C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub> requires 220, found 221 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> Synthesis of 6-(1,1-Dioxo-1,4-thiazinan-4-yl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>50c</b>)</h4><div class="NLM_p last">Compound <b>50c</b> was prepared according to general procedure C using <b>49g</b> (0.242 g, 1.0 mmol) and CDI (0.162 g, 1.0 mmol) in dry MeCN (10 mL). The crude was purified by column chromatography (Cy/EtOAc 70:30) to afford <b>50c</b> as a yellow solid (0.120 g, 45% over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.94 (d, <i>J</i> = 2.4 Hz, 1H), 6.87 (d, <i>J</i> = 8.4 Hz, 1H), 6.72 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 3.70–3.65 (m, 4H), 3.17–3.12 (m, 4H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.15 min. MS (ES) C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>4</sub>S requires 268, found 267 [M-H]<sup>−</sup>.</div></div><div id="sec5_11_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> Synthesis of <i>tert</i>-Butyl 4-(2-Oxo-3<i>H</i>-1,3-benzoxazol-6-yl)piperazine-1-carboxylate (<b>50d</b>)</h4><div class="NLM_p last">Compound <b>50d</b> was prepared according to general procedure C using <b>49h</b> (3.73 g, 12.73 mmol) and CDI (3.096 g, 19.09 mmol) in dry MeCN (25 mL). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>50d</b> as a pink powder (3.046 g, 75% over three steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.34 (bs, 1H), 7.00 (d, <i>J</i> = 2.2 Hz, 1H), 6.94 (d, <i>J</i> = 8.5 Hz, 1H), 6.74 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 3.50–3.40 (m, 4H), 3.05–2.96 (m, 4H), 1.42 (s, 9H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.14 min, MS (ES) C<sub>16</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub> requires 319, found 320 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> Synthesis of 6-Piperazin-1-yl-3<i>H</i>-1,3-benzoxazol-2-one Hydrochloride (<b>50e</b>)</h4><div class="NLM_p last">Compound <b>50e</b> was prepared according to general procedure E using <b>50d</b> (1.50 g, 4.70 mmol). The reaction mixture was concentrated under reduced pressure to afford <b>50e</b> as a gray solid (1.198 g, quant.). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.41 (bs, 1H), 8.80 (bs, 2H), 7.05 (d, <i>J</i> = 2.2 Hz, 1H), 6.97 (d, <i>J</i> = 8.5 Hz, 1H), 6.77 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 3.31–3.18 (m, 8H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.55 min. MS (ES) C<sub>11</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub> requires 219, found 220 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> Synthesis of 6-(4-Methylpiperazin-1-yl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>50f</b>)</h4><div class="NLM_p last">Compound <b>50f</b> was prepared according to general procedure F using <b>50e</b> (0.388 g, 1.52 mmol), 37% aqueous solution of formaldehyde (0.17 mL, 6.08 mmol), NaBH(OAc)<sub>3</sub> (0.21 g, 1.0 mmol), and AcOH (0.096 mL, 0.101 g, 1.68 mmol) in dry MeCN (5 mL). The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.97–6.90 (m, 2H), 6.73–6.69 (m, 1H), 3.09–3.02 (m, 4H), 2.47–2.41 (m, 4H) 2.22 (s, 3H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.85 min. MS (ES) C<sub>12</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub> requires 233, found 234 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> Synthesis of 6-(4-Ethylpiperazin-1-yl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>50g</b>)</h4><div class="NLM_p last">Compound <b>50g</b> was prepared according to general procedure F using <b>50e</b> (0.171 g, 0.67 mmol), NaBH(OAc)<sub>3</sub> (0.21 g, 1.0 mmol), AcOH (0.096 mL, 0.101 g, 1.68 mmol), and acetaldehyde (0.14 mL, 0.70 mmol, 5 M in THF) in dry THF (7 mL). The crude was purified by SCX to afford <b>50g</b> as a white solid (0.150 g, 90%). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.88 min. MS (ES) C<sub>13</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> requires 247, found 248 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> Synthesis of 6-(4-Isopropylpiperazin-1-yl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>50h</b>)</h4><div class="NLM_p last">Compound <b>50h</b> was prepared according to general procedure F using <b>50e</b> (0.256 g, 1.00 mmol), NaBH(OAc)<sub>3</sub> (0.636 g, 3.0 mmol), and AcOH (0.286 mL, 0.300 g, 5.00 mmol) in acetone (10 mL). The crude was purified by SCX to afford <b>50h</b> as a white solid (0.158 g, 60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d<sub>6</sub></i>) δ 11.40 (bs, 1H), 7.10–7.03 (m, 1H), 6.97 (d, <i>J</i> = 8.5 Hz, 1H), 6.78 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 3.94–2.79 (m, overlapped with H<sub>2</sub>O signal, 9H), 1.25 (s, 6H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.99 min, MS (ES) C<sub>14</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub> requires 261, found 262 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> Synthesis of 6-(4-Isobutylpiperazin-1-yl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>50i</b>)</h4><div class="NLM_p last">Compound <b>50i</b> was prepared according to general procedure F using <b>50e</b> (0.256 g, 1.0 mmol), isobutyraldehyde (0.361 g, 5.0 mmol), NaBH(OAc)<sub>3</sub> (0.318 g, 1.50 mmol), and AcOH (0.286 mL, 0.300 g, 5.0 mmol) in dry MeCN (10 mL). The crude was purified by SCX to afford <b>50i</b> as a violet solid (0.220 g, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.88–6.80 (m, 2H), 6.63 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 3.09–2.83 (m, 4H), 2.47–2.39 (m, 4H), 2.07 (d, <i>J</i> = 7.4 Hz, 2H), 1.78 (dt, <i>J</i> = 13.6, 6.8 Hz, 1H), 0.87 (d, <i>J</i> = 6.6 Hz, 6H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.21 min. MS (ES) C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub> requires 275, found 276 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-6-piperidin-1-ium-1-yl-1,3-benzoxazole-3-carboxamide Hydrochloride (<b>23a</b>)</h4><div class="NLM_p last">Compound <b>23a</b> was prepared according to general procedure D (method A) using <b>50a</b> (0.055 g, 0.25 mmol) and 4-phenylbutyl isocyanate (0.047 mL, 0.049 g, 0.86 mmol) in a mixture of toluene/DMF (3 mL, 9:1). The crude was purified by column chromatography (Cy) (0.029 g, 30%). The free base of <b>23a</b> was dissolved in DCM (0.7 mL, 0.1 M) followed by the addition of HCl (0.55 mL, 0.08 g, 2.14 mmol, 4 M in 1,4-dioxane). After evaporation of the solvent, the residue was triturated with Et<sub>2</sub>O to afford <b>23a</b> as a white solid (0.026 g, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.10 (t, <i>J</i> = 5.8 Hz, 1H), 8.06–7.83 (m, 2H), 7.82–7.46 (m, 1H), 7.32–7.24 (m, 2H), 7.23–7.13 (m, 3H), 4.63 (bs, 1H), 3.58–3.40 (m, 4H), 3.34 (q, <i>J</i> = 6.4 Hz, 2H), 2.61 (t, <i>J</i> = 7.2 Hz, 2H), 2.22–1.79 (m 4H), 1.78–1.51 (m, 6H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 152.59, 149.20, 141.91, 141.89, 139.51, 129.29, 128.52, 128.50, 126.05, 118.19, 116.86, 105.34, 58.14, 40.39, 35.52, 29.06, 28.63, 23.14, 21.80. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.33 min. MS (ES) C<sub>23</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub> requires 393, found 394 [M + H]<sup>+</sup>. HRMS C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 394.2131, measured: 394.2122, Δppm −2.3.</div></div><div id="sec5_11_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> Synthesis of 6-Morpholino-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>23b</b>)</h4><div class="NLM_p last">Compound <b>23b</b> was prepared according to general procedure D (method A) using <b>50b</b> (0.130 g, 0.6 mmol) and 4-phenylbutyl isocyanate (0.157 g, 0.9 mmol) in dry MeCN (6 mL). The crude was purified by column chromatography (Cy/EtOAc, 90:10) to afford <b>23b</b> as a white powder (0.142 g, 60%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (t, <i>J</i> = 5.7 Hz, 1H), 7.91 (d, <i>J</i> = 8.6 Hz, 1H), 7.32–7.24 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.20–7.07 (m, 3H), 6.90–6.78 (m, 2H), 3.95–3.82 (m, 4H), 3.44 (q, <i>J</i> = 6.6 Hz, 2H), 3.20–3.10 (m, 4H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 1.78–1.60 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.48, 150.00, 142.91, 142.05, 128.54, 128.51, 126.01, 115.97, 112.77, 98.66, 66.76, 50.27, 40.22, 35.60, 29.22, 28.70. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.63 min. MS (ES) C<sub>22</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub> requires 395, found 396 [M + H]<sup>+</sup>. HRMS C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: calculated 396.1923, measured 396.1925, Δppm 0.5.</div></div><div id="sec5_11_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> Synthesis of 6-(1,1-Dioxo-1,4-thiazinan-4-yl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>23c</b>)</h4><div class="NLM_p last">Compound <b>23c</b> was prepared according to general procedure D (method A) using <b>50c</b> (0.100 g, 0.37 mmol) and 4-phenylbutyl isocyanate (0.20 g, 1.12 mmol) in dry MeCN (4 mL). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>23c</b> as a white powder (0.050 g, 20%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.06 (t, <i>J</i> = 5.8 Hz, 1H), 7.71 (d, <i>J</i> = 8.8 Hz, 1H), 7.32–7.24 (m, 2H), 7.24–7.12 (m, 4H), 6.94 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 3.87–3.67 (m, 4H), 3.42–3.26 (m, 2H), 3.21–3.06 (m, 4H), 2.61 (t, <i>J</i> = 7.2 Hz, 2H), 1.73–1.43 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 152.82, 149.82, 145.77, 143.21, 142.51, 128.76, 128.70, 126.14, 121.16, 115.39, 112.38, 99.29, 50.27, 47.85, 39.90, 35.22, 29.10, 28.63. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.49 min. MS (ES) C<sub>22</sub>H<sub>25</sub>N<sub>3</sub>O<sub>5</sub>S requires 443, found 267 [M–CO(CH<sub>2</sub>)<sub>4</sub>Ph)]<sup>−</sup>. HRMS C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O5S [M + H]<sup>+</sup>: calculated 444.1593, measured 444.1588, Δppm −1.1.</div></div><div id="sec5_11_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> Synthesis of <i>tert</i>-Butyl 4-[2-Oxo-3-(4-phenylbutylcarbamoyl)-1,3-benzoxazol-6-yl]piperazine-1-carboxylate (<b>23d</b>)</h4><div class="NLM_p last">Compound <b>23d</b> was prepared according to general procedure D (method A) using <b>50d</b> (0.10 g, 0.31 mmol), 4-phenylbutyl isocyanate (0.060 g, 0.34 mmol), and DMAP (0.042 g, 0.34 mmol) in dry MeCN (3 mL). The crude was purified by column chromatography (DCM/MeOH, 97:3) to afford <b>23d</b> as a white solid (0.130 g, 85%). UPLC/MS (<i>method B</i>): <i>R<sub>t</sub></i> 2.21 min, MS (ES) C<sub>27</sub>H<sub>34</sub>N<sub>4</sub>O<sub>5</sub> requires 494, found 495 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> Synthesis of 2-Oxo-<i>N</i>-(4-phenylbutyl)-6-piperazin-1-yl-1,3-benzoxazole-3-carboxamide Hydrochloride (<b>23e</b>)</h4><div class="NLM_p last">Compound <b>23e</b> was prepared according to general procedure E using <b>23d</b> (0.120 g, 0.24 mmol). The reaction mixture was concentrated under reduced pressure to afford <b>23e</b> as a white solid (0.103 g, quant.). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.53 (bs, 2H), 8.06 (t, <i>J</i> = 5.8 Hz, 1H), 7.72 (d, <i>J</i> = 8.8 Hz, 1H), 7.33–7.24 (m, 2H), 7.24–7.11 (m, 4H), 6.90 (dd, <i>J</i> = 8.9, 2.4 Hz, 1H), 3.44–3.35 (m, 4H), 3.32 (q, <i>J</i> = 6.4 Hz, 2H), 3.27–3.15 (m, 4H), 2.62 (t, <i>J</i> = 7.2 Hz, 2H), 1.76–1.49 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 152.35, 149.33, 147.49, 142.50, 142.02, 128.28, 128.22, 125.66, 121.16, 114.71, 112.07, 98.98, 45.99, 42.35, 39.42, 34.74, 28.62, 28.14. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.12 min, MS (ES) C<sub>22</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub> requires 394, found 395 [M + H]<sup>+</sup>. HRMS C<sub>22</sub>H<sub>27</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 395.2083, measured 395.2086, Δppm 1.4.</div></div><div id="sec5_11_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> Synthesis of 6-(4-Methylpiperazin-1-yl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>23f</b>)</h4><div class="NLM_p last">Compound <b>23f</b> was prepared according to general procedure D (method A) using <b>50f</b> (0.060 g, 0.26 mmol) and 4-phenylbutyl isocyanate (0.088 mL, 0.090 g, 0.51 mmol) in dry MeCN (3 mL). The crude was purified by column chromatography (DCM/MeOH, 98:2) to afford <b>23f</b> as a white powder (0.080 g, 75%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (t, <i>J</i> = 5.8 Hz, 1H), 7.93–7.85 (m, 1H), 7.33–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.14 (m, 3H), 6.86–6.77 (m, 2H), 3.43 (q, <i>J</i> = 6.4 Hz, 2H), 3.37–3.18 (m, 4H), 2.83–2.70 (m, 4H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H) 2.47 (s, 3H), 1.80–1.61 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.52, 150.03, 142.90, 142.06, 128.55, 128.52, 126.01, 115.93, 113.26, 99.01, 54.79, 49.32, 45.66, 40.21, 35.60, 29.23, 28.71. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.23 min. MS (ES) C<sub>23</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub> requires 408, found 409 [M + H]<sup>+</sup>. HRMS C<sub>23</sub>H<sub>29</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 409.224, measured 409.224, Δppm 0.0.</div></div><div id="sec5_11_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> Synthesis of 6-(4-Ethylpiperazin-1-yl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>23g</b>)</h4><div class="NLM_p last">Compound <b>23g</b> was prepared according to general procedure D (method A) using <b>50g</b> (0.100 g, 0.40 mmol) and 4-phenylbutyl isocyanate (0.077 g, 0.44 mmol) in dry MeCN (4 mL). The crude was purified by column chromatography (DCM/MeOH, 95:5) to afford <b>23g</b> as a yellow solid (0.109 g, 64%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00 (t, <i>J</i> = 5.8 Hz, 1H), 7.87 (d, <i>J</i> = 9.5 Hz, 1H), 7.32–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.14 (m, 3H), 6.83–6.77 (m, 2H), 3.43 (q, <i>J</i> = 6.6 Hz, 2H), 3.24–3.16 (m, 4H), 2.66 (t, <i>J</i> = 7.3 Hz, 2H), 2.64–2.59 (m, 4H), 2.49 (q, <i>J</i> = 7.2 Hz, 2H), 1.78–1.60 (m, overlapped with H<sub>2</sub>O signal, 4H), 1.14 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.57, 150.07, 149.47, 142.92, 142.06, 128.54, 128.50, 125.99, 120.71, 115.82, 112.81, 98.52, 52.79, 52.44, 49.78, 40.18, 35.59, 29.23, 28.70, 12.10. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.24 min, MS (ES) C<sub>24</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub> requires 422, found 423 [M + H]<sup>+</sup>. HRMS C<sub>24</sub>H<sub>31</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 423.2396, measured 423.2397, Δppm 0.2.</div></div><div id="sec5_11_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> Synthesis of 6-(4-Isopropylpiperazin-1-yl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>23h</b>)</h4><div class="NLM_p last">Compound <b>23h</b> was prepared according to general procedure D (method A) using <b>50h</b> (0.100 g, 0.38 mmol) and 4-phenylbutyl isocyanate (0.074 g, 0.42 mmol) in dry MeCN (4 mL). The crude was purified by column chromatography (DCM/MeOH, 95:5) to afford <b>23h</b> as a pink solid (0.050 g, 30%). <sup>1</sup>H NMR (400 MHz, , CDCl<sub>3</sub>) δ 8.00 (t, <i>J</i> = 5.7 Hz, 1H), 7.87 (d, <i>J</i> = 9.5 Hz, 1H), 7.32–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.14 (m, 3H), 6.83–6.77 (m, 2H), 3.43 (q, <i>J</i> = 6.7 Hz, 2H), 3.27–3.11 (m, 4H), 2.79–2.69 (m, 5H), 2.67 (t, <i>J</i> = 7.3 Hz, 2H), 1.80–1.60 (m, 4H), 1.10 (d, <i>J</i> = 6.5 Hz, 6H). <sup>13</sup>C NMR (101 MHz, , CDCl<sub>3</sub>) δ 153.56, 150.07, 149.43, 142.90, 142.06, 128.53, 128.49, 125.99, 120.77, 115.82, 112.89, 98.57, 54.86, 49.96, 48.65, 40.17, 35.59, 29.22, 28.69, 18.59. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.31 min, MS (ES) C<sub>25</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub> requires 436, found 437 [M + H]<sup>+</sup>. HRMS C<sub>25</sub>H<sub>33</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 437.2553, measured 437.2557, Δppm 0.9.</div></div><div id="sec5_11_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> Synthesis of 6-(4-Isobutylpiperazin-1-Yl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>23i</b>)</h4><div class="NLM_p last">Compound <b>23i</b> was prepared according to general procedure D (method A) using <b>50i</b> (0.100 g, 0.36 mmol) and 4-phenylbutyl isocyanate (0.07 mL, 0.07 g, 0.4 mmol) in dry MeCN (4 mL). The crude was purified by column chromatography (DCM/MeOH, 95:5) to afford <b>23i</b> as a white solid (0.116 g, 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00 (t, <i>J</i> = 5.7 Hz, 1H), 7.87 (d, <i>J</i> = 9.5 Hz, 1H), 7.32–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.22–7.14 (m, 3H), 6.83–6.77 (m, 2H), 3.43 (q, <i>J</i> = 6.7 Hz, 2H), 3.26–3.10 (m, 4H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 2.61–2.46 (m, 4H), 2.22–2.06 (m, 2H), 1.90–1.78 (m, 1H), 1.77–1.62 (m, 4H), 0.93 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 150.11, 149.62, 142.93, 142.08, 128.55, 128.51, 126.00, 115.79, 112.76, 98.45, 66.91, 53.51, 49.79, 40.19, 35.60, 29.24, 28.71, 25.56, 21.06. UPLC/MS (<i>method B</i>): <i>R<sub>t</sub></i> 2.08 min. MS (ES) C<sub>26</sub>H<sub>34</sub>N<sub>4</sub>O<sub>3</sub> requires 450, found 451 [M + H]<sup>+</sup>. HRMS C<sub>26</sub>H<sub>35</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 451.2719, measured: 451.2716, Δppm 1.6.</div></div><div id="sec5_11_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> Synthesis of 4-(3-Benzyloxy-4-nitrophenyl)-1-methylpiperazin-2-one (<b>52a</b>)</h4><div class="NLM_p last">Compound <b>52a</b> was prepared according to general procedure G using 2-benzyloxy-4-fluoro-1-nitrobenzene (0.490 g, 2.00 mmol), <b>51a</b> (0.300 g, 2.00 mmol), and Et<sub>3</sub>N (0.55 mL, 0.405 g, 4.00 mmol) in dry MeCN (20 mL), heating at reflux for 16 h. The crude was purified by column chromatography (EtOAc) to afford <b>52a</b> as a yellow solid (0.350 g, 60%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (d, <i>J</i> = 9.3 Hz, 1H), 7.51 (d, <i>J</i> = 7.2 Hz, 2H), 7.40 (t, <i>J</i> = 7.4 Hz, 2H), 7.33 (dd, <i>J</i> = 8.4, 6.3 Hz, 1H), 6.38 (dd, <i>J</i> = 9.3, 2.6 Hz, 1H), 6.29 (d, <i>J</i> = 2.5 Hz, 1H), 5.23 (s, 2H), 3.98 (s, 2H), 3.61 (dd, <i>J</i> = 6.5, 4.2 Hz, 2H), 3.50 (dd, <i>J</i> = 6.5, 4.2 Hz, 2H), 3.07 (s, 3H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.98 min, MS (ES) C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>4</sub> requires 341, found 342 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> Synthesis of 1-(3-Benzyloxy-4-nitrophenyl)-4-methylpiperazin-2-one (<b>52b</b>)</h4><div class="NLM_p last">To a solution of 2-benzyloxy-4-bromo-1-nitrobenzene (1.00 g, 3.25 mmol, 1.0 equiv.) in degassed 1,4-dioxane (26 mL) were added <b>51b</b> (0.410 g, 3.6 mmol, 1.1 equiv.), K<sub>3</sub>PO<sub>4</sub> (1.38 g, 6.50 mmol, 2.0 equiv.), and <i>N</i>,<i>N</i>′-dimethylethylenediamine (0.06 g, 0.07 mL, 0.65 mmol, 0.2 equiv.). The reaction mixture was degassed for another 15 min, and then copper(I) iodide (0.06 g, 0.33 mmol, 0.1 equiv.) was added. The reaction was refluxed for 24 h, then diluted with EtOAc, and filtered through a pad of Celite. The filtrate was concentrated under reduced pressure, and the crude was purified by column chromatography (EtOAc) to afford <b>52b</b> as an orange solid (0.554 g, 50%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.93 (d, <i>J</i> = 8.8 Hz, 1H), 7.46 (d, <i>J</i> = 7.3 Hz, 2H), 7.43–7.36 (m, 2H), 7.36–7.30 (m, 2H), 6.97 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 5.22 (s, 2H), 3.72 (t, <i>J</i> = 5.1 Hz, 2H), 3.33 (s, 2H), 2.83 (s, 2H), 2.43 (s, 3H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.74 min. MS (ES) C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>4</sub> requires 341, found 342 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> Synthesis of 4-(4-Amino-3-hydroxyphenyl)-1-methylpiperazin-2-one (<b>49i</b>)</h4><div class="NLM_p last">Compound <b>49i</b> was prepared according to general procedure B (method A) using <b>52a</b> (0.341 g, 1.00 mmol). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.89 min. MS (ES) C<sub>11</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub> requires 221, found 222 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> Synthesis of 1-(4-Amino-3-hydroxyphenyl)-4-methylpiperazin-2-one (<b>49j</b>)</h4><div class="NLM_p last">Compound <b>49j</b> was prepared according to general procedure B (method A) using <b>52b</b> (0.50 g, 1.46 mmol). UPLC/MS (<i>method C</i>): <i>R<sub>t</sub></i> 1.42 min. MS (ES) C<sub>11</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub> requires 221, found 222 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> Synthesis of 6-(4-Methyl-3-oxo-piperazin-1-yl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>50j</b>)</h4><div class="NLM_p last">Compound <b>50j</b> was prepared according to general procedure C using <b>49i</b> (0.221 g, 1.00 mmol) and CDI (0.162 g, 1.00 mmol) in dry MeCN (10 mL). The crude was purified by column chromatography (DCM/MeOH, 90:10) to afford <b>50j</b> as a violet solid (0.197 g, 80% over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.95 (d, <i>J</i> = 8.5 Hz, 1H), 6.82 (d, <i>J</i> = 2.3 Hz, 1H), 6.67 (dd, <i>J</i> = 2.3, 8.5 Hz, 1H), 3.81 (s, 2H), 3.48 (dd, <i>J</i> = 3.4, 5.8 Hz, 2H), 3.42 (dd, <i>J</i> = 4.0, 6.2 Hz, 2H), 3.04 (s, 3H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.16 min. MS (ES) C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub> requires 247, found 248 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> Synthesis of 6-(4-Methyl-2-oxo-piperazin-1-yl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>50k</b>)</h4><div class="NLM_p last">Compound <b>50k</b> was prepared according to general procedure C using <b>49j</b> (0.323 g, 1.46 mmol) and CDI (0.240 g, 1.46 mmol) in dry MeCN (15 mL). The crude was purified by column chromatography (DCM/MeOH, 80:20) to afford <b>50k</b> as orange oil (0.270 g, 70% over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.73–7.65 (m, 1H), 7.03–6.86 (m, 2H), 3.76–3.66 (m, 2H), 3.29 (s, 2H), 2.87–2.68 (m, 2H), 2.42 (s, 4H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.16 min. MS (ES) C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub> requires 247, found 248 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> Synthesis of 6-(4-Methyl-3-oxo-piperazin-1-yl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>23j</b>)</h4><div class="NLM_p last">Compound <b>23j</b> was prepared according to general procedure D (method A) using <b>50j</b> (0.170 g, 0.69 mmol) and 4-phenylbutyl isocyanate (0.13 mL, 0.130 g, 0.76 mmol) in dry MeCN (7 mL). The crude was purified by column chromatography (DCM/MeOH, 90:10) to afford <b>23j</b> as a white solid (0.060 g, 20%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (t, <i>J</i> = 5.3 Hz, 1H), 7.93 (d, <i>J</i> = 8.7 Hz, 1H), 7.32–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 2H), 7.21–7.14 (m, 3H), 6.82–6.73 (m, 2H), 3.85 (s, 2H), 3.54–3.46 (m, 4H), 3.44 (q, <i>J</i> = 6.7 Hz, 2H), 3.05 (s, 3H), 2.67 (t, <i>J</i> = 7.1 Hz, 2H), 1.77–1.62 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 128.54 (2C), 126.05, 120.78, 115.97, 107.97, 47.76, 46.79, 40.34, 35.58, 35.35, 29.15, 28.67. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.32 min. MS (ES) C<sub>23</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub> requires 422, found 423 [M + H]<sup>+</sup>. HRMS C<sub>23</sub>H<sub>27</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: calculated 423.2032, measured: 423.202, Δppm −2.8.</div></div><div id="sec5_11_101" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> Synthesis of 6-(4-Methyl-2-oxo-piperazin-1-yl)-2-oxo-<i>N</i>-(4-phenylbutyl)-1,3-benzoxazole-3-carboxamide (<b>23k</b>)</h4><div class="NLM_p last">Compound <b>23k</b> was prepared according to general procedure D (method A) using <b>50k</b> (0.288 g, 1.17 mmol) and 4-phenylbutyl isocyanate (0.22 mL, 0.225 g, 1.28 mmol) in dry MeCN (8 mL). The crude was purified by column chromatography (DCM/MeOH, 90:10) to afford <b>23k</b> as a white solid (0.049 g, 10%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.08 (d, <i>J</i> = 8.6 Hz, 1H), 7.98 (t, <i>J</i> = 5.5 Hz, 1H), 7.31–7.26 (m, overlapped with CDCl<sub>3</sub> signal, 3H), 7.24–7.13 (m, 4H), 3.76 (s, 2H), 3.44 (q, <i>J</i> = 6.7 Hz, 2H), 3.33 (s, 2H), 2.93–2.80 (m, 2H), 2.67 (t, <i>J</i> = 7.2 Hz, 2H), 2.45 (s, 3H), 1.79–1.63 (m, 4H).<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.26, 149.71, 142.03, 141.92, 128.56, 128.55, 126.92, 126.05, 122.56, 116.07, 109.05, 59.54, 52.08, 50.30, 45.11, 40.32, 35.60, 29.18, 28.70. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.94 min. MS (ES) C<sub>23</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub> requires 422, found 423 [M + H]<sup>+</sup>. HRMS C<sub>23</sub>H<sub>27</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: calculated 423.2032, measured: 423.2026, Δppm −1.4.</div></div><div id="sec5_11_102" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> Synthesis of <i>tert</i>-Butyl 4-(4-Hydroxy-3-nitrophenyl)-3,6-dihydro-2<i>H</i>-pyridine-1-carboxylate (<b>32a</b>)</h4><div class="NLM_p last">Compound <b>32a</b> was prepared according to general procedure A using 4-bromo-2-nitrophenol (0.500 g, 2.29 mmol), <b>18c</b> (0.92 g, 2.98 mmol), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>4</sub> (0.016 g, 0.023 mmol), and 2 M Na<sub>2</sub>CO<sub>3</sub> (2.87 mL, 5.73 mmol) in degassed 1,4-dioxane (25 mL). The crude was purified by column chromatography (heptane/EtOAc, 90:10) to afford <b>32a</b> as yellow oil (0.700 g, 95%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.54 (s, 1H), 8.07 (d, <i>J</i> = 2.2 Hz, 1H), 7.65 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 7.14 (d, <i>J</i> = 8.8 Hz, 1H), 6.07 (s, 1H), 4.09 (d, <i>J</i> = 2.8 Hz, 2H), 3.65 (t, <i>J</i> = 5.7 Hz, 2H), 3.53 (t, <i>J</i> = 5.8 Hz, 2H), 1.47 (s, 9H). UPLC/MS (<i>method B</i>): <i>R<sub>t</sub></i> 1.48 min. MS (ES) C<sub>16</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub> requires 320, found 319 [M–H]<sup>−</sup>.</div></div><div id="sec5_11_103" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> Synthesis of <i>tert</i>-Butyl 4-(3-Amino-4-hydroxyphenyl)piperidine-1-carboxylate (<b>32b</b>)</h4><div class="NLM_p last">Compound <b>32b</b> was prepared according to general procedure B (method A) using <b>32a</b> (0.078 g, 0.24 mmol). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.51 min. MS (ES) C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub> requires 292, found 291 [M-H]<sup>−</sup>.</div></div><div id="sec5_11_104" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> Synthesis of <i>tert</i>-Butyl 4-(2-Oxo-3<i>H</i>-1,3-benzoxazol-5-yl)piperidine-1-carboxylate (<b>33</b>)</h4><div class="NLM_p last">Compound <b>33</b> was prepared according to general procedure C using <b>32b</b> (0.070 g, 0.24 mmol) and CDI (0.058 g, 0.36 mmol) in dry MeCN (2.5 mL). The crude was purified by column chromatography (Cy/EtOAc, 70:30) to afford <b>33</b> as a white solid (0.046 g, 60% over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.55 (bs, 1H), 7.22–7.14 (m, 1H), 6.99–6.90 (m, 2H), 4.07 (d, <i>J</i> = 13.0 Hz, 2H), 2.98–2.56 (m, 3H), 1.84–1.65 (m, 2H), 1.54–1.44 (m, 2H), 1.42 (s, 9H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.20 min. MS (ES) C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> requires 318, found 319 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_105" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> Synthesis of <i>tert</i>-Butyl 4-[3-(Isobutylcarbamoyl)-2-oxo-1,3-benzoxazol-5-yl]piperidine-1-carboxylate (<b>24a</b>)</h4><div class="NLM_p last">Compound <b>24a</b> was prepared according to general procedure D (method B) using <b>33</b> (0.200 g, 0.63 mmol), isobutylamine (0.094 mL, 0.069 g, 0.94 mmol), and Et<sub>3</sub>N (0.44 mL, 0.318 g, 3.14 mmol) in dry DCM (7 mL). The crude was purified by column chromatography (Cy/EtOAc, 90:10) to afford <b>24a</b> as a white solid (0.186 g, 70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.16 (t, <i>J</i> = 5.8 Hz, 1H), 7.98 (d, <i>J</i> = 1.8 Hz, 1H), 7.18 (d, <i>J</i> = 8.3 Hz, 1H), 7.08 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 4.27 (d, <i>J</i> = 13.2 Hz, 2H), 3.28 (dd, <i>J</i> = 6.8, 5.9 Hz, 2H), 2.89–2.65 (m, 3H), 2.02–1.76 (m, 3H), 1.72–1.59 (m, 2H), 1.50 (s, 9H), 1.02 (d, <i>J</i> = 6.7 Hz, 6H). UPLC/MS (<i>method B</i>): <i>R<sub>t</sub></i> 2.07 min. MS (ES) C<sub>22</sub>H<sub>31</sub>N<sub>3</sub>O<sub>5</sub> requires 417, found 418 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_106" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> Synthesis of <i>N</i>-Isobutyl-2-oxo-5-(4-piperidyl)-1,3-benzoxazole-3-carboxamide Hydrochloride (<b>24b</b>)</h4><div class="NLM_p last">Compound <b>24b</b> was prepared according to general procedure E using <b>24a</b> (0.160 g, 0.38 mmol). The crude was triturated with Et<sub>2</sub>O to afford <b>24b</b> as a white solid (0.128 g, 95%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.16 (bs, 1H), 8.96 (bs, 1H), 8.14 (t, <i>J</i> = 5.9 Hz, 1H), 7.83 (d, <i>J</i> = 1.8 Hz, 1H), 7.39 (d, <i>J</i> = 8.3 Hz, 1H), 7.13 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 3.37 (s, 1H), 3.17 (t, <i>J</i> = 6.4 Hz, 2H), 3.08–2.81 (m, 3H), 2.00–1.77 (m, 5H), 0.92 (d, <i>J</i> = 6.7 Hz, 6H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.78 min. MS (ES) C<sub>17</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub> requires 317, found 318 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_107" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> Synthesis of <i>N</i>-Isobutyl-5-(1-methyl-4-piperidyl)-2-oxo-1,3-benzoxazole-3-carboxamide (<b>24c</b>)</h4><div class="NLM_p last">Compound <b>24c</b> was prepared according to general procedure F using <b>24b</b> (0.088 g, 0.25 mmol), 37% aqueous solution of formaldehyde (0.038 mL, 1.25 mmol), NaBH(OAc)<sub>3</sub> (0.106 g, 0.5 mmol), and AcOH (0.03 mL, 0.024 g, 0.4 mmol) in dry MeCN (3 mL). The crude was triturated with Et<sub>2</sub>O to afford <b>24c</b> as a white solid (0.07 g, 83%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.14 (t, <i>J</i> = 5.1 Hz, 1H), 7.80 (s, 1H), 7.33 (d, <i>J</i> = 8.3 Hz, 1H), 7.15 (d, <i>J</i> = 8.4 Hz, 1H), 3.15–3.07 (t, <i>J</i> = 6.4 Hz, 2H), 2.94–2.79 (m, 2H), 2.59–2.43 (m, overlapped with DMSO signal, 1H), 2.20 (s, 3H), 2.06–1.91 (m, 2H), 1.91–1.79 (m, 1H), 1.79–1.54 (m, 4H), 0.92 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 152.56, 149.50, 142.88, 139.85, 128.14, 122.36, 112.74, 109.60, 55.68, 46.79, 46.12, 41.27, 33.32, 27.90, 19.77. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.81 min. MS (ES) C<sub>18</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> requires 331, found 332 [M + H]<sup>+</sup>. HRMS C<sub>18</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 332.1974, measured: 332.1964, Δppm −3.0.</div></div><div id="sec5_11_108" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> Synthesis of <i>tert</i>-Butyl 4-Hydroxy-4-(2-oxo-3<i>H</i>-1,3-benzoxazol-7-yl)piperidine-1-carboxylate (<b>45</b>)</h4><div class="NLM_p last">Compound <b>45</b> was prepared according to general procedure I using <b>42b</b> (0.793 g, 3.98 mmol), 7-bromo-3<i>H</i>-1,3-benzoxazol-2-one (0.500 g, 2.34 mmol), MeMgBr (1.17 mL, 0.418 g, 3.51 mmol, 3 M in Et<sub>2</sub>O), and <i>n-</i>BuLi (1.12 mL, 2.81 mmol, 2.5 M in hexanes) in dry THF (25 mL). The crude was purified by column chromatography (Cy/EtOAc, 35:65) to afford <b>45</b> as a white solid (0.345 g, 44%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.60 (bs, 1H), 7.26 (dd, <i>J</i> = 8.1, 1.3 Hz, 1H), 7.12 (t, <i>J</i> = 7.9 Hz, 1H), 6.97 (dd, <i>J</i> = 7.7, 1.3 Hz, 1H), 5.34 (s, 1H), 3.97–3.78 (m, 2H), 3.25–2.99 (m, 2H), 2.09 (td, <i>J</i> = 13.1, 4.7 Hz, 2H), 1.63–1.52 (m, 2H), 1.43 (s, 9H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.76 min. MS (ES) C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub> requires 334, found 335 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_109" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> Synthesis of 7-(1,2,3,6-Tetrahydropyridin-4-yl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>46a</b>)</h4><div class="NLM_p last">Compound <b>46a</b> was prepared according to general procedure L using <b>45</b> (0.345 g, 1.03 mmol). The crude was purified by SCX to afford <b>46a</b> as a brown solid (quant.). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.95 min. MS (ES) C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> requires 216, found 217 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_110" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150"> Synthesis of 7-(1-Methyl-3,6-dihydro-2<i>H</i>-pyridin-4-yl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>46b</b>)</h4><div class="NLM_p last">Compound <b>46b</b> was prepared according to general procedure F using <b>46a</b> (0.108 g, 0.5 mmol), NaBH(OAc)<sub>3</sub> (0.318 g, 1.50 mmol), AcOH (0.03 mL, 0.030 g, 0.50 mmol), and 37% aqueous solution of formaldehyde (0.080 mL, 2.5 mmol) in dry MeCN (5 mL). The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.87 (d, <i>J</i> = 7.76 Hz, 1H), 6.80–6.74 (m, 2H), 6.36 (t, <i>J</i> = 3.49 Hz, 1H), 3.07–3.00 (m, 2H), 2.58–2.47 (m, overlapped with DMSO signal, 4H), 2.27 (s, 3H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.98 min. MS (ES) C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> requires 230, found 231 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_111" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> Synthesis of 7-(1-Methyl-4-piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>47</b>)</h4><div class="NLM_p last">Compound <b>47</b> was prepared according to general procedure B (method B) using <b>46b</b> (0.115 g, 0.50 mmol). The crude was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.12–7.06 (m, 1H), 6.94 (t, <i>J</i> = 7.4, 1.2 Hz, 2H), 2.98 (d, <i>J</i> = 11.8, 3.4 Hz, 2H), 2.82–2.69 (m, 1H), 2.31 (s, 3H), 2.25–2.11 (m, 2H), 1.88–1.72 (m, 4H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.98 min, MS (ES) C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> requires 232, found 233 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_112" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> Synthesis of <i>N</i>-Isobutyl-7-(1-methyl-4-piperidyl)-2-oxo-1,3-benzoxazole-3-carboxamide (<b>25</b>)</h4><div class="NLM_p last">Compound <b>25</b> was prepared according to general procedure D (method B) using <b>47</b> (0.116 g, 0.5 mmol), isobutylamine (0.014 g, 0.19 mmol), and Et<sub>3</sub>N (0.15 mL, 0.111 g, 1.10 mmol) in dry DCM (7 mL). The crude was purified by column chromatography (DCM/MeOH, 92:8) to afford <b>25</b> as a pink solid (0.050 g, 30% over three steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.14 (t, <i>J</i> = 5.0 Hz, 1H), 7.91 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H), 7.21 (t, <i>J</i> = 8.0 Hz, 1H), 7.11 (dd, <i>J</i> = 8.1, 1.3 Hz, 1H), 3.30–3.21 (m, 2H), 3.07–2.96 (m, 2H), 2.96–2.82 (m, 1H), 2.35 (s, 3H), 2.13 (td, <i>J</i> = 11.5, 3.2 Hz, 2H), 2.03–1.81 (m, 5H), 0.99 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.43, 150.10, 139.67, 128.76, 127.90, 125.28, 122.48, 113.52, 56.18, 47.71, 46.50, 35.66, 31.80, 28.61, 20.18. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.79 min, MS (ES) C<sub>18</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> requires 331, found 332 [M + H]<sup>+</sup>. HRMS C<sub>18</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 332.1974, measured 332.1967, Δppm −2.1.</div></div><div id="sec5_11_113" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153"> Synthesis of 2-(3-Benzyloxy-4-nitrophenyl)pyridine (<b>35</b>)</h4><div class="NLM_p last">Compound <b>35</b> was prepared according to general procedure A using 2-benzyloxy-4-bromo-1-nitrobenzene (0.309 g, 1.00 mmol), <b>34</b> (0.174 g, 1.10 mmol), Pd(dppf)Cl<sub>2</sub> (0.146 g, 0.2 mmol), KOAc (0.196 g, 2 mmol), and 2 M Na<sub>2</sub>CO<sub>3</sub> (1.30 mL, 2.50 mmol) in degassed 1,4-dioxane (15 mL). The crude was purified by column chromatography (Cy/EtOAc, 80:20) to afford <b>35</b> as a yellow solid (0.121 g, 40%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.75 (ddd, <i>J</i> = 4.8, 1.7, 0.9, 1H), 8.14 (d, <i>J</i> = 8.0 Hz, 1H), 8.12 (d, <i>J</i> = 1.6 Hz, 1H), 8.03 (d, <i>J</i> = 8.5 Hz, 1H), 7.98 (td, <i>J</i> = 7.8, 1.8 Hz, 1H), 7.85 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 7.54–7.32 (m, 6H), 5.45 (s, 2H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.47 min, MS (ES) C<sub>18</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub> requires 306, found 307 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_114" class="NLM_sec NLM_sec_level_3"><div id="ac_i154" class="anchor-spacer"></div><h4 class="article-section__title" id="_i154"> Synthesis of 2-Amino-5-(2-piperidyl)phenol (<b>36</b>)</h4><div class="NLM_p last">Compound <b>36</b> was prepared according to general procedure B (method B) using <b>35</b> (0.520 g, 1.69 mmol). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.93 min. MS (ES) C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O requires 192, found 193 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_115" class="NLM_sec NLM_sec_level_3"><div id="ac_i155" class="anchor-spacer"></div><h4 class="article-section__title" id="_i155"> Synthesis of 6-(2-Piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>37a</b>)</h4><div class="NLM_p last">Compound <b>37a</b> was prepared according to general procedure C using <b>36</b> (0.390 g, 1.69 mmol) and CDI (0.274 g, 1.69 mmol) in dry MeCN (17 mL). The crude was used in the next step without further purification. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.05 min. MS (ES) C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> requires 218, found 219 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_116" class="NLM_sec NLM_sec_level_3"><div id="ac_i156" class="anchor-spacer"></div><h4 class="article-section__title" id="_i156"> Synthesis of 6-(1-Methyl-2-piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>37b</b>)</h4><div class="NLM_p last">Compound <b>37b</b> was prepared according to general procedure F using <b>37a</b> (0.368 g, 1.69 mmol), 37% aqueous solution of formaldehyde (0.09 mL, 3.38 mmol), NaBH(OAc)<sub>3</sub> (1.075 g, 5.07 mmol), and AcOH (0.15 mL, 0.162 g, 2.70 mmol) in dry MeCN (9 mL). The crude was purified by SCX to afford <b>37b</b> as a white solid (0.169 g, 43% over three steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.64 (bs, 1H), 7.14 (d, <i>J</i> = 1.2 Hz, 1H), 7.06–6.95 (m, 2H), 3.01–2.85 (m, 1H), 2.74 (dd, <i>J</i> = 10.8, 2.7 Hz, 1H), 2.01 (td, <i>J</i> = 11.6, 3.2 Hz, 1H), 1.88 (s, 3H), 1.78–1.66 (m, 1H), 1.67–1.50 (m, 3H), 1.50–1.36 (m, 1H), 1.37–1.22 (m, 1H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.04 min. MS (ES) C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> requires 232, found 233 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_117" class="NLM_sec NLM_sec_level_3"><div id="ac_i157" class="anchor-spacer"></div><h4 class="article-section__title" id="_i157"> Synthesis of (±)-<i>N</i>-Isobutyl-6-(1-methyl-2-piperidyl)-2-oxo-1,3-benzoxazole-3-carboxamide (<b>26</b>)</h4><div class="NLM_p last">Compound <b>26</b> was prepared according to general procedure D (method B) using <b>37b</b> (0.170 g, 0.73 mmol) and isobutylamine (0.160 g, 2.19 mmol) in dry DCM (10 mL). The crude was purified by column chromatography (DCM/MeOH, 92:8) to afford <b>26</b> as a white solid (0.069 g, 29%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.10 (t, <i>J</i> = 5.3 Hz, 1H), 7.94 (d, <i>J</i> = 8.2 Hz, 1H), 7.30–7.23 (m, overlapped with CDCl<sub>3</sub> signal, 1H), 7.20 (dd, <i>J</i> = 8.3, 1.6 Hz, 1H), 3.25 (dd, <i>J</i> = 6.8, 5.8 Hz, 2H), 3.09–3.00 (m, 1H), 2.95 (dd, <i>J</i> = 11.1, 2.8 Hz, 1H), 2.80 (dd, <i>J</i> = 11.1, 2.8 Hz, 1H), 2.18–2.05 (m, 1H), 1.98 (s, 3H), 1.96–1.85 (m, 1H), 1.85–1.76 (m, 1H), 1.76–1.65 (m, 2H), 1.61–1.47 (m, 1H), 1.42–1.28 (m, 1H), 0.98 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.56, 150.07, 142.34, 142.16, 126.95, 124.20, 115.37, 108.82, 70.79, 57.48, 47.68, 44.59, 36.37, 28.60, 26.12, 24.94, 20.15. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.88 min, MS (ES) C<sub>18</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> requires 331, found 332 [M + H]<sup>+</sup>. HRMS C<sub>18</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 332.1971, measured 332.1974, Δppm −0.9.</div></div><div id="sec5_11_118" class="NLM_sec NLM_sec_level_3"><div id="ac_i158" class="anchor-spacer"></div><h4 class="article-section__title" id="_i158"> Synthesis of <i>tert</i>-Butyl 5-(3-Hydroxy-4-nitrophenyl)-3,4-dihydro-2<i>H</i>-pyridine-1-carboxylate (<b>39</b>)</h4><div class="NLM_p last">Compound <b>39</b> was prepared according to general procedure A using <b>38</b> (0.834 g, 2.7 mmol), 5-bromo-2-nitrophenol (0.530 g, 2.43 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.156 g, 0.135 mmol), and 2 M Na<sub>2</sub>CO<sub>3</sub> (3.04 mL, 6.075 mmol) in degassed 1,4-dioxane (27 mL). The crude was purified by column chromatography (Cy/EtOAc, 90:10) to afford <b>39</b> as a yellow solid (0.460 g, 53%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.79 (s, 1H), 7.99 (d, <i>J</i> = 8.8 Hz, 1H), 7.82–7.48 (m, 1H), 7.11–6.94 (m, 2H), 3.62 (s, 2H), 2.42 (t, <i>J</i> = 6.0 Hz, 2H), 1.98 (p, <i>J</i> = 6.1 Hz, 2H), 1.54 (s, 9H). UPLC/MS (<i>method B</i>): <i>R<sub>t</sub></i> 1.86 min. MS (ES) C<sub>16</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub> requires 320, found 321 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_119" class="NLM_sec NLM_sec_level_3"><div id="ac_i159" class="anchor-spacer"></div><h4 class="article-section__title" id="_i159"> Synthesis of <i>tert</i>-Butyl 3-(4-Amino-3-hydroxyphenyl)piperidine-1-carboxylate (<b>40</b>)</h4><div class="NLM_p last">Compound <b>40</b> was prepared according to general procedure B (method A) using <b>39</b> (0.450 g, 1.41 mmol). UPLC/MS (<i>method B</i>): <i>R<sub>t</sub></i> 0.73 min. MS (ES) C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O<sub>3</sub> requires 292, found 291 [M-H]<sup>−</sup>.</div></div><div id="sec5_11_120" class="NLM_sec NLM_sec_level_3"><div id="ac_i160" class="anchor-spacer"></div><h4 class="article-section__title" id="_i160"> Synthesis of <i>tert</i>-Butyl 3-(2-Oxo-3<i>H</i>-1,3-benzoxazol-6-yl)piperidine-1-carboxylate (<b>49a</b>)</h4><div class="NLM_p last">Compound <b>49a</b> was prepared according to general procedure C using <b>40</b> (0.412 g, 1.41 mmol) and CDI (0.229 g, 1.41 mmol) in dry MeCN (14 mL). The crude was purified by column chromatography (Cy/EtOAc, 70:30) to afford <b>41a</b> as brown oil (0.403 g, 90% over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.04 (bs, 1H), 7.07–6.88 (m, 3H), 4.20–4.06 (m, 2H), 2.80–2.43 (m, 3H), 2.03–1.93 (m, 1H), 1.72 (dd, <i>J</i> = 3.2, 6.4 Hz, 1H), 1.66–1.52 (m, 2H), 1.44 (s, 9H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 2.19 min. MS (ES) C<sub>17</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> requires 318, found 319 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_121" class="NLM_sec NLM_sec_level_3"><div id="ac_i161" class="anchor-spacer"></div><h4 class="article-section__title" id="_i161"> Synthesis of 6-(3-Piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one Hydrochloride (<b>41b</b>)</h4><div class="NLM_p last">Compound <b>41b</b> was prepared according to general procedure E using <b>41a</b> (0.185 g, 0.58 mmol). The crude was used in the next step without further purification. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 0.99 min. MS (ES) C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> requires 218, found 219 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_122" class="NLM_sec NLM_sec_level_3"><div id="ac_i162" class="anchor-spacer"></div><h4 class="article-section__title" id="_i162"> Synthesis of 6-(1-Methyl-3-piperidyl)-3<i>H</i>-1,3-benzoxazol-2-one (<b>41c</b>)</h4><div class="NLM_p last">Compound <b>41</b> was prepared according to general procedure F using <b>41b</b> (0.147 g, 0.58 mmol), 37% aqueous solution of formaldehyde (0.03 mL, 1.16 mmol), NaBH(OAc)<sub>3</sub> (0.370 g, 1.74 mmol), and AcOH (0.07 mL, 0.070 g, 1.16 mmol) in dry MeCN (3 mL). The crude was purified by SCX to afford <b>41c</b> as a white solid (0.094 g, 70% over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.09 (s, 1H), 7.02 (d, <i>J</i> = 8.2 Hz, 1H), 6.95 (d, <i>J</i> = 8.1 Hz, 1H), 3.01–2.81 (m, 3H), 2.31 (s, 3H), 2.03–1.87 (m, 3H), 1.87–1.67 (m, 2H), 1.39 (qd, <i>J</i> = 12.6, 4.2 Hz, 1H). UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.81 min. MS (ES) C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> requires 232, found 233 [M + H]<sup>+</sup>.</div></div><div id="sec5_11_123" class="NLM_sec NLM_sec_level_3"><div id="ac_i163" class="anchor-spacer"></div><h4 class="article-section__title" id="_i163"> Synthesis of (±)-<i>N</i>-Isobutyl-6-(1-methyl-3-piperidyl)-2-oxo-1,3-benzoxazole-3-carboxamide (<b>27</b>)</h4><div class="NLM_p last">Compound <b>27</b> was prepared according to general procedure D (method B) using <b>41c</b> (0.088 g, 0.28 mmol) and isobutylamine (0.06 mL, 0.06 g, 0.84 mmol) in dry DCM (4 mL). The crude was purified by column chromatography (DCM/MeOH, 90:10) to afford <b>27</b> as a white solid (0.08 g, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.09 (bs, 1H), 7.96 (d, <i>J</i> = 8.9 Hz, 1H), 7.17–7.08 (m, 2H), 3.25 (d, <i>J</i> = 6.59, 2H), 3.03–2.87 (m, 3H), 2.34 (s, 3H), 2.13–1.68 (m, 6H), 1.41 (qd, <i>J</i> = 12.1, 5.5 Hz, 1H), 0.99 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 153.50, 150.05, 142.02, 141.71, 126.47, 123.99, 115.48, 108.69, 63.12, 55.85, 47.69, 46.54, 42.82, 31.21, 28.60, 25.64, 20.16. UPLC/MS (<i>method A</i>): <i>R<sub>t</sub></i> 1.87 min. MS (ES) C<sub>18</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> requires 331, found 332 [M + H]<sup>+</sup>. HRMS C<sub>18</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: calculated 332.1974, measured 332.1972, Δppm −0.9.</div></div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i164" class="anchor-spacer"></div><h3 class="article-section__title" id="_i164"> In Vitro Pharmacological Assay</h3><div id="sec5_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i165" class="anchor-spacer"></div><h4 class="article-section__title" id="_i165"> In Vitro <i>h</i>AC Fluorescence Assay</h4><div id="sec5_12_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i166" class="anchor-spacer"></div><h5 class="article-section__title" id="_i166"> Cell Culture Conditions and Preparation of <i>h</i>AC-Enriched Lysate</h5><div class="NLM_p last">HEK293 cells stably expressing <i>h</i>AC were grown in Dulbecco’s modified Eagle medium (DMEM) containing 10% FBS, 1% glutamine, 1 mM sodium pyruvate, and 500 μg mL<sup>–1</sup> G418. Cells were harvested, and pellets were stored at −80 °C until lysosomal-enriched lysate preparation. Cells were suspended in 20 mM Tris HCl (pH 7.5) with 0.32 M sucrose, sonicated, and centrifuged at 800 × <i>g</i> for 30 min at 4 °C. Supernatants were then centrifuged at 12000 × <i>g</i> for 30 min at 4 °C. Pellets were resuspended in PBS (pH 7.4) and subjected to three freeze–thaw cycles at −80 °C. The suspension was finally centrifuged at 105000 × <i>g</i> for 1 h at 4 °C, and protein concentration was measured in the supernatant with the bicinchoninic acid based protein assay. This <i>h</i>AC-enriched preparation allowed us to further optimize the enzymatic assay and to use small amounts of lysate (2 μg per well) at a 5 μM substrate (Rbm14–12) around its <i>K</i><sub>M</sub> (<i>K</i><sub>M</sub> = 5.0 μM).</div></div><div id="sec5_12_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i167" class="anchor-spacer"></div><h5 class="article-section__title" id="_i167"> Fluorogenic <i>h</i>AC Assay</h5><div class="NLM_p last">The assay was performed in Optiplate 96-well black plates, with each reaction well containing a mixture of 25 mM NaOAc buffer (pH 4.5) and a fixed amount of protein (2 μg) in a volume of 85 μL. After 10 min of preincubation with test compounds (diluted 20× from DMSO stock solutions at different concentrations), the fluorogenic probe was added (diluted 40× from EtOH stock solution, final concentration 5 μM). After 3 h of incubation at 37 °C, reactions were stopped with 50 μL of MeOH and 100 μL of a 2.5 mg mL<sup>–1</sup> NaIO<sub>4</sub> fresh solution in 100 mM glycine/NaOH buffer (pH 10.6). The plates were further incubated for 2 h at 37 °C in the dark, and fluorescence intensities were measured at excitation/emission wavelengths of 355/460 nm. Negative control samples consisted of the same incubation mixture in the absence of protein-enriched extracts. Data were plotted as a function of compound concentrations. IC<sub>50</sub> values were calculated by nonlinear regression analysis using GraphPad Prism 5 (GraphPad Software Inc., CA, USA) applying a standard slope curve fitting. The reported IC<sub>50</sub> values are the mean of at least three independent experiments performed in three technical replicates.</div></div></div><div id="sec5_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i168" class="anchor-spacer"></div><h4 class="article-section__title" id="_i168"> Kinetic Studies</h4><div id="sec5_12_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i169" class="anchor-spacer"></div><h5 class="article-section__title" id="_i169"> Michaelis–Menten Analysis</h5><div class="NLM_p last">Assay conditions for the kinetic studies were the same as those described for the fluorogenic <i>h</i>AC assay. Enzyme-enriched lysate (2 μg) was incubated with the following concentrations of substrate Rbm14–12: 0.25, 0.5, 1, 2.5, 5, 10, 12.5, and 15 μM. Compound <b>22m</b> was used at final concentrations of 100 and 400 nM. Initial velocities (<i>V</i><sub>0</sub>) were determined and automatically fitted to the Michaelis–Menten equation to obtain the kinetic parameters (<i>K</i><sub>M</sub> and <i>V</i><sub>max</sub>). The graph is representative of two independent experiments, each performed in three technical replicates. Graphs and data analysis were performed using GraphPad Prism 5 software (GraphPad Software Inc., CA, USA).</div></div><div id="sec5_12_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i170" class="anchor-spacer"></div><h5 class="article-section__title" id="_i170"> Determination of Kinetic Parameter <i>k</i><sub>i</sub>/<i>K</i><sub>I</sub></h5><div class="NLM_p last"><i>h</i>AC activity was measured as a function of reaction time in the presence of different concentrations of <b>22m</b>. The apparent inactivation rate constant of <i>h</i>AC (<i>k</i><sub>obs</sub>) was analyzed by nonlinear square fitting each data set to the pseudo-first-order rate equation <i>Y</i> = <i>vi</i>(1 – exp(−<i>k</i><sub>obs</sub><i>t</i>))/<i>k</i><sub>obs</sub>. Replotting of calculated <i>k</i><sub>obs</sub> vs [<b>22m</b>] was made, and the kinetic parameter <i>k</i><sub>i</sub>/<i>K</i><sub>I</sub> was calculated by nonlinear square fitting data to the equation <i>Y</i> = <i>k</i><sub>i</sub><i>I</i>/(<i>K</i><sub>I</sub> + <i>I</i>). The graphs are representative of two independent experiments, each performed in two technical replicates.</div></div></div><div id="sec5_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i171" class="anchor-spacer"></div><h4 class="article-section__title" id="_i171"> In Vitro <i>h</i>ASM Assay</h4><div class="NLM_p last"><i>h</i>ASM activity measurement was conducted using the fluorogenic substrate 6-hexadecanoylamino-4-methylumbelliferylphosphorylcholine (HMU-PC, Toronto Research Chemicals) at 0.5 μM and 1.3 nM purified human full-length ASM enzyme (purified in house) in a buffer containing 50 mM citrate, 150 mM NaCl, 5 mM ZnCl<sub>2</sub>, and 0.43 mM Triton X-100 at pH 4.7 in a final volume of 50 μL. The reaction mixtures were incubated for 45 min at rt and stopped by the addition of 150 μL of 1 M glycine at pH 12.5. The formation of the fluorescent product was monitored by a plate reader at excitation/emission wavelengths of 385/450 nm. The average <i>h</i>ASM activity was calculated from two independent experiments, each performed in two technical replicates.</div></div><div id="sec5_12_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i172" class="anchor-spacer"></div><h4 class="article-section__title" id="_i172"> In Vitro <i>h</i>GCase Assay</h4><div class="NLM_p last"><i>h</i>GCase activity measurement was conducted using the fluorogenic substrate 4-methylumbelliferyl-β-<span class="smallcaps smallerCapital">d</span>-glucuronide hydrate (4-MUG, Merck) at 1 mM and 5 nM purified human full-length GCase enzyme and 50 nM of its natural activator SapC (both GCase and SapC were purified in house) in a buffer containing 50 mM citric acid, 174 mM K<sub>2</sub>HPO<sub>4</sub>, 15 μM phosphatidylserine, and 0.32 mM Triton X-100 at pH 4.7 in a final volume of 50 μL. The reaction mixtures were incubated for 15 min at rt and stopped by the addition of 150 μL of 1 M glycine at pH 12.5. The cleavage of 4-MUG was monitored by a plate reader at excitation/emission wavelengths of 365/440 nm. The average <i>h</i>GCase activity was calculated from two independent experiments, each performed in two technical replicates.</div></div><div id="sec5_12_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i173" class="anchor-spacer"></div><h4 class="article-section__title" id="_i173"> In Vitro <i>h</i>NAAA Fluorescence Assay</h4><div id="sec5_12_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i174" class="anchor-spacer"></div><h5 class="article-section__title" id="_i174"> Cell Culture and Preparation of <i>h</i>NAAA-Enriched Lysate</h5><div class="NLM_p last">HEK-293 cells stably transfected with the <i>h</i>NAAA coding sequence cloned from a human spleen cDNA library (catalog no. 639124, Clontech, Mountain View, CA, USA) were used as the enzyme source. Cells were grown in Dulbecco’s modified Eagle medium (DMEM) containing 10% FBS, 1% glutamine, 1 mM sodium pyruvate, and 500 μg mL<sup>–1</sup> G418. Cells were harvested, and pellets were stored at −80 °C until lysosomal-enriched lysate preparation. Cells were suspended in 20 mM Tris HCl (pH 7.4) with 0.32 M sucrose, sonicated, and centrifuged at 800 × <i>g</i> for 30 min at 4 °C. Supernatants were then ultracentrifuged at 12000 × <i>g</i> for 30 min at 4 °C. Pellets were resuspended in PBS buffer (pH 7.4) and subjected to three freeze–thaw cycles at −80 °C. The suspension was finally ultracentrifuged at 105000 × <i>g</i> for 1 h at 4 °C, supernatants were collected, protein concentration was measured, and samples were aliquoted and stored at −80 °C until use.</div></div><div id="sec5_12_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i175" class="anchor-spacer"></div><h5 class="article-section__title" id="_i175"> Fluorogenic <i>h</i>NAAA Assay</h5><div class="NLM_p last">The assay was run in 96-well microplates (Black OptiPlate-96F; PerkinElmer, Massachusetts, USA) in a total reaction volume of 200 μL. <i>h</i>NAAA protein preparation (4.0 μg) was preincubated for 30 min with various concentrations of test compounds or vehicle control (DMSO 5%) in 100 mM citrate/phosphate buffer (pH 4.5) containing 3.0 mM DTT, 0.1% NP40 0.1%, 0.05% BSA, 150 mM NaCl. <i>N</i>-(4-Methyl-2-oxo-chromen-7-yl)-hexadecanamide (PAMCA) was used as a substrate (2.0 μM), and the reaction was carried out for 50 min at 37 °C. Fluorescence was measured with an EnVision 2014 Multilabel Reader (PerkinElmer, Massachusetts, USA) using an excitation wavelength of 355 nm and emission of 460 nm. IC<sub>50</sub> values were calculated by nonlinear regression analysis of log[concentration]/inhibition curves using GraphPad Prism 5 (GraphPad Software Inc., CA, USA) applying a standard slope curve fitting. The reported IC<sub>50</sub> values are the mean of at least three independent experiments performed in three technical replicates.</div></div></div><div id="sec5_12_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i176" class="anchor-spacer"></div><h4 class="article-section__title" id="_i176"> In Vitro <i>h</i>FAAH Fluorescence Assay</h4><div id="sec5_12_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i177" class="anchor-spacer"></div><h5 class="article-section__title" id="_i177"> Cell Culture and Preparation of <i>h</i>FAAH-Enriched Lysate</h5><div class="NLM_p last"><i>h</i>FAAH was obtained from a HEK-293 FAAH-1 overexpressing stable cell line. Cells were grown in Dulbecco’s modified Eagle medium (DMEM) containing 10% FBS, 1% penicillin/streptomycin, 1% glutamine, 1 mM sodium pyruvate, and 500 μg mL<sup>–1</sup> G418. Cells were harvested, and pellets were stored at −80 °C until membrane-enriched lysate preparation. The cell pellet was resuspended in 20 mM Tris HCl (pH 7.4, 0.32 M sucrose), sonicated, and centrifuged at 1000 × <i>g</i> (10 min, 4 °C). The collected supernatant was centrifuged at 12000 × <i>g</i> for 10 min at 4 °C, and the supernatants were further centrifuged at 100000 × <i>g</i> for 1 h at 4 °C. Membrane pellets were resuspended in PBS, protein concentration was measured, and samples were aliquoted and stored at −80 °C until use.</div></div><div id="sec5_12_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i178" class="anchor-spacer"></div><h5 class="article-section__title" id="_i178"> Fluorogenic <i>h</i>FAAH Assay</h5><div class="NLM_p last">The fluorescence assay to measure FAAH activity was performed in 96-well black plates (Black OptiPlate-96F; PerkinElmer, Massachusetts, USA): 2.5 μg of <i>h</i>FAAH membrane preparation was preincubated for 50 min at 37 °C in 190 μL of assay buffer (50 mM Tris HCl pH 7.4, 0.05% fatty acid free BSA), with 5 μL of inhibitor or 5 μL of DMSO to measure FAAH total activity. The background (no activity) samples were prepared using 190 μL of assay buffer without <i>h</i>FAAH and 5 μL of DMSO. The reaction was then started by the addition of 5 μL of substrate (AMC Arachidonyl Amide, A6855, Merck) dissolved in DMSO and used at a final concentration of 800 nM. The reaction was carried out for 45 min at 37 °C, and fluorescence was measured with an EnVision 2014 Multilabel Reader (PerkinElmer, Massachusetts, USA) (excitation wavelength 355 nm/emission wavelength 460 nm). The concentration causing half-maximal inhibition (IC<sub>50</sub>) was determined by nonlinear regression analysis of the log[concentration]/response curves generated with mean replicate values using a four-parameter Hill equation curve fitting with GraphPad Prism 5 (GraphPad Software Inc., CA, USA). The reported IC<sub>50</sub> values are the mean of at least three independent experiments performed in three technical replicates.</div></div></div><div id="sec5_12_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i179" class="anchor-spacer"></div><h4 class="article-section__title" id="_i179"> In Vitro <i>h</i>MAGL Colorimetric Assay</h4><div class="NLM_p last">The colorimetric assay to measure <i>h</i>MAGL activity was performed using an assay kit provided by Cayman Scientific (item. 705192), according to the manufacturer’s instructions. Briefly, in vitro activity was measured in 96-well plates, and DMSO was used as solvent. 10 μL of DMSO (100% initial activity wells: 100% IA) or compounds at two concentrations (1 and 10 μM) were preincubated for 5 min at rt with 150 μL of diluted assay buffer (10 mM Tris HCl, pH 7.2, containing 1 mM EDTA) containing <i>h</i>MAGL. In blank wells, 160 μL of the diluted assay buffer and 10 μL of DMSO were added. The reactions were initiated by adding 10 μL of MAGL substrate to all the wells, and plates were incubated for 10 min at rt. Absorbance values were measured at 405 nm, and percent inhibition was calculated by the following method: 100 – (Inhibitor/100% IA) × 100. The reported percentages of inhibition are the mean of at least three independent experiments performed in three technical replicates.</div></div><div id="sec5_12_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i180" class="anchor-spacer"></div><h4 class="article-section__title" id="_i180"> Cell Culture and Treatments</h4><div class="NLM_p last">SH-SY5Y cells were purchased from Sigma Aldrich (Italy) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum at 37 °C and 5% CO<sub>2</sub>. Drugs were dissolved in DMSO (10 mM) and diluted in the cell culture medium with reduced serum (1%) for cell treatments.</div></div><div id="sec5_12_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i181" class="anchor-spacer"></div><h4 class="article-section__title" id="_i181"> <i>h</i>AC LC/MS-Based Activity Assay</h4><div class="NLM_p last"><i>h</i>AC activity measurement was performed as previously described.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Total lysates from cells were diluted in assay buffer (100 mM sodium phosphate, 0.1% Nonidet P-40, 150 mM NaCl, 3 mM DTT, 100 mM sodium citrate, pH 4.5). Reactions were started by the addition of 50 μM N-lauroyl ceramide (Nu-Chek Prep, Elysian, MN) and carried out for 1 h at 37 °C. Reactions were stopped by addition of a mixture of CHCl<sub>3</sub>/MeOH (2:1) containing 1 nmol of 11-lauroleic acid (Nu-Chek Prep). The organic phases were collected, dried under nitrogen, and analyzed by UPLC/MS (ACQUITY, Waters) in the negative-ion mode monitoring the reaction product (lauric acid, <i>m</i>/<i>z</i>: 199) using 11-lauroleic acid as internal standard. Lipids were eluted on an ACQUITY UPLC BEH C18 column (50 mm length, 2.1 mm ID, 1.7 μm pore size, Waters) at 0.5 mL min<sup>–1</sup> for 1.5 min with a gradient of MeCN and H<sub>2</sub>O, both containing 0.25% acetic acid and 5 mM ammonium acetate (70 to 100% MeCN in 0.5 min, 100% MeCN for 0.5 min, 70% MeCN for 0.4 min). The column temperature was 40 °C. Electrospray ionization (ESI) was in the negative mode, capillary voltage was 1 kV, and cone voltage was 50 V. N<sub>2</sub> was used as drying gas at a flow rate of 500 L h<sup>–1</sup> and at a temperature of 400 °C. The [M–H]<sup>−</sup> ion was monitored in the selected-ion monitoring mode (<i>m</i>/<i>z</i> values: lauric acid 199, 11-lauroleic acid 197.35). Calibration curves were generated with authentic lauric acid (Nu-Chec Prep).</div></div><div id="sec5_12_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i182" class="anchor-spacer"></div><h4 class="article-section__title" id="_i182"> Lipid Extraction and Ceramide Analysis</h4><div class="NLM_p last">Lipid extraction and sphingolipid measurements were performed as previously described.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Lipids were extracted with a CHCl<sub>3</sub>/MeOH mixture (2:1, 3 mL) containing internal standards. The organic phase was collected, dried under nitrogen, and dissolved in CHCl<sub>3</sub>/MeOH (1:3) for LC/MS analyses. Ceramides and sphingosine were analyzed by LC/MS/MS, using a Waters ACQUITY UPLC coupled to a Waters Xevo TQMS and interfaced with an ESI ion source. Separation was performed on a Waters ACQUITY BEH C18 1.7 μm column (2.1 × 50 mm) at 60 °C. A linear gradient of 0.1% formic acid in MeCN/isopropyl alcohol (20:80) as solvent B in 0.1% formic acid in MeCN/H<sub>2</sub>O (20:80) as solvent A was applied at a flow rate of 0.4 mL min<sup>–1</sup>. Detection of sphingolipids was performed in positive-ion mode. Capillary voltage was 3.5 kV, and cone voltage was 25 V. The source temperature and desolvation temperatures were set at 120 and 600 °C, respectively. Desolvation gas and cone gas (N<sub>2</sub>) flows were 800 and 20 L h<sup>–1</sup>, respectively. Ceramides were identified by comparison of their LC retention times and MS/MS fragmentation patterns with those of authentic standards (Avanti Polar Lipids). Multiple Reaction Monitoring (MRM) ion chromatograms were used to quantify myristoyl ceramide (C14:0, <i>m</i>/<i>z</i>: 492.5 > 264.3), palmitoyl ceramide (C16:0, <i>m</i>/<i>z</i> 520.3 > 264.3), stearoyl ceramide (C18:0, <i>m</i>/<i>z</i>: 548.3 > 264.3), lignoceroyl ceramide (C24:0, <i>m</i>/<i>z</i>: 632.3 > 264.3), and nervonoyl ceramide (C24:1 <i>m</i>/<i>z</i>: 630.3 > 264.3) using lauroyl ceramide standard (<i>m</i>/<i>z</i>: 464.5 > 264.3). Detection and analysis were controlled by Waters MassLynx software version 4.1. Sphingosine was identified by comparison of its LC retention times and MS2 fragmentation patterns with those of authentic standards (Avanti Polar Lipids). Extracted ion chromatograms were used to quantify sphingosine standard (d18:1, <i>m</i>/<i>z</i>: 300.5 > 282.5). Detection and analysis were controlled by Waters MassLynx software version 4.1. Calibration curves were prepared for every experiment.</div></div><div id="sec5_12_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i183" class="anchor-spacer"></div><h4 class="article-section__title" id="_i183"> Statistics</h4><div class="NLM_p last">GraphPad Prism software (GraphPad Software, Inc., USA) was used for statistical analysis. Data were analyzed using the Student <i>t</i> test or one-way ANOVA followed by the Bonferroni post hoc test for multiple comparisons. Differences between groups were considered statistically significant at values of <i>p</i> < 0.05. Results are expressed as mean ± S.E.M.</div></div><div id="sec5_12_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i184" class="anchor-spacer"></div><h4 class="article-section__title" id="_i184"> EC<sub>50</sub> Determination in Primary Fibroblast Cells from Krabbe’s Disease Patients</h4><div class="NLM_p last">Cells were plated in a 6-well plate. After 24 h, cells were treated with <b>22m</b> at different concentrations for 2 h. Next, cells were washed with PBS, and cell pellets were washed, collected, and stored at −80 °C. Finally, cell pellets were lysed, and <i>h</i>AC activity in cell lysates was analyzed using the same biochemical fluorogenic assay as described for compound IC<sub>50</sub> determination. Using this methodology, EC<sub>50</sub> was determined to be 0.41 ± 0.1 μM. The EC<sub>50</sub> value is a mean of two independent experiments, each performed in two technical replicates.</div></div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i185" class="anchor-spacer"></div><h3 class="article-section__title" id="_i185"> In Vitro Physicochemical and Metabolic Stability Assays</h3><div id="sec5_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i186" class="anchor-spacer"></div><h4 class="article-section__title" id="_i186"> Aqueous Kinetic Solubility Assay</h4><div class="NLM_p last">The aqueous kinetic solubility was determined from a 10 mM MeCN stock solution of test compound in Phosphate-Buffered Saline (PBS) at pH 7.4. The study was performed by incubation of an aliquot of 10 mM MeCN stock solution in PBS (pH 7.4) at a target concentration of 250 μM. The incubation was carried out under shaking at 25 °C for 1 h followed by centrifugation at 21100 × <i>g</i> for 30 min. The supernatant was analyzed by UPLC/MS for the quantification of the dissolved compound (in μM) by UV at a specific wavelength (215 nm). The aqueous kinetic solubility (in μM) was calculated by dividing the peak area of the dissolved test compound (supernatant) by the peak area of the test compound in the reference (250 μM in MeCN) and further multiplied by the target concentration and dilution factor. The UPLC/MS analyses were performed on a Waters ACQUITY UPLC/MS system consisting of a single quadrupole detector (SQD) Mass Spectrometer (MS) equipped with an Electrospray Ionization (ESI) interface and a Photodiode Array Detector (PDA). The PDA range was 210–400 nm. ESI in positive mode was used in the mass scan range of 100–650 Da. The analyses were run on an ACQUITY UPLC BEH C18 column (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C18 precolumn (5 × 2.1 mm ID, particle size 1.7 μm), using 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O at pH 5 adjusted with AcOH (A) and 10 mM NH<sub>4</sub>OAc in MeCN/H<sub>2</sub>O (95:5) at pH 5 (B) as the mobile phase. Values are reported as mean values of ≥2 experiments performed.</div></div><div id="sec5_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i187" class="anchor-spacer"></div><h4 class="article-section__title" id="_i187"> Chemical Stability Assay</h4><div class="NLM_p last">Chemical stability of selected compounds was evaluated under physiological pH conditions (0.01 M phosphate-buffered saline, pH 7.4) for up to 8 h. The buffer was added with 10% MeCN. Stock solutions of each compound (10 mM) were freshly prepared in MeCN. Each compound was incubated at a final concentration of 1 μM in preheated buffer (37 °C). The sample solutions were divided into aliquots in glass vials (preheated at 37 °C) for each time point. The samples were maintained at 37 °C in the UPLC/MS autosampler during the study (no shaking). A reference solution of each compound (final concentration: 1 μM) in preheated MeCN was prepared from the stock solutions and maintained at 37 °C in the UPLC/MS autosampler during the study. For each time point, the samples were analyzed directly by LC/MS without any further sample preparation. The samples were analyzed by integrating the corresponding MRM peak areas. The relative compound concentration was calculated by dividing the peak area at each time point by the peak area at <i>t</i> = 0 min. The reference solution was analyzed at the beginning (<i>t</i> = 0 min) and at the end of the study (<i>t</i> = 8 h). The apparent half-life (<i>t</i><sub>1/2</sub>) of the disappearance of the compound was calculated using the best fitting equation by GraphPad Prism (GraphPad Software, Inc., USA). The analyses were performed on a Waters ACQUITY UPLC/MS TQD system consisting of a triple quadrupole detector (TQD) MS equipped with an ESI interface and a photodiode array detector. The analyses were run on an ACQUITY UPLC BEH C18 1.7 μm 2.1 × 50 mm column with a VanGuard BEH C18 1.7 μm preolumn at 40 °C. For each compound, the appropriate mobile phase was chosen. ESI was applied in positive mode. Values are the mean of at least two independent experiments performed in two technical replicates.</div></div><div id="sec5_13_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i188" class="anchor-spacer"></div><h4 class="article-section__title" id="_i188"> In Vitro Plasma Stability Study</h4><div class="NLM_p last">Freshly prepared 10 mM MeCN stock solution of test compound was diluted 50-fold with DMSO/H<sub>2</sub>O (1:1) and incubated at 37 °C for 2 h with mouse plasma added in 5% DMSO (preheated at 37 °C for 10 min). The final concentration was 2 μM. At each time point (0, 5, 15, 30, 60, and 120 min), 50 μL of incubation mixture was diluted with 200 μL of cold MeCN spiked with 200 nM internal standard followed by centrifugation at 3300 × <i>g</i> for 20 min. The supernatant was further diluted with H<sub>2</sub>O (1:1) for analysis. The concentration of test compound was quantified by LC/MS/MS on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD MS equipped with an ESI interface. The analyses were run on an ACQUITY UPLC BEH C18 (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C18 precolumn (5 × 2.1 mm ID, particle size 1.7 μm) at 40 °C. For each compound, the appropriate mobile phase was chosen. ESI was applied in positive mode. The response factors, calculated on the basis of the internal standard peak area, were plotted over time. When possible, response vs time profiles were fitted with Prism (GraphPad Software, Inc., USA) to estimate compound <i>t</i><sub>1/2</sub> in plasma. Values are the mean of at least two independent experiments performed in two technical replicates.</div></div><div id="sec5_13_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i189" class="anchor-spacer"></div><h4 class="article-section__title" id="_i189"> In Vitro Microsomal Stability Study</h4><div class="NLM_p last">Freshly prepared 10 mM MeCN stock solution of test compound was preincubated at 37 °C for 15 min with mouse liver microsomes added in 0.1 M Tris HCl buffer (pH 7.4). The final concentration was 4.6 μM. After preincubation, the cofactors (NADPH, G6P, G6PDH, and MgCl<sub>2</sub> predissolved in 0.1 M Tris HCl) were added to the incubation mixture, and the incubation was continued at 37 °C for 1 h. At each time point (0, 5, 15, 30, and 60 min), 30 μL of incubation mixture was diluted with 200 μL of cold MeCN spiked with 200 nM internal standard followed by centrifugation at 3300 × <i>g</i> for 15 min. The supernatant was further diluted with H<sub>2</sub>O (1:1) for analysis. The concentration of the test compound was quantified by LC/MS/MS on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD MS equipped with an ESI interface. The analyses were run on an ACQUITY UPLC BEH C18 (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C18 precolumn (5 × 2.1 mm ID, particle size 1.7 μm) at 40 °C. For each compound, the appropriate mobile phase was chosen. ESI was applied in positive mode. The percentage of test compound remaining at each time point relative to <i>t</i> = 0 was calculated. <i>t</i><sub>1/2</sub> was determined by a one-phase decay equation using a nonlinear regression of compound concentration vs time. Values are the mean of at least two independent experiments performed in two technical replicates.</div></div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i190" class="anchor-spacer"></div><h3 class="article-section__title" id="_i190"> In Vitro Mouse Plasma and Mouse Brain Tissue Protein Binding</h3><div class="NLM_p last">Studies were performed by the DMPK Group at Shanghai ChemPartner Co., Ltd., using the equilibrium dialysis method. Values are the mean of two technical replicates.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i191" class="anchor-spacer"></div><h3 class="article-section__title" id="_i191"> Animal Models</h3><div id="sec5_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i192" class="anchor-spacer"></div><h4 class="article-section__title" id="_i192"> In Vivo Pharmacokinetic Study</h4><div class="NLM_p last">Male CD1 mice (22–24 g, 6 weeks old, SLAC Laboratory Animal Co. Ltd.) were group-housed in ventilated cages and had free access to water and food. They were maintained under a 24 h light/dark cycle at controlled temperature and relative humidity. All efforts were made to minimize animal suffering and to use the minimal number of animals required to produce reliable results. All procedures were performed in accordance with the Ethical Guidelines on the Protection of Animals Used for Scientific Purposes at the DMPK Group at Shanghai ChemPartner Co., Ltd. <b>22m</b> was administrated intravenously (i.v.) at 3 mg kg<sup>–1</sup> (vehicle: 100% saline at 0.6 mg mL<sup>–1</sup>) via tail vein injection (<i>N</i> = 18) and via oral administration (p.o.) at 10 mg kg<sup>–1</sup> (vehicle: 100% saline at 2.0 mg mL<sup>–1</sup>) by oral gavage (<i>N</i> = 18). <i>Sample collection</i>. Samples were collected at 0.25, 0.5, 1, 4, 8, and 24 h. Animals were sacrificed 24 h after <b>22m</b> administration; plasma, brain, and CSF samples were collected and stored at −80 °C. <i>Blood collection</i>: The animal was restrained manually, and approximately 150 μL of blood/time point was collected into the K<sub>2</sub>EDTA tube via retro orbital puncture under anesthesia with isoflurane. The blood sample was put on ice and centrifuged to obtain the plasma sample (2000 × <i>g</i>, 5 min under 4 °C) within 15 min and then acidified following 100 μL of plasma + 1.0 μL of formic acid. An aliquot of 20 μL sample (pretreatment with 1% formic acid) was added with 200 μL of IS (propranolol, 40 ng mL<sup>–1</sup>) in MeCN. The mixture was vortexed for 5 min and centrifuged at 6000 rpm for 10 min. The 0.5 μL mixture was injected into LC/MS/MS. <i>Brain collection:</i> Brain was removed and immediately homogenized immediately for 2 min with three volumes (v/w) of homogenizing solution (PBS:formic acid = 100:1), and then the solution was stored in tubes under −70 °C until analysis. An aliquot of 20 μL sample was added with 200 μL of MeCN, which contains IS (propranolol, 40 ng mL<sup>–1</sup>) for protein precipitation. The mixture was vortexed for 5 min and centrifuged at 6000 rpm for 10 min. The 0.5 μL mixture was injected into LC/MS/MS. <i>CSF collection</i>: A midline incision was made on the neck. The muscle under the skin was cut to expose the cisterna magna. The CSF was collected by capillary. An aliquot of 3 μL sample was added with 90 μL of IS (propranolol, 40 ng mL<sup>–1</sup>) in MeCN:H<sub>2</sub>O = 2:1 (added 1% formic acid). The mixture was vortexed for 5 min and centrifuged at 6000 rpm for 10 min. The 1.5 μL mixture was injected into LC/MS/MS. <b>22m</b> sample levels were monitored on an LC/MS/MS-19 (API5500, Qtriple) system, using the calibration curve and propanol as internal standard. Chromatography was carried out on a Waters BEH C18 column (2.1 × 50 mm, 1.7 μm) at 60 °C, setting a flow rate of 0.60 mL min<sup>–1</sup>. Mobile phases were as follows: A = H<sub>2</sub>O/0.025% formic acid/1 mM NH<sub>4</sub>OAc and B = MeOH/0.025% formic acid/1 mM NH<sub>4</sub>OAc. After the initial 0.20 min at 10% of mobile phase B, the percentage of mobile phase B increased at 70% at 0.50 min, reaching steadily 90% in the range of 0.80–1.30 min. Then the system returned to the initial conditions in a single step until 1.80 min. The following parent (<i>m</i>/<i>z</i>)/daughter (<i>m</i>/<i>z</i>) transitions were monitored: <b>22m</b>: <i>m</i>/<i>z</i> = 332.20/333.20 Da; propanol (IS): <i>m</i>/<i>z</i>: 260.30/116.10 Da.</div></div><div id="sec5_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i193" class="anchor-spacer"></div><h4 class="article-section__title" id="_i193"> Maximum Tolerated Dose (MTD) Study</h4><div class="NLM_p last">An MTD study was conducted on male C57BL/6 mice (15–19 g, 5 weeks old, SLAC Laboratory Animal Co. Ltd.). Animals were injected via intraperitoneal (i.p.) injection with single administration at 20 mg kg<sup>–1</sup> (<i>N</i> = 18, vehicle: 100% saline at 0.6 mg mL<sup>–1</sup>) and multiple administrations for a duration of 4 days at 20 (<i>N</i> = 18, day 1), 40 (<i>N</i> = 18, day 2), 80 (<i>N</i> = 18, day 3), and 120 mg kg<sup>–1</sup> (<i>N</i> = 18, day 4). Clinical observations/samples of plasma, CSF, and brain were collected at 0.25, 0.5, 1, 4, 8, and 24 h. All procedures were performed in accordance with the Ethical Guidelines on the Protection of Animals Used for Scientific Purposes at the DMPK Group at Shanghai ChemPartner Co., Ltd.</div></div><div id="sec5_15_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i194" class="anchor-spacer"></div><h4 class="article-section__title" id="_i194"> In Vivo Mouse Model Studies</h4><div class="NLM_p last">4L;C* mice (C57BL/6 J/129SvEV) were randomly assigned to three treatment groups (<i>N</i> = 4–8 with mixed males and females) and dosed once a day i.p. with 90 or 30 mg kg<sup>–1</sup> of <b>22m</b> or vehicle. Treatment started at 5 days of age for a duration of 14 days. The application volume was set to 10 μL per gram of body weight, and dosage was adjusted accordingly. Animals of all groups were sacrificed 1 h after the last dose, and the brain tissues and plasma were collected. The left brain containing cortex, cerebella, thalamus, and brainstem was analyzed for SphL levels by MS. Data were analyzed using the Student <i>t</i> test. The right brain containing cortex, cerebella, thalamus, and brainstem and plasma were analyzed for drug levels of <b>22m</b>. All mice were housed under pathogen-free conditions in the animal facility, and animal experiment was performed according to the IACUC approved protocol (2018-0056) at Cincinnati Children’s Hospital Research Foundation. Wild Type (WT) (GALC+/+) and Twitcher (Twi) (GALC–/−) mice were genotyped by PCR as previously described.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Twi mice were randomly assigned to three treatment groups (<i>N</i> = 3 males + <i>N</i> = 3 females for each group) and dosed once a day i.p. with 90 or 30 mg kg<sup>–1</sup><b>22m</b> or vehicle for a duration of 20 days. Treatment started at 10 days of age. The application volume was set to 10 μL per gram of body weight, and dosage was adjusted accordingly. Two groups (<i>N</i> = 3 males + <i>N</i> = 3 females for each group) of WT controls treated with vehicle or high dose (90 mg kg<sup>–1</sup>) of <b>22m</b> were also included in the study. Animals of all groups were sacrificed 1 h after the last dose, and the brain tissues and plasma were collected. The left brain containing cortex, cerebella, thalamus, and brainstem was analyzed for SphL levels by MS. Data were analyzed using the Student <i>t</i> test. The right brain containing cortex, cerebella, thalamus, and brainstem and plasma were analyzed for drug levels of <b>22m</b>. All animal work in this study was performed in accordance with approved animal protocols from the Animal Care and Use Committee at the University of Illinois at Chicago.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i195"><a href="/doi/suppl/10.1021/acs.jmedchem.9b02004" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b02004?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02004</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><i>V</i><sub>max</sub> and <i>K</i><sub>M</sub> determinations; concentration–response curve of <b>22m</b> in primary fibroblast cells of Krabbe’s patients; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of the final compounds; retention times and UPLC analytical methods of the final compounds; UPLC traces of the final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02004/suppl_file/jm9b02004_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">A csv file containing molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02004/suppl_file/jm9b02004_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02004/suppl_file/jm9b02004_si_001.pdf">jm9b02004_si_001.pdf (10.13 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02004/suppl_file/jm9b02004_si_002.csv">jm9b02004_si_002.csv (2.78 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b02004" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23736" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23736" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Renato Skerlj</span> - <span class="hlFld-Affiliation affiliation">Lysosomal
Therapeutics Inc., 19
Blackstone Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        X4 Pharmaceuticals, 955 Massachusetts Avenue, 4th Floor, Cambridge, MA 02139, United States (Y.S.)</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b3c1d6ddd2c7dc9dc0d8d6c1dfd9f3cb87c3dbd2c1ded29dd0dcde"><span class="__cf_email__" data-cfemail="a8dacdc6c9dcc786dbc3cddac4c2e8d09cd8c0c9dac5c986cbc7c5">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rita Scarpelli</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2623-306X" title="Orcid link">http://orcid.org/0000-0002-2623-306X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fe8c978a9fd08d9d9f8c8e9b929297be97978ad0978a"><span class="__cf_email__" data-cfemail="61130815004f1202001311040d0d08210808154f0815">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simona Di Martino</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5817-751X" title="Orcid link">http://orcid.org/0000-0001-5817-751X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Piero Tardia</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vincenzo Cilibrasi</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samantha Caputo</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marco Mazzonna</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Debora Russo</span> - <span class="hlFld-Affiliation affiliation">D3-Pharma Chemistry, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ilaria Penna</span> - <span class="hlFld-Affiliation affiliation">D3-Pharma Chemistry, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natalia Realini</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natasha Margaroli</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marco Migliore</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniela Pizzirani</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development (D3)-Validation, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giuliana Ottonello</span> - <span class="hlFld-Affiliation affiliation">Analytical Chemistry Lab, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sine Mandrup Bertozzi</span> - <span class="hlFld-Affiliation affiliation">Analytical Chemistry Lab, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Armirotti</span> - <span class="hlFld-Affiliation affiliation">Analytical Chemistry Lab, , , Fondazione Istituto Italiano di Tecnologia, Via Morego 30, I-16163 Genova, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3766-8755" title="Orcid link">http://orcid.org/0000-0002-3766-8755</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Duc Nguyen</span> - <span class="hlFld-Affiliation affiliation">The Myelin
Regeneration Group at the Dept. Anatomy & Cell Biology, College
of Medicine, University of Illinois at Chicago, Chicago, Illinois, 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying Sun</span> - <span class="hlFld-Affiliation affiliation">The
Division of Human Genetics, Cincinnati Children’s Hospital
Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229-3039, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ernesto R. Bongarzone</span> - <span class="hlFld-Affiliation affiliation">The Myelin
Regeneration Group at the Dept. Anatomy & Cell Biology, College
of Medicine, University of Illinois at Chicago, Chicago, Illinois, 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Lansbury</span> - <span class="hlFld-Affiliation affiliation">Lysosomal
Therapeutics Inc., 19
Blackstone Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Liu</span> - <span class="hlFld-Affiliation affiliation">Lysosomal
Therapeutics Inc., 19
Blackstone Street, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>S.D.M. and P.T. contributed equally. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All the work in the manuscript was funded by Lysosomal Therapeutics Inc. A Sponsored Research Agreement was signed between Fondazione Istituto Italiano di Tecnologia, Drug Discovery and Development (D3)-Validation and Lysosomal Therapeutics Inc.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i198">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18337" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18337" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Silvia Venzano, Luca Goldoni, and Marina Veronesi for their technical support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AC</td><td class="NLM_def"><p class="first last">acid ceramidase</p></td></tr><tr><td class="NLM_term">Cer</td><td class="NLM_def"><p class="first last">ceramide</p></td></tr><tr><td class="NLM_term">GALC</td><td class="NLM_def"><p class="first last">β-galactosyl-ceramidase</p></td></tr><tr><td class="NLM_term">GalCer</td><td class="NLM_def"><p class="first last">galactosylceramide</p></td></tr><tr><td class="NLM_term">GalSph</td><td class="NLM_def"><p class="first last">galactosylsphingosine</p></td></tr><tr><td class="NLM_term">GD</td><td class="NLM_def"><p class="first last">Gaucher’s disease</p></td></tr><tr><td class="NLM_term">GCase</td><td class="NLM_def"><p class="first last">β-glucocerebrosidase</p></td></tr><tr><td class="NLM_term">GluCer</td><td class="NLM_def"><p class="first last">glucosylceramide</p></td></tr><tr><td class="NLM_term">GluSph</td><td class="NLM_def"><p class="first last">glucosylsphingosine</p></td></tr><tr><td class="NLM_term">LSDs</td><td class="NLM_def"><p class="first last">lysosomal storage diseases</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">Krabbe’s disease</p></td></tr><tr><td class="NLM_term">SphLs</td><td class="NLM_def"><p class="first last">sphingolipids</p></td></tr><tr><td class="NLM_term">Sph1P</td><td class="NLM_def"><p class="first last">sphingosine 1-phosphate</p></td></tr><tr><td class="NLM_term">Twi</td><td class="NLM_def"><p class="first last">Twitcher</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">glacial acetic acid</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">NH<sub>4</sub>OAc</td><td class="NLM_def"><p class="first last">ammonium acetate</p></td></tr><tr><td class="NLM_term">NH<sub>4</sub>Cl</td><td class="NLM_def"><p class="first last">ammonium chloride</p></td></tr><tr><td class="NLM_term"><i>n</i>-BuLi</td><td class="NLM_def"><p class="first last"><i>n</i>-butyllithium</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CHCl<sub>3</sub></td><td class="NLM_def"><p class="first last">chloroform</p></td></tr><tr><td class="NLM_term">Cy</td><td class="NLM_def"><p class="first last">cyclohexane</p></td></tr><tr><td class="NLM_term">Celite</td><td class="NLM_def"><p class="first last">diatomaceous earth</p></td></tr><tr><td class="NLM_term">Et<sub>2</sub>O</td><td class="NLM_def"><p class="first last">diethyl ether</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">(Pd(dppf)Cl<sub>2</sub>)</td><td class="NLM_def"><p class="first last">[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">equiv.</td><td class="NLM_def"><p class="first last">equivalent</p></td></tr><tr><td class="NLM_term">HCl</td><td class="NLM_def"><p class="first last">hydrochloric acid</p></td></tr><tr><td class="NLM_term">LiCl</td><td class="NLM_def"><p class="first last">lithium chloride</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">MeMgBr</td><td class="NLM_def"><p class="first last">methylmagnesium bromide</p></td></tr><tr><td class="NLM_term">Pd/C</td><td class="NLM_def"><p class="first last">palladium on carbon</p></td></tr><tr><td class="NLM_term">[B<sub>2</sub>(pin)<sub>2</sub>]</td><td class="NLM_def"><p class="first last">bis(pinacolato)diboron</p></td></tr><tr><td class="NLM_term">KOAc</td><td class="NLM_def"><p class="first last">potassium acetate</p></td></tr><tr><td class="NLM_term">K<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">potassium carbonate</p></td></tr><tr><td class="NLM_term">K<sub>3</sub>PO<sub>4</sub></td><td class="NLM_def"><p class="first last">potassium phosphate tribasic</p></td></tr><tr><td class="NLM_term"><i>R<sub>t</sub></i></td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">SiO<sub>2</sub></td><td class="NLM_def"><p class="first last">silica gel</p></td></tr><tr><td class="NLM_term">NaOAc</td><td class="NLM_def"><p class="first last">sodium acetate</p></td></tr><tr><td class="NLM_term">NaHCO<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium bicarbonate</p></td></tr><tr><td class="NLM_term">Na<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium carbonate</p></td></tr><tr><td class="NLM_term">Na<sub>2</sub>SO<sub>4</sub></td><td class="NLM_def"><p class="first last">sodium sulfate</p></td></tr><tr><td class="NLM_term">NaBH(OAc)<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium triacetoxyborohydride</p></td></tr><tr><td class="NLM_term">Pd(PPh<sub>3</sub>)<sub>4</sub></td><td class="NLM_def"><p class="first last">tetrakis(triphenylphosphine)palladium(0)</p></td></tr><tr><td class="NLM_term">Dess–Martin periodinane</td><td class="NLM_def"><p class="first last">1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1<i>H</i>)-one</p></td></tr><tr><td class="NLM_term">Et<sub>3</sub>N</td><td class="NLM_def"><p class="first last">trimethylamine</p></td></tr><tr><td class="NLM_term">Boc<sub>2</sub>O</td><td class="NLM_def"><p class="first last">di-<i>tert</i>-butyl dicarbonate</p></td></tr><tr><td class="NLM_term">TZD</td><td class="NLM_def"><p class="first last">2,4-thiazolidinedione</p></td></tr><tr><td class="NLM_term"><i>p</i>-TsOH</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid monohydrate</p></td></tr><tr><td class="NLM_term">H<sub>2</sub>O</td><td class="NLM_def"><p class="first last">water</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i200">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02653" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02653" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 58 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gault, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">An overview of sphingolipid metabolism: from synthesis to breakdown</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>688</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1007/978-1-4419-6741-1_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1007%2F978-1-4419-6741-1_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=20919643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=688&publication_year=2010&pages=1-23&author=C.+R.+Gaultauthor=L.+M.+Obeidauthor=Y.+A.+Hannun&title=An+overview+of+sphingolipid+metabolism%3A+from+synthesis+to+breakdown&doi=10.1007%2F978-1-4419-6741-1_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of sphingolipid metabolism: from synthesis to breakdown</span></div><div class="casAuthors">Gault, Christopher R.; Obeid, Lina M.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">688</span>
        (<span class="NLM_cas:issue">Sphingolipids as Signaling and Regulatory Molecules</span>),
    <span class="NLM_cas:pages">1-23</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Sphingolipids constitute a class of lipids defined by their eighteen carbon amino-alc. backbones which are synthesized in the ER from nonsphingolipid precursors.  Modification of this basic structure is what gives rise to the vast family of sphingolipids that play significant roles in membrane biol. and provide many bioactive metabolites that regulate cell function.  Despite the diversity of structure and function of sphingolipids, their creation and destruction are governed by common synthetic and catabolic pathways.  In this regard, sphingolipid metab. can be imagined as an array of interconnected networks that diverge from a single common entry point and converge into a single common breakdown pathway.  In their simplest forms, sphingosine, phytosphingosine and dihydrosphingosine serve as the backbones upon which further complexity is achieved.  For example, phosphorylation of the C1 hydroxyl group yields the final breakdown products and/or the important signaling mols. sphingosine-1-phosphate, phytosphingosine-1-phosphate and dihydrosphingosine-1-phosphate, resp.  On the other hand, acylation of sphingosine, phytosphingosine, or dihydrosphingosine with one of several possible acyl CoA mols. through the action of distinct ceramide synthases produces the mols. defined as ceramide, phytoceramide, or dihydroceramide.  Ceramide, due to the differing acyl CoAs that can be used to produce it, is tech. a class of mols. rather than a single mol. and therefore may have different biol. functions depending on the acyl chain it is composed of.  At the apex of complexity is the group of lipids known as glycosphingolipids (GSL) which contain dozens of different sphingolipid species differing by both the order and type of sugar residues attached to their headgroups.  Since these mols. are produced from ceramide precursors, they too may have differences in their acyl chain compn., revealing an addnl. layer of variation.  The glycosphingolipids are divided broadly into two categories: glucosphingolipids and galactosphingolipids.  The glucosphingolipids depend initially on the enzyme glucosylceramide synthase (GCS) which attaches glucose as the first residue to the C1 hydroxyl position.  Galactosphingolipids, on the other hand, are generated from galactosylceramide synthase (GalCerS), an evolutionarily dissimilar enzyme from GCS.  Glycosphingolipids are further divided based upon further modification by various glycosyltransferases which increases the potential variation in lipid species by several fold.  Far more abundant are the sphingomyelin species which are produced in parallel with glycosphingolipids, however they are defined by a phosphocholine headgroup rather than the addn. of sugar residues.  Although sphingomyelin species all share a common headgroup, they too are produced from a variety of ceramide species and therefore can have differing acyl chains attached to their C-2 amino groups.  Whether or not the differing acyl chain lengths in SMs dictate unique functions or important biophys. distinctions has not yet been established.  Understanding the function of all the existing glycosphingolipids and sphingomyelin species will be a major undertaking in the future since the tools to study and measure these species are only beginning to be developed (see Fig 1 for an illustrated depiction of the various sphingolipid structures).  The simple sphingolipids serve both as the precursors and the breakdown products of the more complex ones.  Importantly, in recent decades, these simple sphingolipids have gained attention for having significant signaling and regulatory roles within cells.  In addn., many tools have emerged to measure the levels of simple sphingolipids and therefore have become the focus of even more intense study in recent years.  With this thought in mind, this chapter will pay tribute to the complex sphingolipids, but focus on the regulation of simple sphingolipid metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-glJUw4HtHrVg90H21EOLACvtfcHk0lh35ZrbTe6clw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFGhtg%253D%253D&md5=512ae1d4d9d2f9f2f231e0e189a2b3a0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-1-4419-6741-1_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4419-6741-1_1%26sid%3Dliteratum%253Aachs%26aulast%3DGault%26aufirst%3DC.%2BR.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DAn%2520overview%2520of%2520sphingolipid%2520metabolism%253A%2520from%2520synthesis%2520to%2520breakdown%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2010%26volume%3D688%26spage%3D1%26epage%3D23%26doi%3D10.1007%2F978-1-4419-6741-1_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and their metabolism in physiology and disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fnrm.2017.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=29165427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKqt7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=175-191&author=Y.+A.+Hannunauthor=L.+M.+Obeid&title=Sphingolipids+and+their+metabolism+in+physiology+and+disease&doi=10.1038%2Fnrm.2017.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and their metabolism in physiology and disease</span></div><div class="casAuthors">Hannun, Yusuf A.; Obeid, Lina M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">175-191</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Studies of bioactive lipids in general and sphingolipids in particular have intensified over the past several years, revealing an unprecedented and unanticipated complexity of the lipidome and its many functions, which rivals, if not exceeds, that of the genome or proteome.  These results highlight crit. roles for bioactive sphingolipids in most, if not all, major cell biol. responses, including all major cell signalling pathways, and they link sphingolipid metab. to key human diseases.  Nevertheless, the fairly nascent field of bioactive sphingolipids still faces challenges in its biochem. and mol. underpinnings, including defining the mol. mechanisms of pathway and enzyme regulation, the study of lipid-protein interactions and the development of cellular probes, suitable biomarkers and therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl9A-uh9uFPrVg90H21EOLACvtfcHk0liZ8qJrUIaMVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKqt7fE&md5=81409d71ab1c29c9dea5f060105032be</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.107%26sid%3Dliteratum%253Aachs%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26atitle%3DSphingolipids%2520and%2520their%2520metabolism%2520in%2520physiology%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2018%26volume%3D19%26spage%3D175%26epage%3D191%26doi%3D10.1038%2Fnrm.2017.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, B.</span>; <span class="NLM_string-name">Johnson, A.</span>; <span class="NLM_string-name">Lewis, J.</span>; <span class="NLM_string-name">Raff, M.</span>; <span class="NLM_string-name">Roberts, K.</span>; <span class="NLM_string-name">Walter, P.</span></span> In  <i>Molecular Biology of the Cell</i>; <span class="NLM_edition">5</span>th ed. th ed.; <span class="NLM_publisher-name">Garland Science</span>: <span class="NLM_publisher-loc">New York, USA, Ed</span>. <span class="NLM_year">2008</span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">787</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=779-787&author=B.+Alberts&author=A.+Johnson&author=J.+Lewis&author=M.+Raff&author=K.+Roberts&author=P.+Walter&title=Molecular+Biology+of+the+Cell"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAlberts%26aufirst%3DB.%26btitle%3DMolecular%2520Biology%2520of%2520the%2520Cell%26pub%3DGarland%2520Science%26date%3D2008%26spage%3D779%26epage%3D787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saftig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumperman, J.</span></span> <span> </span><span class="NLM_article-title">Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1038/nrm2745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fnrm2745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=19672277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsleqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=623-635&author=P.+Saftigauthor=J.+Klumperman&title=Lysosome+biogenesis+and+lysosomal+membrane+proteins%3A+trafficking+meets+function&doi=10.1038%2Fnrm2745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function</span></div><div class="casAuthors">Saftig, Paul; Klumperman, Judith</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">623-635</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lysosomes are the primary catabolic compartments of eukaryotic cells.  They degrade extracellular material that has been internalized by endocytosis and intracellular components that have been sequestered by autophagy.  In addn., specialized cells contain lysosome-related organelles that store and secrete proteins for cell-type-specific functions.  The functioning of a healthy cell is dependent on the proper targeting of newly synthesized lysosomal proteins.  Accumulating evidence suggests that there are multiple lysosomal delivery pathways that together allow the regulated and sequential deposition of lysosomal components.  The importance of lysosomal trafficking pathways is emphasized by recent findings that reveal new roles for lysosomal membrane proteins in cellular physiol. and in an increasing no. of diseases that are characterized by defects in lysosome biogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpby5TZ_C2_I7Vg90H21EOLACvtfcHk0liZ8qJrUIaMVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsleqsrc%253D&md5=e45f191f35eba89f8936a7a9a9f76cdf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm2745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2745%26sid%3Dliteratum%253Aachs%26aulast%3DSaftig%26aufirst%3DP.%26aulast%3DKlumperman%26aufirst%3DJ.%26atitle%3DLysosome%2520biogenesis%2520and%2520lysosomal%2520membrane%2520proteins%253A%2520trafficking%2520meets%2520function%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2009%26volume%3D10%26spage%3D623%26epage%3D635%26doi%3D10.1038%2Fnrm2745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnick, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlinz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhoff, K.</span></span> <span> </span><span class="NLM_article-title">Purification, characterization, and biosynthesis of human acid ceramidase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">11098</span>– <span class="NLM_lpage">11102</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.19.11098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1074%2Fjbc.270.19.11098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=7744740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK2MXls1ejtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=11098-11102&author=K.+Bernardoauthor=R.+Hurwitzauthor=T.+Zenkauthor=R.+J.+Desnickauthor=K.+Ferlinzauthor=E.+H.+Schuchmanauthor=K.+Sandhoff&title=Purification%2C+characterization%2C+and+biosynthesis+of+human+acid+ceramidase&doi=10.1074%2Fjbc.270.19.11098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Purification, characterization, and biosynthesis of human acid ceramidase</span></div><div class="casAuthors">Bernardo, Katussevani; Hurwitz, Robert; Zenk, Thomas; Desnick, Robert J.; Ferlinz, Klaus; Schuchman, Edward H.; Sandhoff, Konrad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11098-102</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23) (I) is the lysosomal enzyme catalyzing the hydrolysis of ceramide to sphingosine and free fatty acid.  Its inherited deficiency causes ceramide accumulation in inherited deficiency causes ceramide accumulation in Faber's disease.  I was purified to apparent homogeneity from human urine by sequential chromatog. on octyl-Sepharose, Con A-Sepharose, Blue-Sepharose, and DEAE-cellulose.  The final prepn., which was enriched ∼4450-fold over the starting material, resulted in a polypeptide of ∼50 kDa and could be reduced into 2 subunits of ∼13 (α) and ∼40 (β) kDa.  Treatment of purified I with endoglycosidase H or peptide N-glycanase F reduced the mol. wt. of the β subunit to ∼30-35 and ∼27 kDa, resp.  In contrast, the mol. wt. of the α subunit was unchanged.  Purified I had an apparent Km of 149 μM and a Vmax of 136 nmol/mg/h using N-lauroylsphingosine as substrate.  Polyclonal antibodies were raised against the purified urinary enzyme and used to investigate the biosynthesis of I.  Immunopptn. studies on metabolically labeled skin fibroblasts indicated that both subunits arise from a single precursor of ∼55 kDa.  A minor protein of newly synthesized I was secreted into the medium as a monomeric 47-kDa protein, indicating that generation of the mature heterodimeric enzyme occurs in endosomal and/or lysosomal compartments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm-1pFxhqHCLVg90H21EOLACvtfcHk0liZ8qJrUIaMVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls1ejtb4%253D&md5=d8f667c773db8a01ca5d22e49dd36123</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.19.11098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.19.11098%26sid%3Dliteratum%253Aachs%26aulast%3DBernardo%26aufirst%3DK.%26aulast%3DHurwitz%26aufirst%3DR.%26aulast%3DZenk%26aufirst%3DT.%26aulast%3DDesnick%26aufirst%3DR.%2BJ.%26aulast%3DFerlinz%26aufirst%3DK.%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26aulast%3DSandhoff%26aufirst%3DK.%26atitle%3DPurification%252C%2520characterization%252C%2520and%2520biosynthesis%2520of%2520human%2520acid%2520ceramidase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D11098%26epage%3D11102%26doi%3D10.1074%2Fjbc.270.19.11098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span> <span> </span><span class="NLM_article-title">Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1781</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2008.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.bbalip.2008.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=18619555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1781&publication_year=2008&pages=424-434&author=C.+Maoauthor=L.+M.+Obeid&title=Ceramidases%3A+regulators+of+cellular+responses+mediated+by+ceramide%2C+sphingosine%2C+and+sphingosine-1-phosphate&doi=10.1016%2Fj.bbalip.2008.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate</span></div><div class="casAuthors">Mao, Cungui; Obeid, Lina M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1781</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">424-434</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Ceramidases catalyze hydrolysis of ceramides to generate sphingosine (SPH), which is phosphorylated to form sphingosine-1-phosphate (S1P).  Ceramide, SPH, and S1P are bioactive lipids that mediate cell proliferation, differentiation, apoptosis, adhesion, and migration.  Presently, 5 human ceramidases encoded by 5 distinct genes have been cloned: acid ceramidase (AC), neutral ceramidase (NC), alk. ceramidase 1 (ACER1), alk. ceramidase 2 (ACER2), and alk. ceramidase 3 (ACER3).  Each human ceramidase has a mouse counterpart.  AC, NC, and ACER1-3 have maximal activities in acidic, neutral, and alk. environments, resp.  ACER1-3 have similar protein sequences but no homol. to AC and NC.  AC and NC also have distinct protein sequences.  The human AC (hAC) was implicated in Farber disease, and hAC may be important for cell survival.  The mouse AC (mAC) is needed for early embryo survival.  NC is protective against inflammatory cytokines, and the mouse NC (mNC) is required for the catabolism of ceramides in the digestive tract.  ACER1 is crit. in mediating cell differentiation by controlling the generation of SPH and S1P and that ACER2's role in cell proliferation and survival depends on its expression or the cell type in which it is found.  Here, we discuss the role of each ceramidase in regulating cellular responses mediated by ceramides, SPH, and S1P.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEgvBkM7CJsLVg90H21EOLACvtfcHk0lgtXFIWXRXlXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrM&md5=0ff10423032645e5c8a9baa1c442b85d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2008.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2008.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DC.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26atitle%3DCeramidases%253A%2520regulators%2520of%2520cellular%2520responses%2520mediated%2520by%2520ceramide%252C%2520sphingosine%252C%2520and%2520sphingosine-1-phosphate%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2008%26volume%3D1781%26spage%3D424%26epage%3D434%26doi%3D10.1016%2Fj.bbalip.2008.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Ceramidases, roles in sphingolipid metabolism and in health and disease</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2016.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.jbior.2016.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=27771292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2017&pages=122-131&author=N.+Coantauthor=W.+Sakamotoauthor=C.+Maoauthor=Y.+A.+Hannun&title=Ceramidases%2C+roles+in+sphingolipid+metabolism+and+in+health+and+disease&doi=10.1016%2Fj.jbior.2016.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidases, roles in sphingolipid metabolism and in health and disease</span></div><div class="casAuthors">Coant, Nicolas; Sakamoto, Wataru; Mao, Cungui; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122-131</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over the past three decades, extensive research has been able to det. the biol. functions for the main bioactive sphingolipids, namely ceramide, sphingosine, and sphingosine 1-phosphate (S1P) (Hannun, 1996; Hannun et al., 1986; Okazaki et al., 1989).  These studies have managed to define the metab., regulation, and function of these bioactive sphingolipids.  This emerging body of literature has also implicated bioactive sphingolipids, particularly S1P and ceramide, as key regulators of cellular homeostasis.  Ceramidases have the important role of cleaving fatty acid from ceramide and producing sphingosine, thereby controlling the interconversion of these two lipids.  Thus far, five human ceramidases encoded by five different genes have been identified: acid ceramidase (AC), neutral ceramidase (NC), alk. ceramidase 1 (ACER1), alk. ceramidase 2 (ACER2), and alk. ceramidase 3 (ACER3).  These ceramidases are classified according to their optimal pH for catalytic activity.  AC, which is localized to the lysosomal compartment, has been assocd. with Farber's disease and is involved in the regulation of cell viability.  Neutral ceramidase, which is localized to the plasma membrane and primarily expressed in the small intestine and colon, is involved in digestion, and has been implicated in colon carcinogenesis.  ACER1 which can be found in the endoplasmic reticulum and is highly expressed in the skin, plays an important role in keratinocyte differentiation.  ACER2, localized to the Golgi complex and highly expressed in the placenta, is involved in programed cell death in response to DNA damage.  ACER3, also localized to the endoplasmic reticulum and the Golgi complex, is ubiquitously expressed, and is involved in motor coordination-assocd. Purkinje cell degeneration.  This review seeks to consolidate the current knowledge regarding these key cellular players.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowWeoXuPUgXrVg90H21EOLACvtfcHk0lgtXFIWXRXlXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK&md5=84e937e947b7a38256761a6ab60a7353</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2016.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2016.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCoant%26aufirst%3DN.%26aulast%3DSakamoto%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramidases%252C%2520roles%2520in%2520sphingolipid%2520metabolism%2520and%2520in%2520health%2520and%2520disease%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2017%26volume%3D63%26spage%3D122%26epage%3D131%26doi%3D10.1016%2Fj.jbior.2016.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Functions of ceramide in coordinating cellular responses to stress</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1859</span>, <span class="refDoi"> DOI: 10.1126/science.274.5294.1855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1126%2Fscience.274.5294.1855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=8943189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK28XnsFGisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1996&pages=1855-1859&author=Y.+A.+Hannun&title=Functions+of+ceramide+in+coordinating+cellular+responses+to+stress&doi=10.1126%2Fscience.274.5294.1855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of ceramide in coordinating cellular responses to stress</span></div><div class="casAuthors">Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">5294</span>),
    <span class="NLM_cas:pages">1855-1859</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 56 refs.  Sphingolipid metabolites participate in key events of signal transduction and cell regulation.  In the sphingomyelin cycle, a no. of extracellular agents and insults (such at tumor necrosis factor, Fas ligands, and chemotherapeutic agents) cause the activation of sphingomyelinases, which act on membrane sphingomyelin and release ceramide.  Multiple exptl. approaches suggest an important role for ceramide in regulating such diverse responses as cell cycle arrest, apoptosis, and cell senescence.  In vitro, ceramide activates a serine-threonine protein phosphatase, and in cells it regulates protein phosphorylation as well as multiple downstream targets [such as interleukin converting enzyme (ICE)-like proteases, stress-activated protein kinases, and the retinoblastoma gene product] that mediate its distinct cellular effects.  This spectrum of inducers of ceramide accumulation and the nature of ceramide-mediated responses suggest that ceramide is a key component of intracellular stress response pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSGWmlfW0IZLVg90H21EOLACvtfcHk0lgX74MOJpLM2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XnsFGisrc%253D&md5=1eddfb8251d80b89adaf48668f375e34</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.274.5294.1855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.274.5294.1855%26sid%3Dliteratum%253Aachs%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DFunctions%2520of%2520ceramide%2520in%2520coordinating%2520cellular%2520responses%2520to%2520stress%26jtitle%3DScience%26date%3D1996%26volume%3D274%26spage%3D1855%26epage%3D1859%26doi%3D10.1126%2Fscience.274.5294.1855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballou, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laulederkind, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosloniec, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghow, R.</span></span> <span> </span><span class="NLM_article-title">Ceramide signalling and the immune response</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1301</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1016/0005-2760(96)00004-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2F0005-2760%2896%2900004-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=8664339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK28XivFKrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1301&publication_year=1996&pages=273-287&author=L.+R.+Ballouauthor=S.+J.+F.+Laulederkindauthor=E.+F.+Rosloniecauthor=R.+Raghow&title=Ceramide+signalling+and+the+immune+response&doi=10.1016%2F0005-2760%2896%2900004-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramide signaling and the immune response</span></div><div class="casAuthors">Ballou, Leslie R.; Laulederkind, Stanley J. F.; Rosloniec, Edward F.; Raghow, Rajendra</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Lipids and Lipid Metabolism</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">1301</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">BBLLA6</span>;
        ISSN:<span class="NLM_cas:issn">0005-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 134 refs.  Discussed are: ceramide and immunomodulation; components of the sphingomyelin pathway; the biol. effects of ceramide; and downstream ceramide signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobIqdyjYsr37Vg90H21EOLACvtfcHk0lgX74MOJpLM2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivFKrurs%253D&md5=ecf2bceea52fdbfd465ba64472e2014e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0005-2760%2896%2900004-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2760%252896%252900004-5%26sid%3Dliteratum%253Aachs%26aulast%3DBallou%26aufirst%3DL.%2BR.%26aulast%3DLaulederkind%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DRosloniec%26aufirst%3DE.%2BF.%26aulast%3DRaghow%26aufirst%3DR.%26atitle%3DCeramide%2520signalling%2520and%2520the%2520immune%2520response%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1996%26volume%3D1301%26spage%3D273%26epage%3D287%26doi%3D10.1016%2F0005-2760%2896%2900004-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruvolo, P. P.</span></span> <span> </span><span class="NLM_article-title">Intracellular signal transduction pathways activated by ceramide and its metabolites</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1016/S1043-6618(03)00050-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2FS1043-6618%2803%2900050-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=12676512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFWlsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=383-392&author=P.+P.+Ruvolo&title=Intracellular+signal+transduction+pathways+activated+by+ceramide+and+its+metabolites&doi=10.1016%2FS1043-6618%2803%2900050-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular signal transduction pathways activated by ceramide and its metabolites</span></div><div class="casAuthors">Ruvolo, Peter P.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">383-392</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The sphingolipid ceramide has proven to be a powerful second-signal effector mol. that regulates diverse cellular processes including apoptosis, cell senescence, the cell cycle, and cellular differentiation.  Ceramide has been shown to activate a no. of enzymes involved in stress signaling cascades including both protein kinases and protein phosphatases.  Ceramide kinase targets include stress-activated protein kinases (SAPKs) such as the jun kinases (JNKs), kinase suppressor of Ras (KSR), and the atypical protein kinase C (PKC) isoform, PKC ζ.  Ceramide also is capable of activating protein phosphatases such as protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A).  It is through these protein phosphatases that ceramide can indirectly inhibit kinases that are key components of pro-growth signaling processes such as the classical and novel PKC isoforms and protein kinase B (PKB; also known as Akt).  However, the mechanisms how ceramide directly activates enzymes such as JNK and PP2A are still not clear.  Elucidation of these mechanisms will reveal how ceramide functions in stress signaling cascades and will provide important information on cellular processes such as apoptosis.  It is becoming clear that the ceramide generation is a near universal feature of programmed cell death.  It is possible that during at least some apoptotic events, ceramide may be required to activate stress-signal cascades that lead to cell death, while concurrently, suppressing growth and survival pathways in the dying cell.  Such a versatile role for ceramide is not unreasonable since ceramide has been implicated as having a role in both intrinsic (i.e. mitochondrial) and extrinsic (i.e. death receptor-mediated) apoptotic pathways.  The recent data suggesting that aberrant glycosylation of ceramide (i.e. inactivation of the mol.) may be an important cause of drug resistance in certain cancers suggests that ceramide-mediated signaling cascades are crit. components of chemotherapy-induced cell killing.  Taken together, these properties of ceramide suggest that this important second-signal mol. may be an important target in anti-neoplastic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoscSCFhDZyR7Vg90H21EOLACvtfcHk0lgX74MOJpLM2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFWlsLc%253D&md5=9dd4127e61cf59ce58ea88acf77b4b0f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS1043-6618%2803%2900050-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1043-6618%252803%252900050-1%26sid%3Dliteratum%253Aachs%26aulast%3DRuvolo%26aufirst%3DP.%2BP.%26atitle%3DIntracellular%2520signal%2520transduction%2520pathways%2520activated%2520by%2520ceramide%2520and%2520its%2520metabolites%26jtitle%3DPharmacol.%2520Res.%26date%3D2003%26volume%3D47%26spage%3D383%26epage%3D392%26doi%3D10.1016%2FS1043-6618%2803%2900050-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Withers, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, R. C.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and lifespan regulation</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1841</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2013.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.bbalip.2013.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGqs7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1841&publication_year=2014&pages=657-664&author=X.+Huangauthor=B.+R.+Withersauthor=R.+C.+Dickson&title=Sphingolipids+and+lifespan+regulation&doi=10.1016%2Fj.bbalip.2013.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and lifespan regulation</span></div><div class="casAuthors">Huang, Xinhe; Withers, Bradley R.; Dickson, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1841</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-664</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Diseases including cancer, type 2 diabetes, cardiovascular and immune dysfunction and neurodegeneration become more prevalent as we age, and combined with the increase in av. human lifespan, place an ever increasing burden on the health care system.  In this chapter we focus on finding ways of modulating sphingolipids to prevent the development of age-assocd. diseases or delay their onset, both of which could improve health in elderly, fragile people.  Reducing the incidence of or delaying the onset of diseases of aging has blossomed in the past decade because of advances in understanding signal transduction pathways and cellular processes, esp. in model organisms, that are largely conserved in most eukaryotes and that can be modulated to reduce signs of aging and increase health span.  In model organisms such interventions must also increase lifespan to be considered significant, but this is not a requirement for use in humans.  The most encouraging interventions in model organisms involve lowering the concn. of one or more sphingolipids so as to reduce the activity of key signaling pathways, one of the most promising being the Target of Rapamycin Complex 1 (TORC1) protein kinase pathway.  Other potential ways in which modulating sphingolipids may contribute to improving the health profile of the elderly is by reducing oxidative stresses, inflammatory responses and growth factor signaling.  Lastly, perhaps the most interesting way to modulate sphingolipids and promote longevity is by lowering the activity of serine palmitoyltransferase, the first enzyme in the de novo sphingolipid biosynthesis pathway.  Available data in yeasts and rodents are encouraging and as we gain insights into mol. mechanisms the strategies for improving human health by modulating sphingolipids will become more apparent.  This article is part of a Special Issue entitled New Frontiers in Sphingolipid Biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1RgynOoylLVg90H21EOLACvtfcHk0lgX74MOJpLM2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGqs7vN&md5=43c74eeb2e56fcd45233c75fde965851</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2013.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2013.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWithers%26aufirst%3DB.%2BR.%26aulast%3DDickson%26aufirst%3DR.%2BC.%26atitle%3DSphingolipids%2520and%2520lifespan%2520regulation%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2014%26volume%3D1841%26spage%3D657%26epage%3D664%26doi%3D10.1016%2Fj.bbalip.2013.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalfant, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Ceramide in apoptosis: an overview and current perspectives</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1585</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/S1388-1981(02)00331-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2FS1388-1981%2802%2900331-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=12531544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVOqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1585&publication_year=2002&pages=114-125&author=B.+J.+Pettusauthor=C.+E.+Chalfantauthor=Y.+A.+Hannun&title=Ceramide+in+apoptosis%3A+an+overview+and+current+perspectives&doi=10.1016%2FS1388-1981%2802%2900331-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramide in apoptosis: an overview and current perspectives</span></div><div class="casAuthors">Pettus, Benjamin J.; Chalfant, Charles E.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1585</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">114-125</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recent years have witnessed significant advances in the understanding of the role of ceramide in apoptosis.  This review summarizes these recent findings and discusses insights from studies of ceramide metab., topol., and effector actions.  The recent identification of several genes for enzymes of ceramide metab., the development of mass spectrometric methods for ceramide anal., and the increasing mol. and pharmacol. tools to probe ceramide metab. and function promise an accelerated phase in defining the mol. and biochem. details of the role of ceramide in apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXIUeERO-epbVg90H21EOLACvtfcHk0lhJtQYzPhWYHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVOqtg%253D%253D&md5=e1cc8bcdf206d5417e085bdd0d6f0096</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1388-1981%2802%2900331-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1388-1981%252802%252900331-1%26sid%3Dliteratum%253Aachs%26aulast%3DPettus%26aufirst%3DB.%2BJ.%26aulast%3DChalfant%26aufirst%3DC.%2BE.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramide%2520in%2520apoptosis%253A%2520an%2520overview%2520and%2520current%2520perspectives%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2002%26volume%3D1585%26spage%3D114%26epage%3D125%26doi%3D10.1016%2FS1388-1981%2802%2900331-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goñi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Checa, J. C.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and cell death</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1007/s10495-007-0721-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1007%2Fs10495-007-0721-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=17294080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFamtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=923-939&author=A.+Moralesauthor=H.+Leeauthor=F.+M.+Go%C3%B1iauthor=R.+Kolesnickauthor=J.+C.+Fernandez-Checa&title=Sphingolipids+and+cell+death&doi=10.1007%2Fs10495-007-0721-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and cell death</span></div><div class="casAuthors">Morales, Albert; Lee, Hyunmi; Goni, Felix M.; Kolesnick, Richard; Fernandez-Checa, Jose C.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">923-939</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Sphingolipids (SLs) have been considered for many years as predominant building blocks of biol. membranes with key structural functions and little relevance in cellular signaling.  However, this view has changed dramatically in recent years with the recognition that certain SLs such as ceramide, sphingosine 1-phosphate and gangliosides, participate actively in signal transduction pathways, regulating many different cell functions such as proliferation, differentiation, adhesion and cell death.  In particular, ceramide has attracted considerable attention in cell biol. and biophysics due to its key role in the modulation of membrane phys. properties, signaling and cell death regulation.  This latter function is largely exerted by the ability of ceramide to activate the major pathways governing cell death such as the endoplasmic reticulum and mitochondria.  Overall, the evidence so far indicates a key function of SLs in disease pathogenesis and hence their regulation may be of potential therapeutic relevance in different pathologies including liver diseases, neurodegeneration and cancer biol. and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO8HgnKrzkeLVg90H21EOLACvtfcHk0lhJtQYzPhWYHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFamtr4%253D&md5=5f7e22e3f90eaab152197336d1f0a37b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10495-007-0721-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-007-0721-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DGo%25C3%25B1i%26aufirst%3DF.%2BM.%26aulast%3DKolesnick%26aufirst%3DR.%26aulast%3DFernandez-Checa%26aufirst%3DJ.%2BC.%26atitle%3DSphingolipids%2520and%2520cell%2520death%26jtitle%3DApoptosis%26date%3D2007%26volume%3D12%26spage%3D923%26epage%3D939%26doi%3D10.1007%2Fs10495-007-0721-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1083/jcb.114.1.155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1083%2Fjcb.114.1.155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=2050740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK3MXksVKku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1991&pages=155-167&author=H.+Zhangauthor=N.+N.+Desaiauthor=A.+Oliveraauthor=T.+Sekiauthor=G.+Brookerauthor=S.+Spiegel&title=Sphingosine-1-phosphate%2C+a+novel+lipid%2C+involved+in+cellular+proliferation&doi=10.1083%2Fjcb.114.1.155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation</span></div><div class="casAuthors">Zhang, Hong; Desai, Naishadh N.; Olivera, Ana; Seki, Takashi; Brooker, Gary; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-67</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    </div><div class="casAbstract">The rapid increase in 32P-labeled sphingosine-1-phosphate levels induced by sphingosine was concn. dependent and correlated with its effect on DNA synthesis.  Similar to the mitogenic effects of sphingosine, low concns. of sphingosine-1-phosphate stimulated DNA synthesis and induced pronounced morphol. alterations.  Both sphingosine and sphingosine-1-phosphate stimulated DNA synthesis in cells made protein kinase C deficient by prolonged treatment with phorbol ester and sphingosine still elicited similar increases in sphingosine-1-phosphate levels in these cells.  Although both sphingosine and sphingosine-1-phosphate acted synergistically with a wide variety of growth factors, there was no additive or synergistic effect in response to a combination of sphingosine and sphingosine-1-phosphate.  Using a digital imaging system for measurement of Ca changes, it was obsd. that both sphingosine and sphingosine-1-phosphate are potent Ca-mobilizing agonists in viable 3T3 fibroblasts.  The rapid rise in cytosolic free Ca was independent of the presence of Ca in the external medium, indicating that the response is due to the mobilization of Ca from internal stores.  Sphingosine-1-phosphate may be a component of the intracellular 2nd messenger system that is involved in Ca release and the regulation of cell growth induced by sphingosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNmAVbQBZTs7Vg90H21EOLACvtfcHk0ljSKR7AsqeiNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksVKku7c%253D&md5=f5991020e4dd2971ef810f20022b8f23</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1083%2Fjcb.114.1.155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.114.1.155%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDesai%26aufirst%3DN.%2BN.%26aulast%3DOlivera%26aufirst%3DA.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DBrooker%26aufirst%3DG.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%252C%2520a%2520novel%2520lipid%252C%2520involved%2520in%2520cellular%2520proliferation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1991%26volume%3D114%26spage%3D155%26epage%3D167%26doi%3D10.1083%2Fjcb.114.1.155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Payne, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: dual messenger functions</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>531</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(02)03480-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2FS0014-5793%2802%2903480-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=12401202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVOjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=531&publication_year=2002&pages=54-57&author=S.+G.+Payneauthor=S.+Milstienauthor=S.+Spiegel&title=Sphingosine-1-phosphate%3A+dual+messenger+functions&doi=10.1016%2FS0014-5793%2802%2903480-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: dual messenger functions</span></div><div class="casAuthors">Payne, Shawn G.; Milstien, Sheldon; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">531</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-57</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The sphingolipid metabolite, sphingosine-1-phosphate (S1P), is a serum-borne lipid that regulates many vital cellular processes.  S1P is the ligand of a family of 5 specific G protein-coupled receptors that are differentially expressed in different tissues and regulate diverse cellular actions.  Much less is known of the intracellular actions of S1P.  It has been suggested that S1P may also function as an intracellular 2nd messenger to regulate Ca2+ mobilization, cell growth, and suppression of apoptosis in response to a variety of extracellular stimuli.  Dissecting the dual actions and identification of intracellular targets of S1P has been challenging, but there is ample evidence to suggest that the balance between S1P and ceramide and/or sphingosine levels in cells is an important determinant of cell fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo76yT7OtSBfLVg90H21EOLACvtfcHk0ljSKR7AsqeiNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVOjtLg%253D&md5=ba8373675f89dc1cdea56cd3a3ad9cd3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2802%2903480-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252802%252903480-4%26sid%3Dliteratum%253Aachs%26aulast%3DPayne%26aufirst%3DS.%2BG.%26aulast%3DMilstien%26aufirst%3DS.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%253A%2520dual%2520messenger%2520functions%26jtitle%3DFEBS%2520Lett.%26date%3D2002%26volume%3D531%26spage%3D54%26epage%3D57%26doi%3D10.1016%2FS0014-5793%2802%2903480-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: an enigmatic signalling lipid</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1038/nrm1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fnrm1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=12728273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=397-407&author=S.+Spiegelauthor=S.+Milstien&title=Sphingosine-1-phosphate%3A+an+enigmatic+signalling+lipid&doi=10.1038%2Fnrm1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: an enigmatic signalling lipid</span></div><div class="casAuthors">Spiegel, Sarah; Milstien, Sheldon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">397-407</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The evolutionarily conserved actions of the sphingolipid metabolite, sphingosine-1-phosphate (S1P), in yeast, plants, and mammals have shown that it has important functions.  In higher eukaryotes, S1P is the ligand for a family of 5 G protein-coupled receptors.  These S1P receptors are differentially expressed, coupled to various G proteins, and regulate angiogenesis, vascular maturation, cardiac development, and immunity, and are important for directed cell movement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos0XUAxYZwqLVg90H21EOLACvtfcHk0ljSKR7AsqeiNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D&md5=689a33cfeb4bae72637b64cd90e6c910</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrm1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1103%26sid%3Dliteratum%253Aachs%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DMilstien%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%253A%2520an%2520enigmatic%2520signalling%2520lipid%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2003%26volume%3D4%26spage%3D397%26epage%3D407%26doi%3D10.1038%2Fnrm1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Export of sphingosine-1-phosphate and cancer progression</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1839</span>– <span class="NLM_lpage">1846</span>, <span class="refDoi"> DOI: 10.1194/jlr.R046656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1194%2Fjlr.R046656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=24474820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGjurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1839-1846&author=K.+Takabeauthor=S.+Spiegel&title=Export+of+sphingosine-1-phosphate+and+cancer+progression&doi=10.1194%2Fjlr.R046656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Export of sphingosine-1-phosphate and cancer progression</span></div><div class="casAuthors">Takabe, Kazuaki; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1839-1846</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator that promotes cell survival, proliferation, migration, angiogenesis, lymphangiogenesis, and immune response; all are crit. processes of cancer progression.  Although some important roles of intracellular S1P have recently been uncovered, the majority of its biol. effects are known to be mediated via activation of five specific G protein-coupled receptors [S1P receptor (S1PR)1-S1PR5] located on the cell surface.  Secretion of S1P produced inside cells by sphingosine kinases can then signal through these receptors in autocrine, paracrine, and/or endocrine manners, coined "inside-out" signaling of S1P.  Numerous studies suggest that secreted S1P plays important roles in cancer progression; thus, understanding the mechanism by which S1P is exported out of cells, particularly cancer cells, is both interesting and important.  Here we will review the current understanding of the transport of S1P out of cancer cells and its potential roles in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpbPqJSPEIt7Vg90H21EOLACvtfcHk0ljSKR7AsqeiNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGjurnN&md5=2371f977febf54b94ccfc91cd00cb0c2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R046656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R046656%26sid%3Dliteratum%253Aachs%26aulast%3DTakabe%26aufirst%3DK.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DExport%2520of%2520sphingosine-1-phosphate%2520and%2520cancer%2520progression%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2014%26volume%3D55%26spage%3D1839%26epage%3D1846%26doi%3D10.1194%2Fjlr.R046656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pontis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase in melanoma: expression, localization, and effects of pharmacological inhibition</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">2422</span>– <span class="NLM_lpage">2434</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.666909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1074%2Fjbc.M115.666909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=26553872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Cqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=2422-2434&author=N.+Realiniauthor=F.+Paleseauthor=D.+Pizziraniauthor=S.+Pontisauthor=A.+Basitauthor=A.+Bachauthor=A.+Ganesanauthor=D.+Piomelli&title=Acid+ceramidase+in+melanoma%3A+expression%2C+localization%2C+and+effects+of+pharmacological+inhibition&doi=10.1074%2Fjbc.M115.666909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Acid Ceramidase in Melanoma. Expression, location, and effects of pharmacological inhibitors</span></div><div class="casAuthors">Realini, Natalia; Palese, Francesca; Pizzirani, Daniela; Pontis, Silvia; Basit, Abdul; Bach, Anders; Ganesan, Anand; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2422-2434</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) is a lysosomal cysteine amidase that controls sphingolipid signaling by lowering the levels of ceramides and concomitantly increasing those of sphingosine and its bioactive metabolite, sphingosine 1-phosphate.  In the present study, we evaluated the role of AC-regulated sphingolipid signaling in melanoma.  We found that AC expression is markedly elevated in normal human melanocytes and proliferative melanoma cell lines, compared with other skin cells (keratinocytes and fibroblasts) and non-melanoma cancer cells.  High AC expression was also obsd. in biopsies from human subjects with Stage II melanoma.  Immunofluorescence studies revealed that the subcellular localization of AC differs between melanocytes (where it is found in both cytosol and nucleus) and melanoma cells (where it is primarily localized to cytosol).  In addn. to having high AC levels, melanoma cells generate lower amts. of ceramides than normal melanocytes do.  This down-regulation in ceramide prodn. appears to result from suppression of the de novo biosynthesis pathway.  To test whether AC might contribute to melanoma cell proliferation, we blocked AC activity using a new potent (IC50 = 12 nm) and stable inhibitor.  AC inhibition increased cellular ceramide levels, decreased sphingosine 1-phosphate levels, and acted synergistically with several, albeit not all, antitumoral agents.  The results suggest that AC-controlled sphingolipid metab. may play an important role in the control of melanoma proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ1pGRTPNfObVg90H21EOLACvtfcHk0lhVODDTJjFm1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Cqsbo%253D&md5=40dd33dee5301d0b79ee77c54b3b3fe3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.666909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.666909%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DPalese%26aufirst%3DF.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DPontis%26aufirst%3DS.%26aulast%3DBasit%26aufirst%3DA.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DAcid%2520ceramidase%2520in%2520melanoma%253A%2520expression%252C%2520localization%252C%2520and%2520effects%2520of%2520pharmacological%2520inhibition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D2422%26epage%3D2434%26doi%3D10.1074%2Fjbc.M115.666909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E. H.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1862</i></span>,  <span class="NLM_fpage">1459</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.1016/j.bbadis.2016.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.bbadis.2016.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=27155573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2016&pages=1459-1471&author=E.+H.+Schuchman&title=Acid+ceramidase+and+the+treatment+of+ceramide+diseases%3A+The+expanding+role+of+enzyme+replacement+therapy&doi=10.1016%2Fj.bbadis.2016.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy</span></div><div class="casAuthors">Schuchman, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1459-1471</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Ceramides are a diverse group of sphingolipids that play important roles in many biol. processes.  Acid ceramidase (AC) is one key enzyme that regulates ceramide metab.  Early research on AC focused on the fact that it is the enzyme deficient in the rare genetic disorder, Farber Lipogranulomatosis.  Recent research has revealed that deficiency of the same enzyme is responsible for a rare form of spinal muscular atrophy assocd. with myoclonic epilepsy (SMA-PME).  Due to their diverse role in biol., accumulation of ceramides also has been implicated in the pathobiol. of many other common diseases, including infectious lung diseases, diabetes, cancers and others.  This has revealed the potential of AC as a therapy for many of these diseases.  This review will focus on the biol. of AC and the potential role of this enzyme in the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxHxbePZKk7rVg90H21EOLACvtfcHk0lhVODDTJjFm1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D&md5=b44a07178d44b3de2ef72da888931fbe</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2016.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2016.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26atitle%3DAcid%2520ceramidase%2520and%2520the%2520treatment%2520of%2520ceramide%2520diseases%253A%2520The%2520expanding%2520role%2520of%2520enzyme%2520replacement%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2016%26volume%3D1862%26spage%3D1459%26epage%3D1471%26doi%3D10.1016%2Fj.bbadis.2016.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwabuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oizumi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamori, K.</span></span> <span> </span><span class="NLM_article-title">Role of ceramide from glycosphingolipids and its metabolites in immunological and inflammatory responses in humans</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1155/2015/120748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1155%2F2015%2F120748" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1-10&author=K.+Iwabuchiauthor=H.+Nakayamaauthor=A.+Oizumiauthor=Y.+Sugaauthor=H.+Ogawaauthor=K.+Takamori&title=Role+of+ceramide+from+glycosphingolipids+and+its+metabolites+in+immunological+and+inflammatory+responses+in+humans&doi=10.1155%2F2015%2F120748"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1155%2F2015%2F120748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F120748%26sid%3Dliteratum%253Aachs%26aulast%3DIwabuchi%26aufirst%3DK.%26aulast%3DNakayama%26aufirst%3DH.%26aulast%3DOizumi%26aufirst%3DA.%26aulast%3DSuga%26aufirst%3DY.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DTakamori%26aufirst%3DK.%26atitle%3DRole%2520of%2520ceramide%2520from%2520glycosphingolipids%2520and%2520its%2520metabolites%2520in%2520immunological%2520and%2520inflammatory%2520responses%2520in%2520humans%26jtitle%3DMediators%2520Inflammation%26date%3D2015%26volume%3D2015%26spage%3D1%26epage%3D10%26doi%3D10.1155%2F2015%2F120748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gieselmann, V.</span></span> <span> </span><span class="NLM_article-title">Lysosomal storage diseases</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>1270</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/0925-4439(94)00075-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2F0925-4439%2894%2900075-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=7727535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK2MXkvFGms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1270&publication_year=1995&pages=103-136&author=V.+Gieselmann&title=Lysosomal+storage+diseases&doi=10.1016%2F0925-4439%2894%2900075-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal storage diseases</span></div><div class="casAuthors">Gieselmann, Volkmar</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1270</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">103-36</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 410 refs. on lipidoses, disorders of glycoprotein degrdn., and mucopolysaccharidoses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM-4LaaOM1orVg90H21EOLACvtfcHk0lhVODDTJjFm1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvFGms7o%253D&md5=533266b4fdac47258d9a924b0dd4a3b4</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0925-4439%2894%2900075-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0925-4439%252894%252900075-2%26sid%3Dliteratum%253Aachs%26aulast%3DGieselmann%26aufirst%3DV.%26atitle%3DLysosomal%2520storage%2520diseases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D1995%26volume%3D1270%26spage%3D103%26epage%3D136%26doi%3D10.1016%2F0925-4439%2894%2900075-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanier, M.-T.</span></span> <span> </span><span class="NLM_article-title">Disorders of Sphingolipid Metabolism</span>. In  <i>Inborn Metabolic Diseases: Diagnosis and Treatment</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, J.</span>; <span class="NLM_string-name">Saudubray, J.-M.</span>; <span class="NLM_string-name">van den Berghe, G.</span>; <span class="NLM_string-name">Walter, J. H.</span></span>, Eds. <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2006</span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">494</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1007%2F978-3-540-28785-8_38" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=479-494&author=M.-T.+Vanierauthor=J.+Fernandes&author=J.-M.+Saudubray&author=G.+van+den+Berghe&author=J.+H.+Walter&title=Inborn+Metabolic+Diseases%3A+Diagnosis+and+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-28785-8_38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-540-28785-8_38%26sid%3Dliteratum%253Aachs%26aulast%3DVanier%26aufirst%3DM.-T.%26atitle%3DDisorders%2520of%2520Sphingolipid%2520Metabolism%26btitle%3DInborn%2520Metabolic%2520Diseases%253A%2520Diagnosis%2520and%2520Treatment%26aulast%3DFernandes%26aufirst%3DJ.%26pub%3DSpringer%26date%3D2006%26spage%3D479%26epage%3D494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballabio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieselmann, V.</span></span> <span> </span><span class="NLM_article-title">Lysosomal disorders: from storage to cellular damage</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1793</i></span>,  <span class="NLM_fpage">684</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2008.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.bbamcr.2008.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=19111581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslOlsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1793&publication_year=2009&pages=684-696&author=A.+Ballabioauthor=V.+Gieselmann&title=Lysosomal+disorders%3A+from+storage+to+cellular+damage&doi=10.1016%2Fj.bbamcr.2008.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal disorders: From storage to cellular damage</span></div><div class="casAuthors">Ballabio, Andrea; Gieselmann, Volkmar</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1793</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">684-696</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Lysosomal storage diseases represent a group of about 50 genetic disorders caused by deficiencies of lysosomal and non-lysosomal proteins.  Patients accumulate compds. which are normally degraded in the lysosome.  In many diseases this accumulation affects various organs leading to severe symptoms and premature death.  The revelation of the mechanism by which stored compds. affect cellular function is the basis for understanding pathophysiol. underlying lysosomal storage diseases.  In the past years it has become clear that storage compds. interfere with various processes on the cellular level.  The spectrum covers e.g. receptor activation by non-physiol. ligands, modulation of receptor response and intracellular effectors of signal transduction cascades, impairment of autophagy, and others.  Importantly, many of these processes are assocd. with accumulation of storage material in non-lysosomal compartments.  Here we summarize current knowledge on the effects that storage material can elicit on the cellular level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphT4XBgFcs3rVg90H21EOLACvtfcHk0ljQsRQ-WrjYlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslOlsbk%253D&md5=618ababe4f0b39bd914c25d235c30693</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2008.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2008.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DBallabio%26aufirst%3DA.%26aulast%3DGieselmann%26aufirst%3DV.%26atitle%3DLysosomal%2520disorders%253A%2520from%2520storage%2520to%2520cellular%2520damage%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2009%26volume%3D1793%26spage%3D684%26epage%3D696%26doi%3D10.1016%2Fj.bbamcr.2008.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cachón-González, M. B.</span></span> <span> </span><span class="NLM_article-title">The cellular pathology of lysosomal diseases</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1002/path.3021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fpath.3021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=21990005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2012&pages=241-254&author=T.+M.+Coxauthor=M.+B.+Cach%C3%B3n-Gonz%C3%A1lez&title=The+cellular+pathology+of+lysosomal+diseases&doi=10.1002%2Fpath.3021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The cellular pathology of lysosomal diseases</span></div><div class="casAuthors">Cox, Timothy M.; Cachon-Gonzalez, M. Begona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">241-254</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  With a constitutive recycling function and the capacity to digest exogenous material as well as endogenous organelles in the process of autophagy, lysosomes are at the heart of the living cell.  Dynamic interactions with other cellular components ensure that the lysosomal compartment is a central point of convergence in countless diverse diseases.  Inborn lysosomal (storage) diseases represent about 70 genetically distinct conditions, with a combined birth frequency of about 1 in 7500.  Many are assocd. with macromol. storage, causing phys. disruption of the organelle and cognate structures; in neurons, ectopic dendritogenesis and axonal swelling due to distension with membraneous tubules and autophagic vacuoles are obsd.  Disordered autophagy is almost universal in lysosomal diseases but biochem. injury due to toxic metabolites such as lysosphingolipid mols., abnormal calcium homeostasis and endoplasmic reticulum stress responses and immune-inflammatory processes occur.  However, in no case have the mechanistic links between individual clinico-pathol. manifestations and the underlying mol. defect been precisely defined.  With access to the external fluid-phase and intracellular trafficking pathways, the lysosome and its diseases are a focus of pioneering investment in biotechnol.; this has generated innovative orphan drugs and, in the case of Gaucher's disease, effective treatment for the haematol. and visceral manifestations.  Given that two-thirds of lysosomal diseases have potentially devastating consequences in the nervous system, future therapeutic research will require an integrative understanding of the unitary steps in their neuro pathogenesis.  Informative genetic variants illustrated by patients with primary defects in this organelle offer unique insights into the central role of lysosomes in human health and disease.  We provide a conspectus of inborn lysosomal diseases and their pathobiol.; the cryptic evolution of events leading to irreversible changes may be dissocd. from the cellular storage phenotype, as revealed by the outcome of therapeutic gene transfer undertaken at different stages of disease.  Copyright © 2011 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL5CDde9M4OLVg90H21EOLACvtfcHk0ljQsRQ-WrjYlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsbvO&md5=d0675527595829b6e888182d8d0f9a76</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fpath.3021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.3021%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DT.%2BM.%26aulast%3DCach%25C3%25B3n-Gonz%25C3%25A1lez%26aufirst%3DM.%2BB.%26atitle%3DThe%2520cellular%2520pathology%2520of%2520lysosomal%2520diseases%26jtitle%3DJ.%2520Pathol.%26date%3D2012%26volume%3D226%26spage%3D241%26epage%3D254%26doi%3D10.1002%2Fpath.3021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brady, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D.</span></span> <span> </span><span class="NLM_article-title">The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2FS0021-9258%2818%2997611-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=14253443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaF2MXhs1arsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=1965&pages=39-43&author=R.+O.+Bradyauthor=J.+Kanferauthor=D.+Shapiro&title=The+metabolism+of+glucocerebrosides.+I.+Purification+and+properties+of+a+glucocerebroside-cleaving+enzyme+from+spleen+tissue"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue</span></div><div class="casAuthors">Brady, Roscoe O.; Kanfer, Julian; Shapiro, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-43</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">A glucocerebroside-cleaving enzyme was found in rat and human spleen tissue.  The enzyme was purified 82-fold from an ext. of human spleen tissue.  The products of the reaction were identified as glucose and N-stearoylsphingosine.  The most highly purified fraction does not catalyze the hydrolysis of galactocerebroside.  The significance of the glucocerebroside-cleaving enzyme with regard to the etiol. of Gaucher's disease is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdpC1PDMb2WLVg90H21EOLACvtfcHk0ljQsRQ-WrjYlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXhs1arsQ%253D%253D&md5=2b36593e551299d34991f85bc248f7df</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2997611-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252997611-8%26sid%3Dliteratum%253Aachs%26aulast%3DBrady%26aufirst%3DR.%2BO.%26aulast%3DKanfer%26aufirst%3DJ.%26aulast%3DShapiro%26aufirst%3DD.%26atitle%3DThe%2520metabolism%2520of%2520glucocerebrosides.%2520I.%2520Purification%2520and%2520properties%2520of%2520a%2520glucocerebroside-cleaving%2520enzyme%2520from%2520spleen%2520tissue%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1965%26volume%3D240%26spage%3D39%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorbera, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaravinayagam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulsat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, E.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targets for Gaucher′s disease</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1001</span>, <span class="refDoi"> DOI: 10.1358/dof.2009.034.12.1444443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1358%2Fdof.2009.034.12.1444443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVaktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=1001&author=L.+A.+Sorberaauthor=D.+Sundaravinayagamauthor=C.+Dulsatauthor=E.+Rosa&title=Therapeutic+targets+for+Gaucher%E2%80%B2s+disease&doi=10.1358%2Fdof.2009.034.12.1444443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targets for Gaucher's disease</span></div><div class="casAuthors">Sorbera, L. A.; Sundaravinayagam, D.; Dulsat, C.; Rosa, E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1001-1004</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Gaucher's disease is an autosomal recessive lysosomal storage disorder caused by mutations in the gene encoding the enzyme glucosyl-ceramidase.  The physiol. result is a deficiency in this enzyme and a consequent accumulation of the lipid substrate glucosylceramide in lysosomes of the monocyte-macrophage system.  Glucosylceramide accumulation in macrophages induces an increase in serum levels of proinflammatory cytokines, while accumulation in other cell types can cause the breakdown or prodn. of addnl. complex glycolipids, consequently leading to anemia, skeletal abnormalities, organ dysfunction, bone pain and neurol. dysfunction.  The therapeutic goal in Gaucher's disease is to achieve equil. within the cell so that degradatory activity can maintain homeostasis and prevent the accumulation of undegraded macromols.  To date, therapeutic strategies include enzyme replacement, substrate redn. and chem. chaperone therapies.  The search continues for more effective treatment strategies for Gaucher's disease, with the investigative focus aimed at identifying novel targets for therapeutic intervention.  This article presents those drug targets that are currently under active investigation for the treatment of Gaucher's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGBb5yJ31z7bVg90H21EOLACvtfcHk0li-WVJQ5X8r5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVaktLs%253D&md5=2a1fe03474230a9ed2118c8718ed172d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1358%2Fdof.2009.034.12.1444443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2009.034.12.1444443%26sid%3Dliteratum%253Aachs%26aulast%3DSorbera%26aufirst%3DL.%2BA.%26aulast%3DSundaravinayagam%26aufirst%3DD.%26aulast%3DDulsat%26aufirst%3DC.%26aulast%3DRosa%26aufirst%3DE.%26atitle%3DTherapeutic%2520targets%2520for%2520Gaucher%25E2%2580%25B2s%2520disease%26jtitle%3DDrugs%2520Future%26date%3D2009%26volume%3D34%26spage%3D1001%26doi%3D10.1358%2Fdof.2009.034.12.1444443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirnemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmatoug, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serratrice, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froissart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caillaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astudillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serratrice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Villemeur, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. G.</span></span> <span> </span><span class="NLM_article-title">A review of Gaucher disease pathophysiology, clinical presentation and treatments</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.3390/ijms18020441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.3390%2Fijms18020441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVSju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=441-471&author=J.+Stirnemannauthor=N.+Belmatougauthor=F.+Camouauthor=C.+Serratriceauthor=R.+Froissartauthor=C.+Caillaudauthor=T.+Levadeauthor=L.+Astudilloauthor=J.+Serratriceauthor=A.+Brassierauthor=C.+Roseauthor=T.+B.+de+Villemeurauthor=M.+G.+Berger&title=A+review+of+Gaucher+disease+pathophysiology%2C+clinical+presentation+and+treatments&doi=10.3390%2Fijms18020441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A review of gaucher disease pathophysiology, clinical presentation and treatments</span></div><div class="casAuthors">Stirnemann, Jerome; Belmatoug, Nadia; Camou, Fabrice; Serratrice, Christine; Froissart, Roseline; Caillaud, Catherine; Levade, Thierry; Astudillo, Leonardo; Serratrice, Jacques; Brassier, Anais; Rose, Christian; Billette de Villemeur, Thierry; Berger, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441/1-441/30</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Gaucher disease (GD, ORPHA355) is a rare, autosomal recessive genetic disorder.  It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages.  In the general population, its incidence is approx. 1/40,000 to 1/60,000 births, rising to 1/800 in Ashkenazi Jews.  The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions assocd. with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells.  Type-1 Gaucher disease, which affects the majority of patients (90% in Europe and USA, but less in other regions), is characterized by effects on the viscera, whereas types 2 and 3 are also assocd. with neurol. impairment, either severe in type 2 or variable in type 3.  A diagnosis of GD can be confirmed by demonstrating the deficiency of acid glucocerebrosidase activity in leukocytes.  Mutations in the GBA1 gene should be identified as they may be of prognostic value in some cases.  Patients with type-1 GD-but also carriers of GBA1 mutation-have been found to be predisposed to developing Parkinson's disease, and the risk of neoplasia assocd. with the disease is still subject to discussion.  Disease-specific treatment consists of i.v. enzyme replacement therapy (ERT) using one of the currently available mols. (imiglucerase, velaglucerase, or taliglucerase).  Orally administered inhibitors of glucosylceramide biosynthesis can also be used (miglustat or eliglustat).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeVOOYHDqyLVg90H21EOLACvtfcHk0li-WVJQ5X8r5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVSju70%253D&md5=38a4c125a4007d25177135c8996f7abe</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3390%2Fijms18020441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18020441%26sid%3Dliteratum%253Aachs%26aulast%3DStirnemann%26aufirst%3DJ.%26aulast%3DBelmatoug%26aufirst%3DN.%26aulast%3DCamou%26aufirst%3DF.%26aulast%3DSerratrice%26aufirst%3DC.%26aulast%3DFroissart%26aufirst%3DR.%26aulast%3DCaillaud%26aufirst%3DC.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DAstudillo%26aufirst%3DL.%26aulast%3DSerratrice%26aufirst%3DJ.%26aulast%3DBrassier%26aufirst%3DA.%26aulast%3DRose%26aufirst%3DC.%26aulast%3Dde%2BVillemeur%26aufirst%3DT.%2BB.%26aulast%3DBerger%26aufirst%3DM.%2BG.%26atitle%3DA%2520review%2520of%2520Gaucher%2520disease%2520pathophysiology%252C%2520clinical%2520presentation%2520and%2520treatments%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D441%26epage%3D471%26doi%3D10.3390%2Fijms18020441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Won, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, I.</span></span> <span> </span><span class="NLM_article-title">Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe’s disease</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1002/jnr.23873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fjnr.23873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=27638584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWltr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=990-1006&author=J.-S.+Wonauthor=A.+K.+Singhauthor=I.+Singh&title=Biochemical%2C+cell+biological%2C+pathological%2C+and+therapeutic+aspects+of+Krabbe%E2%80%99s+disease&doi=10.1002%2Fjnr.23873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease</span></div><div class="casAuthors">Won, Je-Seong; Singh, Avtar K.; Singh, Inderjit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">990-1006</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Krabbe's disease (KD; also called globoid cell leukodystrophy) is a genetic disorder involving demyelination of the central (CNS) and peripheral (PNS) nervous systems.  The disease may be subdivided into three types, an infantile form, which is the most common and severe; a juvenile form; and a rare adult form.  KD is an autosomal recessive disorder caused by a deficiency of galactocerebrosidase activity in lysosomes, leading to accumulation of galactoceramide and neurotoxic galactosylsphingosine (psychosine [PSY]) in macrophages (globoid cells) as well as neural cells, esp. in oligodendrocytes and Schwann cells.  This ultimately results in damage to myelin in both CNS and PNS with assocd. morbidity and mortality.  Accumulation of PSY, a lysolipid with detergent-like properties, over a threshold level could trigger membrane destabilization, leading to cell lysis.  Moreover, subthreshold concns. of PSY trigger cell signaling pathways that induce oxidative stress, mitochondrial dysfunction, apoptosis, inflammation, endothelial/vascular dysfunctions, and neuronal and axonal damage.  From the time the "psychosine hypothesis" was proposed, considerable efforts have been made in search of an effective therapy for lowering PSY load with pharmacol., gene, and stem cell approaches to attenuate PSY-induced neurotoxicity.  This Review focuses on the recent advances and prospective research for understanding disease mechanisms and therapeutic approaches for KD. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiXLjIgjfi7Vg90H21EOLACvtfcHk0ljefvHn5G6BzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWltr3I&md5=4f5306516d90cf3abf8a9023172ac8dc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fjnr.23873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.23873%26sid%3Dliteratum%253Aachs%26aulast%3DWon%26aufirst%3DJ.-S.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DSingh%26aufirst%3DI.%26atitle%3DBiochemical%252C%2520cell%2520biological%252C%2520pathological%252C%2520and%2520therapeutic%2520aspects%2520of%2520Krabbe%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2016%26volume%3D94%26spage%3D990%26epage%3D1006%26doi%3D10.1002%2Fjnr.23873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svennerholm, L.</span></span> <span> </span><span class="NLM_article-title">Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.1982.tb07950.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1111%2Fj.1471-4159.1982.tb07950.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=7097276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaL38Xlt1Ggsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1982&pages=709-718&author=O.+Nilssonauthor=L.+Svennerholm&title=Accumulation+of+glucosylceramide+and+glucosylsphingosine+%28psychosine%29+in+cerebrum+and+cerebellum+in+infantile+and+juvenile+Gaucher+disease&doi=10.1111%2Fj.1471-4159.1982.tb07950.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease</span></div><div class="casAuthors">Nilsson, Olle; Svennerholm, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">709-18</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">Three major clin. variants of Gaucher disease have been defined: Type I, chronic nonneuronopathic; Type II, acute neuronopathic; and Type III, subacute neuronopathic.  In a search for the underlying mol. basis of the neurol. manifestations, the concn. and compn. of cholesterol, phospholipids, neutral glycosphingolipids, and gangliosides were examd. in cerebral and cerebellar cortices of 5 cases of Type II, 8 cases of Type III, and 1 case of presumed Type I/III.  In Type II, the concn. of glucosylceramide was 140-530 in the cerebral cortex and 51-450 μmol/kg in the cerebellar cortex, with the highest values found in the most fulminant cases.  These concns. were 20-80 times greater than normal in cerebral cortex and 5-40 times normal in cerebellar cortex.  In Type III, the concn. of glucosylceramide was 37-65 and 59-1750 μmol/kg in the cerebral and cerebellar cortex, resp.  The highest concns. were found in the cerebellum of patients who had survived splenectomy for several years.  The ceramide compn. of the accumulated glucosylceramide suggested that brain gangliosides were the major precursors of the glucosylceramide in brains of Type II, but in the cerebellar cortex in Type III the glucosylceramide was partly of extracerebral origin.  The levels of lactosylceramide and oligohexaosylceramides were slightly raised in all brain specimens from the Gaucher cases.  The ganglioside concn. was normal, whereas there was an increase in the proportion of GM2 and GM3 gangliosides.  The brain glycosphingolipid changes in the Type I/III case were similar but slightly less than those in Type III cases of corresponding age.  Glucosylsphingosine (psychosine), never detected in normal human brain, was demonstrated in brains from all the Gaucher cases.  The psychosine concn. was highest in Type II cases, 3.8-8.8 and 3.9-12.3 μmol/kg in cerebral and cerebellar cortex, resp., with the highest values found in the most fulminant cases.  In Type III, the psychosine concn. varied more widely, 0.8-4.6 and 1.4-6.3 μmol/kg in cerebral and cerebellar cortex, resp.  The lowest value, 0.7 μmol/kg, was found in the Type I/III case.  The detection method had a sensitivity of 0.01 μmol/kg, which means that the concn. of psychosine was increased at least 100-1000-fold in Gaucher gray matter.  The accumulation of the cell-toxic substance psychosine may be the basis for the extensive neuronal cell loss in Gaucher disease, which is most striking in Type II disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7fRZs3MQ-17Vg90H21EOLACvtfcHk0ljefvHn5G6BzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xlt1Ggsbk%253D&md5=9f8a16715be1b6287749929a5f145c52</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1982.tb07950.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1982.tb07950.x%26sid%3Dliteratum%253Aachs%26aulast%3DNilsson%26aufirst%3DO.%26aulast%3DSvennerholm%26aufirst%3DL.%26atitle%3DAccumulation%2520of%2520glucosylceramide%2520and%2520glucosylsphingosine%2520%2528psychosine%2529%2520in%2520cerebrum%2520and%2520cerebellum%2520in%2520infantile%2520and%2520juvenile%2520Gaucher%2520disease%26jtitle%3DJ.%2520Neurochem.%26date%3D1982%26volume%3D39%26spage%3D709%26epage%3D718%26doi%3D10.1111%2Fj.1471-4159.1982.tb07950.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidransky, E.</span></span> <span> </span><span class="NLM_article-title">Gaucher disease: complexity in a ″simple″ disorder</span>. <i>Mol. Genet. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.ymgme.2004.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.ymgme.2004.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=15464415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2nsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2004&pages=6-15&author=E.+Sidransky&title=Gaucher+disease%3A+complexity+in+a+%E2%80%B3simple%E2%80%B3+disorder&doi=10.1016%2Fj.ymgme.2004.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Gaucher disease: complexity in a "simple" disorder</span></div><div class="casAuthors">Sidransky, Ellen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Genetics and Metabolism</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">6-15</span>CODEN:
                <span class="NLM_cas:coden">MGMEFF</span>;
        ISSN:<span class="NLM_cas:issn">1096-7192</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Gaucher disease, the recessively inherited deficiency of the enzyme glucocerebrosidase and the most common sphingolipidosis, has both non-neurol. and neuronopathic forms and a continuum of diverse clin. manifestations.  Studies of genotype-phenotype correlations reveal significant genotypic heterogeneity among clin. similar patients, and vastly different phenotypes among patients with the same mutations.  The region surrounding the glucocerebrosidase gene (GBA) on chromosome 1q is particularly gene-rich, with a highly homologous pseudogene sequence 16 kb downstream.  Recombination events within the GBA locus contribute to the etiol. of some mutations in Gaucher disease.  Studies of patients with Gaucher disease and atypical manifestations, including Parkinsonism, myoclonic epilepsy, cardiac involvement and collodion skin, seek to define other genetic or environmental factors contributing to the phenotypes.  Recent reports demonstrating an assocn. between Gaucher disease and Parkinsonism provide an example of heterozygosity for a Mendelian disorder acting as a risk factor for a complex disease.  There are rare patients with Gaucher disease and differing genotypes who develop early onset, treatment-refractory Parkinsonism.  Neuropathol. in a group of these patients showed α-synuclein-reactive Lewy bodies in brain regions specifically assocd. with Gaucher disease.  Family studies of these probands suggested that the incidence of Parkinsonism might be more frequent in obligate heterozygotes.  In a complementary finding, the examn. of GBA in autopsy samples from individuals with sporadic Parkinson disease identified alterations in the GBA sequence in 14% of the cohort.  These studies provide evidence that altered glucocerebrosidase may contribute to a vulnerability to Parkinsonism.  Moreover, this research demonstrates how insights from rare, single gene disorders like Gaucher disease can provide a window into the etiol. of more common, multifactorial genetic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolp8Yjv2VnC7Vg90H21EOLACvtfcHk0ljefvHn5G6BzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2nsb8%253D&md5=9ab45d87310ef347edcfbadfdeb2d1fc</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ymgme.2004.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymgme.2004.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DSidransky%26aufirst%3DE.%26atitle%3DGaucher%2520disease%253A%2520complexity%2520in%2520a%2520%25E2%2580%25B3simple%25E2%2580%25B3%2520disorder%26jtitle%3DMol.%2520Genet.%2520Metab.%26date%3D2004%26volume%3D83%26spage%3D6%26epage%3D15%26doi%3D10.1016%2Fj.ymgme.2004.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, A. R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strijland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheij, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouairy, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahav, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boot, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, J. M.</span></span> <span> </span><span class="NLM_article-title">Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>590</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1002/1873-3468.12104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2F1873-3468.12104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=26898341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Krur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=590&publication_year=2016&pages=716-725&author=M.+J.+Ferrazauthor=A.+R.+A.+Marquesauthor=M.+D.+Appelmanauthor=M.+Verhoekauthor=A.+Strijlandauthor=M.+Mirzaianauthor=S.+Scheijauthor=C.+M.+Ouairyauthor=D.+Lahavauthor=P.+Wisseauthor=H.+S.+Overkleeftauthor=R.+G.+Bootauthor=J.+M.+Aerts&title=Lysosomal+glycosphingolipid+catabolism+by+acid+ceramidase%3A+formation+of+glycosphingoid+bases+during+deficiency+of+glycosidases&doi=10.1002%2F1873-3468.12104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases</span></div><div class="casAuthors">Ferraz, Maria J.; Marques, Andre R. A.; Appelman, Monique D.; Verhoek, Marri; Strijland, Anneke; Mirzaian, Mina; Scheij, Saskia; Ouairy, Cecile M.; Lahav, Daniel; Wisse, Patrick; Overkleeft, Herman S.; Boot, Rolf G.; Aerts, Johannes M.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">590</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">716-725</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Glycosphingoid bases are elevated in inherited lysosomal storage disorders with deficient activity of glycosphingolipid catabolizing glycosidases.  We investigated the mol. basis of the formation of glucosyl sphingosine and globotriaosyl sphingosine during deficiency of glucocerebrosidase (Gaucher disease) and α-galactosidase A (Fabry disease).  Independent genetic and pharmacol. evidence is presented pointing to an active role of acid ceramidase in both processes through deacylation of lysosomal glycosphingolipids.  The potential pathophysiol. relevance of elevated glycosphingoid bases generated through this alternative metab. in patients suffering from lysosomal glycosidase defects is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD3HCj2x7-AbVg90H21EOLACvtfcHk0lgLf_P3QGx6AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Krur7N&md5=ecfbbdaaf640b5e567ea771241262e09</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2F1873-3468.12104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1873-3468.12104%26sid%3Dliteratum%253Aachs%26aulast%3DFerraz%26aufirst%3DM.%2BJ.%26aulast%3DMarques%26aufirst%3DA.%2BR.%2BA.%26aulast%3DAppelman%26aufirst%3DM.%2BD.%26aulast%3DVerhoek%26aufirst%3DM.%26aulast%3DStrijland%26aufirst%3DA.%26aulast%3DMirzaian%26aufirst%3DM.%26aulast%3DScheij%26aufirst%3DS.%26aulast%3DOuairy%26aufirst%3DC.%2BM.%26aulast%3DLahav%26aufirst%3DD.%26aulast%3DWisse%26aufirst%3DP.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DBoot%26aufirst%3DR.%2BG.%26aulast%3DAerts%26aufirst%3DJ.%2BM.%26atitle%3DLysosomal%2520glycosphingolipid%2520catabolism%2520by%2520acid%2520ceramidase%253A%2520formation%2520of%2520glycosphingoid%2520bases%2520during%2520deficiency%2520of%2520glycosidases%26jtitle%3DFEBS%2520Lett.%26date%3D2016%26volume%3D590%26spage%3D716%26epage%3D725%26doi%3D10.1002%2F1873-3468.12104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lischuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kacena, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastores, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keutzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, P. K.</span></span> <span> </span><span class="NLM_article-title">Glucosylsphingosine is a key biomarker of Gaucher disease</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">1082</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1002/ajh.24491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fajh.24491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=27441734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs12lt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2016&pages=1082-1089&author=V.+Murugesanauthor=W.-L.+Chuangauthor=J.+Liuauthor=A.+Lischukauthor=K.+Kacenaauthor=H.+Linauthor=G.+M.+Pastoresauthor=R.+Yangauthor=J.+Keutzerauthor=K.+Zhangauthor=P.+K.+Mistry&title=Glucosylsphingosine+is+a+key+biomarker+of+Gaucher+disease&doi=10.1002%2Fajh.24491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Glucosylsphingosine is a key biomarker of Gaucher disease</span></div><div class="casAuthors">Murugesan, Vagishwari; Chuang, Wei-Lien; Liu, Jun; Lischuk, Andrew; Kacena, Katherine; Lin, Haiqun; Pastores, Gregory M.; Yang, Ruhua; Keutzer, Joan; Zhang, Kate; Mistry, Pramod K.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1082-1089</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Gaucher disease (GD) involves the accumulation of glucosylceramide (GL1) and its deacylated lysolipid, glucosylsphingosine (lyso-GL1) which is implicated in mediating immune dysregulation and skeletal disease.  The aim of our study was to assess plasma Lyso-GL1 as a biomarker of GD and its response to therapy.  Plasma lyso-GL1 in 169 patients with GD type 1 (GD1) was measured by LC-MS/MS.  Significant predictors of plasma LGL1 were assessed by Pearson's correlation coeff., Wilcoxon Mann Whitney test and multiple linear regression.  Propensity scores were used to match patients on treatment mode: Enzyme Replacement Therapy (ERT) vs. Eliglustat Tartrate SRT (ELI-SRT).  Plasma Lyso-GL1 levels in healthy controls averaged 1.5 ng/mL (1.3-1.7; 95% CI).  In untreated GD patients, the levels were massively elevated (180.9 ng/mL: 95% CI, 145.4-216.5) and imiglucerase ERT resulted in marked redn. (89 ng/mL: 95% CI, 69.2-129.4) (P < 0.001).  Lyso-GL1 correlated with chitotriosidase (r = 0.59 P < 0.001), CCL18 (r = 0.62 P <0.001), hepatomegaly (r = 0.28 P < 0.001), splenomegaly (r = 0.27 P = 0.003), splenectomy (P = 0.01) and treatment mode (P < 0.001).  By multiple linear regression, the strongest predictors of lyso-GL1 were age (P < 0.001), splenectomy (P = 0.02), Chitotriosidase (P < 0.001) and CCL18 levels (P = 0.001).  After propensity score matching to obtain comparable groups of patients on ERT vs ELI-SRT, lyso-GL1 levels were lower among patients receiving ELI-SRT by 113 ng/mL (95% CI: 136-90.3 ng/mL P < 0.001).  Plasma lyso-GL1 is a key biomarker of GD.  ERT reduced lyso-GL1 levels.  By propensity scoring, ELI-SRT resulted in greater redn. of lyso-GL1 than ERT.  Am. J. Hematol. 91:1082-1089, 2016. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOTf-mirSTVbVg90H21EOLACvtfcHk0lgLf_P3QGx6AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs12lt7%252FK&md5=0c307227fe52cae58331e448a2bb49c8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fajh.24491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.24491%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DV.%26aulast%3DChuang%26aufirst%3DW.-L.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLischuk%26aufirst%3DA.%26aulast%3DKacena%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DPastores%26aufirst%3DG.%2BM.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DKeutzer%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DMistry%26aufirst%3DP.%2BK.%26atitle%3DGlucosylsphingosine%2520is%2520a%2520key%2520biomarker%2520of%2520Gaucher%2520disease%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2016%26volume%3D91%26spage%3D1082%26epage%3D1089%26doi%3D10.1002%2Fajh.24491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span> <span> </span><span class="NLM_article-title">The Twitcher Mouse: A model for Krabbe disease and for experimental therapies</span>. <i>Brain Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1111/j.1750-3639.1995.tb00601.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1111%2Fj.1750-3639.1995.tb00601.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=8520724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A280%3ADyaK28%252FkvVWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=249-258&author=K.+Suzukiauthor=K.+Suzuki&title=The+Twitcher+Mouse%3A+A+model+for+Krabbe+disease+and+for+experimental+therapies&doi=10.1111%2Fj.1750-3639.1995.tb00601.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The twitcher mouse: a model for Krabbe disease and for experimental therapies</span></div><div class="casAuthors">Suzuki K; Suzuki K</div><div class="citationInfo"><span class="NLM_cas:title">Brain pathology (Zurich, Switzerland)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-58</span>
        ISSN:<span class="NLM_cas:issn">1015-6305</span>.
    </div><div class="casAbstract">The twitcher is a naturally-occurring mouse mutant caused by an abnormality in the gene coded for galactosylceramidase.  It is therefore genetically equivalent to human globoid cell leukodystrophy (Krabbe disease).  Affected mice develop clinical symptoms at the onset of the active myelination period and, if untreated, die by 35 +/- days.  The pathology is very similar to that in human disease.  Toxicity of galactosylsphingosine (psychosine) that accumulates abnormally in the nervous system is considered to be primarily responsible for the pathogenesis.  Transplantation of bone marrow cells from normal donors is partially effective and triples the life span of affected mice to 100 +/- days with evidence of remyelination in the CNS.  The mutation responsible for the twitcher mutant has recently been identified.  It is expected that this model will be useful for basic studies on treatment of this group of genetic disorders affecting the brain through transgenic and/or gene therapy approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmjvBl_ptEPBwLZxei1HN8fW6udTcc2eaJPwho-jf_Wbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28%252FkvVWmtw%253D%253D&md5=9a91b101dfa239f91ed1ab66c1d343e8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1750-3639.1995.tb00601.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1750-3639.1995.tb00601.x%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DK.%26atitle%3DThe%2520Twitcher%2520Mouse%253A%2520A%2520model%2520for%2520Krabbe%2520disease%2520and%2520for%2520experimental%2520therapies%26jtitle%3DBrain%2520Pathol.%26date%3D1995%26volume%3D5%26spage%3D249%26epage%3D258%26doi%3D10.1111%2Fj.1750-3639.1995.tb00601.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benitez, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagree, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearborn, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woloszynek, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaramita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsbernd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogler, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, M. S.</span></span> <span> </span><span class="NLM_article-title">Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">20097</span>– <span class="NLM_lpage">20103</span>, <span class="refDoi"> DOI: 10.1073/pnas.1912108116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1073%2Fpnas.1912108116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=31527255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSitrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=20097-20103&author=Y.+Liauthor=Y.+Xuauthor=B.+A.+Benitezauthor=M.+S.+Nagreeauthor=J.+T.+Dearbornauthor=X.+Jiangauthor=M.+A.+Guzmanauthor=J.+C.+Woloszynekauthor=A.+Giaramitaauthor=B.+K.+Yipauthor=J.+Elsberndauthor=M.+C.+Babcockauthor=M.+Loauthor=S.+C.+Fowlerauthor=D.+F.+Wozniakauthor=C.+A.+Voglerauthor=J.+A.+Medinauthor=B.+E.+Crawfordauthor=M.+S.+Sands&title=Genetic+ablation+of+acid+ceramidase+in+Krabbe+disease+confirms+the+psychosine+hypothesis+and+identifies+a+new+therapeutic+target&doi=10.1073%2Fpnas.1912108116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target</span></div><div class="casAuthors">Li, Yedda; Xu, Yue; Benitez, Bruno A.; Nagree, Murtaza S.; Dearborn, Joshua T.; Jiang, Xuntian; Guzman, Miguel A.; Woloszynek, Josh C.; Giaramita, Alex; Yip, Bryan K.; Elsbernd, Joseph; Babcock, Michael C.; Lo, Melanie; Fowler, Stephen C.; Wozniak, David F.; Vogler, Carole A.; Medin, Jeffrey A.; Crawford, Brett E.; Sands, Mark S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">20097-20103</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Infantile globoid cell leukodystrophy (GLD, Krabbe disease) is a fatal demyelinating disorder caused by a deficiency in the lysosomal enzyme galactosylceramidase (GALC).  GALC deficiency leads to the accumulation of the cytotoxic glycolipid, galactosylsphingosine (psychosine).  Complementary evidence suggested that psychosine is synthesized via an anabolic pathway.  Here, we show instead that psychosine is generated catabolically through the deacylation of galactosylceramide by acid ceramidase (ACDase).  This reaction uncouples GALC deficiency from psychosine accumulation, allowing us to test the long-standing "psychosine hypothesis".  We demonstrate that genetic loss of ACDase activity (Farber disease) in the GALC-deficient mouse model of human GLD (twitcher) eliminates psychosine accumulation and cures GLD.  These data suggest that ACDase could be a target for substrate redn. therapy (SRT) in Krabbe patients.  We show that pharmacol. inhibition of ACDase activity with carmofur significantly decreases psychosine accumulation in cells from a Krabbe patient and prolongs the life span of the twitcher (Twi) mouse.  Previous SRT expts. in the Twi mouse utilized L-cycloserine, which inhibits an enzyme several steps upstream of psychosine synthesis, thus altering the balance of other important lipids.  Drugs that directly inhibit ACDase may have a more acceptable safety profile due to their mechanistic proximity to psychosine biogenesis.  In total, these data clarify our understanding of psychosine synthesis, confirm the long-held psychosine hypothesis, and provide the impetus to discover safe and effective inhibitors of ACDase to treat Krabbe disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMIjeCuiB29bVg90H21EOLACvtfcHk0li5Yg4Xkg5tGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSitrfE&md5=921bc583ee05d71e2d55dd98a235fd1b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1912108116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1912108116%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DBenitez%26aufirst%3DB.%2BA.%26aulast%3DNagree%26aufirst%3DM.%2BS.%26aulast%3DDearborn%26aufirst%3DJ.%2BT.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DGuzman%26aufirst%3DM.%2BA.%26aulast%3DWoloszynek%26aufirst%3DJ.%2BC.%26aulast%3DGiaramita%26aufirst%3DA.%26aulast%3DYip%26aufirst%3DB.%2BK.%26aulast%3DElsbernd%26aufirst%3DJ.%26aulast%3DBabcock%26aufirst%3DM.%2BC.%26aulast%3DLo%26aufirst%3DM.%26aulast%3DFowler%26aufirst%3DS.%2BC.%26aulast%3DWozniak%26aufirst%3DD.%2BF.%26aulast%3DVogler%26aufirst%3DC.%2BA.%26aulast%3DMedin%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DB.%2BE.%26aulast%3DSands%26aufirst%3DM.%2BS.%26atitle%3DGenetic%2520ablation%2520of%2520acid%2520ceramidase%2520in%2520Krabbe%2520disease%2520confirms%2520the%2520psychosine%2520hypothesis%2520and%2520identifies%2520a%2520new%2520therapeutic%2520target%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D20097%26epage%3D20103%26doi%3D10.1073%2Fpnas.1912108116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the activation of acid ceramidase</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1621</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-03844-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fs41467-018-03844-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=29692406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjmtl2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1621&author=A.+Gebaiauthor=A.+Gorelikauthor=Z.+Liauthor=K.+Illesauthor=B.+Nagar&title=Structural+basis+for+the+activation+of+acid+ceramidase&doi=10.1038%2Fs41467-018-03844-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the activation of acid ceramidase</span></div><div class="casAuthors">Gebai Ahmad; Gorelik Alexei; Li Zixian; Illes Katalin; Nagar Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1621</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acid ceramidase (aCDase, ASAH1) hydrolyzes lysosomal membrane ceramide into sphingosine, the backbone of all sphingolipids, to regulate many cellular processes.  Abnormal function of aCDase leads to Farber disease, spinal muscular atrophy with progressive myoclonic epilepsy, and is associated with Alzheimer's, diabetes, and cancer.  Here, we present crystal structures of mammalian aCDases in both proenzyme and autocleaved forms.  In the proenzyme, the catalytic center is buried and protected from solvent.  Autocleavage triggers a conformational change exposing a hydrophobic channel leading to the active site.  Substrate modeling suggests distinct catalytic mechanisms for substrate hydrolysis versus autocleavage.  A hydrophobic surface surrounding the substrate binding channel appears to be a site of membrane attachment where the enzyme accepts substrates facilitated by the accessory protein, saposin-D.  Structural mapping of disease mutations reveals that most would destabilize the protein fold.  These results will inform the rational design of aCDase inhibitors and recombinant aCDase for disease therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6RpR0JSKnbwHqQV89nF-2fW6udTcc2ebcb7G1-v02g7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjmtl2rtg%253D%253D&md5=a7fb6f187dc50d25c9a14597053718c1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03844-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03844-2%26sid%3Dliteratum%253Aachs%26aulast%3DGebai%26aufirst%3DA.%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DNagar%26aufirst%3DB.%26atitle%3DStructural%2520basis%2520for%2520the%2520activation%2520of%2520acid%2520ceramidase%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1621%26doi%3D10.1038%2Fs41467-018-03844-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solorzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luciani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costi, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1035</span>, <span class="refDoi"> DOI: 10.1038/srep01035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fsrep01035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=23301156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1035&author=N.+Realiniauthor=C.+Solorzanoauthor=C.+Pagliucaauthor=D.+Pizziraniauthor=A.+Armirottiauthor=R.+Lucianiauthor=M.+P.+Costiauthor=T.+Bandieraauthor=D.+Piomelli&title=Discovery+of+highly+potent+acid+ceramidase+inhibitors+with+in+vitro+tumor+chemosensitizing+activity&doi=10.1038%2Fsrep01035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span></div><div class="casAuthors">Realini, Natalia; Solorzano, Carlos; Pagliuca, Chiara; Pizzirani, Daniela; Armirotti, Andrea; Luciani, Rosaria; Costi, Maria Paola; Bandiera, Tiziano; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">srep01035, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The expression of acid ceramidase (AC) - a cysteine amidase that hydrolyzes the proapoptotic lipid ceramide - is abnormally high in several human tumors, which is suggestive of a role in chemoresistance.  Available AC inhibitors lack, however, the potency and drug-likeness necessary to test this idea.  Here we show that the antineoplastic drug carmofur, which is used in the clinic to treat colorectal cancers, is a potent AC inhibitor and that this property is essential to its anti-proliferative effects.  Modifications in the chem. scaffold of carmofur yield new AC inhibitors that act synergistically with std. antitumoral drugs to prevent cancer cell proliferation.  These findings identify AC as an unexpected target for carmofur, and suggest that this mol. can be used as starting point for the design of novel chemosensitizing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoknWbdLSLhRbVg90H21EOLACvtfcHk0ljvRDVtbQQy4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D&md5=7ff74388fc2bea42c0e97fa8cbcfe61f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fsrep01035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep01035%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DSolorzano%26aufirst%3DC.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DLuciani%26aufirst%3DR.%26aulast%3DCosti%26aufirst%3DM.%2BP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520acid%2520ceramidase%2520inhibitors%2520with%2520in%2520vitro%2520tumor%2520chemosensitizing%2520activity%26jtitle%3DSci.%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D1035%26doi%3D10.1038%2Fsrep01035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branduardi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a new class of highly potent inhibitors of acid ceramidase: synthesis and structure-activity relationship (SAR)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3518</span>– <span class="NLM_lpage">3530</span>, <span class="refDoi"> DOI: 10.1021/jm301879g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301879g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Wjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3518-3530&author=D.+Pizziraniauthor=C.+Pagliucaauthor=N.+Realiniauthor=D.+Branduardiauthor=G.+Bottegoniauthor=M.+Morauthor=F.+Bertozziauthor=R.+Scarpelliauthor=D.+Piomelliauthor=T.+Bandiera&title=Discovery+of+a+new+class+of+highly+potent+inhibitors+of+acid+ceramidase%3A+synthesis+and+structure-activity+relationship+%28SAR%29&doi=10.1021%2Fjm301879g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Class of Highly Potent Inhibitors of Acid Ceramidase: Synthesis and Structure-Activity Relationship (SAR)</span></div><div class="casAuthors">Pizzirani, Daniela; Pagliuca, Chiara; Realini, Natalia; Branduardi, Davide; Bottegoni, Giovanni; Mor, Marco; Bertozzi, Fabio; Scarpelli, Rita; Piomelli, Daniele; Bandiera, Tiziano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3518-3530</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1-(Alkylamino)-2,4-pyrimidinediones such as I [R = H, F, MeO, F3C, Ph; R1 = Me(CH2)nNH; R2 = H, Me, MeO2C; n = 5, 7] were prepd. as inhibitors of acid ceramidase for potential use as antitumor agents.  Uracils bearing an electron-withdrawing substituent at position 5, a substituent such as Me at position 3, and an alkylaminocarbonyl moiety with a six- to eight-carbon alkyl group at position 1 were the most effective inhibitors of acid ceramidase of the compds. tested.  The acid ceramidase inhibition and stability of an alkylaminopyrimidinedione was correlated with the stabilization of the antibonding orbital of its N1-carbonyl bond.  I (R = H, F, Ph; R2 = H, Me; n = 5, 7) inhibited a human cancer cell line (SW403) with IC50 values of 20-24 μM.  I (R = F, F3C, MeO; R2 = H, MeO2C; n = 5, 7) inhibited acid ceramidase with single digit-nanomolar IC50 values (IC50 = 4-7 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSG4lPgE1b1bVg90H21EOLACvtfcHk0ljvRDVtbQQy4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Wjtbo%253D&md5=e8b1cb63aa40e8654de70985febc56dd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm301879g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301879g%26sid%3Dliteratum%253Aachs%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DBranduardi%26aufirst%3DD.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DBertozzi%26aufirst%3DF.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DBandiera%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520new%2520class%2520of%2520highly%2520potent%2520inhibitors%2520of%2520acid%2520ceramidase%253A%2520synthesis%2520and%2520structure-activity%2520relationship%2520%2528SAR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3518%26epage%3D3530%26doi%3D10.1021%2Fjm301879g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diamanti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span> <span> </span><span class="NLM_article-title">Pyrazole-based acid ceramidase inhibitors: design, synthesis, and structure-activity relationships</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2739</span>– <span class="NLM_lpage">2756</span>, <span class="refDoi"> DOI: 10.1055/s-0035-1561456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1055%2Fs-0035-1561456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1ahur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=2739-2756&author=E.+Diamantiauthor=G.+Bottegoniauthor=L.+Goldoniauthor=N.+Realiniauthor=C.+Pagliucaauthor=F.+Bertozziauthor=D.+Piomelliauthor=D.+Pizzirani&title=Pyrazole-based+acid+ceramidase+inhibitors%3A+design%2C+synthesis%2C+and+structure-activity+relationships&doi=10.1055%2Fs-0035-1561456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole-Based Acid Ceramidase Inhibitors: Design, Synthesis, and Structure-Activity Relationships</span></div><div class="casAuthors">Diamanti, Eleonora; Bottegoni, Giovanni; Goldoni, Luca; Realini, Natalia; Pagliuca, Chiara; Bertozzi, Fabio; Piomelli, Daniele; Pizzirani, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2739-2756</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">Acid ceramidase (a.c.) is a lysosomal cysteine amidase responsible for the cleavage of ceramide into sphingosine, which is then phosphorylated to sphingosine 1-phosphate.  AC regulates the intracellular levels of ceramide and sphingosine, and a.c. inhibition may be useful in the treatment of disorders, such as cancer, in which ceramide-mediated signaling may be dysfunctional.  Despite their potential exptl. and therapeutic value, the no. of available small-mol. inhibitors of a.c. activity remains limited.  In the present study is described the discovery of a class of potent pyrazole carboxamide-based a.c. inhibitors, which were identified using the at. property field (APF) approach and developed through systematic SAR studies and in vitro pharmacol. characterization.  The best compd. of this series inhibits a.c. with nanomolar potency and causes ceramide accumulation and sphingosine depletion in intact G361 proliferative melanoma cells.  By expanding the current armamentarium of a.c. inhibitors, these results should facilitate future efforts to unravel the biol. of a.c. and the therapeutic potential of its inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ0V1BSSYCl7Vg90H21EOLACvtfcHk0lhv5uwXLYwdMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1ahur0%253D&md5=3308bc4d0f16df0692358e6cc75235de</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1055%2Fs-0035-1561456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0035-1561456%26sid%3Dliteratum%253Aachs%26aulast%3DDiamanti%26aufirst%3DE.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DGoldoni%26aufirst%3DL.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DF.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DPizzirani%26aufirst%3DD.%26atitle%3DPyrazole-based%2520acid%2520ceramidase%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationships%26jtitle%3DSynthesis%26date%3D2016%26volume%3D48%26spage%3D2739%26epage%3D2756%26doi%3D10.1055%2Fs-0035-1561456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengatto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Benzoxazolone carboxamides: potent and systemically active inhibitors of intracellular acid ceramidase</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1002/anie.201409042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fanie.201409042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=485-489&author=D.+Pizziraniauthor=A.+Bachauthor=N.+Realiniauthor=A.+Armirottiauthor=L.+Mengattoauthor=I.+Bauerauthor=S.+Girottoauthor=C.+Pagliucaauthor=M.+De+Vivoauthor=M.+Summaauthor=A.+Ribeiroauthor=D.+Piomelli&title=Benzoxazolone+carboxamides%3A+potent+and+systemically+active+inhibitors+of+intracellular+acid+ceramidase&doi=10.1002%2Fanie.201409042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fanie.201409042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201409042%26sid%3Dliteratum%253Aachs%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DMengatto%26aufirst%3DL.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%253A%2520potent%2520and%2520systemically%2520active%2520inhibitors%2520of%2520intracellular%2520acid%2520ceramidase%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D54%26spage%3D485%26epage%3D489%26doi%3D10.1002%2Fanie.201409042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vozella, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melzig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Benzoxazolone carboxamides as potent acid ceramidase inhibitors: synthesis and structure-activity relationship (SAR) studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9258</span>– <span class="NLM_lpage">9272</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9258-9272&author=A.+Bachauthor=D.+Pizziraniauthor=N.+Realiniauthor=V.+Vozellaauthor=D.+Russoauthor=I.+Pennaauthor=L.+Melzigauthor=R.+Scarpelliauthor=D.+Piomelli&title=Benzoxazolone+carboxamides+as+potent+acid+ceramidase+inhibitors%3A+synthesis+and+structure-activity+relationship+%28SAR%29+studies&doi=10.1021%2Facs.jmedchem.5b01188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Benzoxazolone Carboxamides as Potent Acid Ceramidase Inhibitors: Synthesis and Structure-Activity Relationship (SAR) Studies</span></div><div class="casAuthors">Bach, Anders; Pizzirani, Daniela; Realini, Natalia; Vozella, Valentina; Russo, Debora; Penna, Ilaria; Melzig, Laurin; Scarpelli, Rita; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9258-9272</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ceramides are lipid-derived intracellular messengers involved in the control of senescence, inflammation, and apoptosis.  The cysteine amidase, acid ceramidase (AC), hydrolyzes these substances into sphingosine and fatty acid and, by doing so, regulates their signaling activity.  AC inhibitors may be useful in the treatment of pathol. conditions, such as cancer, in which ceramide levels are abnormally reduced.  Here, we present a systematic SAR investigation of the benzoxazolone carboxamides, a recently described class of AC inhibitors that display high potency and systemic activity in mice.  We examd. a diverse series of substitutions on both benzoxazolone ring and carboxamide side chain.  Several modifications enhanced potency and stability, and one key compd. with a balanced activity-stability profile I was found to inhibit AC activity in mouse lungs and cerebral cortex after systemic administration.  The results expand our arsenal of AC inhibitors, thereby facilitating the use of these compds. as pharmacol. tools and their potential development as drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXKrFwyTWVt7Vg90H21EOLACvtfcHk0lhv5uwXLYwdMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI&md5=1b8de2b433b0e1b42299cf224d53e33a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01188%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DA.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DVozella%26aufirst%3DV.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DPenna%26aufirst%3DI.%26aulast%3DMelzig%26aufirst%3DL.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%2520as%2520potent%2520acid%2520ceramidase%2520inhibitors%253A%2520synthesis%2520and%2520structure-activity%2520relationship%2520%2528SAR%2529%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9258%26epage%3D9272%26doi%3D10.1021%2Facs.jmedchem.5b01188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arencibia, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Sala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgogno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification and scaffold exploration to discover novel, potent, and chemically stable inhibitors of acid ceramidase in melanoma cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5800</span>– <span class="NLM_lpage">5815</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00472</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00472" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5800-5815&author=J.+A.+Ortegaauthor=J.+M.+Arencibiaauthor=G.+La+Salaauthor=M.+Borgognoauthor=I.+Bauerauthor=L.+Bonoauthor=C.+Bracciaauthor=A.+Armirottiauthor=S.+Girottoauthor=A.+Ganesanauthor=M.+De+Vivo&title=Pharmacophore+identification+and+scaffold+exploration+to+discover+novel%2C+potent%2C+and+chemically+stable+inhibitors+of+acid+ceramidase+in+melanoma+cells&doi=10.1021%2Facs.jmedchem.7b00472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells</span></div><div class="casAuthors">Ortega, Jose Antonio; Arencibia, Jose M.; La Sala, Giuseppina; Borgogno, Marco; Bauer, Inga; Bono, Luca; Braccia, Clarissa; Armirotti, Andrea; Girotto, Stefania; Ganesan, Anand; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5800-5815</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) hydrolyzes ceramides, which are central lipid messengers for metab. and signaling of sphingolipids.  A growing body of evidence links deregulation of sphingolipids to several diseases, including cancer.  Indeed, AC expression is abnormally high in melanoma cells.  AC inhibition may thus be key to treating malignant melanoma.  Here, the authors have used a systematic scaffold exploration to design a general pharmacophore for AC inhibition.  This pharmacophore comprises a 6+5 fused ring heterocycle linked to an aliph. substituent via a urea moiety.  The authors have thus identified the novel benzimidazole derivs., which are highly potent AC inhibitors.  Their chem. and metabolic stability is comparable or superior to that of previously reported AC inhibitors.  Moreover, they are potent against endogenous AC in intact melanoma cells.  These novel inhibitors merit further characterization and can serve as a promising starting point for the discovery of new antimelanoma therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsJbGrbc7g0bVg90H21EOLACvtfcHk0ljSzf1uWYAkMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsr4%253D&md5=9ad5f49ead19498e6080e7dbed47c5be</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00472%26sid%3Dliteratum%253Aachs%26aulast%3DOrtega%26aufirst%3DJ.%2BA.%26aulast%3DArencibia%26aufirst%3DJ.%2BM.%26aulast%3DLa%2BSala%26aufirst%3DG.%26aulast%3DBorgogno%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DBono%26aufirst%3DL.%26aulast%3DBraccia%26aufirst%3DC.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DPharmacophore%2520identification%2520and%2520scaffold%2520exploration%2520to%2520discover%2520novel%252C%2520potent%252C%2520and%2520chemically%2520stable%2520inhibitors%2520of%2520acid%2520ceramidase%2520in%2520melanoma%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5800%26epage%3D5815%26doi%3D10.1021%2Facs.jmedchem.7b00472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spink, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballentine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Player, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, W.</span></span> <span> </span><span class="NLM_article-title">Process development for scale-up of a novel 3,5-substituted thiazolidine-2,4-dione compound as a potent inhibitor for estrogen-related receptor 1</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1021/op400325r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op400325r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=321-330&author=X.+Liauthor=R.+K.+Russellauthor=J.+Spinkauthor=S.+Ballentineauthor=C.+Telehaauthor=S.+Branumauthor=K.+Wellsauthor=D.+Beauchampauthor=R.+Patchauthor=H.+Huangauthor=M.+Playerauthor=W.+Murray&title=Process+development+for+scale-up+of+a+novel+3%2C5-substituted+thiazolidine-2%2C4-dione+compound+as+a+potent+inhibitor+for+estrogen-related+receptor+1&doi=10.1021%2Fop400325r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development for Scale-Up of a Novel 3,5-Substituted Thiazolidine-2,4-dione Compound as a Potent Inhibitor for Estrogen-Related Receptor 1</span></div><div class="casAuthors">Li, Xun; Russell, Ronald K.; Spink, Jan; Ballentine, Scott; Teleha, Christopher; Branum, Shawn; Wells, Kenneth; Beauchamp, Derek; Patch, Raymond; Huang, Hui; Player, Mark; Murray, William</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">321-330</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a reproducible process for multihundred gram prodn. of (Z)-5-((1-(4-chloro-2-(trifluoromethyl)benzyl)-1H-indazol-5-yl)methylene)-3-((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)thiazolidine-2,4-dione (26), a potent and selective inhibitor of estrogen-related receptor 1 (ERR1), is described.  This multihundred gram synthesis was achieved via magnesium perchlorate-catalyzed regioselective epoxide ring-opening of tert-Bu 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate (9) with thiazolidine-2,4-dione (6, TZD) to form a diastereomeric mixt. tert-Bu 4-(2,4-dioxothiazolidin-3-yl)-3-hydroxypiperidine-1-carboxylate (17), of which the 3-hydroxyl group was functionally transformed to 3-fluoro deriv. 19 after treatment with Deoxo-Fluor.  Chiral sepn. of 19 provided the desired diastereomer (3R,4R)-21 that was converted to the secondary amine 23 TFA salt.  Reductive amination of 23 produced the key intermediate N-Me 24.  Knoevenagel condensation of 24 with 1-(4-chloro-2-(trifluoromethyl)benzyl)-1H-indazole-5-carbaldehyde (5) produced the final product 26 in 10% overall yield (99.7% HPLC area% with ≥99.5% de) after a convergent eight synthetic steps with the only column purifn. being the chiral HPLC sepn. of 3R,4R-21 from 3S,4S-22.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHhIJERVpKQrVg90H21EOLACvtfcHk0livcSO1qGJcPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCmtg%253D%253D&md5=1470607da3279b379eb1ac19ed6cf6e0</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fop400325r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop400325r%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DRussell%26aufirst%3DR.%2BK.%26aulast%3DSpink%26aufirst%3DJ.%26aulast%3DBallentine%26aufirst%3DS.%26aulast%3DTeleha%26aufirst%3DC.%26aulast%3DBranum%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DK.%26aulast%3DBeauchamp%26aufirst%3DD.%26aulast%3DPatch%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DPlayer%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DW.%26atitle%3DProcess%2520development%2520for%2520scale-up%2520of%2520a%2520novel%25203%252C5-substituted%2520thiazolidine-2%252C4-dione%2520compound%2520as%2520a%2520potent%2520inhibitor%2520for%2520estrogen-related%2520receptor%25201%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D321%26epage%3D330%26doi%3D10.1021%2Fop400325r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeOrazio, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikam, S. S.</span></span> <span> </span><span class="NLM_article-title">A simple strategy for the preparation of 6-substituted 3H-benzoxazol-2-ones and 3H-benzothiazol-2-ones</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">3551</span>– <span class="NLM_lpage">3555</span>, <span class="refDoi"> DOI: 10.1080/00397911.2010.519093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1080%2F00397911.2010.519093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=3551-3555&author=R.+J.+DeOrazioauthor=J.-H.+Maengauthor=D.+D.+Manningauthor=B.+A.+Shererauthor=I.+L.+Scottauthor=S.+S.+Nikam&title=A+simple+strategy+for+the+preparation+of+6-substituted+3H-benzoxazol-2-ones+and+3H-benzothiazol-2-ones&doi=10.1080%2F00397911.2010.519093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A simple strategy for the preparation of 6-substituted 3H-benzoxazol-2-ones and 3H-benzothiazol-2-ones</span></div><div class="casAuthors">DeOrazio, Russell J.; Maeng, Jun-Ho; Manning, David D.; Sherer, Brian A.; Scott, Ian L.; Nikam, Sham S.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3551-3555</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">The double metalation of 6-bromo-3H-benzothiazol-2-one and 6-bromo-3H-benzoxazol-2-one with Me magnesium bromide and alkyllithium bases was described.  Alkylation with a variety of electrophiles occurs at the 6-position of the heterocycles in good yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHej54DCHWz7Vg90H21EOLACvtfcHk0livcSO1qGJcPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWns7c%253D&md5=81906606c280b08f272cbd7092d8a48b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F00397911.2010.519093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397911.2010.519093%26sid%3Dliteratum%253Aachs%26aulast%3DDeOrazio%26aufirst%3DR.%2BJ.%26aulast%3DMaeng%26aufirst%3DJ.-H.%26aulast%3DManning%26aufirst%3DD.%2BD.%26aulast%3DSherer%26aufirst%3DB.%2BA.%26aulast%3DScott%26aufirst%3DI.%2BL.%26aulast%3DNikam%26aufirst%3DS.%2BS.%26atitle%3DA%2520simple%2520strategy%2520for%2520the%2520preparation%2520of%25206-substituted%25203H-benzoxazol-2-ones%2520and%25203H-benzothiazol-2-ones%26jtitle%3DSynth.%2520Commun.%26date%3D2011%26volume%3D41%26spage%3D3551%26epage%3D3555%26doi%3D10.1080%2F00397911.2010.519093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rynearson, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrette, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerneke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dibrov, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, T.</span></span> <span> </span><span class="NLM_article-title">2-Aminobenzoxazole ligands of the hepatitis C virus internal ribosome entry site</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3521</span>– <span class="NLM_lpage">3525</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.bmcl.2014.05.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=24930829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWhurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3521-3525&author=K.+D.+Rynearsonauthor=B.+Charretteauthor=C.+Gabrielauthor=J.+Morenoauthor=M.+A.+Boernekeauthor=S.+M.+Dibrovauthor=T.+Hermann&title=2-Aminobenzoxazole+ligands+of+the+hepatitis+C+virus+internal+ribosome+entry+site&doi=10.1016%2Fj.bmcl.2014.05.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminobenzoxazole ligands of the hepatitis C virus internal ribosome entry site</span></div><div class="casAuthors">Rynearson, Kevin D.; Charrette, Brian; Gabriel, Christopher; Moreno, Jesus; Boerneke, Mark A.; Dibrov, Sergey M.; Hermann, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3521-3525</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">2-Aminobenzoxazoles were synthesized as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA.  The compds. were designed to explore the less basic benzoxazole system as a replacement for the core scaffold in previously discovered benzimidazole viral translation inhibitors.  Structure-activity relationships in the target binding of substituted benzoxazole ligands were studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqluR-xVpgaqrVg90H21EOLACvtfcHk0liWe2Ifk_df5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWhurfO&md5=e9e7bf1b26d177446884e60af25a9de9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.088%26sid%3Dliteratum%253Aachs%26aulast%3DRynearson%26aufirst%3DK.%2BD.%26aulast%3DCharrette%26aufirst%3DB.%26aulast%3DGabriel%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DJ.%26aulast%3DBoerneke%26aufirst%3DM.%2BA.%26aulast%3DDibrov%26aufirst%3DS.%2BM.%26aulast%3DHermann%26aufirst%3DT.%26atitle%3D2-Aminobenzoxazole%2520ligands%2520of%2520the%2520hepatitis%2520C%2520virus%2520internal%2520ribosome%2520entry%2520site%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3521%26epage%3D3525%26doi%3D10.1016%2Fj.bmcl.2014.05.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesquière, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span> <span> </span><span class="NLM_article-title">Synthesis of N-(iodophenyl)-amides via an unprecedented Ullmann-Finkelstein tandem reaction</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1186</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2005.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.tetlet.2005.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFOjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=1181-1186&author=P.+Totoauthor=J.-C.+Gesqui%C3%A8reauthor=B.+Deprezauthor=N.+Willand&title=Synthesis+of+N-%28iodophenyl%29-amides+via+an+unprecedented+Ullmann-Finkelstein+tandem+reaction&doi=10.1016%2Fj.tetlet.2005.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of N-(iodophenyl)-amides via an unprecedented Ullmann-Finkelstein tandem reaction</span></div><div class="casAuthors">Toto, Patrick; Gesquiere, Jean-Claude; Deprez, Benoit; Willand, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1181-1186</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using a new Ullmann-Finkelstein tandem reaction, N-iodophenyl amides were synthesized from the corresponding amides and iodobromobenzenes.  The catalyst/ligand couple CuI/N,N'-dimethylcyclohexane-1,2-diamine was used for this reaction in dioxane with K3PO4 as base.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3NWxYFhLpLrVg90H21EOLACvtfcHk0liWe2Ifk_df5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFOjsA%253D%253D&md5=6d5fe8b9ba071cbcc772563317d14219</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2005.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2005.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DToto%26aufirst%3DP.%26aulast%3DGesqui%25C3%25A8re%26aufirst%3DJ.-C.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DWilland%26aufirst%3DN.%26atitle%3DSynthesis%2520of%2520N-%2528iodophenyl%2529-amides%2520via%2520an%2520unprecedented%2520Ullmann-Finkelstein%2520tandem%2520reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D2006%26volume%3D47%26spage%3D1181%26epage%3D1186%26doi%3D10.1016%2Fj.tetlet.2005.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knöelker, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braxmeier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlechtingen, G.</span></span> <span> </span><span class="NLM_article-title">A novel method for the synthesis of isocyanates under mild conditions</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2500</span>, <span class="refDoi"> DOI: 10.1002/anie.199524971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fanie.199524971" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK2MXpslOnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1995&pages=2497-2500&author=H.-J.+Kn%C3%B6elkerauthor=T.+Braxmeierauthor=G.+Schlechtingen&title=A+novel+method+for+the+synthesis+of+isocyanates+under+mild+conditions&doi=10.1002%2Fanie.199524971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A novel method for the synthesis of isocyanates under mild conditions</span></div><div class="casAuthors">Knoelker, Hans-Joachim; Braxmeier, Tobias; Schlechtingen, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition in English</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2497-500</span>CODEN:
                <span class="NLM_cas:coden">ACIEAY</span>;
        ISSN:<span class="NLM_cas:issn">0570-0833</span>.
    
            (<span class="NLM_cas:orgname">VCH</span>)
        </div><div class="casAbstract">The title process converts alkyl- and arylamines into isocyanates in high yields by reaction with activated carbonates in the presence of a catalytic amt. of a nucleophilic N base at room temp.  Thus, 2,4,6-(MeO)3C6H2NH2 was treated with (Me3CO2C)2O and 4-(dimethylamino)pyridine in MeCN to give 97% 2,4,6-(MeO)3C6H2NCO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgmvefL7Nk7rVg90H21EOLACvtfcHk0liWe2Ifk_df5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpslOnu7c%253D&md5=d51dd730927d3f5a9aa05e17c346c824</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fanie.199524971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.199524971%26sid%3Dliteratum%253Aachs%26aulast%3DKn%25C3%25B6elker%26aufirst%3DH.-J.%26aulast%3DBraxmeier%26aufirst%3DT.%26aulast%3DSchlechtingen%26aufirst%3DG.%26atitle%3DA%2520novel%2520method%2520for%2520the%2520synthesis%2520of%2520isocyanates%2520under%2520mild%2520conditions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1995%26volume%3D34%26spage%3D2497%26epage%3D2500%26doi%3D10.1002%2Fanie.199524971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forster, B.</span></span> <span> </span><span class="NLM_article-title">Triphosgene, a crystalline phosgene substitute</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">894</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1002/anie.198708941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fanie.198708941" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1987&pages=894-895&author=H.+Eckertauthor=B.+Forster&title=Triphosgene%2C+a+crystalline+phosgene+substitute&doi=10.1002%2Fanie.198708941"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.198708941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.198708941%26sid%3Dliteratum%253Aachs%26aulast%3DEckert%26aufirst%3DH.%26aulast%3DForster%26aufirst%3DB.%26atitle%3DTriphosgene%252C%2520a%2520crystalline%2520phosgene%2520substitute%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1987%26volume%3D26%26spage%3D894%26epage%3D895%26doi%3D10.1002%2Fanie.198708941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dementiev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joachimiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelsomino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, E.-Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, N.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of inhibition of acid ceramidase by carmofur</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01723</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01723" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=987-992&author=A.+Dementievauthor=A.+Joachimiakauthor=H.+Nguyenauthor=A.+Gorelikauthor=K.+Illesauthor=S.+Shabaniauthor=M.+Gelsominoauthor=E.-Y.+E.+Ahnauthor=B.+Nagarauthor=N.+Doan&title=Molecular+mechanism+of+inhibition+of+acid+ceramidase+by+carmofur&doi=10.1021%2Facs.jmedchem.8b01723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of inhibition of acid ceramidase by carmofur</span></div><div class="casAuthors">Dementiev, Alexey; Joachimiak, Andrzej; Nguyen, Ha; Gorelik, Alexei; Illes, Katalin; Shabani, Saman; Gelsomino, Michael; Ahn, Eun-Young Erin; Nagar, Bhushan; Doan, Ninh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">987-992</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human acid ceramidase (AC) is a lysosomal cysteine amidase, which has received a great deal of interest in recent years as a potential target for the development of new therapeutics against melanoma and glioblastoma tumors.  Despite the strong interest in obtaining structural information, only the structures of the apo-AC enzyme in its zymogen and activated conformations are available.  In this work, the crystal structure of AC in complex with the covalent carmofur inhibitor is presented.  Carmofur (1-hexylcarbamoyl-5-fluorouracil) is an antineoplastic drug contg. an electrophilic carbonyl reactive group that targets the catalytic cysteine.  This novel structural data explains the basis of the AC inhibition, provides insights into the enzymic properties of the protein, and is a great aid toward the structure-based drug design of potent inhibitors for AC, providing the detailed mechanism, which has eluded the scientific community for more than 30 years, of carmofur's mysterious 5-fluorouracil-independent antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLv97-NENYSbVg90H21EOLACvtfcHk0liLR5XG1oR0bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLrE&md5=b88fa5e1014bc879d160e210dd1c2dfa</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01723%26sid%3Dliteratum%253Aachs%26aulast%3DDementiev%26aufirst%3DA.%26aulast%3DJoachimiak%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DShabani%26aufirst%3DS.%26aulast%3DGelsomino%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DE.-Y.%2BE.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DDoan%26aufirst%3DN.%26atitle%3DMolecular%2520mechanism%2520of%2520inhibition%2520of%2520acid%2520ceramidase%2520by%2520carmofur%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D987%26epage%3D992%26doi%3D10.1021%2Facs.jmedchem.8b01723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. J.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase, an emerging target for anti-cancer and anti-angiogenesis</span>. <i>Arch. Pharmacal Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1007/s12272-019-01114-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1007%2Fs12272-019-01114-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=30661200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVOqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=232-243&author=S.+M.+Choauthor=H.+J.+Kwon&title=Acid+ceramidase%2C+an+emerging+target+for+anti-cancer+and+anti-angiogenesis&doi=10.1007%2Fs12272-019-01114-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase, an emerging target for anti-cancer and anti-angiogenesis</span></div><div class="casAuthors">Cho, Sung Min; Kwon, Ho Jeong</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">232-243</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">Sphingolipid metab. plays an important role in detg. the fate of a cell.  Among several sphingolipid metabolites, ceramide is a key player in intracellular signal transduction.  Ceramide is usually converted to various metabolites such as sphingomyelin, sphingosine, ceramide-1-phosphate, and glucosylceramide.  If ceramide is accumulated in the cell, it induces apoptosis.  On the other hand, its metabolite sphingosine is converted to sphingosine-1-phosphate (S1P), which promotes angiogenesis via G protein coupled receptor signaling.  Therefore, the equil. in ceramide and S1P levels in cells plays an important role in angiogenesis as well as cell death.  Acid ceramidase (AC) is a promising target protein in the development of multi-targeted anticancer drugs as its inhibition can simultaneously inhibit angiogenesis via the Akt and ERK 1/2 pathway and limit cancer growth through ceramide-induced apoptosis.  Although some inhibitors of AC have been reported, they have not been proven effective for human therapy.  Recent advancement in the elucidation of AC structure will facilitate the development of better inhibitors for treating human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbhz9fnHvbDrVg90H21EOLACvtfcHk0liLR5XG1oR0bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVOqsbw%253D&md5=3ce3e0c43bf4e0b6e93516a3cfcf68c3</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs12272-019-01114-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-019-01114-3%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BM.%26aulast%3DKwon%26aufirst%3DH.%2BJ.%26atitle%3DAcid%2520ceramidase%252C%2520an%2520emerging%2520target%2520for%2520anti-cancer%2520and%2520anti-angiogenesis%26jtitle%3DArch.%2520Pharmacal%2520Res.%26date%3D2019%26volume%3D42%26spage%3D232%26epage%3D243%26doi%3D10.1007%2Fs12272-019-01114-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0liLR5XG1oR0bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Improving drug design: an update on recent applications of efficiency metrics, strategies for replacing problematic elements, and compounds in nontraditional drug space</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=564-616&author=N.+A.+Meanwell&title=Improving+drug+design%3A+an+update+on+recent+applications+of+efficiency+metrics%2C+strategies+for+replacing+problematic+elements%2C+and+compounds+in+nontraditional+drug+space&doi=10.1021%2Facs.chemrestox.6b00043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">564-616</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug discovery and development is a complex and lengthy enterprise that suffers from high rates of candidate attrition at all stages of the process.  The phys., biol., and toxicol. properties of a drug candidate are inextricably linked to its structure, and once a mol. has been synthesized, all subsequent studies along the development path are focused only on assessing and understanding its properties in greater detail.  Unfortunately, a full prediction of the biol. properties of a mol. from an anal. of its 2- or 3-dimensional structure is currently beyond our expertise.  This backdrop mandates that considerable care be taken at the design stage if a mol. is to be successful in testing a mechanistic concept underlying a disease process and to progress into late stage clin. trials and, ultimately, marketing approval.  While there are multiple potential causes of candidate attrition, an introspective anal. of drug design practices over the past decade has focused attention on the perception that contemporary mols. are unnecessarily obese, burdened by high mol. wt. and excessive lipophilicity.  This practice is believed to have its roots in the singular pursuit of enhancing potency during lead optimization rather than adopting a more holistic approach to drug design that gives broader consideration to how structural features affect developability properties.  In an effort to provide the medicinal chem. community with practical guideposts to enhancing compd. quality in the drug design phase and which can readily be applied, a series of efficiency indexes have been proposed that attempt to define aspects of compd. quality in the context of a series of physicochem. parameters.  Of these metrics, lipophilic ligand efficiency (LLE or LipE), which provides an index of the dependence of the potency of a mol. on its intrinsic lipophilicity, has been characterized as the most robust metric that has potential for broad-based application.  In this review, after describing the background literature behind the derivation of efficiency metrics and approaches to assessing compd. aesthetics, synopses of some recent practical application in lead optimization campaigns are presented.  However, mols. that fall into space beyond that assocd. with traditional drug-like properties are an important part of the current and future landscape, exemplified by the summary of direct acting hepatitis C virus NS3 and NS5A inhibitors that have transformed clin. therapy for this chronic disease.  While drug development in nontraditional drug-like space is more challenging and the rules for compd. quality will be different with much still to be understood, careful and disciplined drug design practices will be an essential element of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpotJb_EhGoW7Vg90H21EOLACvtfcHk0lig2jXLtF8laQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D&md5=aef48399fb698b5f958c1cc11e1d25aa</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00043%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520drug%2520design%253A%2520an%2520update%2520on%2520recent%2520applications%2520of%2520efficiency%2520metrics%252C%2520strategies%2520for%2520replacing%2520problematic%2520elements%252C%2520and%2520compounds%2520in%2520nontraditional%2520drug%2520space%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D564%26epage%3D616%26doi%3D10.1021%2Facs.chemrestox.6b00043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <i>Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists</i>; <span class="NLM_publisher-name">Wiley-Interscience</span>: <span class="NLM_publisher-loc">Hoboken, New Jersey, USA, Ed</span>. <span class="NLM_year">2005</span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">248</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=48-248&author=R.+A.+Copeland&title=Evaluation+of+Enzyme+Inhibitors+in+Drug+Discovery%3A+A+Guide+for+Medicinal+Chemists+and+Pharmacologists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26btitle%3DEvaluation%2520of%2520Enzyme%2520Inhibitors%2520in%2520Drug%2520Discovery%253A%2520A%2520Guide%2520for%2520Medicinal%2520Chemists%2520and%2520Pharmacologists%26pub%3DWiley-Interscience%26date%3D2005%26spage%3D48%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strelow, J. D. W.</span>; <span class="NLM_string-name">Iversen, P. W.</span>; <span class="NLM_string-name">Brooks, H. B.</span>; <span class="NLM_string-name">Radding, J. A.</span>; <span class="NLM_string-name">McGee, J.</span>; <span class="NLM_string-name">Weidner, J.</span></span>, In  <i>Assay Guidance Manual</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sittampalam, G. S. G. A.</span>; <span class="NLM_string-name">Brimacombe, K.</span>; <span class="NLM_string-name">Arkin, M.</span>; <span class="NLM_string-name">Auld, D.</span>; <span class="NLM_string-name">Austin, C. P.</span>; <span class="NLM_string-name">Baell, J.</span>; <span class="NLM_string-name">Bejcek, B.</span>; <span class="NLM_string-name">Caaveiro, J. M. M.</span>; <span class="NLM_string-name">Chung, T. D. Y.</span>; <span class="NLM_string-name">Coussens, N. P.</span>; <span class="NLM_string-name">Dahlin, J. L.</span>; <span class="NLM_string-name">Devanaryan, V.</span>; <span class="NLM_string-name">Foley, T. L.</span>; <span class="NLM_string-name">Glicksman, M.</span>; <span class="NLM_string-name">Hall, M. D.</span>; <span class="NLM_string-name">Haas, J. V.</span>; <span class="NLM_string-name">Hoare, S. R. J.</span>; <span class="NLM_string-name">Inglese, J.</span>; <span class="NLM_string-name">Iversen, P. W.</span>; <span class="NLM_string-name">Kahl, S. D.</span>; <span class="NLM_string-name">Kales, S. C.</span>; <span class="NLM_string-name">Kirshner, S.</span>; <span class="NLM_string-name">Lal-Nag, M.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">McGee, J.</span>; <span class="NLM_string-name">McManus, O.</span>; <span class="NLM_string-name">Riss, T.</span>; <span class="NLM_string-name">Saradjian, P.</span>; <span class="NLM_string-name">Trask, O. J.</span>; <span class="NLM_string-name">Weidner,  Jr., J. R.</span>; <span class="NLM_string-name">Wildey, M. J.</span>; <span class="NLM_string-name">Xia, M.</span>; <span class="NLM_string-name">Xu, X.</span></span>, Ed. <span class="NLM_publisher-name">Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences</span>, <span class="NLM_year">2004</span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">86</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=65-86&author=J.+D.+W.+Strelow&author=P.+W.+Iversen&author=H.+B.+Brooks&author=J.+A.+Radding&author=J.+McGee&author=J.+Weidnerauthor=G.+S.+G.+A.+Sittampalam&author=K.+Brimacombe&author=M.+Arkin&author=D.+Auld&author=C.+P.+Austin&author=J.+Baell&author=B.+Bejcek&author=J.+M.+M.+Caaveiro&author=T.+D.+Y.+Chung&author=N.+P.+Coussens&author=J.+L.+Dahlin&author=V.+Devanaryan&author=T.+L.+Foley&author=M.+Glicksman&author=M.+D.+Hall&author=J.+V.+Haas&author=S.+R.+J.+Hoare&author=J.+Inglese&author=P.+W.+Iversen&author=S.+D.+Kahl&author=S.+C.+Kales&author=S.+Kirshner&author=M.+Lal-Nag&author=Z.+Li&author=J.+McGee&author=O.+McManus&author=T.+Riss&author=P.+Saradjian&author=O.+J.+Trask&author=J.+R.+Weidner&author=M.+J.+Wildey&author=M.+Xia&author=X.+Xu&title=Assay+Guidance+Manual"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DStrelow%26aufirst%3DJ.%2BD.%2BW.%26btitle%3DAssay%2520Guidance%2520Manual%26aulast%3DSittampalam%26aufirst%3DG.%2BS.%2BG.%2BA.%26pub%3DBethesda%2520%2528MD%2529%253A%2520Eli%2520Lilly%2520%2526%2520Company%2520and%2520the%2520National%2520Center%2520for%2520Advancing%2520Translational%2520Sciences%26date%3D2004%26spage%3D65%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of activation of the immunoregulatory amidase NAAA</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E10032</span>– <span class="NLM_lpage">E10040</span>, <span class="refDoi"> DOI: 10.1073/pnas.1811759115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1073%2Fpnas.1811759115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=30301806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyhsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E10032-E10040&author=A.+Gorelikauthor=A.+Gebaiauthor=K.+Illesauthor=D.+Piomelliauthor=B.+Nagar&title=Molecular+mechanism+of+activation+of+the+immunoregulatory+amidase+NAAA&doi=10.1073%2Fpnas.1811759115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of activation of the immunoregulatory amidase NAAA</span></div><div class="casAuthors">Gorelik, Alexei; Gebai, Ahmad; Illes, Katalin; Piomelli, Daniele; Nagar, Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">E10032-E10040</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Palmitoylethanolamide is a bioactive lipid that strongly alleviates pain and inflammation in animal models and in humans.  Its signaling activity is terminated through degrdn. by N-acylethanolamine acid amidase (NAAA), a cysteine hydrolase expressed at high levels in immune cells.  Pharmacol. inhibitors of NAAA activity exert profound analgesic and antiinflammatory effects in rodent models, pointing to this protein as a potential target for therapeutic drug discovery.  To facilitate these efforts and to better understand the mol. mechanism of action of NAAA, we detd. crystal structures of this enzyme in various activation states and in complex with several ligands, including both a covalent and a reversible inhibitor.  Self-proteolysis exposes the otherwise buried active site of NAAA to allow catalysis.  Formation of a stable substrate- or inhibitor-binding site appears to be conformationally coupled to the interaction of a pair of hydrophobic helixes in the enzyme with lipid membranes, resulting in the creation of a linear hydrophobic cavity near the active site that accommodates the liganda's acyl chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe4SyudaY7MrVg90H21EOLACvtfcHk0lig2jXLtF8laQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyhsLvP&md5=9debd68d3239a82bd60849c9cf98e8ae</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1811759115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1811759115%26sid%3Dliteratum%253Aachs%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DGebai%26aufirst%3DA.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DNagar%26aufirst%3DB.%26atitle%3DMolecular%2520mechanism%2520of%2520activation%2520of%2520the%2520immunoregulatory%2520amidase%2520NAAA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE10032%26epage%3DE10040%26doi%3D10.1073%2Fpnas.1811759115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Enzymatic pathways that regulate endocannabinoid signaling in the nervous system</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">1687</span>– <span class="NLM_lpage">1707</span>, <span class="refDoi"> DOI: 10.1021/cr0782067</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0782067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFKhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2008&pages=1687-1707&author=K.+Ahnauthor=M.+K.+McKinneyauthor=B.+F.+Cravatt&title=Enzymatic+pathways+that+regulate+endocannabinoid+signaling+in+the+nervous+system&doi=10.1021%2Fcr0782067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Enzymatic pathways that regulate endocannabinoid signaling in the nervous system</span></div><div class="casAuthors">Ahn, Kay; McKinney, Michele K.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1687-1707</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Recent advances in the understanding of the compn. and regulation of endocannabinoid metabolic pathways, esp. with respect to the nervous system, are reviewed.  The current state of the understanding of the 4 major pathways for endocannabinoid metab. are discussed.  These include (1) anandamide degrdn.; (2) anandamide biosynthesis; (3) 2-arachidonoylglycerol (2-AG) degrdn.; and (4) 2-AG biosynthesis.  Some of these pathways, such as anandamide degrdn., are relatively well characterized, at least in terms of the participating enzymes, esp. fatty acid amide hydrolase (FAAH), and the advent of specific research tools to probe their function in vivo.  For the other pathways, candidate enzymes have been identified, but the specific roles that these proteins play in regulating endocannabinoid metab. in vivo remains to be elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcfjZNs7jWWrVg90H21EOLACvtfcHk0lhYtSAE-aYb1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFKhs7s%253D&md5=4c74194ab87393de8f0fcbab198d089c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fcr0782067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0782067%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DMcKinney%26aufirst%3DM.%2BK.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DEnzymatic%2520pathways%2520that%2520regulate%2520endocannabinoid%2520signaling%2520in%2520the%2520nervous%2520system%26jtitle%3DChem.%2520Rev.%26date%3D2008%26volume%3D108%26spage%3D1687%26epage%3D1707%26doi%3D10.1021%2Fcr0782067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blankman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2007.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.chembiol.2007.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=18096503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1347-1356&author=J.+L.+Blankmanauthor=G.+M.+Simonauthor=B.+F.+Cravatt&title=A+Comprehensive+profile+of+brain+enzymes+that+hydrolyze+the+endocannabinoid+2-arachidonoylglycerol&doi=10.1016%2Fj.chembiol.2007.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol</span></div><div class="casAuthors">Blankman, Jacqueline L.; Simon, Gabriel M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Endogenous ligands for cannabinoid receptors ("endocannabinoids") include the lipid transmitters anandamide and 2-arachidonoylglycerol (2-AG).  Endocannabinoids modulate a diverse set of physiol. processes and are tightly regulated by enzymic biosynthesis and degrdn.  Termination of anandamide signaling by fatty acid amide hydrolase (FAAH) is well characterized, but less is known about the inactivation of 2-AG, which can be hydrolyzed by multiple enzymes in vitro, including FAAH and monoacylglycerol lipase (MAGL).  Here, we have taken a functional proteomic approach to comprehensively map 2-AG hydrolases in the mouse brain.  Our data reveal that ∼85% of brain 2-AG hydrolase activity can be ascribed to MAGL, and that the remaining 15% is mostly catalyzed by two uncharacterized enzymes, ABHD6 and ABHD12.  Interestingly, MAGL, ABHD6, and ABHD12 display distinct subcellular distributions, suggesting that they may control different pools of 2-AG in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF_Kmd_7v5urVg90H21EOLACvtfcHk0lhYtSAE-aYb1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE&md5=78c6355a3909bff3cbae25989ab6a956</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DSimon%26aufirst%3DG.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520Comprehensive%2520profile%2520of%2520brain%2520enzymes%2520that%2520hydrolyze%2520the%2520endocannabinoid%25202-arachidonoylglycerol%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D1347%26epage%3D1356%26doi%3D10.1016%2Fj.chembiol.2007.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Marzo, V.</span></span> <span> </span><span class="NLM_article-title">New approaches and challenges to targeting the endocannabinoid system</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fnrd.2018.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=30116049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFans73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=623-639&author=V.+Di%0AMarzo&title=New+approaches+and+challenges+to+targeting+the+endocannabinoid+system&doi=10.1038%2Fnrd.2018.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">New approaches and challenges to targeting the endocannabinoid system</span></div><div class="casAuthors">Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">623-639</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid signalling system was discovered because receptors in this system are the targets of compds. present in psychotropic prepns. of Cannabis sativa.  The search for new therapeutics that target endocannabinoid signalling is both challenging and potentially rewarding, as endocannabinoids are implicated in numerous physiol. and pathol. processes.  Hundreds of mediators chem. related to the endocannabinoids, often with similar metabolic pathways but different targets, have complicated the development of inhibitors of endocannabinoid metabolic enzymes but have also stimulated the rational design of multi-target drugs.  Meanwhile, drugs based on botanical cannabinoids have come to the clin. forefront, synthetic agonists designed to bind cannabinoid receptor 1 with very high affinity have become a societal threat and the gut microbiome has been found to signal in part through the endocannabinoid network.  The current development of drugs that alter endocannabinoid signalling and how this complex system could be pharmacol. manipulated in the future are described in this Opinion article.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsITgIPYFrrVg90H21EOLACvtfcHk0lhYtSAE-aYb1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFans73O&md5=7a48b4e8a8c27a5da3e8ba0f80222a32</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.115%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DNew%2520approaches%2520and%2520challenges%2520to%2520targeting%2520the%2520endocannabinoid%2520system%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D623%26epage%3D639%26doi%3D10.1038%2Fnrd.2018.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorhees, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitatani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, G. A.</span></span> <span> </span><span class="NLM_article-title">Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1088</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddp580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1093%2Fhmg%2Fddp580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=20047948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivV2jtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=1088-1097&author=Y.+Sunauthor=B.+Liouauthor=H.+Ranauthor=M.+R.+Skeltonauthor=M.+T.+Williamsauthor=C.+V.+Vorheesauthor=K.+Kitataniauthor=Y.+A.+Hannunauthor=D.+P.+Witteauthor=Y.-H.+Xuauthor=G.+A.+Grabowski&title=Neuronopathic+Gaucher+disease+in+the+mouse%3A+viable+combined+selective+saposin+C+deficiency+and+mutant+glucocerebrosidase+%28V394L%29+mice+with+glucosylsphingosine+and+glucosylceramide+accumulation+and+progressive+neurological+deficits&doi=10.1093%2Fhmg%2Fddp580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits</span></div><div class="casAuthors">Sun, Ying; Liou, Benjamin; Ran, Huimin; Skelton, Matthew R.; Williams, Michael T.; Vorhees, Charles V.; Kitatani, Kazuyuki; Hannun, Yusuf A.; Witte, David P.; Xu, You-Hai; Grabowski, Gregory A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1088-1097</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Gaucher disease is caused by defective acid β-glucosidase (GCase) function.  Saposin C is a lysosomal protein needed for optimal GCase activity.  To test the in vivo effects of saposin C on GCase, saposin C deficient mice (C-/-) were backcrossed to point mutated GCase (V394L/V394L) mice.  The resultant mice (4L;C*) began to exhibit CNS abnormalities ∼30 days: first as hindlimb paresis, then progressive tremor and ataxia.  Death occurred ∼48 days due to neurol. deficits.  Axonal degeneration was evident in brain stem, spinal cord and white matter of cerebellum accompanied by increasing infiltration of the brain stem, cortex and thalamus by CD68 pos. microglial cells and activation of astrocytes.  Electron microscopy showed inclusion bodies in neuronal processes and degenerating cells.  Accumulation of p62 and Lamp2 were prominent in the brain suggesting the impairment of autophagosome/lysosome function.  This phenotype was different from either V394L/V394L or C-/- alone.  Relative to V394L/V394L mice, 4L;C* mice had diminished GCase protein and activity.  Marked increases (20- to 30-fold) of glucosylsphingosine (GS) and moderate elevation (1.5- to 3-fold) of glucosylceramide (GC) were in 4L;C* brains.  Visceral tissues had increases of GS and GC, but no storage cells were found.  Neuronal cells in thick hippocampal slices from 4L;C* mice had significantly attenuated long-term potentiation, presumably resulting from substrate accumulation.  The 4L;C* mouse mimics the CNS phenotype and biochem. of some type 3 (neuronopathic) variants of Gaucher disease and is a unique model suitable for testing pharmacol. chaperone and substrate redn. therapies, and investigating the mechanisms of neuronopathic Gaucher disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKDrO8Mgd_jLVg90H21EOLACvtfcHk0lgl06RWO-RW1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivV2jtL0%253D&md5=6ebf539139467d32fd6d970c96cad73e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddp580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddp580%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLiou%26aufirst%3DB.%26aulast%3DRan%26aufirst%3DH.%26aulast%3DSkelton%26aufirst%3DM.%2BR.%26aulast%3DWilliams%26aufirst%3DM.%2BT.%26aulast%3DVorhees%26aufirst%3DC.%2BV.%26aulast%3DKitatani%26aufirst%3DK.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26aulast%3DXu%26aufirst%3DY.-H.%26aulast%3DGrabowski%26aufirst%3DG.%2BA.%26atitle%3DNeuronopathic%2520Gaucher%2520disease%2520in%2520the%2520mouse%253A%2520viable%2520combined%2520selective%2520saposin%2520C%2520deficiency%2520and%2520mutant%2520glucocerebrosidase%2520%2528V394L%2529%2520mice%2520with%2520glucosylsphingosine%2520and%2520glucosylceramide%2520accumulation%2520and%2520progressive%2520neurological%2520deficits%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2010%26volume%3D19%26spage%3D1088%26epage%3D1097%26doi%3D10.1093%2Fhmg%2Fddp580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Samantha Caputo, Simona Di Martino, Vincenzo Cilibrasi, Piero Tardia, Marco Mazzonna, Debora Russo, Ilaria Penna, Maria Summa, Sine Mandrup Bertozzi, Natalia Realini, Natasha Margaroli, Marco Migliore, Giuliana Ottonello, Min Liu, Peter Lansbury, Andrea Armirotti, Rosalia Bertorelli, Soumya S. Ray, Renato Skerlj, <span class="NLM_string-name hlFld-ContribAuthor">Rita Scarpelli</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15821-15851. <a href="https://doi.org/10.1021/acs.jmedchem.0c01561" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01561%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252Ba%252BSeries%252Bof%252BOxazolone%252BCarboxamides%252Bas%252Ba%252BNovel%252BClass%252Bof%252BAcid%252BCeramidase%252BInhibitors%26aulast%3DCaputo%26aufirst%3DSamantha%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07092020%26date%3D08122020%26volume%3D63%26issue%3D24%26spage%3D15821%26epage%3D15851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mookda Pattarawarapan, Dolnapa Yamano, Nittaya Wiriya, Saranphong Yimklan, <span class="NLM_string-name hlFld-ContribAuthor">Wong Phakhodee</span>. </span><span class="cited-content_cbyCitation_article-title">Simultaneous Formation and Functionalization of Aryliminophosphoranes Using 1,3-Dihydro-1H-benzimidazol-2-ones as Precursors. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (20)
                                     , 13330-13338. <a href="https://doi.org/10.1021/acs.joc.0c01979" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01979</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01979%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSimultaneous%252BFormation%252Band%252BFunctionalization%252Bof%252BAryliminophosphoranes%252BUsing%252B1%25252C3-Dihydro-1H-benzimidazol-2-ones%252Bas%252BPrecursors%26aulast%3DPattarawarapan%26aufirst%3DMookda%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17082020%26date%3D02102020%26volume%3D85%26issue%3D20%26spage%3D13330%26epage%3D13338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Allison M.  Bradbury</span>, <span class="hlFld-ContribAuthor ">Ernesto R.  Bongarzone</span>, <span class="hlFld-ContribAuthor ">Mark S.  Sands</span>. </span><span class="cited-content_cbyCitation_article-title">Krabbe disease: New hope for an old disease. </span><span class="cited-content_cbyCitation_journal-name">Neuroscience Letters</span><span> <strong>2021,</strong> <em>752 </em>, 135841. <a href="https://doi.org/10.1016/j.neulet.2021.135841" title="DOI URL">https://doi.org/10.1016/j.neulet.2021.135841</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neulet.2021.135841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neulet.2021.135841%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuroscience%2520Letters%26atitle%3DKrabbe%252Bdisease%25253A%252BNew%252Bhope%252Bfor%252Ban%252Bold%252Bdisease%26aulast%3DBradbury%26aufirst%3DAllison%2BM.%26date%3D2021%26volume%3D752%26spage%3D135841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0028.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Some potential applications of AC inhibition therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0027.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of representative known AC inhibitors (<b>1</b>–<b>4</b>) (top) and general structure of the benzoxazolone carboxamide series <b>5</b> explored in this study (bottom).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0020.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>8a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CDI, MeCN, rt, 2 h; (b) 4-phenylbutyl isocyanate, DMAP, toluene/DMF, rt, 2 h (20–60% over two steps for <b>8a</b> and <b>8b</b>); 4-phenylbutyl isocyanate, Et<sub>3</sub>N, MeCN, rt, 2 h (20–26% for <b>8c</b> and <b>8d</b>).</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0019.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of fused bicyclic piperidine-oxazolone derivatives <b>12a</b>–<b>e</b>, <b>17a</b>, and <b>17b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: for the synthesis of <b>12a</b>–<b>e</b>: (a) TZD, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 2 h (85%); (b) <i>t</i>BuOK, THF, rt, 30 min (60%); (c) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 16 h (68%); (d) 4 M HCl, dioxane, rt, 1 h (60%); (e) HCHO (for <b>12c</b>) or PhCHO (for <b>12d</b>), NaBH(OAc)<sub>3</sub>, AcOH, MeCN, rt, 3 h (56–90%); (f) AcCl, Et<sub>3</sub>N, DCM, rt, 3 h (62%). For the synthesis of <b>17a</b> and <b>17b</b>: (a) TZD, Mg(ClO<sub>4</sub>)<sub>2</sub>, DMF, 115 °C, 5 h (50%); (b) Dess–Martin reagent, DCM, 0 °C to rt, 12 h (70%); (c) <i>t</i>BuOK, THF, rt, 30 min; (d) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 30 min (25% over two steps); (e) 4 M HCl, dioxane, rt, 1 h (60%).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0018.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of C(6)-substituted benzoxazolone carboxamides <b>22a</b>–<b>d</b> and <b>22i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-bromo-2-nitrophenol (for <b>19a</b>–<b>c</b>), 5-bromo-4-fluoro-2-nitrophenol (for <b>19d</b>), Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, dioxane, reflux, 18 h (56–90%); (b) H-Cube, Pd/C, EtOAc, rt, 1–2 h; (c) CDI, MeCN, 60 °C, 2 h (60–84% over two steps); (d) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 16 h (50–98%); (e) 4 M HCl, dioxane, rt, 3 h (86%); (f) AcCl, Et<sub>3</sub>N, THF, rt, 4 h (90%).</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0017.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of C(6)-substituted benzoxazolone carboxamides <b>22e</b>–<b>h</b> and <b>22j</b>–<b>p</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4 M HCl, dioxane, rt, 3 h; (b) RCHO, AcOH, NaBH(OAc)<sub>3</sub>, DCE, THF or MeCN, rt, 1–3 h (40% over two steps for <b>21i</b>, quant. For <b>21h</b>); (c) RNCO, DMAP, MeCN, rt, 2–16 h (50–73% for <b>22e</b>–<b>h</b>, <b>22k</b>, and <b>22p</b>); or RNH<sub>2</sub>, triphosgene, Et<sub>3</sub>N, DCM, 0 °C to rt, 2 h (45% for <b>22m</b>), or RNH<sub>2</sub>, Boc<sub>2</sub>O, DMAP, MeCN, rt, 1 h (24–40% for <b>22j</b>, <b>22l</b>, <b>22n</b>, and <b>22o</b>).</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0016.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>22q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>,<i>N</i>-bis(trifluoromethanesulfonyl)aniline, Et<sub>3</sub>N, THF, 0 °C, 16 h (74%); (b) Pd(dppf)Cl<sub>2</sub>, [B<sub>2</sub>(pin)<sub>2</sub>], KOAc, dioxane, 70 °C, 3 h; (c) 2-(benzyloxy)-4-bromo-1-nitrobenzene, Na<sub>2</sub>CO<sub>3</sub> 2 M, 70 °C, 1 h (93% over two steps) (d) NaH, MeI, THF, 0 °C, 20 h (45%); (e) H<sub>2</sub>, 10% Pd/C, EtOH, rt, 1 h; (f) CDI, MeCN, rt, 1 h (70% over two steps); (g) 4-phenylbutyl isocyanate, DMAP, pyridine, rt, 16 h (90%).</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>24c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-bromo-2-nitrophenol, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 2 M Na<sub>2</sub>CO<sub>3</sub>, dioxane, reflux, 2 h (95%); (b) 10% Pd/C, cyclohexene, MeOH, reflux, 4 h; (c) CDI, MeCN, rt, 3 h (60% over two steps); (d) isobutylamine, triphosgene, Et<sub>3</sub>N, DCM (70%); (e) 4 M HCl, dioxane (95%); (f) HCHO, NaBH(OAc)<sub>3</sub>, AcOH, MeCN, rt, 2 h (83%).</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0014.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of <b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-benzyloxy-4-bromo-1-nitrobenzene, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane, reflux, 16 h (40%); (b) cyclohexene, Pd/C, MeOH, 70 °C, 2 h; (c) CDI, MeCN, rt, 16 h; (d) HCHO, NaBH(OAc)<sub>3</sub>, AcOH, MeCN, rt, 2 h (43% over three steps); (e) isobutylamine, triphosgene, Et<sub>3</sub>N, DCM, rt, 4 h (30%).</p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0013.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-bromo-2-nitrophenol, Pd(dppf)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, dioxane, reflux, 2 h (53%); (b) 10% Pd/C, cyclohexene, EtOH, 65 °C, 4 h; (c) CDI, MeCN, rt, 1 h (90% over two steps) (d) 4 M HCl, dioxane, rt, 30 min; (e) HCHO, NaBH(OAc)<sub>3</sub>, AcOH, MeCN, rt, 30 min (70% over two steps); (f) isobutylamine, triphosgene, Et<sub>3</sub>N, DCM, rt, 3 h (70%).</p></p></figure><figure data-id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0012.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of <b>22r</b> and <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: for the synthesis of <b>22r</b>: (a) 6-bromo-3<i>H</i>-1,3-benzoxazol-2-one, MeMgBr, <i>n</i>-BuLi, THF, −78 °C, 2 h (30%); (b) <i>p</i>-TsOH, toluene, reflux, 1 h (quant.); (c) H<sub>2</sub>, 10% Pd/C, MeOH, 60 °C, 2 h; (d) 4-phenylbutyl isocyanate, DMAP, pyridine (73% over two steps). For the synthesis of <b>25</b>: (a) 7-bromo-3<i>H</i>-1,3-benzoxazol-2-one, MeMgBr, <i>n</i>-BuLi, THF, −78 °C 1.5 h (44%); (b) <i>p</i>-TsOH, toluene, 90 °C, 3 h (quant.); (c) HCHO, NaBH(OAc)<sub>3</sub>, MeCN, rt, 16 h; (d) H<sub>2</sub>, Pd/C, MeOH, 40 °C, 2 h; (e) isobutylamine, triphosgene, Et<sub>3</sub>N, DCM (30% over three steps).</p></p></figure><figure data-id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0011.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of C(6)-substituted benzoxazolone carboxamides <b>23a</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 5-fluoro-2-nitrophenol, DIPEA, MeCN, 60–80 °C, 15 h (40% for <b>49c</b>); (b) 10% Pd/C, cyclohexene, MeOH, reflux, 2–16 h; (c) CDI, MeCN, rt (or 50 °C for <b>49g</b>), 2 h (75–80% over three steps for <b>50a</b> and <b>50d</b>; 45–60% over two steps for <b>50b</b> and <b>50c</b>); (d) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 16 h (20–85%); (e) 4 M HCl, dioxane, rt, 3 h (quant.); (f) RCHO, AcOH, NaBH(OAc)<sub>3</sub>, DCE, THF or MeCN, rt, 2 h (60–90%); (g) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 16 h (30–75%).</p></p></figure><figure data-id="sch11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0010.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of <b>23j</b> and <b>23</b>k<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1-methylpiperazin-2-one (for <b>52a</b>), Et<sub>3</sub>N, MeCN, 80 °C, 16 h (60%); 4-methylpiperazin-2-one (for <b>52b</b>), CuI, K<sub>3</sub>PO<sub>4</sub>, <i>N</i>,<i>N</i>-dimethyl-1,2-ethanediamine, dioxane, reflux, 24 h (50%); (b) 10% Pd/C, cyclohexene, EtOH, 65 °C, 16 h; (c) CDI, MeCN, rt, 1 h (70–80% over two steps); (d) 4-phenylbutyl isocyanate, DMAP, MeCN, rt, 16 h (10–20%).</p></p></figure><figure data-id="fig3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0026.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibitory potencies (IC<sub>50</sub> in μM) of compounds <b>2d</b>–<b>g</b>, <b>8a</b>–<b>d</b>, <b>12b</b>–<b>e</b>, and <b>17b</b> on the activity of <i>h</i>AC expressed in HEK-293 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0025.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Concentration–response curve for inhibition of <i>h</i>AC activity by <b>22m</b>; (B) Michaelis–Menten analysis of the reaction of <i>h</i>AC in the presence of vehicle (DMSO 1%, ●) or <b>22m</b> (100 nM, ▲; 400 nM, ■). Rbm 14–12: fluorogenic substrate of <i>h</i>AC; (C) time-dependent inhibition of <i>h</i>AC by <b>22m</b> (two independent experiments, each performed in two technical replicates); (D) determination of kinetic parameter <i>k</i><sub>i</sub>/<i>K</i><sub>I</sub> of <b>22m</b> (two independent experiments, each performed in two technical replicates).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0024.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of <b>22m</b> in SH-SY5Y cells after a 3 h of incubation. Concentration dependence of the effects on AC activity (A) and sphingolipid levels (B–F). GraphPad Prism software (GraphPad Software, Inc., USA) was used for statistical analysis. Data were analyzed using the Student <i>t</i> test or one-way ANOVA followed by the Bonferroni post hoc test for multiple comparisons. Differences between groups were considered statistically significant at values of <i>p</i> < 0.05. Values are expressed as means ± S.E.M of at least six determinations. Experiments were repeated twice with similar results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0023.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Time course of the effects of <b>22m</b> (10 μM) in SH-SY5Y cells on AC activity (A) and sphingolipid levels (B–F). GraphPad Prism software (GraphPad Software, Inc., USA) was used for statistical analysis. Data were analyzed using the Student <i>t</i> test or one-way ANOVA followed by the Bonferroni post hoc test for multiple comparisons. Differences between groups were considered statistically significant at values of <i>p</i> < 0.05. Values are expressed as means ± S.E.M of at least six determinations. Experiments were repeated twice with similar results.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0022.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose response reduction of brain levels of GluSph (d18:1) after intraperitoneal injection of <b>22m</b> at 30 and 90 mg kg<sup>–1</sup> in 4L;C* mice (<i>N</i> = 4–8 with mixed males and females for each group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/medium/jm9b02004_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0021.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dose response reduction of brain levels of GalSph (d18:1) after intraperitoneal injection of <b>22m</b> at 30 and 90 mg kg<sup>–1</sup> in Twitcher (Twi) mice (<i>N</i> = 3 males + <i>N</i> = 3 females for each group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-7/acs.jmedchem.9b02004/20210220/images/large/jm9b02004_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02004&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i200">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76173" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76173" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 58 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gault, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">An overview of sphingolipid metabolism: from synthesis to breakdown</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>688</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1007/978-1-4419-6741-1_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1007%2F978-1-4419-6741-1_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=20919643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=688&publication_year=2010&pages=1-23&author=C.+R.+Gaultauthor=L.+M.+Obeidauthor=Y.+A.+Hannun&title=An+overview+of+sphingolipid+metabolism%3A+from+synthesis+to+breakdown&doi=10.1007%2F978-1-4419-6741-1_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of sphingolipid metabolism: from synthesis to breakdown</span></div><div class="casAuthors">Gault, Christopher R.; Obeid, Lina M.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">688</span>
        (<span class="NLM_cas:issue">Sphingolipids as Signaling and Regulatory Molecules</span>),
    <span class="NLM_cas:pages">1-23</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Sphingolipids constitute a class of lipids defined by their eighteen carbon amino-alc. backbones which are synthesized in the ER from nonsphingolipid precursors.  Modification of this basic structure is what gives rise to the vast family of sphingolipids that play significant roles in membrane biol. and provide many bioactive metabolites that regulate cell function.  Despite the diversity of structure and function of sphingolipids, their creation and destruction are governed by common synthetic and catabolic pathways.  In this regard, sphingolipid metab. can be imagined as an array of interconnected networks that diverge from a single common entry point and converge into a single common breakdown pathway.  In their simplest forms, sphingosine, phytosphingosine and dihydrosphingosine serve as the backbones upon which further complexity is achieved.  For example, phosphorylation of the C1 hydroxyl group yields the final breakdown products and/or the important signaling mols. sphingosine-1-phosphate, phytosphingosine-1-phosphate and dihydrosphingosine-1-phosphate, resp.  On the other hand, acylation of sphingosine, phytosphingosine, or dihydrosphingosine with one of several possible acyl CoA mols. through the action of distinct ceramide synthases produces the mols. defined as ceramide, phytoceramide, or dihydroceramide.  Ceramide, due to the differing acyl CoAs that can be used to produce it, is tech. a class of mols. rather than a single mol. and therefore may have different biol. functions depending on the acyl chain it is composed of.  At the apex of complexity is the group of lipids known as glycosphingolipids (GSL) which contain dozens of different sphingolipid species differing by both the order and type of sugar residues attached to their headgroups.  Since these mols. are produced from ceramide precursors, they too may have differences in their acyl chain compn., revealing an addnl. layer of variation.  The glycosphingolipids are divided broadly into two categories: glucosphingolipids and galactosphingolipids.  The glucosphingolipids depend initially on the enzyme glucosylceramide synthase (GCS) which attaches glucose as the first residue to the C1 hydroxyl position.  Galactosphingolipids, on the other hand, are generated from galactosylceramide synthase (GalCerS), an evolutionarily dissimilar enzyme from GCS.  Glycosphingolipids are further divided based upon further modification by various glycosyltransferases which increases the potential variation in lipid species by several fold.  Far more abundant are the sphingomyelin species which are produced in parallel with glycosphingolipids, however they are defined by a phosphocholine headgroup rather than the addn. of sugar residues.  Although sphingomyelin species all share a common headgroup, they too are produced from a variety of ceramide species and therefore can have differing acyl chains attached to their C-2 amino groups.  Whether or not the differing acyl chain lengths in SMs dictate unique functions or important biophys. distinctions has not yet been established.  Understanding the function of all the existing glycosphingolipids and sphingomyelin species will be a major undertaking in the future since the tools to study and measure these species are only beginning to be developed (see Fig 1 for an illustrated depiction of the various sphingolipid structures).  The simple sphingolipids serve both as the precursors and the breakdown products of the more complex ones.  Importantly, in recent decades, these simple sphingolipids have gained attention for having significant signaling and regulatory roles within cells.  In addn., many tools have emerged to measure the levels of simple sphingolipids and therefore have become the focus of even more intense study in recent years.  With this thought in mind, this chapter will pay tribute to the complex sphingolipids, but focus on the regulation of simple sphingolipid metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-glJUw4HtHrVg90H21EOLACvtfcHk0lj_ine_xr5vqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFGhtg%253D%253D&md5=512ae1d4d9d2f9f2f231e0e189a2b3a0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-1-4419-6741-1_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4419-6741-1_1%26sid%3Dliteratum%253Aachs%26aulast%3DGault%26aufirst%3DC.%2BR.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DAn%2520overview%2520of%2520sphingolipid%2520metabolism%253A%2520from%2520synthesis%2520to%2520breakdown%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2010%26volume%3D688%26spage%3D1%26epage%3D23%26doi%3D10.1007%2F978-1-4419-6741-1_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and their metabolism in physiology and disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fnrm.2017.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=29165427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKqt7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=175-191&author=Y.+A.+Hannunauthor=L.+M.+Obeid&title=Sphingolipids+and+their+metabolism+in+physiology+and+disease&doi=10.1038%2Fnrm.2017.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and their metabolism in physiology and disease</span></div><div class="casAuthors">Hannun, Yusuf A.; Obeid, Lina M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">175-191</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Studies of bioactive lipids in general and sphingolipids in particular have intensified over the past several years, revealing an unprecedented and unanticipated complexity of the lipidome and its many functions, which rivals, if not exceeds, that of the genome or proteome.  These results highlight crit. roles for bioactive sphingolipids in most, if not all, major cell biol. responses, including all major cell signalling pathways, and they link sphingolipid metab. to key human diseases.  Nevertheless, the fairly nascent field of bioactive sphingolipids still faces challenges in its biochem. and mol. underpinnings, including defining the mol. mechanisms of pathway and enzyme regulation, the study of lipid-protein interactions and the development of cellular probes, suitable biomarkers and therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl9A-uh9uFPrVg90H21EOLACvtfcHk0li9prBxHX-T5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKqt7fE&md5=81409d71ab1c29c9dea5f060105032be</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.107%26sid%3Dliteratum%253Aachs%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26atitle%3DSphingolipids%2520and%2520their%2520metabolism%2520in%2520physiology%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2018%26volume%3D19%26spage%3D175%26epage%3D191%26doi%3D10.1038%2Fnrm.2017.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, B.</span>; <span class="NLM_string-name">Johnson, A.</span>; <span class="NLM_string-name">Lewis, J.</span>; <span class="NLM_string-name">Raff, M.</span>; <span class="NLM_string-name">Roberts, K.</span>; <span class="NLM_string-name">Walter, P.</span></span> In  <i>Molecular Biology of the Cell</i>; <span class="NLM_edition">5</span>th ed. th ed.; <span class="NLM_publisher-name">Garland Science</span>: <span class="NLM_publisher-loc">New York, USA, Ed</span>. <span class="NLM_year">2008</span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">787</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=779-787&author=B.+Alberts&author=A.+Johnson&author=J.+Lewis&author=M.+Raff&author=K.+Roberts&author=P.+Walter&title=Molecular+Biology+of+the+Cell"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAlberts%26aufirst%3DB.%26btitle%3DMolecular%2520Biology%2520of%2520the%2520Cell%26pub%3DGarland%2520Science%26date%3D2008%26spage%3D779%26epage%3D787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saftig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumperman, J.</span></span> <span> </span><span class="NLM_article-title">Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1038/nrm2745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fnrm2745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=19672277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsleqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=623-635&author=P.+Saftigauthor=J.+Klumperman&title=Lysosome+biogenesis+and+lysosomal+membrane+proteins%3A+trafficking+meets+function&doi=10.1038%2Fnrm2745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function</span></div><div class="casAuthors">Saftig, Paul; Klumperman, Judith</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">623-635</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lysosomes are the primary catabolic compartments of eukaryotic cells.  They degrade extracellular material that has been internalized by endocytosis and intracellular components that have been sequestered by autophagy.  In addn., specialized cells contain lysosome-related organelles that store and secrete proteins for cell-type-specific functions.  The functioning of a healthy cell is dependent on the proper targeting of newly synthesized lysosomal proteins.  Accumulating evidence suggests that there are multiple lysosomal delivery pathways that together allow the regulated and sequential deposition of lysosomal components.  The importance of lysosomal trafficking pathways is emphasized by recent findings that reveal new roles for lysosomal membrane proteins in cellular physiol. and in an increasing no. of diseases that are characterized by defects in lysosome biogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpby5TZ_C2_I7Vg90H21EOLACvtfcHk0li1jDwCOaiL3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsleqsrc%253D&md5=e45f191f35eba89f8936a7a9a9f76cdf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrm2745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2745%26sid%3Dliteratum%253Aachs%26aulast%3DSaftig%26aufirst%3DP.%26aulast%3DKlumperman%26aufirst%3DJ.%26atitle%3DLysosome%2520biogenesis%2520and%2520lysosomal%2520membrane%2520proteins%253A%2520trafficking%2520meets%2520function%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2009%26volume%3D10%26spage%3D623%26epage%3D635%26doi%3D10.1038%2Fnrm2745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnick, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlinz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhoff, K.</span></span> <span> </span><span class="NLM_article-title">Purification, characterization, and biosynthesis of human acid ceramidase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">11098</span>– <span class="NLM_lpage">11102</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.19.11098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1074%2Fjbc.270.19.11098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=7744740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK2MXls1ejtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=11098-11102&author=K.+Bernardoauthor=R.+Hurwitzauthor=T.+Zenkauthor=R.+J.+Desnickauthor=K.+Ferlinzauthor=E.+H.+Schuchmanauthor=K.+Sandhoff&title=Purification%2C+characterization%2C+and+biosynthesis+of+human+acid+ceramidase&doi=10.1074%2Fjbc.270.19.11098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Purification, characterization, and biosynthesis of human acid ceramidase</span></div><div class="casAuthors">Bernardo, Katussevani; Hurwitz, Robert; Zenk, Thomas; Desnick, Robert J.; Ferlinz, Klaus; Schuchman, Edward H.; Sandhoff, Konrad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11098-102</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23) (I) is the lysosomal enzyme catalyzing the hydrolysis of ceramide to sphingosine and free fatty acid.  Its inherited deficiency causes ceramide accumulation in inherited deficiency causes ceramide accumulation in Faber's disease.  I was purified to apparent homogeneity from human urine by sequential chromatog. on octyl-Sepharose, Con A-Sepharose, Blue-Sepharose, and DEAE-cellulose.  The final prepn., which was enriched ∼4450-fold over the starting material, resulted in a polypeptide of ∼50 kDa and could be reduced into 2 subunits of ∼13 (α) and ∼40 (β) kDa.  Treatment of purified I with endoglycosidase H or peptide N-glycanase F reduced the mol. wt. of the β subunit to ∼30-35 and ∼27 kDa, resp.  In contrast, the mol. wt. of the α subunit was unchanged.  Purified I had an apparent Km of 149 μM and a Vmax of 136 nmol/mg/h using N-lauroylsphingosine as substrate.  Polyclonal antibodies were raised against the purified urinary enzyme and used to investigate the biosynthesis of I.  Immunopptn. studies on metabolically labeled skin fibroblasts indicated that both subunits arise from a single precursor of ∼55 kDa.  A minor protein of newly synthesized I was secreted into the medium as a monomeric 47-kDa protein, indicating that generation of the mature heterodimeric enzyme occurs in endosomal and/or lysosomal compartments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm-1pFxhqHCLVg90H21EOLACvtfcHk0li1jDwCOaiL3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls1ejtb4%253D&md5=d8f667c773db8a01ca5d22e49dd36123</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.19.11098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.19.11098%26sid%3Dliteratum%253Aachs%26aulast%3DBernardo%26aufirst%3DK.%26aulast%3DHurwitz%26aufirst%3DR.%26aulast%3DZenk%26aufirst%3DT.%26aulast%3DDesnick%26aufirst%3DR.%2BJ.%26aulast%3DFerlinz%26aufirst%3DK.%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26aulast%3DSandhoff%26aufirst%3DK.%26atitle%3DPurification%252C%2520characterization%252C%2520and%2520biosynthesis%2520of%2520human%2520acid%2520ceramidase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D11098%26epage%3D11102%26doi%3D10.1074%2Fjbc.270.19.11098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obeid, L. M.</span></span> <span> </span><span class="NLM_article-title">Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1781</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2008.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.bbalip.2008.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=18619555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1781&publication_year=2008&pages=424-434&author=C.+Maoauthor=L.+M.+Obeid&title=Ceramidases%3A+regulators+of+cellular+responses+mediated+by+ceramide%2C+sphingosine%2C+and+sphingosine-1-phosphate&doi=10.1016%2Fj.bbalip.2008.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate</span></div><div class="casAuthors">Mao, Cungui; Obeid, Lina M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1781</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">424-434</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Ceramidases catalyze hydrolysis of ceramides to generate sphingosine (SPH), which is phosphorylated to form sphingosine-1-phosphate (S1P).  Ceramide, SPH, and S1P are bioactive lipids that mediate cell proliferation, differentiation, apoptosis, adhesion, and migration.  Presently, 5 human ceramidases encoded by 5 distinct genes have been cloned: acid ceramidase (AC), neutral ceramidase (NC), alk. ceramidase 1 (ACER1), alk. ceramidase 2 (ACER2), and alk. ceramidase 3 (ACER3).  Each human ceramidase has a mouse counterpart.  AC, NC, and ACER1-3 have maximal activities in acidic, neutral, and alk. environments, resp.  ACER1-3 have similar protein sequences but no homol. to AC and NC.  AC and NC also have distinct protein sequences.  The human AC (hAC) was implicated in Farber disease, and hAC may be important for cell survival.  The mouse AC (mAC) is needed for early embryo survival.  NC is protective against inflammatory cytokines, and the mouse NC (mNC) is required for the catabolism of ceramides in the digestive tract.  ACER1 is crit. in mediating cell differentiation by controlling the generation of SPH and S1P and that ACER2's role in cell proliferation and survival depends on its expression or the cell type in which it is found.  Here, we discuss the role of each ceramidase in regulating cellular responses mediated by ceramides, SPH, and S1P.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEgvBkM7CJsLVg90H21EOLACvtfcHk0ljYHD1IgkdmFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrM&md5=0ff10423032645e5c8a9baa1c442b85d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2008.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2008.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DC.%26aulast%3DObeid%26aufirst%3DL.%2BM.%26atitle%3DCeramidases%253A%2520regulators%2520of%2520cellular%2520responses%2520mediated%2520by%2520ceramide%252C%2520sphingosine%252C%2520and%2520sphingosine-1-phosphate%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2008%26volume%3D1781%26spage%3D424%26epage%3D434%26doi%3D10.1016%2Fj.bbalip.2008.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coant, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Ceramidases, roles in sphingolipid metabolism and in health and disease</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2016.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.jbior.2016.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=27771292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2017&pages=122-131&author=N.+Coantauthor=W.+Sakamotoauthor=C.+Maoauthor=Y.+A.+Hannun&title=Ceramidases%2C+roles+in+sphingolipid+metabolism+and+in+health+and+disease&doi=10.1016%2Fj.jbior.2016.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramidases, roles in sphingolipid metabolism and in health and disease</span></div><div class="casAuthors">Coant, Nicolas; Sakamoto, Wataru; Mao, Cungui; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122-131</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over the past three decades, extensive research has been able to det. the biol. functions for the main bioactive sphingolipids, namely ceramide, sphingosine, and sphingosine 1-phosphate (S1P) (Hannun, 1996; Hannun et al., 1986; Okazaki et al., 1989).  These studies have managed to define the metab., regulation, and function of these bioactive sphingolipids.  This emerging body of literature has also implicated bioactive sphingolipids, particularly S1P and ceramide, as key regulators of cellular homeostasis.  Ceramidases have the important role of cleaving fatty acid from ceramide and producing sphingosine, thereby controlling the interconversion of these two lipids.  Thus far, five human ceramidases encoded by five different genes have been identified: acid ceramidase (AC), neutral ceramidase (NC), alk. ceramidase 1 (ACER1), alk. ceramidase 2 (ACER2), and alk. ceramidase 3 (ACER3).  These ceramidases are classified according to their optimal pH for catalytic activity.  AC, which is localized to the lysosomal compartment, has been assocd. with Farber's disease and is involved in the regulation of cell viability.  Neutral ceramidase, which is localized to the plasma membrane and primarily expressed in the small intestine and colon, is involved in digestion, and has been implicated in colon carcinogenesis.  ACER1 which can be found in the endoplasmic reticulum and is highly expressed in the skin, plays an important role in keratinocyte differentiation.  ACER2, localized to the Golgi complex and highly expressed in the placenta, is involved in programed cell death in response to DNA damage.  ACER3, also localized to the endoplasmic reticulum and the Golgi complex, is ubiquitously expressed, and is involved in motor coordination-assocd. Purkinje cell degeneration.  This review seeks to consolidate the current knowledge regarding these key cellular players.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowWeoXuPUgXrVg90H21EOLACvtfcHk0ljYHD1IgkdmFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSqsbvK&md5=84e937e947b7a38256761a6ab60a7353</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2016.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2016.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCoant%26aufirst%3DN.%26aulast%3DSakamoto%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramidases%252C%2520roles%2520in%2520sphingolipid%2520metabolism%2520and%2520in%2520health%2520and%2520disease%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2017%26volume%3D63%26spage%3D122%26epage%3D131%26doi%3D10.1016%2Fj.jbior.2016.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Functions of ceramide in coordinating cellular responses to stress</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1859</span>, <span class="refDoi"> DOI: 10.1126/science.274.5294.1855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1126%2Fscience.274.5294.1855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=8943189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK28XnsFGisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1996&pages=1855-1859&author=Y.+A.+Hannun&title=Functions+of+ceramide+in+coordinating+cellular+responses+to+stress&doi=10.1126%2Fscience.274.5294.1855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Functions of ceramide in coordinating cellular responses to stress</span></div><div class="casAuthors">Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">5294</span>),
    <span class="NLM_cas:pages">1855-1859</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review with 56 refs.  Sphingolipid metabolites participate in key events of signal transduction and cell regulation.  In the sphingomyelin cycle, a no. of extracellular agents and insults (such at tumor necrosis factor, Fas ligands, and chemotherapeutic agents) cause the activation of sphingomyelinases, which act on membrane sphingomyelin and release ceramide.  Multiple exptl. approaches suggest an important role for ceramide in regulating such diverse responses as cell cycle arrest, apoptosis, and cell senescence.  In vitro, ceramide activates a serine-threonine protein phosphatase, and in cells it regulates protein phosphorylation as well as multiple downstream targets [such as interleukin converting enzyme (ICE)-like proteases, stress-activated protein kinases, and the retinoblastoma gene product] that mediate its distinct cellular effects.  This spectrum of inducers of ceramide accumulation and the nature of ceramide-mediated responses suggest that ceramide is a key component of intracellular stress response pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSGWmlfW0IZLVg90H21EOLACvtfcHk0lh9vLdNgN8orQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XnsFGisrc%253D&md5=1eddfb8251d80b89adaf48668f375e34</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.274.5294.1855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.274.5294.1855%26sid%3Dliteratum%253Aachs%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DFunctions%2520of%2520ceramide%2520in%2520coordinating%2520cellular%2520responses%2520to%2520stress%26jtitle%3DScience%26date%3D1996%26volume%3D274%26spage%3D1855%26epage%3D1859%26doi%3D10.1126%2Fscience.274.5294.1855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballou, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laulederkind, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosloniec, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghow, R.</span></span> <span> </span><span class="NLM_article-title">Ceramide signalling and the immune response</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1301</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1016/0005-2760(96)00004-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2F0005-2760%2896%2900004-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=8664339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK28XivFKrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1301&publication_year=1996&pages=273-287&author=L.+R.+Ballouauthor=S.+J.+F.+Laulederkindauthor=E.+F.+Rosloniecauthor=R.+Raghow&title=Ceramide+signalling+and+the+immune+response&doi=10.1016%2F0005-2760%2896%2900004-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramide signaling and the immune response</span></div><div class="casAuthors">Ballou, Leslie R.; Laulederkind, Stanley J. F.; Rosloniec, Edward F.; Raghow, Rajendra</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Lipids and Lipid Metabolism</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">1301</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-287</span>CODEN:
                <span class="NLM_cas:coden">BBLLA6</span>;
        ISSN:<span class="NLM_cas:issn">0005-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 134 refs.  Discussed are: ceramide and immunomodulation; components of the sphingomyelin pathway; the biol. effects of ceramide; and downstream ceramide signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobIqdyjYsr37Vg90H21EOLACvtfcHk0lh9vLdNgN8orQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivFKrurs%253D&md5=ecf2bceea52fdbfd465ba64472e2014e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0005-2760%2896%2900004-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2760%252896%252900004-5%26sid%3Dliteratum%253Aachs%26aulast%3DBallou%26aufirst%3DL.%2BR.%26aulast%3DLaulederkind%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DRosloniec%26aufirst%3DE.%2BF.%26aulast%3DRaghow%26aufirst%3DR.%26atitle%3DCeramide%2520signalling%2520and%2520the%2520immune%2520response%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1996%26volume%3D1301%26spage%3D273%26epage%3D287%26doi%3D10.1016%2F0005-2760%2896%2900004-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruvolo, P. P.</span></span> <span> </span><span class="NLM_article-title">Intracellular signal transduction pathways activated by ceramide and its metabolites</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1016/S1043-6618(03)00050-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2FS1043-6618%2803%2900050-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=12676512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFWlsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=383-392&author=P.+P.+Ruvolo&title=Intracellular+signal+transduction+pathways+activated+by+ceramide+and+its+metabolites&doi=10.1016%2FS1043-6618%2803%2900050-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular signal transduction pathways activated by ceramide and its metabolites</span></div><div class="casAuthors">Ruvolo, Peter P.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">383-392</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The sphingolipid ceramide has proven to be a powerful second-signal effector mol. that regulates diverse cellular processes including apoptosis, cell senescence, the cell cycle, and cellular differentiation.  Ceramide has been shown to activate a no. of enzymes involved in stress signaling cascades including both protein kinases and protein phosphatases.  Ceramide kinase targets include stress-activated protein kinases (SAPKs) such as the jun kinases (JNKs), kinase suppressor of Ras (KSR), and the atypical protein kinase C (PKC) isoform, PKC ζ.  Ceramide also is capable of activating protein phosphatases such as protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A).  It is through these protein phosphatases that ceramide can indirectly inhibit kinases that are key components of pro-growth signaling processes such as the classical and novel PKC isoforms and protein kinase B (PKB; also known as Akt).  However, the mechanisms how ceramide directly activates enzymes such as JNK and PP2A are still not clear.  Elucidation of these mechanisms will reveal how ceramide functions in stress signaling cascades and will provide important information on cellular processes such as apoptosis.  It is becoming clear that the ceramide generation is a near universal feature of programmed cell death.  It is possible that during at least some apoptotic events, ceramide may be required to activate stress-signal cascades that lead to cell death, while concurrently, suppressing growth and survival pathways in the dying cell.  Such a versatile role for ceramide is not unreasonable since ceramide has been implicated as having a role in both intrinsic (i.e. mitochondrial) and extrinsic (i.e. death receptor-mediated) apoptotic pathways.  The recent data suggesting that aberrant glycosylation of ceramide (i.e. inactivation of the mol.) may be an important cause of drug resistance in certain cancers suggests that ceramide-mediated signaling cascades are crit. components of chemotherapy-induced cell killing.  Taken together, these properties of ceramide suggest that this important second-signal mol. may be an important target in anti-neoplastic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoscSCFhDZyR7Vg90H21EOLACvtfcHk0lh9vLdNgN8orQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFWlsLc%253D&md5=9dd4127e61cf59ce58ea88acf77b4b0f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS1043-6618%2803%2900050-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1043-6618%252803%252900050-1%26sid%3Dliteratum%253Aachs%26aulast%3DRuvolo%26aufirst%3DP.%2BP.%26atitle%3DIntracellular%2520signal%2520transduction%2520pathways%2520activated%2520by%2520ceramide%2520and%2520its%2520metabolites%26jtitle%3DPharmacol.%2520Res.%26date%3D2003%26volume%3D47%26spage%3D383%26epage%3D392%26doi%3D10.1016%2FS1043-6618%2803%2900050-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Withers, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, R. C.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and lifespan regulation</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1841</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2013.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.bbalip.2013.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGqs7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1841&publication_year=2014&pages=657-664&author=X.+Huangauthor=B.+R.+Withersauthor=R.+C.+Dickson&title=Sphingolipids+and+lifespan+regulation&doi=10.1016%2Fj.bbalip.2013.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and lifespan regulation</span></div><div class="casAuthors">Huang, Xinhe; Withers, Bradley R.; Dickson, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1841</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-664</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Diseases including cancer, type 2 diabetes, cardiovascular and immune dysfunction and neurodegeneration become more prevalent as we age, and combined with the increase in av. human lifespan, place an ever increasing burden on the health care system.  In this chapter we focus on finding ways of modulating sphingolipids to prevent the development of age-assocd. diseases or delay their onset, both of which could improve health in elderly, fragile people.  Reducing the incidence of or delaying the onset of diseases of aging has blossomed in the past decade because of advances in understanding signal transduction pathways and cellular processes, esp. in model organisms, that are largely conserved in most eukaryotes and that can be modulated to reduce signs of aging and increase health span.  In model organisms such interventions must also increase lifespan to be considered significant, but this is not a requirement for use in humans.  The most encouraging interventions in model organisms involve lowering the concn. of one or more sphingolipids so as to reduce the activity of key signaling pathways, one of the most promising being the Target of Rapamycin Complex 1 (TORC1) protein kinase pathway.  Other potential ways in which modulating sphingolipids may contribute to improving the health profile of the elderly is by reducing oxidative stresses, inflammatory responses and growth factor signaling.  Lastly, perhaps the most interesting way to modulate sphingolipids and promote longevity is by lowering the activity of serine palmitoyltransferase, the first enzyme in the de novo sphingolipid biosynthesis pathway.  Available data in yeasts and rodents are encouraging and as we gain insights into mol. mechanisms the strategies for improving human health by modulating sphingolipids will become more apparent.  This article is part of a Special Issue entitled New Frontiers in Sphingolipid Biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-1RgynOoylLVg90H21EOLACvtfcHk0lijnTajfigKag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGqs7vN&md5=43c74eeb2e56fcd45233c75fde965851</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2013.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2013.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWithers%26aufirst%3DB.%2BR.%26aulast%3DDickson%26aufirst%3DR.%2BC.%26atitle%3DSphingolipids%2520and%2520lifespan%2520regulation%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2014%26volume%3D1841%26spage%3D657%26epage%3D664%26doi%3D10.1016%2Fj.bbalip.2013.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalfant, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span> <span> </span><span class="NLM_article-title">Ceramide in apoptosis: an overview and current perspectives</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1585</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/S1388-1981(02)00331-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2FS1388-1981%2802%2900331-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=12531544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVOqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1585&publication_year=2002&pages=114-125&author=B.+J.+Pettusauthor=C.+E.+Chalfantauthor=Y.+A.+Hannun&title=Ceramide+in+apoptosis%3A+an+overview+and+current+perspectives&doi=10.1016%2FS1388-1981%2802%2900331-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ceramide in apoptosis: an overview and current perspectives</span></div><div class="casAuthors">Pettus, Benjamin J.; Chalfant, Charles E.; Hannun, Yusuf A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1585</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">114-125</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recent years have witnessed significant advances in the understanding of the role of ceramide in apoptosis.  This review summarizes these recent findings and discusses insights from studies of ceramide metab., topol., and effector actions.  The recent identification of several genes for enzymes of ceramide metab., the development of mass spectrometric methods for ceramide anal., and the increasing mol. and pharmacol. tools to probe ceramide metab. and function promise an accelerated phase in defining the mol. and biochem. details of the role of ceramide in apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXIUeERO-epbVg90H21EOLACvtfcHk0lijnTajfigKag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVOqtg%253D%253D&md5=e1cc8bcdf206d5417e085bdd0d6f0096</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1388-1981%2802%2900331-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1388-1981%252802%252900331-1%26sid%3Dliteratum%253Aachs%26aulast%3DPettus%26aufirst%3DB.%2BJ.%26aulast%3DChalfant%26aufirst%3DC.%2BE.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26atitle%3DCeramide%2520in%2520apoptosis%253A%2520an%2520overview%2520and%2520current%2520perspectives%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2002%26volume%3D1585%26spage%3D114%26epage%3D125%26doi%3D10.1016%2FS1388-1981%2802%2900331-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goñi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Checa, J. C.</span></span> <span> </span><span class="NLM_article-title">Sphingolipids and cell death</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1007/s10495-007-0721-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1007%2Fs10495-007-0721-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=17294080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFamtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=923-939&author=A.+Moralesauthor=H.+Leeauthor=F.+M.+Go%C3%B1iauthor=R.+Kolesnickauthor=J.+C.+Fernandez-Checa&title=Sphingolipids+and+cell+death&doi=10.1007%2Fs10495-007-0721-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingolipids and cell death</span></div><div class="casAuthors">Morales, Albert; Lee, Hyunmi; Goni, Felix M.; Kolesnick, Richard; Fernandez-Checa, Jose C.</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">923-939</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Sphingolipids (SLs) have been considered for many years as predominant building blocks of biol. membranes with key structural functions and little relevance in cellular signaling.  However, this view has changed dramatically in recent years with the recognition that certain SLs such as ceramide, sphingosine 1-phosphate and gangliosides, participate actively in signal transduction pathways, regulating many different cell functions such as proliferation, differentiation, adhesion and cell death.  In particular, ceramide has attracted considerable attention in cell biol. and biophysics due to its key role in the modulation of membrane phys. properties, signaling and cell death regulation.  This latter function is largely exerted by the ability of ceramide to activate the major pathways governing cell death such as the endoplasmic reticulum and mitochondria.  Overall, the evidence so far indicates a key function of SLs in disease pathogenesis and hence their regulation may be of potential therapeutic relevance in different pathologies including liver diseases, neurodegeneration and cancer biol. and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO8HgnKrzkeLVg90H21EOLACvtfcHk0lgxWBRPxrl7nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFamtr4%253D&md5=5f7e22e3f90eaab152197336d1f0a37b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10495-007-0721-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-007-0721-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorales%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DGo%25C3%25B1i%26aufirst%3DF.%2BM.%26aulast%3DKolesnick%26aufirst%3DR.%26aulast%3DFernandez-Checa%26aufirst%3DJ.%2BC.%26atitle%3DSphingolipids%2520and%2520cell%2520death%26jtitle%3DApoptosis%26date%3D2007%26volume%3D12%26spage%3D923%26epage%3D939%26doi%3D10.1007%2Fs10495-007-0721-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1083/jcb.114.1.155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1083%2Fjcb.114.1.155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=2050740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK3MXksVKku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1991&pages=155-167&author=H.+Zhangauthor=N.+N.+Desaiauthor=A.+Oliveraauthor=T.+Sekiauthor=G.+Brookerauthor=S.+Spiegel&title=Sphingosine-1-phosphate%2C+a+novel+lipid%2C+involved+in+cellular+proliferation&doi=10.1083%2Fjcb.114.1.155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation</span></div><div class="casAuthors">Zhang, Hong; Desai, Naishadh N.; Olivera, Ana; Seki, Takashi; Brooker, Gary; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-67</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    </div><div class="casAbstract">The rapid increase in 32P-labeled sphingosine-1-phosphate levels induced by sphingosine was concn. dependent and correlated with its effect on DNA synthesis.  Similar to the mitogenic effects of sphingosine, low concns. of sphingosine-1-phosphate stimulated DNA synthesis and induced pronounced morphol. alterations.  Both sphingosine and sphingosine-1-phosphate stimulated DNA synthesis in cells made protein kinase C deficient by prolonged treatment with phorbol ester and sphingosine still elicited similar increases in sphingosine-1-phosphate levels in these cells.  Although both sphingosine and sphingosine-1-phosphate acted synergistically with a wide variety of growth factors, there was no additive or synergistic effect in response to a combination of sphingosine and sphingosine-1-phosphate.  Using a digital imaging system for measurement of Ca changes, it was obsd. that both sphingosine and sphingosine-1-phosphate are potent Ca-mobilizing agonists in viable 3T3 fibroblasts.  The rapid rise in cytosolic free Ca was independent of the presence of Ca in the external medium, indicating that the response is due to the mobilization of Ca from internal stores.  Sphingosine-1-phosphate may be a component of the intracellular 2nd messenger system that is involved in Ca release and the regulation of cell growth induced by sphingosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNmAVbQBZTs7Vg90H21EOLACvtfcHk0lgxWBRPxrl7nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksVKku7c%253D&md5=f5991020e4dd2971ef810f20022b8f23</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1083%2Fjcb.114.1.155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.114.1.155%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDesai%26aufirst%3DN.%2BN.%26aulast%3DOlivera%26aufirst%3DA.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DBrooker%26aufirst%3DG.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%252C%2520a%2520novel%2520lipid%252C%2520involved%2520in%2520cellular%2520proliferation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1991%26volume%3D114%26spage%3D155%26epage%3D167%26doi%3D10.1083%2Fjcb.114.1.155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Payne, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: dual messenger functions</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>531</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(02)03480-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2FS0014-5793%2802%2903480-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=12401202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVOjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=531&publication_year=2002&pages=54-57&author=S.+G.+Payneauthor=S.+Milstienauthor=S.+Spiegel&title=Sphingosine-1-phosphate%3A+dual+messenger+functions&doi=10.1016%2FS0014-5793%2802%2903480-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: dual messenger functions</span></div><div class="casAuthors">Payne, Shawn G.; Milstien, Sheldon; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">531</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-57</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The sphingolipid metabolite, sphingosine-1-phosphate (S1P), is a serum-borne lipid that regulates many vital cellular processes.  S1P is the ligand of a family of 5 specific G protein-coupled receptors that are differentially expressed in different tissues and regulate diverse cellular actions.  Much less is known of the intracellular actions of S1P.  It has been suggested that S1P may also function as an intracellular 2nd messenger to regulate Ca2+ mobilization, cell growth, and suppression of apoptosis in response to a variety of extracellular stimuli.  Dissecting the dual actions and identification of intracellular targets of S1P has been challenging, but there is ample evidence to suggest that the balance between S1P and ceramide and/or sphingosine levels in cells is an important determinant of cell fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo76yT7OtSBfLVg90H21EOLACvtfcHk0ljPtfjohUtPNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVOjtLg%253D&md5=ba8373675f89dc1cdea56cd3a3ad9cd3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2802%2903480-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252802%252903480-4%26sid%3Dliteratum%253Aachs%26aulast%3DPayne%26aufirst%3DS.%2BG.%26aulast%3DMilstien%26aufirst%3DS.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%253A%2520dual%2520messenger%2520functions%26jtitle%3DFEBS%2520Lett.%26date%3D2002%26volume%3D531%26spage%3D54%26epage%3D57%26doi%3D10.1016%2FS0014-5793%2802%2903480-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milstien, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate: an enigmatic signalling lipid</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1038/nrm1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fnrm1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=12728273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=397-407&author=S.+Spiegelauthor=S.+Milstien&title=Sphingosine-1-phosphate%3A+an+enigmatic+signalling+lipid&doi=10.1038%2Fnrm1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate: an enigmatic signalling lipid</span></div><div class="casAuthors">Spiegel, Sarah; Milstien, Sheldon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">397-407</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The evolutionarily conserved actions of the sphingolipid metabolite, sphingosine-1-phosphate (S1P), in yeast, plants, and mammals have shown that it has important functions.  In higher eukaryotes, S1P is the ligand for a family of 5 G protein-coupled receptors.  These S1P receptors are differentially expressed, coupled to various G proteins, and regulate angiogenesis, vascular maturation, cardiac development, and immunity, and are important for directed cell movement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos0XUAxYZwqLVg90H21EOLACvtfcHk0liLKJLEmOtmiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlalt7o%253D&md5=689a33cfeb4bae72637b64cd90e6c910</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrm1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1103%26sid%3Dliteratum%253Aachs%26aulast%3DSpiegel%26aufirst%3DS.%26aulast%3DMilstien%26aufirst%3DS.%26atitle%3DSphingosine-1-phosphate%253A%2520an%2520enigmatic%2520signalling%2520lipid%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2003%26volume%3D4%26spage%3D397%26epage%3D407%26doi%3D10.1038%2Fnrm1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, S.</span></span> <span> </span><span class="NLM_article-title">Export of sphingosine-1-phosphate and cancer progression</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1839</span>– <span class="NLM_lpage">1846</span>, <span class="refDoi"> DOI: 10.1194/jlr.R046656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1194%2Fjlr.R046656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=24474820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGjurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1839-1846&author=K.+Takabeauthor=S.+Spiegel&title=Export+of+sphingosine-1-phosphate+and+cancer+progression&doi=10.1194%2Fjlr.R046656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Export of sphingosine-1-phosphate and cancer progression</span></div><div class="casAuthors">Takabe, Kazuaki; Spiegel, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1839-1846</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator that promotes cell survival, proliferation, migration, angiogenesis, lymphangiogenesis, and immune response; all are crit. processes of cancer progression.  Although some important roles of intracellular S1P have recently been uncovered, the majority of its biol. effects are known to be mediated via activation of five specific G protein-coupled receptors [S1P receptor (S1PR)1-S1PR5] located on the cell surface.  Secretion of S1P produced inside cells by sphingosine kinases can then signal through these receptors in autocrine, paracrine, and/or endocrine manners, coined "inside-out" signaling of S1P.  Numerous studies suggest that secreted S1P plays important roles in cancer progression; thus, understanding the mechanism by which S1P is exported out of cells, particularly cancer cells, is both interesting and important.  Here we will review the current understanding of the transport of S1P out of cancer cells and its potential roles in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpbPqJSPEIt7Vg90H21EOLACvtfcHk0liLKJLEmOtmiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGjurnN&md5=2371f977febf54b94ccfc91cd00cb0c2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R046656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R046656%26sid%3Dliteratum%253Aachs%26aulast%3DTakabe%26aufirst%3DK.%26aulast%3DSpiegel%26aufirst%3DS.%26atitle%3DExport%2520of%2520sphingosine-1-phosphate%2520and%2520cancer%2520progression%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2014%26volume%3D55%26spage%3D1839%26epage%3D1846%26doi%3D10.1194%2Fjlr.R046656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pontis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase in melanoma: expression, localization, and effects of pharmacological inhibition</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">2422</span>– <span class="NLM_lpage">2434</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.666909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1074%2Fjbc.M115.666909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=26553872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Cqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=2422-2434&author=N.+Realiniauthor=F.+Paleseauthor=D.+Pizziraniauthor=S.+Pontisauthor=A.+Basitauthor=A.+Bachauthor=A.+Ganesanauthor=D.+Piomelli&title=Acid+ceramidase+in+melanoma%3A+expression%2C+localization%2C+and+effects+of+pharmacological+inhibition&doi=10.1074%2Fjbc.M115.666909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Acid Ceramidase in Melanoma. Expression, location, and effects of pharmacological inhibitors</span></div><div class="casAuthors">Realini, Natalia; Palese, Francesca; Pizzirani, Daniela; Pontis, Silvia; Basit, Abdul; Bach, Anders; Ganesan, Anand; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2422-2434</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) is a lysosomal cysteine amidase that controls sphingolipid signaling by lowering the levels of ceramides and concomitantly increasing those of sphingosine and its bioactive metabolite, sphingosine 1-phosphate.  In the present study, we evaluated the role of AC-regulated sphingolipid signaling in melanoma.  We found that AC expression is markedly elevated in normal human melanocytes and proliferative melanoma cell lines, compared with other skin cells (keratinocytes and fibroblasts) and non-melanoma cancer cells.  High AC expression was also obsd. in biopsies from human subjects with Stage II melanoma.  Immunofluorescence studies revealed that the subcellular localization of AC differs between melanocytes (where it is found in both cytosol and nucleus) and melanoma cells (where it is primarily localized to cytosol).  In addn. to having high AC levels, melanoma cells generate lower amts. of ceramides than normal melanocytes do.  This down-regulation in ceramide prodn. appears to result from suppression of the de novo biosynthesis pathway.  To test whether AC might contribute to melanoma cell proliferation, we blocked AC activity using a new potent (IC50 = 12 nm) and stable inhibitor.  AC inhibition increased cellular ceramide levels, decreased sphingosine 1-phosphate levels, and acted synergistically with several, albeit not all, antitumoral agents.  The results suggest that AC-controlled sphingolipid metab. may play an important role in the control of melanoma proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ1pGRTPNfObVg90H21EOLACvtfcHk0liLKJLEmOtmiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Cqsbo%253D&md5=40dd33dee5301d0b79ee77c54b3b3fe3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.666909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.666909%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DPalese%26aufirst%3DF.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DPontis%26aufirst%3DS.%26aulast%3DBasit%26aufirst%3DA.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DAcid%2520ceramidase%2520in%2520melanoma%253A%2520expression%252C%2520localization%252C%2520and%2520effects%2520of%2520pharmacological%2520inhibition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D2422%26epage%3D2434%26doi%3D10.1074%2Fjbc.M115.666909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuchman, E. H.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1862</i></span>,  <span class="NLM_fpage">1459</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.1016/j.bbadis.2016.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.bbadis.2016.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=27155573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1862&publication_year=2016&pages=1459-1471&author=E.+H.+Schuchman&title=Acid+ceramidase+and+the+treatment+of+ceramide+diseases%3A+The+expanding+role+of+enzyme+replacement+therapy&doi=10.1016%2Fj.bbadis.2016.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy</span></div><div class="casAuthors">Schuchman, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1862</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1459-1471</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Ceramides are a diverse group of sphingolipids that play important roles in many biol. processes.  Acid ceramidase (AC) is one key enzyme that regulates ceramide metab.  Early research on AC focused on the fact that it is the enzyme deficient in the rare genetic disorder, Farber Lipogranulomatosis.  Recent research has revealed that deficiency of the same enzyme is responsible for a rare form of spinal muscular atrophy assocd. with myoclonic epilepsy (SMA-PME).  Due to their diverse role in biol., accumulation of ceramides also has been implicated in the pathobiol. of many other common diseases, including infectious lung diseases, diabetes, cancers and others.  This has revealed the potential of AC as a therapy for many of these diseases.  This review will focus on the biol. of AC and the potential role of this enzyme in the treatment of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxHxbePZKk7rVg90H21EOLACvtfcHk0liT6LGwyQMesQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsV2gsL0%253D&md5=b44a07178d44b3de2ef72da888931fbe</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2016.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2016.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSchuchman%26aufirst%3DE.%2BH.%26atitle%3DAcid%2520ceramidase%2520and%2520the%2520treatment%2520of%2520ceramide%2520diseases%253A%2520The%2520expanding%2520role%2520of%2520enzyme%2520replacement%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2016%26volume%3D1862%26spage%3D1459%26epage%3D1471%26doi%3D10.1016%2Fj.bbadis.2016.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwabuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oizumi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamori, K.</span></span> <span> </span><span class="NLM_article-title">Role of ceramide from glycosphingolipids and its metabolites in immunological and inflammatory responses in humans</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1155/2015/120748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1155%2F2015%2F120748" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=1-10&author=K.+Iwabuchiauthor=H.+Nakayamaauthor=A.+Oizumiauthor=Y.+Sugaauthor=H.+Ogawaauthor=K.+Takamori&title=Role+of+ceramide+from+glycosphingolipids+and+its+metabolites+in+immunological+and+inflammatory+responses+in+humans&doi=10.1155%2F2015%2F120748"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1155%2F2015%2F120748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F120748%26sid%3Dliteratum%253Aachs%26aulast%3DIwabuchi%26aufirst%3DK.%26aulast%3DNakayama%26aufirst%3DH.%26aulast%3DOizumi%26aufirst%3DA.%26aulast%3DSuga%26aufirst%3DY.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DTakamori%26aufirst%3DK.%26atitle%3DRole%2520of%2520ceramide%2520from%2520glycosphingolipids%2520and%2520its%2520metabolites%2520in%2520immunological%2520and%2520inflammatory%2520responses%2520in%2520humans%26jtitle%3DMediators%2520Inflammation%26date%3D2015%26volume%3D2015%26spage%3D1%26epage%3D10%26doi%3D10.1155%2F2015%2F120748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gieselmann, V.</span></span> <span> </span><span class="NLM_article-title">Lysosomal storage diseases</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>1270</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/0925-4439(94)00075-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2F0925-4439%2894%2900075-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=7727535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK2MXkvFGms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1270&publication_year=1995&pages=103-136&author=V.+Gieselmann&title=Lysosomal+storage+diseases&doi=10.1016%2F0925-4439%2894%2900075-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal storage diseases</span></div><div class="casAuthors">Gieselmann, Volkmar</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1270</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">103-36</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review with 410 refs. on lipidoses, disorders of glycoprotein degrdn., and mucopolysaccharidoses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM-4LaaOM1orVg90H21EOLACvtfcHk0lgtCm_0TRthbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvFGms7o%253D&md5=533266b4fdac47258d9a924b0dd4a3b4</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0925-4439%2894%2900075-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0925-4439%252894%252900075-2%26sid%3Dliteratum%253Aachs%26aulast%3DGieselmann%26aufirst%3DV.%26atitle%3DLysosomal%2520storage%2520diseases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D1995%26volume%3D1270%26spage%3D103%26epage%3D136%26doi%3D10.1016%2F0925-4439%2894%2900075-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanier, M.-T.</span></span> <span> </span><span class="NLM_article-title">Disorders of Sphingolipid Metabolism</span>. In  <i>Inborn Metabolic Diseases: Diagnosis and Treatment</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, J.</span>; <span class="NLM_string-name">Saudubray, J.-M.</span>; <span class="NLM_string-name">van den Berghe, G.</span>; <span class="NLM_string-name">Walter, J. H.</span></span>, Eds. <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2006</span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">494</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1007%2F978-3-540-28785-8_38" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=479-494&author=M.-T.+Vanierauthor=J.+Fernandes&author=J.-M.+Saudubray&author=G.+van+den+Berghe&author=J.+H.+Walter&title=Inborn+Metabolic+Diseases%3A+Diagnosis+and+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-28785-8_38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-540-28785-8_38%26sid%3Dliteratum%253Aachs%26aulast%3DVanier%26aufirst%3DM.-T.%26atitle%3DDisorders%2520of%2520Sphingolipid%2520Metabolism%26btitle%3DInborn%2520Metabolic%2520Diseases%253A%2520Diagnosis%2520and%2520Treatment%26aulast%3DFernandes%26aufirst%3DJ.%26pub%3DSpringer%26date%3D2006%26spage%3D479%26epage%3D494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballabio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieselmann, V.</span></span> <span> </span><span class="NLM_article-title">Lysosomal disorders: from storage to cellular damage</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1793</i></span>,  <span class="NLM_fpage">684</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2008.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.bbamcr.2008.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=19111581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslOlsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1793&publication_year=2009&pages=684-696&author=A.+Ballabioauthor=V.+Gieselmann&title=Lysosomal+disorders%3A+from+storage+to+cellular+damage&doi=10.1016%2Fj.bbamcr.2008.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal disorders: From storage to cellular damage</span></div><div class="casAuthors">Ballabio, Andrea; Gieselmann, Volkmar</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1793</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">684-696</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Lysosomal storage diseases represent a group of about 50 genetic disorders caused by deficiencies of lysosomal and non-lysosomal proteins.  Patients accumulate compds. which are normally degraded in the lysosome.  In many diseases this accumulation affects various organs leading to severe symptoms and premature death.  The revelation of the mechanism by which stored compds. affect cellular function is the basis for understanding pathophysiol. underlying lysosomal storage diseases.  In the past years it has become clear that storage compds. interfere with various processes on the cellular level.  The spectrum covers e.g. receptor activation by non-physiol. ligands, modulation of receptor response and intracellular effectors of signal transduction cascades, impairment of autophagy, and others.  Importantly, many of these processes are assocd. with accumulation of storage material in non-lysosomal compartments.  Here we summarize current knowledge on the effects that storage material can elicit on the cellular level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphT4XBgFcs3rVg90H21EOLACvtfcHk0lgtCm_0TRthbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslOlsbk%253D&md5=618ababe4f0b39bd914c25d235c30693</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2008.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2008.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DBallabio%26aufirst%3DA.%26aulast%3DGieselmann%26aufirst%3DV.%26atitle%3DLysosomal%2520disorders%253A%2520from%2520storage%2520to%2520cellular%2520damage%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2009%26volume%3D1793%26spage%3D684%26epage%3D696%26doi%3D10.1016%2Fj.bbamcr.2008.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cachón-González, M. B.</span></span> <span> </span><span class="NLM_article-title">The cellular pathology of lysosomal diseases</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1002/path.3021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fpath.3021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=21990005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2012&pages=241-254&author=T.+M.+Coxauthor=M.+B.+Cach%C3%B3n-Gonz%C3%A1lez&title=The+cellular+pathology+of+lysosomal+diseases&doi=10.1002%2Fpath.3021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The cellular pathology of lysosomal diseases</span></div><div class="casAuthors">Cox, Timothy M.; Cachon-Gonzalez, M. Begona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">241-254</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  With a constitutive recycling function and the capacity to digest exogenous material as well as endogenous organelles in the process of autophagy, lysosomes are at the heart of the living cell.  Dynamic interactions with other cellular components ensure that the lysosomal compartment is a central point of convergence in countless diverse diseases.  Inborn lysosomal (storage) diseases represent about 70 genetically distinct conditions, with a combined birth frequency of about 1 in 7500.  Many are assocd. with macromol. storage, causing phys. disruption of the organelle and cognate structures; in neurons, ectopic dendritogenesis and axonal swelling due to distension with membraneous tubules and autophagic vacuoles are obsd.  Disordered autophagy is almost universal in lysosomal diseases but biochem. injury due to toxic metabolites such as lysosphingolipid mols., abnormal calcium homeostasis and endoplasmic reticulum stress responses and immune-inflammatory processes occur.  However, in no case have the mechanistic links between individual clinico-pathol. manifestations and the underlying mol. defect been precisely defined.  With access to the external fluid-phase and intracellular trafficking pathways, the lysosome and its diseases are a focus of pioneering investment in biotechnol.; this has generated innovative orphan drugs and, in the case of Gaucher's disease, effective treatment for the haematol. and visceral manifestations.  Given that two-thirds of lysosomal diseases have potentially devastating consequences in the nervous system, future therapeutic research will require an integrative understanding of the unitary steps in their neuro pathogenesis.  Informative genetic variants illustrated by patients with primary defects in this organelle offer unique insights into the central role of lysosomes in human health and disease.  We provide a conspectus of inborn lysosomal diseases and their pathobiol.; the cryptic evolution of events leading to irreversible changes may be dissocd. from the cellular storage phenotype, as revealed by the outcome of therapeutic gene transfer undertaken at different stages of disease.  Copyright © 2011 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL5CDde9M4OLVg90H21EOLACvtfcHk0lgtCm_0TRthbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsbvO&md5=d0675527595829b6e888182d8d0f9a76</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fpath.3021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.3021%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DT.%2BM.%26aulast%3DCach%25C3%25B3n-Gonz%25C3%25A1lez%26aufirst%3DM.%2BB.%26atitle%3DThe%2520cellular%2520pathology%2520of%2520lysosomal%2520diseases%26jtitle%3DJ.%2520Pathol.%26date%3D2012%26volume%3D226%26spage%3D241%26epage%3D254%26doi%3D10.1002%2Fpath.3021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brady, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D.</span></span> <span> </span><span class="NLM_article-title">The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2FS0021-9258%2818%2997611-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=14253443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaF2MXhs1arsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=1965&pages=39-43&author=R.+O.+Bradyauthor=J.+Kanferauthor=D.+Shapiro&title=The+metabolism+of+glucocerebrosides.+I.+Purification+and+properties+of+a+glucocerebroside-cleaving+enzyme+from+spleen+tissue"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue</span></div><div class="casAuthors">Brady, Roscoe O.; Kanfer, Julian; Shapiro, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-43</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">A glucocerebroside-cleaving enzyme was found in rat and human spleen tissue.  The enzyme was purified 82-fold from an ext. of human spleen tissue.  The products of the reaction were identified as glucose and N-stearoylsphingosine.  The most highly purified fraction does not catalyze the hydrolysis of galactocerebroside.  The significance of the glucocerebroside-cleaving enzyme with regard to the etiol. of Gaucher's disease is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdpC1PDMb2WLVg90H21EOLACvtfcHk0lhQNJ6ojQM-rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXhs1arsQ%253D%253D&md5=2b36593e551299d34991f85bc248f7df</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2997611-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252997611-8%26sid%3Dliteratum%253Aachs%26aulast%3DBrady%26aufirst%3DR.%2BO.%26aulast%3DKanfer%26aufirst%3DJ.%26aulast%3DShapiro%26aufirst%3DD.%26atitle%3DThe%2520metabolism%2520of%2520glucocerebrosides.%2520I.%2520Purification%2520and%2520properties%2520of%2520a%2520glucocerebroside-cleaving%2520enzyme%2520from%2520spleen%2520tissue%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1965%26volume%3D240%26spage%3D39%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorbera, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaravinayagam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulsat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosa, E.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targets for Gaucher′s disease</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1001</span>, <span class="refDoi"> DOI: 10.1358/dof.2009.034.12.1444443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1358%2Fdof.2009.034.12.1444443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVaktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=1001&author=L.+A.+Sorberaauthor=D.+Sundaravinayagamauthor=C.+Dulsatauthor=E.+Rosa&title=Therapeutic+targets+for+Gaucher%E2%80%B2s+disease&doi=10.1358%2Fdof.2009.034.12.1444443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targets for Gaucher's disease</span></div><div class="casAuthors">Sorbera, L. A.; Sundaravinayagam, D.; Dulsat, C.; Rosa, E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1001-1004</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Gaucher's disease is an autosomal recessive lysosomal storage disorder caused by mutations in the gene encoding the enzyme glucosyl-ceramidase.  The physiol. result is a deficiency in this enzyme and a consequent accumulation of the lipid substrate glucosylceramide in lysosomes of the monocyte-macrophage system.  Glucosylceramide accumulation in macrophages induces an increase in serum levels of proinflammatory cytokines, while accumulation in other cell types can cause the breakdown or prodn. of addnl. complex glycolipids, consequently leading to anemia, skeletal abnormalities, organ dysfunction, bone pain and neurol. dysfunction.  The therapeutic goal in Gaucher's disease is to achieve equil. within the cell so that degradatory activity can maintain homeostasis and prevent the accumulation of undegraded macromols.  To date, therapeutic strategies include enzyme replacement, substrate redn. and chem. chaperone therapies.  The search continues for more effective treatment strategies for Gaucher's disease, with the investigative focus aimed at identifying novel targets for therapeutic intervention.  This article presents those drug targets that are currently under active investigation for the treatment of Gaucher's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGBb5yJ31z7bVg90H21EOLACvtfcHk0lhQNJ6ojQM-rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVaktLs%253D&md5=2a1fe03474230a9ed2118c8718ed172d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1358%2Fdof.2009.034.12.1444443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2009.034.12.1444443%26sid%3Dliteratum%253Aachs%26aulast%3DSorbera%26aufirst%3DL.%2BA.%26aulast%3DSundaravinayagam%26aufirst%3DD.%26aulast%3DDulsat%26aufirst%3DC.%26aulast%3DRosa%26aufirst%3DE.%26atitle%3DTherapeutic%2520targets%2520for%2520Gaucher%25E2%2580%25B2s%2520disease%26jtitle%3DDrugs%2520Future%26date%3D2009%26volume%3D34%26spage%3D1001%26doi%3D10.1358%2Fdof.2009.034.12.1444443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stirnemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmatoug, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serratrice, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froissart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caillaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levade, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astudillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serratrice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Villemeur, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. G.</span></span> <span> </span><span class="NLM_article-title">A review of Gaucher disease pathophysiology, clinical presentation and treatments</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.3390/ijms18020441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.3390%2Fijms18020441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVSju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=441-471&author=J.+Stirnemannauthor=N.+Belmatougauthor=F.+Camouauthor=C.+Serratriceauthor=R.+Froissartauthor=C.+Caillaudauthor=T.+Levadeauthor=L.+Astudilloauthor=J.+Serratriceauthor=A.+Brassierauthor=C.+Roseauthor=T.+B.+de+Villemeurauthor=M.+G.+Berger&title=A+review+of+Gaucher+disease+pathophysiology%2C+clinical+presentation+and+treatments&doi=10.3390%2Fijms18020441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A review of gaucher disease pathophysiology, clinical presentation and treatments</span></div><div class="casAuthors">Stirnemann, Jerome; Belmatoug, Nadia; Camou, Fabrice; Serratrice, Christine; Froissart, Roseline; Caillaud, Catherine; Levade, Thierry; Astudillo, Leonardo; Serratrice, Jacques; Brassier, Anais; Rose, Christian; Billette de Villemeur, Thierry; Berger, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441/1-441/30</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Gaucher disease (GD, ORPHA355) is a rare, autosomal recessive genetic disorder.  It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages.  In the general population, its incidence is approx. 1/40,000 to 1/60,000 births, rising to 1/800 in Ashkenazi Jews.  The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions assocd. with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells.  Type-1 Gaucher disease, which affects the majority of patients (90% in Europe and USA, but less in other regions), is characterized by effects on the viscera, whereas types 2 and 3 are also assocd. with neurol. impairment, either severe in type 2 or variable in type 3.  A diagnosis of GD can be confirmed by demonstrating the deficiency of acid glucocerebrosidase activity in leukocytes.  Mutations in the GBA1 gene should be identified as they may be of prognostic value in some cases.  Patients with type-1 GD-but also carriers of GBA1 mutation-have been found to be predisposed to developing Parkinson's disease, and the risk of neoplasia assocd. with the disease is still subject to discussion.  Disease-specific treatment consists of i.v. enzyme replacement therapy (ERT) using one of the currently available mols. (imiglucerase, velaglucerase, or taliglucerase).  Orally administered inhibitors of glucosylceramide biosynthesis can also be used (miglustat or eliglustat).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeVOOYHDqyLVg90H21EOLACvtfcHk0lhQNJ6ojQM-rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVSju70%253D&md5=38a4c125a4007d25177135c8996f7abe</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3390%2Fijms18020441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18020441%26sid%3Dliteratum%253Aachs%26aulast%3DStirnemann%26aufirst%3DJ.%26aulast%3DBelmatoug%26aufirst%3DN.%26aulast%3DCamou%26aufirst%3DF.%26aulast%3DSerratrice%26aufirst%3DC.%26aulast%3DFroissart%26aufirst%3DR.%26aulast%3DCaillaud%26aufirst%3DC.%26aulast%3DLevade%26aufirst%3DT.%26aulast%3DAstudillo%26aufirst%3DL.%26aulast%3DSerratrice%26aufirst%3DJ.%26aulast%3DBrassier%26aufirst%3DA.%26aulast%3DRose%26aufirst%3DC.%26aulast%3Dde%2BVillemeur%26aufirst%3DT.%2BB.%26aulast%3DBerger%26aufirst%3DM.%2BG.%26atitle%3DA%2520review%2520of%2520Gaucher%2520disease%2520pathophysiology%252C%2520clinical%2520presentation%2520and%2520treatments%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D441%26epage%3D471%26doi%3D10.3390%2Fijms18020441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Won, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, I.</span></span> <span> </span><span class="NLM_article-title">Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe’s disease</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1002/jnr.23873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fjnr.23873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=27638584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWltr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=990-1006&author=J.-S.+Wonauthor=A.+K.+Singhauthor=I.+Singh&title=Biochemical%2C+cell+biological%2C+pathological%2C+and+therapeutic+aspects+of+Krabbe%E2%80%99s+disease&doi=10.1002%2Fjnr.23873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease</span></div><div class="casAuthors">Won, Je-Seong; Singh, Avtar K.; Singh, Inderjit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">990-1006</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Krabbe's disease (KD; also called globoid cell leukodystrophy) is a genetic disorder involving demyelination of the central (CNS) and peripheral (PNS) nervous systems.  The disease may be subdivided into three types, an infantile form, which is the most common and severe; a juvenile form; and a rare adult form.  KD is an autosomal recessive disorder caused by a deficiency of galactocerebrosidase activity in lysosomes, leading to accumulation of galactoceramide and neurotoxic galactosylsphingosine (psychosine [PSY]) in macrophages (globoid cells) as well as neural cells, esp. in oligodendrocytes and Schwann cells.  This ultimately results in damage to myelin in both CNS and PNS with assocd. morbidity and mortality.  Accumulation of PSY, a lysolipid with detergent-like properties, over a threshold level could trigger membrane destabilization, leading to cell lysis.  Moreover, subthreshold concns. of PSY trigger cell signaling pathways that induce oxidative stress, mitochondrial dysfunction, apoptosis, inflammation, endothelial/vascular dysfunctions, and neuronal and axonal damage.  From the time the "psychosine hypothesis" was proposed, considerable efforts have been made in search of an effective therapy for lowering PSY load with pharmacol., gene, and stem cell approaches to attenuate PSY-induced neurotoxicity.  This Review focuses on the recent advances and prospective research for understanding disease mechanisms and therapeutic approaches for KD. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiXLjIgjfi7Vg90H21EOLACvtfcHk0lj_3-pmgofFxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWltr3I&md5=4f5306516d90cf3abf8a9023172ac8dc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fjnr.23873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.23873%26sid%3Dliteratum%253Aachs%26aulast%3DWon%26aufirst%3DJ.-S.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DSingh%26aufirst%3DI.%26atitle%3DBiochemical%252C%2520cell%2520biological%252C%2520pathological%252C%2520and%2520therapeutic%2520aspects%2520of%2520Krabbe%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2016%26volume%3D94%26spage%3D990%26epage%3D1006%26doi%3D10.1002%2Fjnr.23873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svennerholm, L.</span></span> <span> </span><span class="NLM_article-title">Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.1982.tb07950.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1111%2Fj.1471-4159.1982.tb07950.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=7097276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaL38Xlt1Ggsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1982&pages=709-718&author=O.+Nilssonauthor=L.+Svennerholm&title=Accumulation+of+glucosylceramide+and+glucosylsphingosine+%28psychosine%29+in+cerebrum+and+cerebellum+in+infantile+and+juvenile+Gaucher+disease&doi=10.1111%2Fj.1471-4159.1982.tb07950.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease</span></div><div class="casAuthors">Nilsson, Olle; Svennerholm, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">709-18</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">Three major clin. variants of Gaucher disease have been defined: Type I, chronic nonneuronopathic; Type II, acute neuronopathic; and Type III, subacute neuronopathic.  In a search for the underlying mol. basis of the neurol. manifestations, the concn. and compn. of cholesterol, phospholipids, neutral glycosphingolipids, and gangliosides were examd. in cerebral and cerebellar cortices of 5 cases of Type II, 8 cases of Type III, and 1 case of presumed Type I/III.  In Type II, the concn. of glucosylceramide was 140-530 in the cerebral cortex and 51-450 μmol/kg in the cerebellar cortex, with the highest values found in the most fulminant cases.  These concns. were 20-80 times greater than normal in cerebral cortex and 5-40 times normal in cerebellar cortex.  In Type III, the concn. of glucosylceramide was 37-65 and 59-1750 μmol/kg in the cerebral and cerebellar cortex, resp.  The highest concns. were found in the cerebellum of patients who had survived splenectomy for several years.  The ceramide compn. of the accumulated glucosylceramide suggested that brain gangliosides were the major precursors of the glucosylceramide in brains of Type II, but in the cerebellar cortex in Type III the glucosylceramide was partly of extracerebral origin.  The levels of lactosylceramide and oligohexaosylceramides were slightly raised in all brain specimens from the Gaucher cases.  The ganglioside concn. was normal, whereas there was an increase in the proportion of GM2 and GM3 gangliosides.  The brain glycosphingolipid changes in the Type I/III case were similar but slightly less than those in Type III cases of corresponding age.  Glucosylsphingosine (psychosine), never detected in normal human brain, was demonstrated in brains from all the Gaucher cases.  The psychosine concn. was highest in Type II cases, 3.8-8.8 and 3.9-12.3 μmol/kg in cerebral and cerebellar cortex, resp., with the highest values found in the most fulminant cases.  In Type III, the psychosine concn. varied more widely, 0.8-4.6 and 1.4-6.3 μmol/kg in cerebral and cerebellar cortex, resp.  The lowest value, 0.7 μmol/kg, was found in the Type I/III case.  The detection method had a sensitivity of 0.01 μmol/kg, which means that the concn. of psychosine was increased at least 100-1000-fold in Gaucher gray matter.  The accumulation of the cell-toxic substance psychosine may be the basis for the extensive neuronal cell loss in Gaucher disease, which is most striking in Type II disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7fRZs3MQ-17Vg90H21EOLACvtfcHk0lj_3-pmgofFxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xlt1Ggsbk%253D&md5=9f8a16715be1b6287749929a5f145c52</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1982.tb07950.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1982.tb07950.x%26sid%3Dliteratum%253Aachs%26aulast%3DNilsson%26aufirst%3DO.%26aulast%3DSvennerholm%26aufirst%3DL.%26atitle%3DAccumulation%2520of%2520glucosylceramide%2520and%2520glucosylsphingosine%2520%2528psychosine%2529%2520in%2520cerebrum%2520and%2520cerebellum%2520in%2520infantile%2520and%2520juvenile%2520Gaucher%2520disease%26jtitle%3DJ.%2520Neurochem.%26date%3D1982%26volume%3D39%26spage%3D709%26epage%3D718%26doi%3D10.1111%2Fj.1471-4159.1982.tb07950.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidransky, E.</span></span> <span> </span><span class="NLM_article-title">Gaucher disease: complexity in a ″simple″ disorder</span>. <i>Mol. Genet. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.ymgme.2004.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.ymgme.2004.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=15464415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2nsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2004&pages=6-15&author=E.+Sidransky&title=Gaucher+disease%3A+complexity+in+a+%E2%80%B3simple%E2%80%B3+disorder&doi=10.1016%2Fj.ymgme.2004.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Gaucher disease: complexity in a "simple" disorder</span></div><div class="casAuthors">Sidransky, Ellen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Genetics and Metabolism</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">6-15</span>CODEN:
                <span class="NLM_cas:coden">MGMEFF</span>;
        ISSN:<span class="NLM_cas:issn">1096-7192</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Gaucher disease, the recessively inherited deficiency of the enzyme glucocerebrosidase and the most common sphingolipidosis, has both non-neurol. and neuronopathic forms and a continuum of diverse clin. manifestations.  Studies of genotype-phenotype correlations reveal significant genotypic heterogeneity among clin. similar patients, and vastly different phenotypes among patients with the same mutations.  The region surrounding the glucocerebrosidase gene (GBA) on chromosome 1q is particularly gene-rich, with a highly homologous pseudogene sequence 16 kb downstream.  Recombination events within the GBA locus contribute to the etiol. of some mutations in Gaucher disease.  Studies of patients with Gaucher disease and atypical manifestations, including Parkinsonism, myoclonic epilepsy, cardiac involvement and collodion skin, seek to define other genetic or environmental factors contributing to the phenotypes.  Recent reports demonstrating an assocn. between Gaucher disease and Parkinsonism provide an example of heterozygosity for a Mendelian disorder acting as a risk factor for a complex disease.  There are rare patients with Gaucher disease and differing genotypes who develop early onset, treatment-refractory Parkinsonism.  Neuropathol. in a group of these patients showed α-synuclein-reactive Lewy bodies in brain regions specifically assocd. with Gaucher disease.  Family studies of these probands suggested that the incidence of Parkinsonism might be more frequent in obligate heterozygotes.  In a complementary finding, the examn. of GBA in autopsy samples from individuals with sporadic Parkinson disease identified alterations in the GBA sequence in 14% of the cohort.  These studies provide evidence that altered glucocerebrosidase may contribute to a vulnerability to Parkinsonism.  Moreover, this research demonstrates how insights from rare, single gene disorders like Gaucher disease can provide a window into the etiol. of more common, multifactorial genetic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolp8Yjv2VnC7Vg90H21EOLACvtfcHk0lj_3-pmgofFxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2nsb8%253D&md5=9ab45d87310ef347edcfbadfdeb2d1fc</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ymgme.2004.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymgme.2004.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DSidransky%26aufirst%3DE.%26atitle%3DGaucher%2520disease%253A%2520complexity%2520in%2520a%2520%25E2%2580%25B3simple%25E2%2580%25B3%2520disorder%26jtitle%3DMol.%2520Genet.%2520Metab.%26date%3D2004%26volume%3D83%26spage%3D6%26epage%3D15%26doi%3D10.1016%2Fj.ymgme.2004.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, A. R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strijland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheij, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouairy, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahav, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boot, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, J. M.</span></span> <span> </span><span class="NLM_article-title">Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>590</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1002/1873-3468.12104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2F1873-3468.12104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=26898341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Krur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=590&publication_year=2016&pages=716-725&author=M.+J.+Ferrazauthor=A.+R.+A.+Marquesauthor=M.+D.+Appelmanauthor=M.+Verhoekauthor=A.+Strijlandauthor=M.+Mirzaianauthor=S.+Scheijauthor=C.+M.+Ouairyauthor=D.+Lahavauthor=P.+Wisseauthor=H.+S.+Overkleeftauthor=R.+G.+Bootauthor=J.+M.+Aerts&title=Lysosomal+glycosphingolipid+catabolism+by+acid+ceramidase%3A+formation+of+glycosphingoid+bases+during+deficiency+of+glycosidases&doi=10.1002%2F1873-3468.12104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases</span></div><div class="casAuthors">Ferraz, Maria J.; Marques, Andre R. A.; Appelman, Monique D.; Verhoek, Marri; Strijland, Anneke; Mirzaian, Mina; Scheij, Saskia; Ouairy, Cecile M.; Lahav, Daniel; Wisse, Patrick; Overkleeft, Herman S.; Boot, Rolf G.; Aerts, Johannes M.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">590</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">716-725</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Glycosphingoid bases are elevated in inherited lysosomal storage disorders with deficient activity of glycosphingolipid catabolizing glycosidases.  We investigated the mol. basis of the formation of glucosyl sphingosine and globotriaosyl sphingosine during deficiency of glucocerebrosidase (Gaucher disease) and α-galactosidase A (Fabry disease).  Independent genetic and pharmacol. evidence is presented pointing to an active role of acid ceramidase in both processes through deacylation of lysosomal glycosphingolipids.  The potential pathophysiol. relevance of elevated glycosphingoid bases generated through this alternative metab. in patients suffering from lysosomal glycosidase defects is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD3HCj2x7-AbVg90H21EOLACvtfcHk0ljVW85YosiMrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Krur7N&md5=ecfbbdaaf640b5e567ea771241262e09</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2F1873-3468.12104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1873-3468.12104%26sid%3Dliteratum%253Aachs%26aulast%3DFerraz%26aufirst%3DM.%2BJ.%26aulast%3DMarques%26aufirst%3DA.%2BR.%2BA.%26aulast%3DAppelman%26aufirst%3DM.%2BD.%26aulast%3DVerhoek%26aufirst%3DM.%26aulast%3DStrijland%26aufirst%3DA.%26aulast%3DMirzaian%26aufirst%3DM.%26aulast%3DScheij%26aufirst%3DS.%26aulast%3DOuairy%26aufirst%3DC.%2BM.%26aulast%3DLahav%26aufirst%3DD.%26aulast%3DWisse%26aufirst%3DP.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DBoot%26aufirst%3DR.%2BG.%26aulast%3DAerts%26aufirst%3DJ.%2BM.%26atitle%3DLysosomal%2520glycosphingolipid%2520catabolism%2520by%2520acid%2520ceramidase%253A%2520formation%2520of%2520glycosphingoid%2520bases%2520during%2520deficiency%2520of%2520glycosidases%26jtitle%3DFEBS%2520Lett.%26date%3D2016%26volume%3D590%26spage%3D716%26epage%3D725%26doi%3D10.1002%2F1873-3468.12104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugesan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lischuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kacena, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastores, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keutzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, P. K.</span></span> <span> </span><span class="NLM_article-title">Glucosylsphingosine is a key biomarker of Gaucher disease</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">1082</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1002/ajh.24491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fajh.24491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=27441734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs12lt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2016&pages=1082-1089&author=V.+Murugesanauthor=W.-L.+Chuangauthor=J.+Liuauthor=A.+Lischukauthor=K.+Kacenaauthor=H.+Linauthor=G.+M.+Pastoresauthor=R.+Yangauthor=J.+Keutzerauthor=K.+Zhangauthor=P.+K.+Mistry&title=Glucosylsphingosine+is+a+key+biomarker+of+Gaucher+disease&doi=10.1002%2Fajh.24491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Glucosylsphingosine is a key biomarker of Gaucher disease</span></div><div class="casAuthors">Murugesan, Vagishwari; Chuang, Wei-Lien; Liu, Jun; Lischuk, Andrew; Kacena, Katherine; Lin, Haiqun; Pastores, Gregory M.; Yang, Ruhua; Keutzer, Joan; Zhang, Kate; Mistry, Pramod K.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1082-1089</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Gaucher disease (GD) involves the accumulation of glucosylceramide (GL1) and its deacylated lysolipid, glucosylsphingosine (lyso-GL1) which is implicated in mediating immune dysregulation and skeletal disease.  The aim of our study was to assess plasma Lyso-GL1 as a biomarker of GD and its response to therapy.  Plasma lyso-GL1 in 169 patients with GD type 1 (GD1) was measured by LC-MS/MS.  Significant predictors of plasma LGL1 were assessed by Pearson's correlation coeff., Wilcoxon Mann Whitney test and multiple linear regression.  Propensity scores were used to match patients on treatment mode: Enzyme Replacement Therapy (ERT) vs. Eliglustat Tartrate SRT (ELI-SRT).  Plasma Lyso-GL1 levels in healthy controls averaged 1.5 ng/mL (1.3-1.7; 95% CI).  In untreated GD patients, the levels were massively elevated (180.9 ng/mL: 95% CI, 145.4-216.5) and imiglucerase ERT resulted in marked redn. (89 ng/mL: 95% CI, 69.2-129.4) (P < 0.001).  Lyso-GL1 correlated with chitotriosidase (r = 0.59 P < 0.001), CCL18 (r = 0.62 P <0.001), hepatomegaly (r = 0.28 P < 0.001), splenomegaly (r = 0.27 P = 0.003), splenectomy (P = 0.01) and treatment mode (P < 0.001).  By multiple linear regression, the strongest predictors of lyso-GL1 were age (P < 0.001), splenectomy (P = 0.02), Chitotriosidase (P < 0.001) and CCL18 levels (P = 0.001).  After propensity score matching to obtain comparable groups of patients on ERT vs ELI-SRT, lyso-GL1 levels were lower among patients receiving ELI-SRT by 113 ng/mL (95% CI: 136-90.3 ng/mL P < 0.001).  Plasma lyso-GL1 is a key biomarker of GD.  ERT reduced lyso-GL1 levels.  By propensity scoring, ELI-SRT resulted in greater redn. of lyso-GL1 than ERT.  Am. J. Hematol. 91:1082-1089, 2016. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOTf-mirSTVbVg90H21EOLACvtfcHk0ljVW85YosiMrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs12lt7%252FK&md5=0c307227fe52cae58331e448a2bb49c8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fajh.24491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.24491%26sid%3Dliteratum%253Aachs%26aulast%3DMurugesan%26aufirst%3DV.%26aulast%3DChuang%26aufirst%3DW.-L.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLischuk%26aufirst%3DA.%26aulast%3DKacena%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DPastores%26aufirst%3DG.%2BM.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DKeutzer%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DMistry%26aufirst%3DP.%2BK.%26atitle%3DGlucosylsphingosine%2520is%2520a%2520key%2520biomarker%2520of%2520Gaucher%2520disease%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2016%26volume%3D91%26spage%3D1082%26epage%3D1089%26doi%3D10.1002%2Fajh.24491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span> <span> </span><span class="NLM_article-title">The Twitcher Mouse: A model for Krabbe disease and for experimental therapies</span>. <i>Brain Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1111/j.1750-3639.1995.tb00601.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1111%2Fj.1750-3639.1995.tb00601.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=8520724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A280%3ADyaK28%252FkvVWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=249-258&author=K.+Suzukiauthor=K.+Suzuki&title=The+Twitcher+Mouse%3A+A+model+for+Krabbe+disease+and+for+experimental+therapies&doi=10.1111%2Fj.1750-3639.1995.tb00601.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The twitcher mouse: a model for Krabbe disease and for experimental therapies</span></div><div class="casAuthors">Suzuki K; Suzuki K</div><div class="citationInfo"><span class="NLM_cas:title">Brain pathology (Zurich, Switzerland)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-58</span>
        ISSN:<span class="NLM_cas:issn">1015-6305</span>.
    </div><div class="casAbstract">The twitcher is a naturally-occurring mouse mutant caused by an abnormality in the gene coded for galactosylceramidase.  It is therefore genetically equivalent to human globoid cell leukodystrophy (Krabbe disease).  Affected mice develop clinical symptoms at the onset of the active myelination period and, if untreated, die by 35 +/- days.  The pathology is very similar to that in human disease.  Toxicity of galactosylsphingosine (psychosine) that accumulates abnormally in the nervous system is considered to be primarily responsible for the pathogenesis.  Transplantation of bone marrow cells from normal donors is partially effective and triples the life span of affected mice to 100 +/- days with evidence of remyelination in the CNS.  The mutation responsible for the twitcher mutant has recently been identified.  It is expected that this model will be useful for basic studies on treatment of this group of genetic disorders affecting the brain through transgenic and/or gene therapy approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmjvBl_ptEPBwLZxei1HN8fW6udTcc2eZCHfdy6RqDlbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28%252FkvVWmtw%253D%253D&md5=9a91b101dfa239f91ed1ab66c1d343e8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1750-3639.1995.tb00601.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1750-3639.1995.tb00601.x%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DK.%26atitle%3DThe%2520Twitcher%2520Mouse%253A%2520A%2520model%2520for%2520Krabbe%2520disease%2520and%2520for%2520experimental%2520therapies%26jtitle%3DBrain%2520Pathol.%26date%3D1995%26volume%3D5%26spage%3D249%26epage%3D258%26doi%3D10.1111%2Fj.1750-3639.1995.tb00601.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benitez, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagree, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearborn, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woloszynek, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaramita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsbernd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babcock, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogler, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, M. S.</span></span> <span> </span><span class="NLM_article-title">Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">20097</span>– <span class="NLM_lpage">20103</span>, <span class="refDoi"> DOI: 10.1073/pnas.1912108116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1073%2Fpnas.1912108116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=31527255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSitrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=20097-20103&author=Y.+Liauthor=Y.+Xuauthor=B.+A.+Benitezauthor=M.+S.+Nagreeauthor=J.+T.+Dearbornauthor=X.+Jiangauthor=M.+A.+Guzmanauthor=J.+C.+Woloszynekauthor=A.+Giaramitaauthor=B.+K.+Yipauthor=J.+Elsberndauthor=M.+C.+Babcockauthor=M.+Loauthor=S.+C.+Fowlerauthor=D.+F.+Wozniakauthor=C.+A.+Voglerauthor=J.+A.+Medinauthor=B.+E.+Crawfordauthor=M.+S.+Sands&title=Genetic+ablation+of+acid+ceramidase+in+Krabbe+disease+confirms+the+psychosine+hypothesis+and+identifies+a+new+therapeutic+target&doi=10.1073%2Fpnas.1912108116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target</span></div><div class="casAuthors">Li, Yedda; Xu, Yue; Benitez, Bruno A.; Nagree, Murtaza S.; Dearborn, Joshua T.; Jiang, Xuntian; Guzman, Miguel A.; Woloszynek, Josh C.; Giaramita, Alex; Yip, Bryan K.; Elsbernd, Joseph; Babcock, Michael C.; Lo, Melanie; Fowler, Stephen C.; Wozniak, David F.; Vogler, Carole A.; Medin, Jeffrey A.; Crawford, Brett E.; Sands, Mark S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">20097-20103</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Infantile globoid cell leukodystrophy (GLD, Krabbe disease) is a fatal demyelinating disorder caused by a deficiency in the lysosomal enzyme galactosylceramidase (GALC).  GALC deficiency leads to the accumulation of the cytotoxic glycolipid, galactosylsphingosine (psychosine).  Complementary evidence suggested that psychosine is synthesized via an anabolic pathway.  Here, we show instead that psychosine is generated catabolically through the deacylation of galactosylceramide by acid ceramidase (ACDase).  This reaction uncouples GALC deficiency from psychosine accumulation, allowing us to test the long-standing "psychosine hypothesis".  We demonstrate that genetic loss of ACDase activity (Farber disease) in the GALC-deficient mouse model of human GLD (twitcher) eliminates psychosine accumulation and cures GLD.  These data suggest that ACDase could be a target for substrate redn. therapy (SRT) in Krabbe patients.  We show that pharmacol. inhibition of ACDase activity with carmofur significantly decreases psychosine accumulation in cells from a Krabbe patient and prolongs the life span of the twitcher (Twi) mouse.  Previous SRT expts. in the Twi mouse utilized L-cycloserine, which inhibits an enzyme several steps upstream of psychosine synthesis, thus altering the balance of other important lipids.  Drugs that directly inhibit ACDase may have a more acceptable safety profile due to their mechanistic proximity to psychosine biogenesis.  In total, these data clarify our understanding of psychosine synthesis, confirm the long-held psychosine hypothesis, and provide the impetus to discover safe and effective inhibitors of ACDase to treat Krabbe disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMIjeCuiB29bVg90H21EOLACvtfcHk0lhUTa8qp6fTWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSitrfE&md5=921bc583ee05d71e2d55dd98a235fd1b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1912108116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1912108116%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DBenitez%26aufirst%3DB.%2BA.%26aulast%3DNagree%26aufirst%3DM.%2BS.%26aulast%3DDearborn%26aufirst%3DJ.%2BT.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DGuzman%26aufirst%3DM.%2BA.%26aulast%3DWoloszynek%26aufirst%3DJ.%2BC.%26aulast%3DGiaramita%26aufirst%3DA.%26aulast%3DYip%26aufirst%3DB.%2BK.%26aulast%3DElsbernd%26aufirst%3DJ.%26aulast%3DBabcock%26aufirst%3DM.%2BC.%26aulast%3DLo%26aufirst%3DM.%26aulast%3DFowler%26aufirst%3DS.%2BC.%26aulast%3DWozniak%26aufirst%3DD.%2BF.%26aulast%3DVogler%26aufirst%3DC.%2BA.%26aulast%3DMedin%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DB.%2BE.%26aulast%3DSands%26aufirst%3DM.%2BS.%26atitle%3DGenetic%2520ablation%2520of%2520acid%2520ceramidase%2520in%2520Krabbe%2520disease%2520confirms%2520the%2520psychosine%2520hypothesis%2520and%2520identifies%2520a%2520new%2520therapeutic%2520target%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D20097%26epage%3D20103%26doi%3D10.1073%2Fpnas.1912108116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the activation of acid ceramidase</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1621</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-03844-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fs41467-018-03844-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=29692406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A280%3ADC%252BC1Mjmtl2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1621&author=A.+Gebaiauthor=A.+Gorelikauthor=Z.+Liauthor=K.+Illesauthor=B.+Nagar&title=Structural+basis+for+the+activation+of+acid+ceramidase&doi=10.1038%2Fs41467-018-03844-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the activation of acid ceramidase</span></div><div class="casAuthors">Gebai Ahmad; Gorelik Alexei; Li Zixian; Illes Katalin; Nagar Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1621</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acid ceramidase (aCDase, ASAH1) hydrolyzes lysosomal membrane ceramide into sphingosine, the backbone of all sphingolipids, to regulate many cellular processes.  Abnormal function of aCDase leads to Farber disease, spinal muscular atrophy with progressive myoclonic epilepsy, and is associated with Alzheimer's, diabetes, and cancer.  Here, we present crystal structures of mammalian aCDases in both proenzyme and autocleaved forms.  In the proenzyme, the catalytic center is buried and protected from solvent.  Autocleavage triggers a conformational change exposing a hydrophobic channel leading to the active site.  Substrate modeling suggests distinct catalytic mechanisms for substrate hydrolysis versus autocleavage.  A hydrophobic surface surrounding the substrate binding channel appears to be a site of membrane attachment where the enzyme accepts substrates facilitated by the accessory protein, saposin-D.  Structural mapping of disease mutations reveals that most would destabilize the protein fold.  These results will inform the rational design of aCDase inhibitors and recombinant aCDase for disease therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6RpR0JSKnbwHqQV89nF-2fW6udTcc2eZMWg7wyHguqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mjmtl2rtg%253D%253D&md5=a7fb6f187dc50d25c9a14597053718c1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03844-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03844-2%26sid%3Dliteratum%253Aachs%26aulast%3DGebai%26aufirst%3DA.%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DNagar%26aufirst%3DB.%26atitle%3DStructural%2520basis%2520for%2520the%2520activation%2520of%2520acid%2520ceramidase%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D1621%26doi%3D10.1038%2Fs41467-018-03844-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solorzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luciani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costi, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1035</span>, <span class="refDoi"> DOI: 10.1038/srep01035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fsrep01035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=23301156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1035&author=N.+Realiniauthor=C.+Solorzanoauthor=C.+Pagliucaauthor=D.+Pizziraniauthor=A.+Armirottiauthor=R.+Lucianiauthor=M.+P.+Costiauthor=T.+Bandieraauthor=D.+Piomelli&title=Discovery+of+highly+potent+acid+ceramidase+inhibitors+with+in+vitro+tumor+chemosensitizing+activity&doi=10.1038%2Fsrep01035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity</span></div><div class="casAuthors">Realini, Natalia; Solorzano, Carlos; Pagliuca, Chiara; Pizzirani, Daniela; Armirotti, Andrea; Luciani, Rosaria; Costi, Maria Paola; Bandiera, Tiziano; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">srep01035, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The expression of acid ceramidase (AC) - a cysteine amidase that hydrolyzes the proapoptotic lipid ceramide - is abnormally high in several human tumors, which is suggestive of a role in chemoresistance.  Available AC inhibitors lack, however, the potency and drug-likeness necessary to test this idea.  Here we show that the antineoplastic drug carmofur, which is used in the clinic to treat colorectal cancers, is a potent AC inhibitor and that this property is essential to its anti-proliferative effects.  Modifications in the chem. scaffold of carmofur yield new AC inhibitors that act synergistically with std. antitumoral drugs to prevent cancer cell proliferation.  These findings identify AC as an unexpected target for carmofur, and suggest that this mol. can be used as starting point for the design of novel chemosensitizing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoknWbdLSLhRbVg90H21EOLACvtfcHk0liAFpl-PMvTSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFaqt7w%253D&md5=7ff74388fc2bea42c0e97fa8cbcfe61f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fsrep01035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep01035%26sid%3Dliteratum%253Aachs%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DSolorzano%26aufirst%3DC.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DLuciani%26aufirst%3DR.%26aulast%3DCosti%26aufirst%3DM.%2BP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520highly%2520potent%2520acid%2520ceramidase%2520inhibitors%2520with%2520in%2520vitro%2520tumor%2520chemosensitizing%2520activity%26jtitle%3DSci.%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D1035%26doi%3D10.1038%2Fsrep01035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branduardi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a new class of highly potent inhibitors of acid ceramidase: synthesis and structure-activity relationship (SAR)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3518</span>– <span class="NLM_lpage">3530</span>, <span class="refDoi"> DOI: 10.1021/jm301879g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301879g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Wjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3518-3530&author=D.+Pizziraniauthor=C.+Pagliucaauthor=N.+Realiniauthor=D.+Branduardiauthor=G.+Bottegoniauthor=M.+Morauthor=F.+Bertozziauthor=R.+Scarpelliauthor=D.+Piomelliauthor=T.+Bandiera&title=Discovery+of+a+new+class+of+highly+potent+inhibitors+of+acid+ceramidase%3A+synthesis+and+structure-activity+relationship+%28SAR%29&doi=10.1021%2Fjm301879g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Class of Highly Potent Inhibitors of Acid Ceramidase: Synthesis and Structure-Activity Relationship (SAR)</span></div><div class="casAuthors">Pizzirani, Daniela; Pagliuca, Chiara; Realini, Natalia; Branduardi, Davide; Bottegoni, Giovanni; Mor, Marco; Bertozzi, Fabio; Scarpelli, Rita; Piomelli, Daniele; Bandiera, Tiziano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3518-3530</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1-(Alkylamino)-2,4-pyrimidinediones such as I [R = H, F, MeO, F3C, Ph; R1 = Me(CH2)nNH; R2 = H, Me, MeO2C; n = 5, 7] were prepd. as inhibitors of acid ceramidase for potential use as antitumor agents.  Uracils bearing an electron-withdrawing substituent at position 5, a substituent such as Me at position 3, and an alkylaminocarbonyl moiety with a six- to eight-carbon alkyl group at position 1 were the most effective inhibitors of acid ceramidase of the compds. tested.  The acid ceramidase inhibition and stability of an alkylaminopyrimidinedione was correlated with the stabilization of the antibonding orbital of its N1-carbonyl bond.  I (R = H, F, Ph; R2 = H, Me; n = 5, 7) inhibited a human cancer cell line (SW403) with IC50 values of 20-24 μM.  I (R = F, F3C, MeO; R2 = H, MeO2C; n = 5, 7) inhibited acid ceramidase with single digit-nanomolar IC50 values (IC50 = 4-7 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSG4lPgE1b1bVg90H21EOLACvtfcHk0liAFpl-PMvTSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Wjtbo%253D&md5=e8b1cb63aa40e8654de70985febc56dd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm301879g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301879g%26sid%3Dliteratum%253Aachs%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DBranduardi%26aufirst%3DD.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DBertozzi%26aufirst%3DF.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DBandiera%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520new%2520class%2520of%2520highly%2520potent%2520inhibitors%2520of%2520acid%2520ceramidase%253A%2520synthesis%2520and%2520structure-activity%2520relationship%2520%2528SAR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3518%26epage%3D3530%26doi%3D10.1021%2Fjm301879g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diamanti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottegoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span> <span> </span><span class="NLM_article-title">Pyrazole-based acid ceramidase inhibitors: design, synthesis, and structure-activity relationships</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2739</span>– <span class="NLM_lpage">2756</span>, <span class="refDoi"> DOI: 10.1055/s-0035-1561456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1055%2Fs-0035-1561456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1ahur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=2739-2756&author=E.+Diamantiauthor=G.+Bottegoniauthor=L.+Goldoniauthor=N.+Realiniauthor=C.+Pagliucaauthor=F.+Bertozziauthor=D.+Piomelliauthor=D.+Pizzirani&title=Pyrazole-based+acid+ceramidase+inhibitors%3A+design%2C+synthesis%2C+and+structure-activity+relationships&doi=10.1055%2Fs-0035-1561456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole-Based Acid Ceramidase Inhibitors: Design, Synthesis, and Structure-Activity Relationships</span></div><div class="casAuthors">Diamanti, Eleonora; Bottegoni, Giovanni; Goldoni, Luca; Realini, Natalia; Pagliuca, Chiara; Bertozzi, Fabio; Piomelli, Daniele; Pizzirani, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2739-2756</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">1437-210X</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">Acid ceramidase (a.c.) is a lysosomal cysteine amidase responsible for the cleavage of ceramide into sphingosine, which is then phosphorylated to sphingosine 1-phosphate.  AC regulates the intracellular levels of ceramide and sphingosine, and a.c. inhibition may be useful in the treatment of disorders, such as cancer, in which ceramide-mediated signaling may be dysfunctional.  Despite their potential exptl. and therapeutic value, the no. of available small-mol. inhibitors of a.c. activity remains limited.  In the present study is described the discovery of a class of potent pyrazole carboxamide-based a.c. inhibitors, which were identified using the at. property field (APF) approach and developed through systematic SAR studies and in vitro pharmacol. characterization.  The best compd. of this series inhibits a.c. with nanomolar potency and causes ceramide accumulation and sphingosine depletion in intact G361 proliferative melanoma cells.  By expanding the current armamentarium of a.c. inhibitors, these results should facilitate future efforts to unravel the biol. of a.c. and the therapeutic potential of its inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ0V1BSSYCl7Vg90H21EOLACvtfcHk0liUi2PJcgvhtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1ahur0%253D&md5=3308bc4d0f16df0692358e6cc75235de</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1055%2Fs-0035-1561456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0035-1561456%26sid%3Dliteratum%253Aachs%26aulast%3DDiamanti%26aufirst%3DE.%26aulast%3DBottegoni%26aufirst%3DG.%26aulast%3DGoldoni%26aufirst%3DL.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DF.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DPizzirani%26aufirst%3DD.%26atitle%3DPyrazole-based%2520acid%2520ceramidase%2520inhibitors%253A%2520design%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationships%26jtitle%3DSynthesis%26date%3D2016%26volume%3D48%26spage%3D2739%26epage%3D2756%26doi%3D10.1055%2Fs-0035-1561456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengatto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Benzoxazolone carboxamides: potent and systemically active inhibitors of intracellular acid ceramidase</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1002/anie.201409042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fanie.201409042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=485-489&author=D.+Pizziraniauthor=A.+Bachauthor=N.+Realiniauthor=A.+Armirottiauthor=L.+Mengattoauthor=I.+Bauerauthor=S.+Girottoauthor=C.+Pagliucaauthor=M.+De+Vivoauthor=M.+Summaauthor=A.+Ribeiroauthor=D.+Piomelli&title=Benzoxazolone+carboxamides%3A+potent+and+systemically+active+inhibitors+of+intracellular+acid+ceramidase&doi=10.1002%2Fanie.201409042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fanie.201409042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201409042%26sid%3Dliteratum%253Aachs%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DBach%26aufirst%3DA.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DMengatto%26aufirst%3DL.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DPagliuca%26aufirst%3DC.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DM.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%253A%2520potent%2520and%2520systemically%2520active%2520inhibitors%2520of%2520intracellular%2520acid%2520ceramidase%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D54%26spage%3D485%26epage%3D489%26doi%3D10.1002%2Fanie.201409042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzirani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Realini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vozella, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penna, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melzig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span> <span> </span><span class="NLM_article-title">Benzoxazolone carboxamides as potent acid ceramidase inhibitors: synthesis and structure-activity relationship (SAR) studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9258</span>– <span class="NLM_lpage">9272</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9258-9272&author=A.+Bachauthor=D.+Pizziraniauthor=N.+Realiniauthor=V.+Vozellaauthor=D.+Russoauthor=I.+Pennaauthor=L.+Melzigauthor=R.+Scarpelliauthor=D.+Piomelli&title=Benzoxazolone+carboxamides+as+potent+acid+ceramidase+inhibitors%3A+synthesis+and+structure-activity+relationship+%28SAR%29+studies&doi=10.1021%2Facs.jmedchem.5b01188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Benzoxazolone Carboxamides as Potent Acid Ceramidase Inhibitors: Synthesis and Structure-Activity Relationship (SAR) Studies</span></div><div class="casAuthors">Bach, Anders; Pizzirani, Daniela; Realini, Natalia; Vozella, Valentina; Russo, Debora; Penna, Ilaria; Melzig, Laurin; Scarpelli, Rita; Piomelli, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9258-9272</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ceramides are lipid-derived intracellular messengers involved in the control of senescence, inflammation, and apoptosis.  The cysteine amidase, acid ceramidase (AC), hydrolyzes these substances into sphingosine and fatty acid and, by doing so, regulates their signaling activity.  AC inhibitors may be useful in the treatment of pathol. conditions, such as cancer, in which ceramide levels are abnormally reduced.  Here, we present a systematic SAR investigation of the benzoxazolone carboxamides, a recently described class of AC inhibitors that display high potency and systemic activity in mice.  We examd. a diverse series of substitutions on both benzoxazolone ring and carboxamide side chain.  Several modifications enhanced potency and stability, and one key compd. with a balanced activity-stability profile I was found to inhibit AC activity in mouse lungs and cerebral cortex after systemic administration.  The results expand our arsenal of AC inhibitors, thereby facilitating the use of these compds. as pharmacol. tools and their potential development as drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXKrFwyTWVt7Vg90H21EOLACvtfcHk0liUi2PJcgvhtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbvI&md5=1b8de2b433b0e1b42299cf224d53e33a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01188%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DA.%26aulast%3DPizzirani%26aufirst%3DD.%26aulast%3DRealini%26aufirst%3DN.%26aulast%3DVozella%26aufirst%3DV.%26aulast%3DRusso%26aufirst%3DD.%26aulast%3DPenna%26aufirst%3DI.%26aulast%3DMelzig%26aufirst%3DL.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DBenzoxazolone%2520carboxamides%2520as%2520potent%2520acid%2520ceramidase%2520inhibitors%253A%2520synthesis%2520and%2520structure-activity%2520relationship%2520%2528SAR%2529%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9258%26epage%3D9272%26doi%3D10.1021%2Facs.jmedchem.5b01188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arencibia, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Sala, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgogno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armirotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girotto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification and scaffold exploration to discover novel, potent, and chemically stable inhibitors of acid ceramidase in melanoma cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5800</span>– <span class="NLM_lpage">5815</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00472</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00472" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5800-5815&author=J.+A.+Ortegaauthor=J.+M.+Arencibiaauthor=G.+La+Salaauthor=M.+Borgognoauthor=I.+Bauerauthor=L.+Bonoauthor=C.+Bracciaauthor=A.+Armirottiauthor=S.+Girottoauthor=A.+Ganesanauthor=M.+De+Vivo&title=Pharmacophore+identification+and+scaffold+exploration+to+discover+novel%2C+potent%2C+and+chemically+stable+inhibitors+of+acid+ceramidase+in+melanoma+cells&doi=10.1021%2Facs.jmedchem.7b00472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells</span></div><div class="casAuthors">Ortega, Jose Antonio; Arencibia, Jose M.; La Sala, Giuseppina; Borgogno, Marco; Bauer, Inga; Bono, Luca; Braccia, Clarissa; Armirotti, Andrea; Girotto, Stefania; Ganesan, Anand; De Vivo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5800-5815</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acid ceramidase (AC) hydrolyzes ceramides, which are central lipid messengers for metab. and signaling of sphingolipids.  A growing body of evidence links deregulation of sphingolipids to several diseases, including cancer.  Indeed, AC expression is abnormally high in melanoma cells.  AC inhibition may thus be key to treating malignant melanoma.  Here, the authors have used a systematic scaffold exploration to design a general pharmacophore for AC inhibition.  This pharmacophore comprises a 6+5 fused ring heterocycle linked to an aliph. substituent via a urea moiety.  The authors have thus identified the novel benzimidazole derivs., which are highly potent AC inhibitors.  Their chem. and metabolic stability is comparable or superior to that of previously reported AC inhibitors.  Moreover, they are potent against endogenous AC in intact melanoma cells.  These novel inhibitors merit further characterization and can serve as a promising starting point for the discovery of new antimelanoma therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsJbGrbc7g0bVg90H21EOLACvtfcHk0liO4nim1pQyxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsr4%253D&md5=9ad5f49ead19498e6080e7dbed47c5be</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00472%26sid%3Dliteratum%253Aachs%26aulast%3DOrtega%26aufirst%3DJ.%2BA.%26aulast%3DArencibia%26aufirst%3DJ.%2BM.%26aulast%3DLa%2BSala%26aufirst%3DG.%26aulast%3DBorgogno%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DI.%26aulast%3DBono%26aufirst%3DL.%26aulast%3DBraccia%26aufirst%3DC.%26aulast%3DArmirotti%26aufirst%3DA.%26aulast%3DGirotto%26aufirst%3DS.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26atitle%3DPharmacophore%2520identification%2520and%2520scaffold%2520exploration%2520to%2520discover%2520novel%252C%2520potent%252C%2520and%2520chemically%2520stable%2520inhibitors%2520of%2520acid%2520ceramidase%2520in%2520melanoma%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5800%26epage%3D5815%26doi%3D10.1021%2Facs.jmedchem.7b00472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spink, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballentine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teleha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Player, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, W.</span></span> <span> </span><span class="NLM_article-title">Process development for scale-up of a novel 3,5-substituted thiazolidine-2,4-dione compound as a potent inhibitor for estrogen-related receptor 1</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1021/op400325r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op400325r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=321-330&author=X.+Liauthor=R.+K.+Russellauthor=J.+Spinkauthor=S.+Ballentineauthor=C.+Telehaauthor=S.+Branumauthor=K.+Wellsauthor=D.+Beauchampauthor=R.+Patchauthor=H.+Huangauthor=M.+Playerauthor=W.+Murray&title=Process+development+for+scale-up+of+a+novel+3%2C5-substituted+thiazolidine-2%2C4-dione+compound+as+a+potent+inhibitor+for+estrogen-related+receptor+1&doi=10.1021%2Fop400325r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development for Scale-Up of a Novel 3,5-Substituted Thiazolidine-2,4-dione Compound as a Potent Inhibitor for Estrogen-Related Receptor 1</span></div><div class="casAuthors">Li, Xun; Russell, Ronald K.; Spink, Jan; Ballentine, Scott; Teleha, Christopher; Branum, Shawn; Wells, Kenneth; Beauchamp, Derek; Patch, Raymond; Huang, Hui; Player, Mark; Murray, William</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">321-330</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a reproducible process for multihundred gram prodn. of (Z)-5-((1-(4-chloro-2-(trifluoromethyl)benzyl)-1H-indazol-5-yl)methylene)-3-((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)thiazolidine-2,4-dione (26), a potent and selective inhibitor of estrogen-related receptor 1 (ERR1), is described.  This multihundred gram synthesis was achieved via magnesium perchlorate-catalyzed regioselective epoxide ring-opening of tert-Bu 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate (9) with thiazolidine-2,4-dione (6, TZD) to form a diastereomeric mixt. tert-Bu 4-(2,4-dioxothiazolidin-3-yl)-3-hydroxypiperidine-1-carboxylate (17), of which the 3-hydroxyl group was functionally transformed to 3-fluoro deriv. 19 after treatment with Deoxo-Fluor.  Chiral sepn. of 19 provided the desired diastereomer (3R,4R)-21 that was converted to the secondary amine 23 TFA salt.  Reductive amination of 23 produced the key intermediate N-Me 24.  Knoevenagel condensation of 24 with 1-(4-chloro-2-(trifluoromethyl)benzyl)-1H-indazole-5-carbaldehyde (5) produced the final product 26 in 10% overall yield (99.7% HPLC area% with ≥99.5% de) after a convergent eight synthetic steps with the only column purifn. being the chiral HPLC sepn. of 3R,4R-21 from 3S,4S-22.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHhIJERVpKQrVg90H21EOLACvtfcHk0liO4nim1pQyxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCmtg%253D%253D&md5=1470607da3279b379eb1ac19ed6cf6e0</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fop400325r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop400325r%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DRussell%26aufirst%3DR.%2BK.%26aulast%3DSpink%26aufirst%3DJ.%26aulast%3DBallentine%26aufirst%3DS.%26aulast%3DTeleha%26aufirst%3DC.%26aulast%3DBranum%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DK.%26aulast%3DBeauchamp%26aufirst%3DD.%26aulast%3DPatch%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DPlayer%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DW.%26atitle%3DProcess%2520development%2520for%2520scale-up%2520of%2520a%2520novel%25203%252C5-substituted%2520thiazolidine-2%252C4-dione%2520compound%2520as%2520a%2520potent%2520inhibitor%2520for%2520estrogen-related%2520receptor%25201%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D321%26epage%3D330%26doi%3D10.1021%2Fop400325r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeOrazio, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikam, S. S.</span></span> <span> </span><span class="NLM_article-title">A simple strategy for the preparation of 6-substituted 3H-benzoxazol-2-ones and 3H-benzothiazol-2-ones</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">3551</span>– <span class="NLM_lpage">3555</span>, <span class="refDoi"> DOI: 10.1080/00397911.2010.519093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1080%2F00397911.2010.519093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=3551-3555&author=R.+J.+DeOrazioauthor=J.-H.+Maengauthor=D.+D.+Manningauthor=B.+A.+Shererauthor=I.+L.+Scottauthor=S.+S.+Nikam&title=A+simple+strategy+for+the+preparation+of+6-substituted+3H-benzoxazol-2-ones+and+3H-benzothiazol-2-ones&doi=10.1080%2F00397911.2010.519093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A simple strategy for the preparation of 6-substituted 3H-benzoxazol-2-ones and 3H-benzothiazol-2-ones</span></div><div class="casAuthors">DeOrazio, Russell J.; Maeng, Jun-Ho; Manning, David D.; Sherer, Brian A.; Scott, Ian L.; Nikam, Sham S.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3551-3555</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">The double metalation of 6-bromo-3H-benzothiazol-2-one and 6-bromo-3H-benzoxazol-2-one with Me magnesium bromide and alkyllithium bases was described.  Alkylation with a variety of electrophiles occurs at the 6-position of the heterocycles in good yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHej54DCHWz7Vg90H21EOLACvtfcHk0lg0redREp_c3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWns7c%253D&md5=81906606c280b08f272cbd7092d8a48b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F00397911.2010.519093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397911.2010.519093%26sid%3Dliteratum%253Aachs%26aulast%3DDeOrazio%26aufirst%3DR.%2BJ.%26aulast%3DMaeng%26aufirst%3DJ.-H.%26aulast%3DManning%26aufirst%3DD.%2BD.%26aulast%3DSherer%26aufirst%3DB.%2BA.%26aulast%3DScott%26aufirst%3DI.%2BL.%26aulast%3DNikam%26aufirst%3DS.%2BS.%26atitle%3DA%2520simple%2520strategy%2520for%2520the%2520preparation%2520of%25206-substituted%25203H-benzoxazol-2-ones%2520and%25203H-benzothiazol-2-ones%26jtitle%3DSynth.%2520Commun.%26date%3D2011%26volume%3D41%26spage%3D3551%26epage%3D3555%26doi%3D10.1080%2F00397911.2010.519093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rynearson, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrette, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerneke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dibrov, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, T.</span></span> <span> </span><span class="NLM_article-title">2-Aminobenzoxazole ligands of the hepatitis C virus internal ribosome entry site</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3521</span>– <span class="NLM_lpage">3525</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.bmcl.2014.05.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=24930829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWhurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3521-3525&author=K.+D.+Rynearsonauthor=B.+Charretteauthor=C.+Gabrielauthor=J.+Morenoauthor=M.+A.+Boernekeauthor=S.+M.+Dibrovauthor=T.+Hermann&title=2-Aminobenzoxazole+ligands+of+the+hepatitis+C+virus+internal+ribosome+entry+site&doi=10.1016%2Fj.bmcl.2014.05.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminobenzoxazole ligands of the hepatitis C virus internal ribosome entry site</span></div><div class="casAuthors">Rynearson, Kevin D.; Charrette, Brian; Gabriel, Christopher; Moreno, Jesus; Boerneke, Mark A.; Dibrov, Sergey M.; Hermann, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3521-3525</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">2-Aminobenzoxazoles were synthesized as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA.  The compds. were designed to explore the less basic benzoxazole system as a replacement for the core scaffold in previously discovered benzimidazole viral translation inhibitors.  Structure-activity relationships in the target binding of substituted benzoxazole ligands were studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqluR-xVpgaqrVg90H21EOLACvtfcHk0lg0redREp_c3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWhurfO&md5=e9e7bf1b26d177446884e60af25a9de9</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.088%26sid%3Dliteratum%253Aachs%26aulast%3DRynearson%26aufirst%3DK.%2BD.%26aulast%3DCharrette%26aufirst%3DB.%26aulast%3DGabriel%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DJ.%26aulast%3DBoerneke%26aufirst%3DM.%2BA.%26aulast%3DDibrov%26aufirst%3DS.%2BM.%26aulast%3DHermann%26aufirst%3DT.%26atitle%3D2-Aminobenzoxazole%2520ligands%2520of%2520the%2520hepatitis%2520C%2520virus%2520internal%2520ribosome%2520entry%2520site%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3521%26epage%3D3525%26doi%3D10.1016%2Fj.bmcl.2014.05.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesquière, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willand, N.</span></span> <span> </span><span class="NLM_article-title">Synthesis of N-(iodophenyl)-amides via an unprecedented Ullmann-Finkelstein tandem reaction</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1186</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2005.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.tetlet.2005.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFOjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=1181-1186&author=P.+Totoauthor=J.-C.+Gesqui%C3%A8reauthor=B.+Deprezauthor=N.+Willand&title=Synthesis+of+N-%28iodophenyl%29-amides+via+an+unprecedented+Ullmann-Finkelstein+tandem+reaction&doi=10.1016%2Fj.tetlet.2005.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of N-(iodophenyl)-amides via an unprecedented Ullmann-Finkelstein tandem reaction</span></div><div class="casAuthors">Toto, Patrick; Gesquiere, Jean-Claude; Deprez, Benoit; Willand, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1181-1186</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using a new Ullmann-Finkelstein tandem reaction, N-iodophenyl amides were synthesized from the corresponding amides and iodobromobenzenes.  The catalyst/ligand couple CuI/N,N'-dimethylcyclohexane-1,2-diamine was used for this reaction in dioxane with K3PO4 as base.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3NWxYFhLpLrVg90H21EOLACvtfcHk0lg0redREp_c3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFOjsA%253D%253D&md5=6d5fe8b9ba071cbcc772563317d14219</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2005.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2005.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DToto%26aufirst%3DP.%26aulast%3DGesqui%25C3%25A8re%26aufirst%3DJ.-C.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DWilland%26aufirst%3DN.%26atitle%3DSynthesis%2520of%2520N-%2528iodophenyl%2529-amides%2520via%2520an%2520unprecedented%2520Ullmann-Finkelstein%2520tandem%2520reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D2006%26volume%3D47%26spage%3D1181%26epage%3D1186%26doi%3D10.1016%2Fj.tetlet.2005.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knöelker, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braxmeier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlechtingen, G.</span></span> <span> </span><span class="NLM_article-title">A novel method for the synthesis of isocyanates under mild conditions</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2500</span>, <span class="refDoi"> DOI: 10.1002/anie.199524971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fanie.199524971" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADyaK2MXpslOnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1995&pages=2497-2500&author=H.-J.+Kn%C3%B6elkerauthor=T.+Braxmeierauthor=G.+Schlechtingen&title=A+novel+method+for+the+synthesis+of+isocyanates+under+mild+conditions&doi=10.1002%2Fanie.199524971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A novel method for the synthesis of isocyanates under mild conditions</span></div><div class="casAuthors">Knoelker, Hans-Joachim; Braxmeier, Tobias; Schlechtingen, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition in English</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2497-500</span>CODEN:
                <span class="NLM_cas:coden">ACIEAY</span>;
        ISSN:<span class="NLM_cas:issn">0570-0833</span>.
    
            (<span class="NLM_cas:orgname">VCH</span>)
        </div><div class="casAbstract">The title process converts alkyl- and arylamines into isocyanates in high yields by reaction with activated carbonates in the presence of a catalytic amt. of a nucleophilic N base at room temp.  Thus, 2,4,6-(MeO)3C6H2NH2 was treated with (Me3CO2C)2O and 4-(dimethylamino)pyridine in MeCN to give 97% 2,4,6-(MeO)3C6H2NCO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgmvefL7Nk7rVg90H21EOLACvtfcHk0li8aA-lx-FNjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpslOnu7c%253D&md5=d51dd730927d3f5a9aa05e17c346c824</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fanie.199524971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.199524971%26sid%3Dliteratum%253Aachs%26aulast%3DKn%25C3%25B6elker%26aufirst%3DH.-J.%26aulast%3DBraxmeier%26aufirst%3DT.%26aulast%3DSchlechtingen%26aufirst%3DG.%26atitle%3DA%2520novel%2520method%2520for%2520the%2520synthesis%2520of%2520isocyanates%2520under%2520mild%2520conditions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1995%26volume%3D34%26spage%3D2497%26epage%3D2500%26doi%3D10.1002%2Fanie.199524971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forster, B.</span></span> <span> </span><span class="NLM_article-title">Triphosgene, a crystalline phosgene substitute</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">894</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1002/anie.198708941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1002%2Fanie.198708941" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1987&pages=894-895&author=H.+Eckertauthor=B.+Forster&title=Triphosgene%2C+a+crystalline+phosgene+substitute&doi=10.1002%2Fanie.198708941"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.198708941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.198708941%26sid%3Dliteratum%253Aachs%26aulast%3DEckert%26aufirst%3DH.%26aulast%3DForster%26aufirst%3DB.%26atitle%3DTriphosgene%252C%2520a%2520crystalline%2520phosgene%2520substitute%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1987%26volume%3D26%26spage%3D894%26epage%3D895%26doi%3D10.1002%2Fanie.198708941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dementiev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joachimiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelsomino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, E.-Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, N.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of inhibition of acid ceramidase by carmofur</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01723</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01723" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=987-992&author=A.+Dementievauthor=A.+Joachimiakauthor=H.+Nguyenauthor=A.+Gorelikauthor=K.+Illesauthor=S.+Shabaniauthor=M.+Gelsominoauthor=E.-Y.+E.+Ahnauthor=B.+Nagarauthor=N.+Doan&title=Molecular+mechanism+of+inhibition+of+acid+ceramidase+by+carmofur&doi=10.1021%2Facs.jmedchem.8b01723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of inhibition of acid ceramidase by carmofur</span></div><div class="casAuthors">Dementiev, Alexey; Joachimiak, Andrzej; Nguyen, Ha; Gorelik, Alexei; Illes, Katalin; Shabani, Saman; Gelsomino, Michael; Ahn, Eun-Young Erin; Nagar, Bhushan; Doan, Ninh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">987-992</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human acid ceramidase (AC) is a lysosomal cysteine amidase, which has received a great deal of interest in recent years as a potential target for the development of new therapeutics against melanoma and glioblastoma tumors.  Despite the strong interest in obtaining structural information, only the structures of the apo-AC enzyme in its zymogen and activated conformations are available.  In this work, the crystal structure of AC in complex with the covalent carmofur inhibitor is presented.  Carmofur (1-hexylcarbamoyl-5-fluorouracil) is an antineoplastic drug contg. an electrophilic carbonyl reactive group that targets the catalytic cysteine.  This novel structural data explains the basis of the AC inhibition, provides insights into the enzymic properties of the protein, and is a great aid toward the structure-based drug design of potent inhibitors for AC, providing the detailed mechanism, which has eluded the scientific community for more than 30 years, of carmofur's mysterious 5-fluorouracil-independent antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLv97-NENYSbVg90H21EOLACvtfcHk0li8aA-lx-FNjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLrE&md5=b88fa5e1014bc879d160e210dd1c2dfa</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01723%26sid%3Dliteratum%253Aachs%26aulast%3DDementiev%26aufirst%3DA.%26aulast%3DJoachimiak%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DShabani%26aufirst%3DS.%26aulast%3DGelsomino%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DE.-Y.%2BE.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DDoan%26aufirst%3DN.%26atitle%3DMolecular%2520mechanism%2520of%2520inhibition%2520of%2520acid%2520ceramidase%2520by%2520carmofur%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D987%26epage%3D992%26doi%3D10.1021%2Facs.jmedchem.8b01723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. J.</span></span> <span> </span><span class="NLM_article-title">Acid ceramidase, an emerging target for anti-cancer and anti-angiogenesis</span>. <i>Arch. Pharmacal Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1007/s12272-019-01114-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1007%2Fs12272-019-01114-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=30661200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVOqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=232-243&author=S.+M.+Choauthor=H.+J.+Kwon&title=Acid+ceramidase%2C+an+emerging+target+for+anti-cancer+and+anti-angiogenesis&doi=10.1007%2Fs12272-019-01114-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Acid ceramidase, an emerging target for anti-cancer and anti-angiogenesis</span></div><div class="casAuthors">Cho, Sung Min; Kwon, Ho Jeong</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">232-243</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">Sphingolipid metab. plays an important role in detg. the fate of a cell.  Among several sphingolipid metabolites, ceramide is a key player in intracellular signal transduction.  Ceramide is usually converted to various metabolites such as sphingomyelin, sphingosine, ceramide-1-phosphate, and glucosylceramide.  If ceramide is accumulated in the cell, it induces apoptosis.  On the other hand, its metabolite sphingosine is converted to sphingosine-1-phosphate (S1P), which promotes angiogenesis via G protein coupled receptor signaling.  Therefore, the equil. in ceramide and S1P levels in cells plays an important role in angiogenesis as well as cell death.  Acid ceramidase (AC) is a promising target protein in the development of multi-targeted anticancer drugs as its inhibition can simultaneously inhibit angiogenesis via the Akt and ERK 1/2 pathway and limit cancer growth through ceramide-induced apoptosis.  Although some inhibitors of AC have been reported, they have not been proven effective for human therapy.  Recent advancement in the elucidation of AC structure will facilitate the development of better inhibitors for treating human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbhz9fnHvbDrVg90H21EOLACvtfcHk0lgr132lpiWDCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVOqsbw%253D&md5=3ce3e0c43bf4e0b6e93516a3cfcf68c3</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs12272-019-01114-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-019-01114-3%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BM.%26aulast%3DKwon%26aufirst%3DH.%2BJ.%26atitle%3DAcid%2520ceramidase%252C%2520an%2520emerging%2520target%2520for%2520anti-cancer%2520and%2520anti-angiogenesis%26jtitle%3DArch.%2520Pharmacal%2520Res.%26date%3D2019%26volume%3D42%26spage%3D232%26epage%3D243%26doi%3D10.1007%2Fs12272-019-01114-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0lgr132lpiWDCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Improving drug design: an update on recent applications of efficiency metrics, strategies for replacing problematic elements, and compounds in nontraditional drug space</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=564-616&author=N.+A.+Meanwell&title=Improving+drug+design%3A+an+update+on+recent+applications+of+efficiency+metrics%2C+strategies+for+replacing+problematic+elements%2C+and+compounds+in+nontraditional+drug+space&doi=10.1021%2Facs.chemrestox.6b00043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">564-616</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug discovery and development is a complex and lengthy enterprise that suffers from high rates of candidate attrition at all stages of the process.  The phys., biol., and toxicol. properties of a drug candidate are inextricably linked to its structure, and once a mol. has been synthesized, all subsequent studies along the development path are focused only on assessing and understanding its properties in greater detail.  Unfortunately, a full prediction of the biol. properties of a mol. from an anal. of its 2- or 3-dimensional structure is currently beyond our expertise.  This backdrop mandates that considerable care be taken at the design stage if a mol. is to be successful in testing a mechanistic concept underlying a disease process and to progress into late stage clin. trials and, ultimately, marketing approval.  While there are multiple potential causes of candidate attrition, an introspective anal. of drug design practices over the past decade has focused attention on the perception that contemporary mols. are unnecessarily obese, burdened by high mol. wt. and excessive lipophilicity.  This practice is believed to have its roots in the singular pursuit of enhancing potency during lead optimization rather than adopting a more holistic approach to drug design that gives broader consideration to how structural features affect developability properties.  In an effort to provide the medicinal chem. community with practical guideposts to enhancing compd. quality in the drug design phase and which can readily be applied, a series of efficiency indexes have been proposed that attempt to define aspects of compd. quality in the context of a series of physicochem. parameters.  Of these metrics, lipophilic ligand efficiency (LLE or LipE), which provides an index of the dependence of the potency of a mol. on its intrinsic lipophilicity, has been characterized as the most robust metric that has potential for broad-based application.  In this review, after describing the background literature behind the derivation of efficiency metrics and approaches to assessing compd. aesthetics, synopses of some recent practical application in lead optimization campaigns are presented.  However, mols. that fall into space beyond that assocd. with traditional drug-like properties are an important part of the current and future landscape, exemplified by the summary of direct acting hepatitis C virus NS3 and NS5A inhibitors that have transformed clin. therapy for this chronic disease.  While drug development in nontraditional drug-like space is more challenging and the rules for compd. quality will be different with much still to be understood, careful and disciplined drug design practices will be an essential element of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpotJb_EhGoW7Vg90H21EOLACvtfcHk0lgr132lpiWDCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D&md5=aef48399fb698b5f958c1cc11e1d25aa</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00043%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520drug%2520design%253A%2520an%2520update%2520on%2520recent%2520applications%2520of%2520efficiency%2520metrics%252C%2520strategies%2520for%2520replacing%2520problematic%2520elements%252C%2520and%2520compounds%2520in%2520nontraditional%2520drug%2520space%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D564%26epage%3D616%26doi%3D10.1021%2Facs.chemrestox.6b00043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <i>Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists</i>; <span class="NLM_publisher-name">Wiley-Interscience</span>: <span class="NLM_publisher-loc">Hoboken, New Jersey, USA, Ed</span>. <span class="NLM_year">2005</span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">248</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=48-248&author=R.+A.+Copeland&title=Evaluation+of+Enzyme+Inhibitors+in+Drug+Discovery%3A+A+Guide+for+Medicinal+Chemists+and+Pharmacologists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26btitle%3DEvaluation%2520of%2520Enzyme%2520Inhibitors%2520in%2520Drug%2520Discovery%253A%2520A%2520Guide%2520for%2520Medicinal%2520Chemists%2520and%2520Pharmacologists%26pub%3DWiley-Interscience%26date%3D2005%26spage%3D48%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strelow, J. D. W.</span>; <span class="NLM_string-name">Iversen, P. W.</span>; <span class="NLM_string-name">Brooks, H. B.</span>; <span class="NLM_string-name">Radding, J. A.</span>; <span class="NLM_string-name">McGee, J.</span>; <span class="NLM_string-name">Weidner, J.</span></span>, In  <i>Assay Guidance Manual</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sittampalam, G. S. G. A.</span>; <span class="NLM_string-name">Brimacombe, K.</span>; <span class="NLM_string-name">Arkin, M.</span>; <span class="NLM_string-name">Auld, D.</span>; <span class="NLM_string-name">Austin, C. P.</span>; <span class="NLM_string-name">Baell, J.</span>; <span class="NLM_string-name">Bejcek, B.</span>; <span class="NLM_string-name">Caaveiro, J. M. M.</span>; <span class="NLM_string-name">Chung, T. D. Y.</span>; <span class="NLM_string-name">Coussens, N. P.</span>; <span class="NLM_string-name">Dahlin, J. L.</span>; <span class="NLM_string-name">Devanaryan, V.</span>; <span class="NLM_string-name">Foley, T. L.</span>; <span class="NLM_string-name">Glicksman, M.</span>; <span class="NLM_string-name">Hall, M. D.</span>; <span class="NLM_string-name">Haas, J. V.</span>; <span class="NLM_string-name">Hoare, S. R. J.</span>; <span class="NLM_string-name">Inglese, J.</span>; <span class="NLM_string-name">Iversen, P. W.</span>; <span class="NLM_string-name">Kahl, S. D.</span>; <span class="NLM_string-name">Kales, S. C.</span>; <span class="NLM_string-name">Kirshner, S.</span>; <span class="NLM_string-name">Lal-Nag, M.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">McGee, J.</span>; <span class="NLM_string-name">McManus, O.</span>; <span class="NLM_string-name">Riss, T.</span>; <span class="NLM_string-name">Saradjian, P.</span>; <span class="NLM_string-name">Trask, O. J.</span>; <span class="NLM_string-name">Weidner,  Jr., J. R.</span>; <span class="NLM_string-name">Wildey, M. J.</span>; <span class="NLM_string-name">Xia, M.</span>; <span class="NLM_string-name">Xu, X.</span></span>, Ed. <span class="NLM_publisher-name">Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences</span>, <span class="NLM_year">2004</span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">86</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=65-86&author=J.+D.+W.+Strelow&author=P.+W.+Iversen&author=H.+B.+Brooks&author=J.+A.+Radding&author=J.+McGee&author=J.+Weidnerauthor=G.+S.+G.+A.+Sittampalam&author=K.+Brimacombe&author=M.+Arkin&author=D.+Auld&author=C.+P.+Austin&author=J.+Baell&author=B.+Bejcek&author=J.+M.+M.+Caaveiro&author=T.+D.+Y.+Chung&author=N.+P.+Coussens&author=J.+L.+Dahlin&author=V.+Devanaryan&author=T.+L.+Foley&author=M.+Glicksman&author=M.+D.+Hall&author=J.+V.+Haas&author=S.+R.+J.+Hoare&author=J.+Inglese&author=P.+W.+Iversen&author=S.+D.+Kahl&author=S.+C.+Kales&author=S.+Kirshner&author=M.+Lal-Nag&author=Z.+Li&author=J.+McGee&author=O.+McManus&author=T.+Riss&author=P.+Saradjian&author=O.+J.+Trask&author=J.+R.+Weidner&author=M.+J.+Wildey&author=M.+Xia&author=X.+Xu&title=Assay+Guidance+Manual"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DStrelow%26aufirst%3DJ.%2BD.%2BW.%26btitle%3DAssay%2520Guidance%2520Manual%26aulast%3DSittampalam%26aufirst%3DG.%2BS.%2BG.%2BA.%26pub%3DBethesda%2520%2528MD%2529%253A%2520Eli%2520Lilly%2520%2526%2520Company%2520and%2520the%2520National%2520Center%2520for%2520Advancing%2520Translational%2520Sciences%26date%3D2004%26spage%3D65%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, B.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of activation of the immunoregulatory amidase NAAA</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E10032</span>– <span class="NLM_lpage">E10040</span>, <span class="refDoi"> DOI: 10.1073/pnas.1811759115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1073%2Fpnas.1811759115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=30301806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyhsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E10032-E10040&author=A.+Gorelikauthor=A.+Gebaiauthor=K.+Illesauthor=D.+Piomelliauthor=B.+Nagar&title=Molecular+mechanism+of+activation+of+the+immunoregulatory+amidase+NAAA&doi=10.1073%2Fpnas.1811759115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of activation of the immunoregulatory amidase NAAA</span></div><div class="casAuthors">Gorelik, Alexei; Gebai, Ahmad; Illes, Katalin; Piomelli, Daniele; Nagar, Bhushan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">E10032-E10040</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Palmitoylethanolamide is a bioactive lipid that strongly alleviates pain and inflammation in animal models and in humans.  Its signaling activity is terminated through degrdn. by N-acylethanolamine acid amidase (NAAA), a cysteine hydrolase expressed at high levels in immune cells.  Pharmacol. inhibitors of NAAA activity exert profound analgesic and antiinflammatory effects in rodent models, pointing to this protein as a potential target for therapeutic drug discovery.  To facilitate these efforts and to better understand the mol. mechanism of action of NAAA, we detd. crystal structures of this enzyme in various activation states and in complex with several ligands, including both a covalent and a reversible inhibitor.  Self-proteolysis exposes the otherwise buried active site of NAAA to allow catalysis.  Formation of a stable substrate- or inhibitor-binding site appears to be conformationally coupled to the interaction of a pair of hydrophobic helixes in the enzyme with lipid membranes, resulting in the creation of a linear hydrophobic cavity near the active site that accommodates the liganda's acyl chain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe4SyudaY7MrVg90H21EOLACvtfcHk0li6CnQnXMTDaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyhsLvP&md5=9debd68d3239a82bd60849c9cf98e8ae</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1811759115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1811759115%26sid%3Dliteratum%253Aachs%26aulast%3DGorelik%26aufirst%3DA.%26aulast%3DGebai%26aufirst%3DA.%26aulast%3DIlles%26aufirst%3DK.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DNagar%26aufirst%3DB.%26atitle%3DMolecular%2520mechanism%2520of%2520activation%2520of%2520the%2520immunoregulatory%2520amidase%2520NAAA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE10032%26epage%3DE10040%26doi%3D10.1073%2Fpnas.1811759115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Enzymatic pathways that regulate endocannabinoid signaling in the nervous system</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">1687</span>– <span class="NLM_lpage">1707</span>, <span class="refDoi"> DOI: 10.1021/cr0782067</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0782067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFKhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2008&pages=1687-1707&author=K.+Ahnauthor=M.+K.+McKinneyauthor=B.+F.+Cravatt&title=Enzymatic+pathways+that+regulate+endocannabinoid+signaling+in+the+nervous+system&doi=10.1021%2Fcr0782067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Enzymatic pathways that regulate endocannabinoid signaling in the nervous system</span></div><div class="casAuthors">Ahn, Kay; McKinney, Michele K.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1687-1707</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Recent advances in the understanding of the compn. and regulation of endocannabinoid metabolic pathways, esp. with respect to the nervous system, are reviewed.  The current state of the understanding of the 4 major pathways for endocannabinoid metab. are discussed.  These include (1) anandamide degrdn.; (2) anandamide biosynthesis; (3) 2-arachidonoylglycerol (2-AG) degrdn.; and (4) 2-AG biosynthesis.  Some of these pathways, such as anandamide degrdn., are relatively well characterized, at least in terms of the participating enzymes, esp. fatty acid amide hydrolase (FAAH), and the advent of specific research tools to probe their function in vivo.  For the other pathways, candidate enzymes have been identified, but the specific roles that these proteins play in regulating endocannabinoid metab. in vivo remains to be elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcfjZNs7jWWrVg90H21EOLACvtfcHk0ljar64YLeGiJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFKhs7s%253D&md5=4c74194ab87393de8f0fcbab198d089c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fcr0782067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0782067%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DMcKinney%26aufirst%3DM.%2BK.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DEnzymatic%2520pathways%2520that%2520regulate%2520endocannabinoid%2520signaling%2520in%2520the%2520nervous%2520system%26jtitle%3DChem.%2520Rev.%26date%3D2008%26volume%3D108%26spage%3D1687%26epage%3D1707%26doi%3D10.1021%2Fcr0782067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blankman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2007.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1016%2Fj.chembiol.2007.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=18096503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1347-1356&author=J.+L.+Blankmanauthor=G.+M.+Simonauthor=B.+F.+Cravatt&title=A+Comprehensive+profile+of+brain+enzymes+that+hydrolyze+the+endocannabinoid+2-arachidonoylglycerol&doi=10.1016%2Fj.chembiol.2007.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol</span></div><div class="casAuthors">Blankman, Jacqueline L.; Simon, Gabriel M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Endogenous ligands for cannabinoid receptors ("endocannabinoids") include the lipid transmitters anandamide and 2-arachidonoylglycerol (2-AG).  Endocannabinoids modulate a diverse set of physiol. processes and are tightly regulated by enzymic biosynthesis and degrdn.  Termination of anandamide signaling by fatty acid amide hydrolase (FAAH) is well characterized, but less is known about the inactivation of 2-AG, which can be hydrolyzed by multiple enzymes in vitro, including FAAH and monoacylglycerol lipase (MAGL).  Here, we have taken a functional proteomic approach to comprehensively map 2-AG hydrolases in the mouse brain.  Our data reveal that ∼85% of brain 2-AG hydrolase activity can be ascribed to MAGL, and that the remaining 15% is mostly catalyzed by two uncharacterized enzymes, ABHD6 and ABHD12.  Interestingly, MAGL, ABHD6, and ABHD12 display distinct subcellular distributions, suggesting that they may control different pools of 2-AG in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF_Kmd_7v5urVg90H21EOLACvtfcHk0ljar64YLeGiJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOktrfE&md5=78c6355a3909bff3cbae25989ab6a956</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlankman%26aufirst%3DJ.%2BL.%26aulast%3DSimon%26aufirst%3DG.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520Comprehensive%2520profile%2520of%2520brain%2520enzymes%2520that%2520hydrolyze%2520the%2520endocannabinoid%25202-arachidonoylglycerol%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D1347%26epage%3D1356%26doi%3D10.1016%2Fj.chembiol.2007.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Marzo, V.</span></span> <span> </span><span class="NLM_article-title">New approaches and challenges to targeting the endocannabinoid system</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1038%2Fnrd.2018.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=30116049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFans73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=623-639&author=V.+Di%0AMarzo&title=New+approaches+and+challenges+to+targeting+the+endocannabinoid+system&doi=10.1038%2Fnrd.2018.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">New approaches and challenges to targeting the endocannabinoid system</span></div><div class="casAuthors">Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">623-639</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid signalling system was discovered because receptors in this system are the targets of compds. present in psychotropic prepns. of Cannabis sativa.  The search for new therapeutics that target endocannabinoid signalling is both challenging and potentially rewarding, as endocannabinoids are implicated in numerous physiol. and pathol. processes.  Hundreds of mediators chem. related to the endocannabinoids, often with similar metabolic pathways but different targets, have complicated the development of inhibitors of endocannabinoid metabolic enzymes but have also stimulated the rational design of multi-target drugs.  Meanwhile, drugs based on botanical cannabinoids have come to the clin. forefront, synthetic agonists designed to bind cannabinoid receptor 1 with very high affinity have become a societal threat and the gut microbiome has been found to signal in part through the endocannabinoid network.  The current development of drugs that alter endocannabinoid signalling and how this complex system could be pharmacol. manipulated in the future are described in this Opinion article.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsITgIPYFrrVg90H21EOLACvtfcHk0lg4L-2HsftMFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFans73O&md5=7a48b4e8a8c27a5da3e8ba0f80222a32</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.115%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DNew%2520approaches%2520and%2520challenges%2520to%2520targeting%2520the%2520endocannabinoid%2520system%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D623%26epage%3D639%26doi%3D10.1038%2Fnrd.2018.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorhees, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitatani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannun, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, G. A.</span></span> <span> </span><span class="NLM_article-title">Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1088</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddp580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=10.1093%2Fhmg%2Fddp580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=20047948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivV2jtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=1088-1097&author=Y.+Sunauthor=B.+Liouauthor=H.+Ranauthor=M.+R.+Skeltonauthor=M.+T.+Williamsauthor=C.+V.+Vorheesauthor=K.+Kitataniauthor=Y.+A.+Hannunauthor=D.+P.+Witteauthor=Y.-H.+Xuauthor=G.+A.+Grabowski&title=Neuronopathic+Gaucher+disease+in+the+mouse%3A+viable+combined+selective+saposin+C+deficiency+and+mutant+glucocerebrosidase+%28V394L%29+mice+with+glucosylsphingosine+and+glucosylceramide+accumulation+and+progressive+neurological+deficits&doi=10.1093%2Fhmg%2Fddp580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits</span></div><div class="casAuthors">Sun, Ying; Liou, Benjamin; Ran, Huimin; Skelton, Matthew R.; Williams, Michael T.; Vorhees, Charles V.; Kitatani, Kazuyuki; Hannun, Yusuf A.; Witte, David P.; Xu, You-Hai; Grabowski, Gregory A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1088-1097</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Gaucher disease is caused by defective acid β-glucosidase (GCase) function.  Saposin C is a lysosomal protein needed for optimal GCase activity.  To test the in vivo effects of saposin C on GCase, saposin C deficient mice (C-/-) were backcrossed to point mutated GCase (V394L/V394L) mice.  The resultant mice (4L;C*) began to exhibit CNS abnormalities ∼30 days: first as hindlimb paresis, then progressive tremor and ataxia.  Death occurred ∼48 days due to neurol. deficits.  Axonal degeneration was evident in brain stem, spinal cord and white matter of cerebellum accompanied by increasing infiltration of the brain stem, cortex and thalamus by CD68 pos. microglial cells and activation of astrocytes.  Electron microscopy showed inclusion bodies in neuronal processes and degenerating cells.  Accumulation of p62 and Lamp2 were prominent in the brain suggesting the impairment of autophagosome/lysosome function.  This phenotype was different from either V394L/V394L or C-/- alone.  Relative to V394L/V394L mice, 4L;C* mice had diminished GCase protein and activity.  Marked increases (20- to 30-fold) of glucosylsphingosine (GS) and moderate elevation (1.5- to 3-fold) of glucosylceramide (GC) were in 4L;C* brains.  Visceral tissues had increases of GS and GC, but no storage cells were found.  Neuronal cells in thick hippocampal slices from 4L;C* mice had significantly attenuated long-term potentiation, presumably resulting from substrate accumulation.  The 4L;C* mouse mimics the CNS phenotype and biochem. of some type 3 (neuronopathic) variants of Gaucher disease and is a unique model suitable for testing pharmacol. chaperone and substrate redn. therapies, and investigating the mechanisms of neuronopathic Gaucher disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKDrO8Mgd_jLVg90H21EOLACvtfcHk0lg6ExQs_m2Nww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivV2jtL0%253D&md5=6ebf539139467d32fd6d970c96cad73e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddp580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddp580%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLiou%26aufirst%3DB.%26aulast%3DRan%26aufirst%3DH.%26aulast%3DSkelton%26aufirst%3DM.%2BR.%26aulast%3DWilliams%26aufirst%3DM.%2BT.%26aulast%3DVorhees%26aufirst%3DC.%2BV.%26aulast%3DKitatani%26aufirst%3DK.%26aulast%3DHannun%26aufirst%3DY.%2BA.%26aulast%3DWitte%26aufirst%3DD.%2BP.%26aulast%3DXu%26aufirst%3DY.-H.%26aulast%3DGrabowski%26aufirst%3DG.%2BA.%26atitle%3DNeuronopathic%2520Gaucher%2520disease%2520in%2520the%2520mouse%253A%2520viable%2520combined%2520selective%2520saposin%2520C%2520deficiency%2520and%2520mutant%2520glucocerebrosidase%2520%2528V394L%2529%2520mice%2520with%2520glucosylsphingosine%2520and%2520glucosylceramide%2520accumulation%2520and%2520progressive%2520neurological%2520deficits%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2010%26volume%3D19%26spage%3D1088%26epage%3D1097%26doi%3D10.1093%2Fhmg%2Fddp580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i195"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02004">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_45547"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b02004?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02004</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><i>V</i><sub>max</sub> and <i>K</i><sub>M</sub> determinations; concentration–response curve of <b>22m</b> in primary fibroblast cells of Krabbe’s patients; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of the final compounds; retention times and UPLC analytical methods of the final compounds; UPLC traces of the final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02004/suppl_file/jm9b02004_si_001.pdf">PDF</a>)</p></li><li><p class="inline">A csv file containing molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02004/suppl_file/jm9b02004_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02004/suppl_file/jm9b02004_si_001.pdf">jm9b02004_si_001.pdf (10.13 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02004/suppl_file/jm9b02004_si_002.csv">jm9b02004_si_002.csv (2.78 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02004&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-7%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02004%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02004" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995e8658c23d18","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
